
==== Front
Br J PharmacolBr. J. Pharmacol10.1111/(ISSN)1476-5381BPHBritish Journal of Pharmacology0007-11881476-5381John Wiley and Sons Inc. Hoboken 10.1111/bph.14748BPH1474810.1111/bph.14748The Concise Guide to Pharmacology 2019/20The Concise Guide to Pharmacology 2019/20THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptorsAlexander Stephen PH https://orcid.org/0000-0003-4417-497X
1
Christopoulos Arthur https://orcid.org/0000-0003-4442-3294
2
Davenport Anthony P https://orcid.org/0000-0002-2096-3117
3
Kelly Eamonn 
4
Mathie Alistair https://orcid.org/0000-0001-6094-2890
5
Peters John A https://orcid.org/0000-0002-4277-4245
6
Veale Emma L https://orcid.org/0000-0002-6778-9929
5
Armstrong Jane F https://orcid.org/0000-0002-0524-0260
7
Faccenda Elena https://orcid.org/0000-0001-9855-7103
7
Harding Simon D https://orcid.org/0000-0002-9262-8318
7
Pawson Adam J https://orcid.org/0000-0003-2280-845X
7
Sharman Joanna L https://orcid.org/0000-0002-5275-6446
7
Southan Christopher https://orcid.org/0000-0001-9580-0446
7
Davies Jamie A https://orcid.org/0000-0001-6660-4032
7
CGTP Collaborators Abbracchio Maria P https://orcid.org/0000-0002-7833-3388
8
Alexander Wayne 
9
Al-hosaini Khaled 
10
Bäck Magnus https://orcid.org/0000-0003-0853-5141
11
Beaulieu Jean‐Martin https://orcid.org/0000-0002-0446-7447
12
Bernstein Kenneth E. 
9
Bettler Bernhard 
13
Birdsall Nigel JM 
14
Blaho Victoria https://orcid.org/0000-0001-8499-2278
15
Bousquet Corinne https://orcid.org/0000-0002-2501-0593
16
Bräuner-Osborne Hans https://orcid.org/0000-0001-9495-7388
17
Burnstock Geoffrey https://orcid.org/0000-0001-8152-7979
18
Caló Girolamo 
19
Castaño Justo P 
20
Catt Kevin J 
21
Ceruti Stefania https://orcid.org/0000-0003-1663-4211
8
Chazot Paul https://orcid.org/0000-0002-5453-0379
22
Chiang Nan https://orcid.org/0000-0003-1963-1585
23
Chun Jerold https://orcid.org/0000-0003-3964-0921
15
Cianciulli Antonia 
24
Clapp Lucie H https://orcid.org/0000-0001-7802-4481
14
Couture Réjean 
25
Csaba Zsolt 
26
Dent Gordon https://orcid.org/0000-0001-9419-2952
27
Singh Khuraijam Dhanachandra https://orcid.org/0000-0003-0506-6896
28
Douglas Steven D 
29
Dournaud Pascal 
26
Eguchi Satoru 
29
Escher Emanuel 
30
Filardo Edward 
31
Fong Tung M 
32
Fumagalli Marta https://orcid.org/0000-0002-0158-842X
8
Gainetdinov Raul R https://orcid.org/0000-0003-2951-6038
33
de Gasparo Marc 
13
Gershengorn Marvin 
21
Gobeil Fernand 
30
Goodfriend Theodore L 
34
Goudet Cyril https://orcid.org/0000-0002-8255-3535
35
Gregory Karen J https://orcid.org/0000-0002-3833-2137
36
Gundlach Andrew L 
36
Hamann Jörg 
37
Hanson Julien https://orcid.org/0000-0001-7063-7590
38
Hauger Richard L 
15
Hay Debbie https://orcid.org/0000-0002-9558-5122
39
Heinemann Akos https://orcid.org/0000-0002-8554-2372
40
Hollenberg Morley D 
41
Holliday Nicholas D https://orcid.org/0000-0002-2900-828X
42
Horiuchi Mastgugu 
43
Hoyer Daniel https://orcid.org/0000-0002-1405-7089
18
Hunyady László 
44
Husain Ahsan 
45
Ijzerman Adriaan P https://orcid.org/0000-0002-1182-2259
46
Inagami Tadashi 
47
Jacobson Kenneth A https://orcid.org/0000-0001-8104-1493
21
Jensen Robert T 
21
Jockers Ralf https://orcid.org/0000-0002-4354-1750
26
Jonnalagadda Deepa https://orcid.org/0000-0002-1511-8197
15
Karnik Sadashiva 
28
Kaupmann Klemens 
13
Kemp Jacqueline 
28
Kennedy Charles https://orcid.org/0000-0001-9661-5437
48
Kihara Yasuyuki https://orcid.org/0000-0001-7462-3006
15
Kozielewicz Paweł https://orcid.org/0000-0003-1414-3566
11
Kreienkamp Hans‐Jürgen 
49
Kukkonen Jyrki P https://orcid.org/0000-0002-6989-1564
50
Langenhan Tobias https://orcid.org/0000-0002-9061-3809
51
Leach Katie https://orcid.org/0000-0002-9280-1803
18
Lecca Davide https://orcid.org/0000-0002-3258-363X
8
Lee John D https://orcid.org/0000-0002-9976-7396
52
Leeman Susan E 
23
Leprince Jérôme https://orcid.org/0000-0002-7814-9927
53
Lolait Stephen J https://orcid.org/0000-0001-7228-8072
54
Lupp Amelie 
55
Macrae Robyn 
56
Maguire Janet https://orcid.org/0000-0002-9254-7040
56
Mazella Jean https://orcid.org/0000-0002-5627-0742
57
McArdle Craig A https://orcid.org/0000-0003-4836-5351
54
Melmed Shlomo 
58
Michel Martin C https://orcid.org/0000-0003-4161-8467
59
Miller Laurence https://orcid.org/0000-0002-4554-3872
60
Mitolo Vincenzo 
24
Mouillac Bernard https://orcid.org/0000-0002-3906-8673
35
Murphy Philip M 
21
Nahon Jean‐Louis https://orcid.org/0000-0001-9572-7779
57
Norel Xavier https://orcid.org/0000-0003-0734-3359
26
Nyimanu Duuamene 
56
O'Carroll Anne‐Marie https://orcid.org/0000-0001-5255-8506
54
Offermanns Stefan https://orcid.org/0000-0001-8676-6805
61
Panaro Maria A 
24
Pertwee Roger G https://orcid.org/0000-0003-3227-2783
62
Pin Jean‐Philippe https://orcid.org/0000-0002-1423-345X
35
Prossnitz Eric https://orcid.org/0000-0001-9190-8302
63
Ramachandran Rithwik https://orcid.org/0000-0001-9557-9905
64
Reinscheid Rainer K 
65
Rondard Philippe https://orcid.org/0000-0003-1134-2738
35
Rovati G Enrico https://orcid.org/0000-0002-8788-9783
8
Ruzza Chiara 
19
Sanger Gareth https://orcid.org/0000-0002-4231-1945
14
Schöneberg Torsten 
51
Schulte Gunnar https://orcid.org/0000-0002-2700-7013
11
Schulz Stefan 
55
Segaloff Deborah L 
31
Serhan Charles N https://orcid.org/0000-0003-4627-8545
23
Stoddart Leigh A https://orcid.org/0000-0002-4469-0600
42
Sugimoto Yukihiko https://orcid.org/0000-0001-6973-932X
66
Summers Roger https://orcid.org/0000-0002-8367-4056
36
Tan Valerie https://orcid.org/0000-0002-7308-1601
15
Thomas Walter 
67
Timmermans Pieter BMWM 
68
Tirupula Kalyan 
28
Tulipano Giovanni 
69
Unal Hamiyet 
28
Unger Thomas 
70
Vanderheyden Patrick 
71
Vaudry David 
53
Vaudry Hubert 
53
Vilardaga Jean‐Pierre 
72
Walker Christopher S https://orcid.org/0000-0001-8151-4123
39
Ward Donald T https://orcid.org/0000-0003-1342-9458
73
Wester Hans‐Jürgen 
74
Willars Gary B 
75
Williams Tom Lloyd 
56
Woodruff Trent M https://orcid.org/0000-0003-1382-911X
52
Yao Chengcan https://orcid.org/0000-0003-3754-2842
76

1 
School of Life Sciences
University of Nottingham Medical School
Nottingham
NG7 2UH
UK

2 
Monash Institute of Pharmaceutical Sciences and Department of Pharmacology
Monash University
Parkville
Victoria
3052
Australia

3 
Clinical Pharmacology Unit
University of Cambridge
Cambridge
CB2 0QQ
UK

4 
School of Physiology, Pharmacology and Neuroscience
University of Bristol
Bristol
BS8 1TD
UK

5 
Medway School of Pharmacy
The Universities of Greenwich and Kent at Medway
Anson Building, Central Avenue, Chatham Maritime
Chatham, Kent
ME4 4TB
UK

6 
Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School
University of Dundee
Dundee
DD1 9SY
UK

7 
Centre for Discovery Brain Sciences
University of Edinburgh
Edinburgh
EH8 9XD
UK

8 
Milan
Italy

9 
Atlanta
USA

10 
Riyadh
Saudi Arabia

11 
Stockholm
Sweden

12 
Toronto
Canada

13 
Basel
Switzerland

14 
London
UK

15 
La Jolla
USA

16 
Toulouse
France

17 
Copenhagen
Denmark

18 
Melbourne
Australia

19 
Ferrara
Italy

20 
Córdoba
Spain

21 
Bethesda
USA

22 
Durham
UK

23 
Boston
USA

24 
Bari
Italy

25 
Montréal
Canada

26 
Paris
France

27 
Keele
UK

28 
Cleveland
USA

29 
Philadelphia
USA

30 
Sherbrooke
Canada

31 
Iowa City
USA

32 
Princeton
USA

33 
Saint Petersburg
Russia

34 
Madison
USA

35 
Montpellier
France

36 
Parkville
Australia

37 
Amsterdam
The Netherlands

38 
Liège
Belgium

39 
Auckland
New Zealand

40 
Graz
Austria

41 
Calgary
Canada

42 
Nottingham
UK

43 
Ehime
Japan

44 
Budapest
Hungary

45 
Birmingham
USA

46 
Leiden
The Netherlands

47 
Nashville
USA

48 
Glasgow
UK

49 
Hamburg
Germany

50 
Helsinki
Finland

51 
Leipzig
Germany

52 
Brisbane
Australia

53 
Rouen
France

54 
Bristol
UK

55 
Jena
Germany

56 
Cambridge
UK

57 
Valbonne
France

58 
Los Angeles
USA

59 
Mainz
Germany

60 
Scottsdale
USA

61 
Bad Nauheim
Germany

62 
Aberdeen
UK

63 
Albuquerque
USA

64 
London
Canada

65 
Munster
Germany

66 
Kumamoto
Japan

67 
Queensland
Australia

68 
San Francisco
USA

69 
Brescia
Italy

70 
Kiel
Germany

71 
Brussels
Belgium

72 
Pittsburgh
USA

73 
Manchester
UK

74 
Munich
Germany

75 
Leicester
UK

76 
Edinburgh
UK
11 11 2019 12 2019 11 11 2019 176 Suppl 1 10.1111/bph.v176.S1S21 S141 © 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The British Pharmacological Society.This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (http://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14748. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

 source-schema-version-number2.0cover-dateDecember 2019details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:5.7.1 mode:remove_FC converted:11.11.2019


Stephen PH 
Alexander 
, 
Arthur 
Christopoulos 
, 
Anthony P 
Davenport 
, 
Eamonn 
Kelly 
, 
Alistair 
Mathie 
, 
John A 
Peters 
, 
Emma L 
Veale 
, 
Jane F 
Armstrong 
, 
Elena 
Faccenda 
, 
Simon D 
Harding 
, 
Adam J 
Pawson 
, 
Joanna L 
Sharman 
, 
Christopher 
Southan 
, 
Jamie A 
Davies 
 and CGTP Collaborators 
(2019 ) THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors . British Journal of Pharmacology , 176 : S21 –S141 . doi: 10.1111/bph.14748 .
==== Body
1 Conflict of interest
The authors state that there are no conflicts of interest to disclose.

Overview
G protein‐coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term "7TM receptor" is commonly used interchangeably with "GPCR", although there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular N‐terminus, an intracellular C‐terminus and seven hydrophobic transmembrane domains (TM1‐TM7) linked by three extracellular loops (ECL1‐ECL3) and three intracellular loops (ICL1‐ICL3). About 800 GPCRs have been identified in man, of which about half have sensory functions, mediating olfaction (˜400), taste (33), light perception (10) and pheromone signalling (5) [http://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus]. The remaining 350 non‐sensory GPCRs mediate signalling by ligands that range in size from small molecules to peptides to large proteins; they are the targets for the majority of drugs in clinical usage [http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus], although only a minority of these receptors are exploited therapeutically. The first classification scheme to be proposed for GPCRs [http://www.ncbi.nlm.nih.gov/pubmed/8081729?dopt=AbstractPlus] divided them, on the basic of sequence homology, into six classes. These classes and their prototype members were as follows: Class A (rhodopsin‐like), Class B (secretin receptor family), Class C (metabotropic glutamate), Class D (fungal mating pheromone receptors), Class E (cyclic AMP receptors) and Class F (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classification scheme "GRAFS" [http://www.ncbi.nlm.nih.gov/pubmed/15862553?dopt=AbstractPlus] divides vertebrate GPCRs into five classes, overlapping with the A‐F nomenclature, viz:


Glutamate family (http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=C), which includes metabotropic glutamate receptors, a calcium‐sensing receptor and GABAB receptors, as well as three taste type 1 receptors and a family of pheromone receptors (V2 receptors) that are abundant in rodents but absent in man [http://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus].


Rhodopsin family (http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=A), which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2 receptors and five pheromone receptors (V1 receptors).


http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=Adhesion GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N‐termini that are autoproteolytically cleaved from their 7TM domains at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger (320 residue) "GPCR autoproteolysis‐inducing" (GAIN) domain, an evolutionary ancient mofif also found in polycystic kidney disease 1 (PKD1)‐like proteins, which has been suggested to be both required and sufficient for autoproteolysis [http://www.ncbi.nlm.nih.gov/pubmed/23850273?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/GPCRListForward?class=Frizzled consists of 10 Frizzled proteins (FZD(1‐10)) and Smoothened (SMO). The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).


Secretin family, encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27‐141 amino acid residues; nine of the mammalian receptors respond to ligands that are structurally related to one another (glucagon, glucagon‐like peptides (GLP‐1, GLP‐2), glucose‐dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase‐activating polypeptide (PACAP) and growth‐hormone‐releasing hormone (GHRH)) [http://www.ncbi.nlm.nih.gov/pubmed/11790261?dopt=AbstractPlus].

GPCR families


Family
	
Class A
	
Class B (Secretin)
	
Class C (Glutamate)
	
Adhesion
	
Frizzled
	

Receptors with known ligands
	197	15	12	0	11	

Orphans
	87 (54)a
	‐	8 (1)a
	26 (6)a
	0	

Sensory (olfaction)
	390b,c
	‐	‐	‐	‐	

Sensory (vision)
	10d opsins	‐	‐	‐	‐	

Sensory (taste)
	30c taste 2	‐	3c taste 1	‐	‐	

Sensory (pheromone)
	5c vomeronasal 1	‐	‐	‐	‐	

Total
	719	15	22	33	11	




aNumbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus]; b[http://www.ncbi.nlm.nih.gov/pubmed/19129093?dopt=AbstractPlus]; c[http://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus]; d[http://www.ncbi.nlm.nih.gov/pubmed/15774036?dopt=AbstractPlus].

Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the β2 adrenoceptor, the latter culminating in the award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka [http://www.ncbi.nlm.nih.gov/pubmed/23650120?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23650015?dopt=AbstractPlus].

Pseudogenes
Below is a curated list of pseudogenes that in humans are non‐coding for receptor protein. In some cases these have a shared ancestry with genes that encode functional receptors in rats and mice.


https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19240, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16341, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4529, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16291, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7959, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4513, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31924, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31925, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19103, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19106, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19107, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20615, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20640, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20641, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20642, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:43898, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:43905, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20616. A more detailed listing containg further information can be viewed http://www.guidetopharmacology.org/GRAC//DATA/GPCR_pseudogenes.xlsx.

Olfactory receptors
Olfactory receptors are also seven‐transmembrane spanning G protein‐coupled receptors, responsible for the detection of odorants. These are not currently included as they are not yet associated with extensive pharmacological data but are curated in the following databases: The gene list of olfactory receptors at https://www.genenames.org/cgi‐bin/genefamilies/set/141, and curated by https://genome.weizmann.ac.il/horde/ and https://senselab.med.yale.edu/ordb/.

Further reading on G protein‐coupled receptors
Kenakin T. (2018) Is the Quest for Signaling Bias Worth the Effort? Mol. Pharmacol.
93: 266‐269 [https://www.ncbi.nlm.nih.gov/pubmed/29348268?dopt=AbstractPlus]

Michel MC et al. (2018) Biased Agonism in Drug Discovery‐Is It Too Soon to Choose a Path? Mol. Pharmacol.
93: 259‐265 [https://www.ncbi.nlm.nih.gov/pubmed/29326242?dopt=AbstractPlus]

Roth BL et al. (2017) Discovery of new GPCR ligands to illuminate new biology. Nat. Chem. Biol.
13: 1143‐1151 [https://www.ncbi.nlm.nih.gov/pubmed/29045379?dopt=AbstractPlus]

Sriram K et al. (2018) G Protein‐Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Mol. Pharmacol.
93: 251‐258 [https://www.ncbi.nlm.nih.gov/pubmed/29298813?dopt=AbstractPlus]

Family structure

S23 Orphan and other 7TM receptors



S24 Class A Orphans


– http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=706



S33 Class C Orphans


–http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=975



S33 Taste 1 receptors



S34 Taste 2 receptors



S35 Other 7TM proteins



S36 5‐Hydroxytryptamine receptors



S39 Acetylcholine receptors (muscarinic)



S41 Adenosine receptors



S42 Adhesion Class GPCRs



S45 Adrenoceptors



S48 Angiotensin receptors



S50 Apelin receptor



S51 Bile acid receptor



S51 Bombesin receptors



S53 Bradykinin receptors



S54 Calcitonin receptors



S56 Calcium‐sensing receptor



S57 Cannabinoid receptors



S58 Chemerin receptors



S59 Chemokine receptors



S63 Cholecystokinin receptors



S64 Class Frizzled GPCRs



S67 Complement peptide receptors



S68 Corticotropin‐releasing factor receptors



S69 Dopamine receptors



S71 Endothelin receptors



S72 G protein‐coupled estrogen receptor



S73 Formylpeptide receptors



S74 Free fatty acid receptors



S76 GABAB receptors



S78 Galanin receptors



S79 Ghrelin receptor



S80 Glucagon receptor family



S81 Glycoprotein hormone receptors



S82 Gonadotrophin‐releasing hormone receptors



S83 GPR18, GPR55 and GPR119



S84 Histamine receptors



S86 Hydroxycarboxylic acid receptors



S87 Kisspeptin receptor



S88 Leukotriene receptors



S89 Lysophospholipid (LPA) receptors



S90 Lysophospholipid (S1P) receptors



S92 Melanin‐concentrating hormone receptors



S93 Melanocortin receptors



S94 Melatonin receptors



S95 Metabotropic glutamate receptors



S97 Motilin receptor



S98 Neuromedin U receptors



S99 Neuropeptide FF/neuropeptide AF receptors



S100 Neuropeptide S receptor



S101 Neuropeptide W/neuropeptide B receptors



S102 Neuropeptide Y receptors



S103 Neurotensin receptors



S104 Opioid receptors



S106 Orexin receptors



S107 Oxoglutarate receptor



S108 P2Y receptors



S110 Parathyroid hormone receptors



S111 Platelet‐activating factor receptor



S112 Prokineticin receptors



S113 Prolactin‐releasing peptide receptor



S114 Prostanoid receptors



S116 Proteinase‐activated receptors



S117 QRFP receptor



S118 Relaxin family peptide receptors



S120 Somatostatin receptors



S121 Succinate receptor



S122 Tachykinin receptors



S123 Thyrotropin‐releasing hormone receptors



S124 Trace amine receptor



S125 Urotensin receptor



S126 Vasopressin and oxytocin receptors



S127 VIP and PACAP receptors



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115

Overview
This set contains ’orphan’ G protein coupled receptors where the endogenous ligand(s) is not known, and other 7TM receptors.


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=16

Overview
Table 1 lists a number of putative GPCRs identified by NC‐IUPHAR[http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. These GPCRs have recently been reviewed in detail [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus]. The GPCRs in Table 1 are all Class A, rhodopsin‐like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with as‐yet unidentified endogenous ligands.

Table 1
Class A orphan GPCRs with putative endogenous ligands

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=83
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=84
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=85
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=86
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=87
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=88
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=91
	

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=93
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=96
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=98
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=101
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=102
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=103
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=105
	

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=107
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=112
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=113
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=114
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=115
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=120
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=122
	

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=123
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=128
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=135
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=141
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=81
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=147
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=148
	

http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=149
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=150
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=152
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=156
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=157
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=165
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=167
	



In addition the orphan receptors http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=89, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=109 and http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=83
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=84
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=85
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4484, http://www.uniprot.org/uniprot/P46089
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4497, http://www.uniprot.org/uniprot/P46093
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4515, http://www.uniprot.org/uniprot/P46095
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7802 [http://www.ncbi.nlm.nih.gov/pubmed/24633425?dopt=AbstractPlus]	–	–	
Endogenous ligands	–	Protons	–	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 was reported to be an endogenous agonist [http://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus], but this finding was not replicated in subsequent studies [http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus]. Reported to activate adenylyl cyclase constitutively through Gs [http://www.ncbi.nlm.nih.gov/pubmed/7639700?dopt=AbstractPlus]. Gene disruption results in premature ovarian ageing [http://www.ncbi.nlm.nih.gov/pubmed/15956199?dopt=AbstractPlus], reduced β‐amyloid deposition [http://www.ncbi.nlm.nih.gov/pubmed/19213921?dopt=AbstractPlus] and hypersensitivity to thermal pain [http://www.ncbi.nlm.nih.gov/pubmed/21352831?dopt=AbstractPlus] in mice. First small molecule inverse agonist [http://www.ncbi.nlm.nih.gov/pubmed/25442311?dopt=AbstractPlus] and agonists identified [http://www.ncbi.nlm.nih.gov/pubmed/24633425?dopt=AbstractPlus]	An initial report suggesting activation by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032 [http://www.ncbi.nlm.nih.gov/pubmed/11535583?dopt=AbstractPlus] has been retracted [http://www.ncbi.nlm.nih.gov/pubmed/16498716?dopt=AbstractPlus]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus]. Gene disruption is associated with increased perinatal mortality and impaired vascular proliferation [http://www.ncbi.nlm.nih.gov/pubmed/17145776?dopt=AbstractPlus]. Negative allosteric modulators of GPR4 have been reported [http://www.ncbi.nlm.nih.gov/pubmed/26070068?dopt=AbstractPlus].	An initial report that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 (S1P) was a high‐affinity ligand (EC50 value of 39nM) [http://www.ncbi.nlm.nih.gov/pubmed/14592418?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus] was not repeated in arrestin‐based assays [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus]. Reported to activate adenylyl cyclase constitutively through Gs and to be located intracellularly [http://www.ncbi.nlm.nih.gov/pubmed/19059244?dopt=AbstractPlus]. GPR6‐deficient mice showed reduced striatal cyclic AMP production in vitro and selected alterations in instrumental conditioning in vivo. [http://www.ncbi.nlm.nih.gov/pubmed/17934457?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=86
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=87
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=88
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4466, http://www.uniprot.org/uniprot/P47775
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4469, http://www.uniprot.org/uniprot/P49685
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4471, http://www.uniprot.org/uniprot/Q13304
	
Endogenous agonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783 [http://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 [http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1782 [http://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749 [http://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353[http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus]	
Comments	Reports that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 is a ligand of GPR12 [http://www.ncbi.nlm.nih.gov/pubmed/12574419?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus] have not been replicated in arrestin‐based assays [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus]. Gene disruption results in dyslipidemia and obesity [http://www.ncbi.nlm.nih.gov/pubmed/16887097?dopt=AbstractPlus].	Reported to act as a co‐receptor for HIV [http://www.ncbi.nlm.nih.gov/pubmed/9405683?dopt=AbstractPlus]. In an infection‐induced colitis model, Gpr15 knockout mice were more prone to tissue damage and inflammatory cytokine expression [http://www.ncbi.nlm.nih.gov/pubmed/23661644?dopt=AbstractPlus].	Reported to be a dual leukotriene and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749 receptor [http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus]. Another group instead proposed that GPR17 functions as a negative regulator of the CysLT1 receptor response to leukotriene D4 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353). For further discussion, see [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus]. Reported to antagonize CysLT1 receptor signalling in vivo and in vitro [http://www.ncbi.nlm.nih.gov/pubmed/19561298?dopt=AbstractPlus]. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=90
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=91
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=92
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=93
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=95
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=96
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=97
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4473, http://www.uniprot.org/uniprot/Q15760
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4475, http://www.uniprot.org/uniprot/Q99678
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4476, http://www.uniprot.org/uniprot/Q99679
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4477, http://www.uniprot.org/uniprot/Q99680
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4480, http://www.uniprot.org/uniprot/O00155
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4481, http://www.uniprot.org/uniprot/Q8NDV2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4482, http://www.uniprot.org/uniprot/Q9NS67
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9573 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24838, http://www.uniprot.org/uniprot/Q6UWT2) [http://www.ncbi.nlm.nih.gov/pubmed/28476646?dopt=AbstractPlus]	–	–	–	–	–	–	
Comments	–	Reported to inhibit adenylyl cyclase constitutively through Gi/o [http://www.ncbi.nlm.nih.gov/pubmed/18347022?dopt=AbstractPlus]. GPR20 deficient mice exhibit hyperactivity characterised by increased total distance travelled in an open field test [230].	
Gpr21 knockout mice were resistant to diet‐induced obesity, exhibiting an increase in glucose tolerance and insulin sensitivity, as well as a modest lean phenotype [http://www.ncbi.nlm.nih.gov/pubmed/22653059?dopt=AbstractPlus].	Gene disruption results in increased severity of functional decompensation following aortic banding [http://www.ncbi.nlm.nih.gov/pubmed/18539757?dopt=AbstractPlus]. Identified as a susceptibility locus for osteoarthritis [http://www.ncbi.nlm.nih.gov/pubmed/21068099?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20112360?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20090528?dopt=AbstractPlus].	–	Has been reported to activate adenylyl cyclase constitutively through Gs [http://www.ncbi.nlm.nih.gov/pubmed/17363172?dopt=AbstractPlus]. Gpr26 knockout mice show increased levels of anxiety and depression‐like behaviours [http://www.ncbi.nlm.nih.gov/pubmed/21924326?dopt=AbstractPlus].	Knockdown of Gpr27 reduces endogenous mouse insulin promotor activity and glucose‐stimulated insulin secretion [http://www.ncbi.nlm.nih.gov/pubmed/22253604?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=98
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=99
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=100
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=101
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4486, http://www.uniprot.org/uniprot/O00270
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4487, http://www.uniprot.org/uniprot/O75388
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4489, http://www.uniprot.org/uniprot/Q49SQ1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4490, http://www.uniprot.org/uniprot/Q9UPC5
	
Potency order of endogenous ligands	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034
	–	–	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404 [http://www.ncbi.nlm.nih.gov/pubmed/21712392?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4064 [http://www.ncbi.nlm.nih.gov/pubmed/22343749?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16460680?dopt=AbstractPlus]	
Labelled ligands	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4356 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus]	–	–	
Comments	See [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] for discussion of pairing.	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 has been demonstrated to activate GPR32 in two publications [http://www.ncbi.nlm.nih.gov/pubmed/22538616?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus]. The pairing was not replicated in a recent study based on arrestin recruitment [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]. GPR32 is a pseudogene in mice and rats. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	
GPR33 is a pseudogene in most individuals, containing a premature stop codon within the coding sequence of the second intracellular loop [http://www.ncbi.nlm.nih.gov/pubmed/15987686?dopt=AbstractPlus].	Lysophosphatidylserine has been reported to be a ligand of GPR34 in several publications, but the pairing was not replicated in a recent study based on arrestin recruitment [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]. Fails to respond to a variety of lipid‐derived agents [http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus]. Gene disruption results in an enhanced immune response [http://www.ncbi.nlm.nih.gov/pubmed/21097509?dopt=AbstractPlus]. Characterization of agonists at this receptor is discussed in [http://www.ncbi.nlm.nih.gov/pubmed/25970039?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=102
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=103
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4492, http://www.uniprot.org/uniprot/Q9HC97
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4494, http://www.uniprot.org/uniprot/O15354
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2936 [http://www.ncbi.nlm.nih.gov/pubmed/20361937?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2918 [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16754668?dopt=AbstractPlus]	–	
Agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2496 [http://www.ncbi.nlm.nih.gov/pubmed/16443751?dopt=AbstractPlus]	
Comments	Several studies have shown that kynurenic acid is an agonist of GPR35 but it remains controversial whether the proposed endogenous ligand reaches sufficient tissue concentrations to activate the receptor [http://www.ncbi.nlm.nih.gov/pubmed/18235993?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2936 has also been proposed as an endogenous ligand [http://www.ncbi.nlm.nih.gov/pubmed/20361937?dopt=AbstractPlus] but these results were not replicated in an arrestin assay [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]. The phosphodiesterase inhibitor http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919 [http://www.ncbi.nlm.nih.gov/pubmed/16934253?dopt=AbstractPlus] has become widely used as a surrogate agonist to investigate GPR35 pharmacology and signalling [http://www.ncbi.nlm.nih.gov/pubmed/16934253?dopt=AbstractPlus]. GPR35 is also activated by the pharmaceutical adjunct http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2920 [http://www.ncbi.nlm.nih.gov/pubmed/20826425?dopt=AbstractPlus]. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/25805994?dopt=AbstractPlus].	Reported to associate and regulate the dopamine transporter [http://www.ncbi.nlm.nih.gov/pubmed/17519329?dopt=AbstractPlus] and to be a substrate for parkin [http://www.ncbi.nlm.nih.gov/pubmed/19398891?dopt=AbstractPlus]. Gene disruption results in altered striatal signalling [http://www.ncbi.nlm.nih.gov/pubmed/21372109?dopt=AbstractPlus]. The peptides prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1 [http://www.ncbi.nlm.nih.gov/pubmed/23690594?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=104
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=105
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=106
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=107
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14923, http://www.uniprot.org/uniprot/O60883
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4496, http://www.uniprot.org/uniprot/O43194
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4503, http://www.uniprot.org/uniprot/Q9Y5Y3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4506, http://www.uniprot.org/uniprot/Q13585
	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566 [http://www.ncbi.nlm.nih.gov/pubmed/16959833?dopt=AbstractPlus]	–	–	
Comments	The peptides prosaptide and prosaposin are proposed as endogenous ligands for GPR37 and GPR37L1 [http://www.ncbi.nlm.nih.gov/pubmed/23690594?dopt=AbstractPlus].	Zn2+ has been reported to be a potent and efficacious agonist of human, mouse and rat GPR39 [http://www.ncbi.nlm.nih.gov/pubmed/17214962?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5336 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3), a fragment from the ghrelin precursor, was reported initially as an endogenous ligand, but subsequent studies failed to reproduce these findings. GPR39 has been reported to be down‐regulated in adipose tissue in obesity‐related diabetes [http://www.ncbi.nlm.nih.gov/pubmed/17371481?dopt=AbstractPlus]. Gene disruption results in obesity and altered adipocyte metabolism [http://www.ncbi.nlm.nih.gov/pubmed/21784784?dopt=AbstractPlus]. Reviewed in [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	–	GPR50 is structurally related to MT1 and MT2 melatonin receptors, with which it heterodimerises constitutively and specifically [http://www.ncbi.nlm.nih.gov/pubmed/16778767?dopt=AbstractPlus]. Gpr50 knockout mice display abnormal thermoregulation and are much more likely than wild‐type mice to enter fasting‐induced torpor [http://www.ncbi.nlm.nih.gov/pubmed/22197240?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=108
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=110
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=111
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=112
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4508, http://www.uniprot.org/uniprot/Q9Y2T5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13300, http://www.uniprot.org/uniprot/Q9BZJ8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13301, http://www.uniprot.org/uniprot/Q9BZJ7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13302, http://www.uniprot.org/uniprot/Q9BZJ6
	
Comments	First small molecule agonist reported [http://www.ncbi.nlm.nih.gov/pubmed/24884590?dopt=AbstractPlus].	GPR61 deficient mice exhibit obesity associated with hyperphagia [http://www.ncbi.nlm.nih.gov/pubmed/21971119?dopt=AbstractPlus]. Although no endogenous ligands have been identified, 5‐(nonyloxy)tryptamine has been reported to be a low affinity inverse agonist [http://www.ncbi.nlm.nih.gov/pubmed/15173198?dopt=AbstractPlus].	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5512 have been reported to be low affinity agonists for GPR63 [http://www.ncbi.nlm.nih.gov/pubmed/12618218?dopt=AbstractPlus] but this finding was not replicated in an arrestin‐based assay [http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=113
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=114
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4517, http://www.uniprot.org/uniprot/Q8IYL9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4519, http://www.uniprot.org/uniprot/Q15743
	
Endogenous ligands	Protons	Protons	
Allosteric modulators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9155 (Positive) (pK
B 5) [http://www.ncbi.nlm.nih.gov/pubmed/26550826?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5884 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/26550826?dopt=AbstractPlus]	
Comments	GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus]. Reported to activate adenylyl cyclase; gene disruption leads to reduced eosinophilia in models of allergic airway disease [http://www.ncbi.nlm.nih.gov/pubmed/19641187?dopt=AbstractPlus].	GPR68 was previously identified as a receptor for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4032 (SPC) [http://www.ncbi.nlm.nih.gov/pubmed/10806476?dopt=AbstractPlus], but the original publication has been retracted [http://www.ncbi.nlm.nih.gov/pubmed/16508674?dopt=AbstractPlus]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus]. A family of 3,5‐disubstituted isoxazoles were identified as agonists of GPR68 [http://www.ncbi.nlm.nih.gov/pubmed/22462679?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=115
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=116
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=117
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=118
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4526, http://www.uniprot.org/uniprot/O95800
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4528, http://www.uniprot.org/uniprot/Q96P69
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4529, –	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4533, http://www.uniprot.org/uniprot/Q96P67
	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758(https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10632, http://www.uniprot.org/uniprot/P13501) was reported to be an agonist of GPR75 [http://www.ncbi.nlm.nih.gov/pubmed/17001303?dopt=AbstractPlus], but the pairing could not be repeated in an arrestin assay [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus].	GPR78 has been reported to be constitutively active, coupled to elevated cAMP production [http://www.ncbi.nlm.nih.gov/pubmed/17363172?dopt=AbstractPlus].	–	Mice with Gpr82 knockout have a lower body weight and body fat content associated with reduced food intake, decreased serum triglyceride levels, as well as higher insulin sensitivity and glucose tolerance [http://www.ncbi.nlm.nih.gov/pubmed/22216272?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=119
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=120
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=121
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=122
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=123
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=125
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4523, http://www.uniprot.org/uniprot/Q9NYM4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4535, http://www.uniprot.org/uniprot/Q9NQS5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4536, http://www.uniprot.org/uniprot/P60893
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4538, http://www.uniprot.org/uniprot/Q9BY21
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4539, http://www.uniprot.org/uniprot/Q9GZN0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14963, http://www.uniprot.org/uniprot/Q96P66
	
Endogenous agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906 [http://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17905198?dopt=AbstractPlus]	–	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9139 {Mouse} [http://www.ncbi.nlm.nih.gov/pubmed/27117253?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566 [http://www.ncbi.nlm.nih.gov/pubmed/23335960?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5532 [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5533[http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5534[http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus]	–	–	–	–	
Comments	One isoform has been implicated in the induction of CD4(+) CD25(+) regulatory T cells (Tregs) during inflammatory immune responses [http://www.ncbi.nlm.nih.gov/pubmed/20200545?dopt=AbstractPlus]. The extracellular N‐terminal domain is reported as an intramolecular inverse agonist [http://www.ncbi.nlm.nih.gov/pubmed/25516095?dopt=AbstractPlus].	Medium chain free fatty acids with carbon chain lengths of 9‐14 activate GPR84 [http://www.ncbi.nlm.nih.gov/pubmed/23449982?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus]. A surrogate ligand for GPR84, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5846 has also been proposed [http://www.ncbi.nlm.nih.gov/pubmed/23449982?dopt=AbstractPlus]. See review [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] for discussion of classification. Mutational analysis and molecular modelling of GPR84 has been reported [http://www.ncbi.nlm.nih.gov/pubmed/25425658?dopt=AbstractPlus].	Proposed to regulate hippocampal neurogenesis in the adult, as well as neurogenesis‐dependent learning and memory [http://www.ncbi.nlm.nih.gov/pubmed/22697179?dopt=AbstractPlus].	–	Gene disruption results in altered striatal signalling [http://www.ncbi.nlm.nih.gov/pubmed/19796684?dopt=AbstractPlus]. Small molecule agonists have been reported [http://www.ncbi.nlm.nih.gov/pubmed/25754495?dopt=AbstractPlus].	Mutations in GPR101 have been linked to gigantism and acromegaly [http://www.ncbi.nlm.nih.gov/pubmed/25470569?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=128
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=129
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=130
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=131
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=132
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=133
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17482, http://www.uniprot.org/uniprot/Q9UNW8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19991, http://www.uniprot.org/uniprot/Q8IZ08
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19995, http://www.uniprot.org/uniprot/Q6DWJ6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19997, http://www.uniprot.org/uniprot/Q7Z602
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20088, http://www.uniprot.org/uniprot/Q7Z601
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21718, http://www.uniprot.org/uniprot/Q96CH1
	
Endogenous ligands	Protons	–	–	–	–	–	
Comments	GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing receptors detecting acidic pH [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus]. Reported to respond to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508 [http://www.ncbi.nlm.nih.gov/pubmed/11474113?dopt=AbstractPlus], but later retracted [http://www.ncbi.nlm.nih.gov/pubmed/15653487?dopt=AbstractPlus].	–	Peptide agonists have been reported [http://www.ncbi.nlm.nih.gov/pubmed/24826842?dopt=AbstractPlus].	–	Small molecule agonists have been reported [http://www.ncbi.nlm.nih.gov/pubmed/24900747?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24900757?dopt=AbstractPlus].	Yosten et al. demonstrated inhibition of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6145 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6081, http://www.uniprot.org/uniprot/P01308)‐induced stimulation of cFos expression folllowing knockdown of GPR146 in KATO III cells, suggesting proinsulin C‐peptide as an endogenous ligand of the receptor [http://www.ncbi.nlm.nih.gov/pubmed/23759446?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=134
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=135
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=136
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=137
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=138
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=139
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=140
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23623, http://www.uniprot.org/uniprot/Q8TDV2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23627, http://www.uniprot.org/uniprot/Q86SP6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23628, http://www.uniprot.org/uniprot/Q8NGU9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23624, http://www.uniprot.org/uniprot/Q8TDV0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23622, http://www.uniprot.org/uniprot/Q8TDT2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23618, http://www.uniprot.org/uniprot/Q6NV75
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23693, http://www.uniprot.org/uniprot/Q9UJ42
	
Comments	–	
Gpr149 knockout mice displayed increased fertility and enhanced ovulation, with increased levels of FSH receptor and cyclin D2 mRNA levels [http://www.ncbi.nlm.nih.gov/pubmed/19887567?dopt=AbstractPlus].	–	GPR151 responded to galanin with an EC50 value of 2 μM, suggesting that the endogenous ligand shares structural features with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4114, http://www.uniprot.org/uniprot/P22466) [http://www.ncbi.nlm.nih.gov/pubmed/15111018?dopt=AbstractPlus].	–	–	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=141
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=142
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=143
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=144
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23694, http://www.uniprot.org/uniprot/Q8N6U8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16693, http://www.uniprot.org/uniprot/Q16538
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30057, http://www.uniprot.org/uniprot/O14626
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18186, http://www.uniprot.org/uniprot/Q9NS66
	
Comments	A C‐terminal truncation (deletion) mutation in Gpr161 causes congenital cataracts and neural tube defects in the vacuolated lens (vl) mouse mutant [http://www.ncbi.nlm.nih.gov/pubmed/18250320?dopt=AbstractPlus]. The mutated receptor is associated with cataract, spina bifida and white belly spot phenotypes in mice [http://www.ncbi.nlm.nih.gov/pubmed/18796533?dopt=AbstractPlus]. Gene disruption is associated with a failure of asymmetric embryonic development in zebrafish [http://www.ncbi.nlm.nih.gov/pubmed/18755178?dopt=AbstractPlus].	–	GPR171 has been shown to be activated by the endogenous peptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6704 {Mouse}. This receptor‐peptide interaction is believed to be involved in regulating feeding and metabolism responses [http://www.ncbi.nlm.nih.gov/pubmed/24043826?dopt=AbstractPlus].	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=145
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=637
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=146
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=81
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30245, http://www.uniprot.org/uniprot/Q9BXC1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32370, http://www.uniprot.org/uniprot/Q14439
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13708, http://www.uniprot.org/uniprot/O15218
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3128, http://www.uniprot.org/uniprot/P32249
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4064 [http://www.ncbi.nlm.nih.gov/pubmed/22983457?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4350 [http://www.ncbi.nlm.nih.gov/pubmed/21796212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4353[http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4355[http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4354[http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus]	
Comments	See [http://www.ncbi.nlm.nih.gov/pubmed/25970039?dopt=AbstractPlus] which discusses characterization of agonists at this receptor.	–	Rat GPR182 was first proposed as the adrenomedullin receptor [http://www.ncbi.nlm.nih.gov/pubmed/7592696?dopt=AbstractPlus]. However, it was later reported that rat and human GPR182 did not respond to adrenomedullin [http://www.ncbi.nlm.nih.gov/pubmed/9535752?dopt=AbstractPlus] and GPR182 is not currently considered to be a genuine adrenomedullin receptor [http://www.ncbi.nlm.nih.gov/pubmed/21051558?dopt=AbstractPlus].	Two independent publications have shown that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4350 is an agonist of GPR183 and have demonstrated by mass spectrometry that this oxysterol is present endogenously in tissues [http://www.ncbi.nlm.nih.gov/pubmed/21796212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus]. Gpr183‐deficient mice show a reduction in the early antibody response to a T‐dependent antigen. GPR183‐deficient B cells fail to migrate to the outer follicle and instead stay in the follicle centre [http://www.ncbi.nlm.nih.gov/pubmed/21844396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19597478?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=147
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=148
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=149
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13299, http://www.uniprot.org/uniprot/Q9BXB1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4504, http://www.uniprot.org/uniprot/O75473
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19719, http://www.uniprot.org/uniprot/Q9HBX8
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28583, http://www.uniprot.org/uniprot/Q6UXX9) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21679, http://www.uniprot.org/uniprot/Q2MKA7) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20866, http://www.uniprot.org/uniprot/Q9BXY4) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16175, http://www.uniprot.org/uniprot/Q2I0M5) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28583, http://www.uniprot.org/uniprot/Q6UXX9) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21679, http://www.uniprot.org/uniprot/Q2MKA7) http://www.uniprot.org/uniprot/Q2MKA7], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20866, http://www.uniprot.org/uniprot/Q9BXY4) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16175, http://www.uniprot.org/uniprot/Q2I0M5) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3697 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21679, http://www.uniprot.org/uniprot/Q2MKA7) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3698 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28583, http://www.uniprot.org/uniprot/Q6UXX9) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3699 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20866, http://www.uniprot.org/uniprot/Q9BXY4) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16175, http://www.uniprot.org/uniprot/Q2I0M5) [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus]	
Comments	LGR4 does not couple to heterotrimeric G proteins or recruit arrestins when stimulated by the R‐spondins, indicating a unique mechanism of action. R‐spondins bind to LGR4, which specifically associates with Frizzled and LDL receptor‐related proteins (LRPs) that are activated by the extracellular Wnt molecules and then trigger canonical Wnt signalling to increase gene expression [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22815884?dopt=AbstractPlus]. Gene disruption leads to multiple developmental disorders [http://www.ncbi.nlm.nih.gov/pubmed/18487371?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19605502?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18955481?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18424556?dopt=AbstractPlus].	The four R‐spondins can bind to LGR4, LGR5, and LGR6, which specifically associate with Frizzled and LDL receptor‐related proteins (LRPs), proteins that are activated by extracellular Wnt molecules and which then trigger canonical Wnt signalling to increase gene expression [http://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus].	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=150
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=151
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6899, http://www.uniprot.org/uniprot/P04201
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13961, http://www.uniprot.org/uniprot/P35410
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) [http://www.ncbi.nlm.nih.gov/pubmed/21670420?dopt=AbstractPlus] – Mouse	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=152
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=153
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=154
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=155
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29626, http://www.uniprot.org/uniprot/Q8TDS7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30694, http://www.uniprot.org/uniprot/Q86SM8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24828, http://www.uniprot.org/uniprot/Q96AM1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24829, http://www.uniprot.org/uniprot/Q86SM5
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365 [http://www.ncbi.nlm.nih.gov/pubmed/15037633?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]	–	–	–	
Comments	An endogenous peptide with a high degree of sequence similarity to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6065 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333), was shown to promote NO release in MRGPRD‐transfected cells. The binding of alamandine to MRGPRD to was shown to be blocked by D‐Pro7‐angiotensin‐(1‐7), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2365 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=597 [http://www.ncbi.nlm.nih.gov/pubmed/23446738?dopt=AbstractPlus]. Genetic ablation of MRGPRD+ neurons of adult mice decreased behavioural sensitivity to mechanical stimuli but not to thermal stimuli [http://www.ncbi.nlm.nih.gov/pubmed/19451647?dopt=AbstractPlus]. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	MRGPRF has been reported to respond to stimulation by angiotensin metabolites [http://www.ncbi.nlm.nih.gov/pubmed/18636314?dopt=AbstractPlus]. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=156
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=157
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=158
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=159
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=164
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=165
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17962, http://www.uniprot.org/uniprot/Q96LB2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17983, http://www.uniprot.org/uniprot/Q96LB1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17980, http://www.uniprot.org/uniprot/Q96LB0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17617, http://www.uniprot.org/uniprot/Q96LA9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15524, http://www.uniprot.org/uniprot/Q86VZ1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19906, http://www.uniprot.org/uniprot/O00398
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4058 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210) [http://www.ncbi.nlm.nih.gov/pubmed/15163697?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11850634?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4057 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) [http://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus]	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 [http://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906 [http://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus]	
Agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2007 {Mouse, Rat} [http://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28288109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12915402?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]	–	–	–	–	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4056) [http://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus]	–	–	–	–	
Comments	Reported to mediate the sensation of itch [http://www.ncbi.nlm.nih.gov/pubmed/20004959?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21593341?dopt=AbstractPlus]. Reports that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4058 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210) was the most potent of a series of proenkephalin A‐derived peptides as an agonist of MRGPRX1 in assays of calcium mobilisation and radioligand binding [http://www.ncbi.nlm.nih.gov/pubmed/11850634?dopt=AbstractPlus] were replicated in an independent study using an arrestin recruitment assay [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	A diverse range of substances has been reported to be agonists of MRGPRX2, with cortistatin 14 the highest potency agonist in assays of calcium mobilisation [http://www.ncbi.nlm.nih.gov/pubmed/12915402?dopt=AbstractPlus], also confirmed in an independent study using an arrestin recruitment assay [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]. See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	–	See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus].	–	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=167
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=168
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=169
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=170
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=171
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=172
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=173
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4514, http://www.uniprot.org/uniprot/Q9P1P5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4513, http://www.uniprot.org/uniprot/Q9P1P4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31924, –	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30236, http://www.uniprot.org/uniprot/O14804
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20978, http://www.uniprot.org/uniprot/Q96RI8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14964, http://www.uniprot.org/uniprot/Q969N4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20977, http://www.uniprot.org/uniprot/Q96RI9
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125 [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus]	–	–	–	–	–	–	
Comments	Probable pseudogene in 10–15% of Asians due to a polymorphism (rs8192646) producing a premature stop codon at amino acid 168 [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	
TAAR3 is thought to be a pseudogene in man though functional in rodents [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	Pseudogene in man but functional in rodents [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].	Trimethylamine is reported as an agonist [http://www.ncbi.nlm.nih.gov/pubmed/23393561?dopt=AbstractPlus] and 3‐iodothyronamine an inverse agonist [http://www.ncbi.nlm.nih.gov/pubmed/25706283?dopt=AbstractPlus].	–	–	
TAAR9 appears to be functional in most individuals but has a polymorphic premature stop codon at amino acid 61 (rs2842899) with an allele frequency of 10–30% in different populations [http://www.ncbi.nlm.nih.gov/pubmed/14559210?dopt=AbstractPlus].	



Further reading on Class A Orphans
McNeil BD et al. (2015) Identification of a mast‐cell‐specific receptor crucial for pseudo‐allergic drug reactions. Nature
519: 237–41 [https://www.ncbi.nlm.nih.gov/pubmed/25517090?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=18

Overview
This set contains class C ’orphan’ G protein coupled receptors where the endogenous ligand(s) is not known.
Nomenclature http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=209
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=210
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=211
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=258
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=259
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=260
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=261
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=55
	
HGNC, UniProt https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20844, http://www.uniprot.org/uniprot/Q8NFN8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23689, http://www.uniprot.org/uniprot/Q5T848
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:31371, http://www.uniprot.org/uniprot/Q6PRD1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9836, http://www.uniprot.org/uniprot/Q8NFJ5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13308, http://www.uniprot.org/uniprot/Q9NZH0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13309, http://www.uniprot.org/uniprot/Q9NQ84
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13310, http://www.uniprot.org/uniprot/Q9NZD1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18510, http://www.uniprot.org/uniprot/Q5T6X5
	
Comments	–	–	–	–	–	–	GPRC6 is a Gq‐coupled receptor which responds to basic amino acids [http://www.ncbi.nlm.nih.gov/pubmed/15576628?dopt=AbstractPlus].	



Further reading on Class C Orphans
Harpse K et al. (2017) Structural insight to mutation effects uncover a common allosteric site in class C GPCRs. Bioinformatics
33: 1116–1120 [https://www.ncbi.nlm.nih.gov/pubmed/28011766?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=116

Overview
Whilst the taste of acid and salty foods appear to be sensed by regulation of ion channel activity, bitter, sweet and umami tastes are sensed by specialised GPCR. Two classes of taste GPCR have been identified, T1R and T2R, which are similar in sequence and structure to Class C and Class A GPCR, respectively. Activation of taste receptors appears to involve gustducin‐ (Gαt3) and Gα14‐mediated signalling, although the precise mechanisms remain obscure. Gene disruption studies suggest the involvement of PLCβ2 [http://www.ncbi.nlm.nih.gov/pubmed/12581520?dopt=AbstractPlus], TRPM5 [http://www.ncbi.nlm.nih.gov/pubmed/12581520?dopt=AbstractPlus] and IP3 [http://www.ncbi.nlm.nih.gov/pubmed/17925404?dopt=AbstractPlus] receptors in postreceptor signalling of taste receptors. Although predominantly associated with the oral cavity, taste receptors are also located elsewhere, including further down the gastrointestinal system, in the lungs and in the brain.

Sweet/Umami
T1R3 acts as an obligate partner in T1R1/T1R3 and T1R2/T1R3 heterodimers, which sense umami or sweet, respectively. T1R1/T1R3 heterodimers respond to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 and may be positively allosterically modulated by 5’‐nucleoside monophosphates, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5123 [http://www.ncbi.nlm.nih.gov/pubmed/12013525?dopt=AbstractPlus]. T1R2/T1R3 heterodimers respond to sugars, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5411, and artificial sweeteners, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5432 [http://www.ncbi.nlm.nih.gov/pubmed/11509186?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=656
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=657
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=658
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14448, http://www.uniprot.org/uniprot/Q7RTX1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14905, http://www.uniprot.org/uniprot/Q8TE23
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15661, http://www.uniprot.org/uniprot/Q7RTX0
	



Comments
Positive allosteric modulators of T1R2/T1R3 have been reported [2363]. Such compounds enhance the sweet taste of sucrose mediated by these receptors, but are tasteless on their own.

Further reading on Taste 1 receptors
Palmer RK. (2019) A Pharmacological Perspective on the Study of Taste. Pharmacol. Rev.
71: 20–48 [https://www.ncbi.nlm.nih.gov/pubmed/30559245?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=117

G protein‐coupled receptors → Orphan and other 7TM receptors → Taste 2 receptors

Overview
The composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand specificity or much broader responsiveness. For example, T2R5 responded to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5433, but not 10 other bitter compounds [http://www.ncbi.nlm.nih.gov/pubmed/10761935?dopt=AbstractPlus], while T2R14 responded to at least eight different bitter tastants, including (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5344‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5344 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2291 [http://www.ncbi.nlm.nih.gov/pubmed/15178431?dopt=AbstractPlus].

Specialist database http://bitterdb.agri.huji.ac.il/dbbitter.php contains additional information on bitter compounds and receptors [http://www.ncbi.nlm.nih.gov/pubmed/21940398?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=659
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=660
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=661
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=662
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=663
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=664
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=665
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14909, http://www.uniprot.org/uniprot/Q9NYW7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14910, http://www.uniprot.org/uniprot/Q9NYW6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14911, http://www.uniprot.org/uniprot/Q9NYW5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14912, http://www.uniprot.org/uniprot/Q9NYW4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14913, http://www.uniprot.org/uniprot/Q9NYW3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14915, http://www.uniprot.org/uniprot/Q9NYW2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14917, http://www.uniprot.org/uniprot/Q9NYW1
	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=666
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=667
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=668
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=669
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=670
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=671
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=673
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14918, http://www.uniprot.org/uniprot/Q9NYW0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14919, http://www.uniprot.org/uniprot/Q9NYV9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14920, http://www.uniprot.org/uniprot/Q9NYV8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14921, http://www.uniprot.org/uniprot/Q9NYV7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19108, http://www.uniprot.org/uniprot/P59542
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19109, http://www.uniprot.org/uniprot/P59543
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19112, http://www.uniprot.org/uniprot/P59541
	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=674
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=682
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=675
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=676
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19113, http://www.uniprot.org/uniprot/P59538
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9584, http://www.uniprot.org/uniprot/P59533
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18886, http://www.uniprot.org/uniprot/P59534
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18885, http://www.uniprot.org/uniprot/P59535
	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9111 (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/21650152?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9112 (pIC50 5.1–5.2) [http://www.ncbi.nlm.nih.gov/pubmed/20537538?dopt=AbstractPlus]	–	–	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=680
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=672
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=678
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2828
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=679
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=677
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=681
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18883, http://www.uniprot.org/uniprot/P59536
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18888, http://www.uniprot.org/uniprot/Q7RTR8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18875, http://www.uniprot.org/uniprot/P59537
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18876, http://www.uniprot.org/uniprot/P59539
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18877, http://www.uniprot.org/uniprot/P59540
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18882, http://www.uniprot.org/uniprot/P59544
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20639, http://www.uniprot.org/uniprot/P59551
	



Further reading on Taste 2 receptors
Palmer RK. (2019) A Pharmacological Perspective on the Study of Taste. Pharmacol. Rev.
71: 20–48 [https://www.ncbi.nlm.nih.gov/pubmed/30559245?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=113


Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=651
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=652
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=655
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=203
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=205
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17830, http://www.uniprot.org/uniprot/Q5VW38
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24300, http://www.uniprot.org/uniprot/Q96N19
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30413, http://www.uniprot.org/uniprot/Q86W33
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20145, http://www.uniprot.org/uniprot/P51810
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23687, http://www.uniprot.org/uniprot/Q5UAW9
	
Endogenous agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639 [http://www.ncbi.nlm.nih.gov/pubmed/18828673?dopt=AbstractPlus]	–	
Comments	GPR107 is a member of the LUSTR family of proteins found in both plants and animals, having similar topology to G protein‐coupled receptors [http://www.ncbi.nlm.nih.gov/pubmed/17454009?dopt=AbstractPlus]	–	TPRA1 shows no homology to known G protein‐coupled receptors.	Loss‐of‐function mutations underlie ocular albinism type 1 [http://www.ncbi.nlm.nih.gov/pubmed/7647783?dopt=AbstractPlus].	GPR157 has ambiguous sequence similarities to several different GPCR families (class A, class B and the slime mould cyclic AMP receptor). Because of its distant relationship to other GPCRs, it cannot be readily classified.	



Further reading on Orphan and other 7TM receptors
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein‐coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev.
65: 967–86 [https://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus]

Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacol. Ther.
159: 56–65 [https://www.ncbi.nlm.nih.gov/pubmed/26808164?dopt=AbstractPlus]

Insel PA et al. (2015) G Protein‐Coupled Receptor (GPCR) Expression in Native Cells: “Novel” endoGPCRs as Physiologic Regulators and Therapeutic Targets. Mol. Pharmacol.
88: 181‐7 [https://www.ncbi.nlm.nih.gov/pubmed/25737495?dopt=AbstractPlus]

Khan MZ et al. (2017) Neuro‐psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein‐coupled receptors. Psychopharmacology (Berl.)
234: 1181‐1207 [https://www.ncbi.nlm.nih.gov/pubmed/28289782?dopt=AbstractPlus]

Mackenzie AE et al. (2017) The emerging pharmacology and function of GPR35 in the nervous system. Neuropharmacology
113: 661–671 [https://www.ncbi.nlm.nih.gov/pubmed/26232640?dopt=AbstractPlus]

Ngo T et al. (2016) Identifying ligands at orphan GPCRs: current status using structure‐based approaches. Br. J. Pharmacol.
173: 2934‐51 [https://www.ncbi.nlm.nih.gov/pubmed/26837045?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1

Overview
5‐HT receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on 5‐HT receptors [http://www.ncbi.nlm.nih.gov/pubmed/7938165?dopt=AbstractPlus] and subsequently revised [http://www.ncbi.nlm.nih.gov/pubmed/8936345?dopt=AbstractPlus]) are, with the exception of the ionotropic 5‐HT3 class, GPCRs where the endogenous agonist is http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5. The diversity of metabotropic 5‐HT receptors is increased by alternative splicing that produces isoforms of the 5‐HT2A (non‐functional), 5‐HT2C (non‐functional), 5‐HT4, 5‐HT6 (non‐functional) and 5‐HT7 receptors. Unique amongst the GPCRs, RNA editing produces 5‐HT2C receptor isoforms that differ in function, such as efficiency and specificity of coupling to Gq/11 and also pharmacology [http://www.ncbi.nlm.nih.gov/pubmed/16896947?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18554725?dopt=AbstractPlus]. Most 5‐HT receptors (except 5‐ht1e and 5‐ht5b) play specific roles mediating functional responses in different tissues (reviewed by [http://www.ncbi.nlm.nih.gov/pubmed/19086344?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17703282?dopt=AbstractPlus]).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5286, http://www.uniprot.org/uniprot/P08908
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5287, http://www.uniprot.org/uniprot/P28222
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=30 [http://www.ncbi.nlm.nih.gov/pubmed/7965808?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7427 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/19499624?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15 [http://www.ncbi.nlm.nih.gov/pubmed/10513577?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=45 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=40[http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7191 [http://www.ncbi.nlm.nih.gov/pubmed/9986723?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=60 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=51 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7 [http://www.ncbi.nlm.nih.gov/pubmed/9495870?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12527336?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15628665?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9067310?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1386736?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3924 [http://www.ncbi.nlm.nih.gov/pubmed/19154445?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3221 [1122]	
Antagonists	(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=61 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=80 (pK
i 7.9–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=72 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9336327?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=130 (Inverse agonist) (pK
i 8.2–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/9548813?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11040052?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9776361?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3231 (Inverse agonist) (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/10443589?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=113 (pK
B 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/11888546?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=82 (Antagonist) (pK
d 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/9851589?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3251 (Antagonist) (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/9048968?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=31 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11101361?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15628665?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10431754?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3925 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/20799027?dopt=AbstractPlus], [[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3252 (Antagonist) [http://www.ncbi.nlm.nih.gov/pubmed/15689356?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3227 (Antagonist) [http://www.ncbi.nlm.nih.gov/pubmed/16330560?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3219 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/19401496?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=131 (Selective Antagonist) (pK
d 8.6–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/10513577?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10452531?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=117 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3250 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1738002?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8361548?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=118 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=119 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3926 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/20424633?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=4
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=5
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5289, http://www.uniprot.org/uniprot/P28221
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5291, http://www.uniprot.org/uniprot/P28566
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5292, http://www.uniprot.org/uniprot/P30939
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121 [http://www.ncbi.nlm.nih.gov/pubmed/1652050?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8967979?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149 [http://www.ncbi.nlm.nih.gov/pubmed/10715164?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=15 [http://www.ncbi.nlm.nih.gov/pubmed/9855638?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=45 [http://www.ncbi.nlm.nih.gov/pubmed/9303569?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7780656?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=60[http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7191 [http://www.ncbi.nlm.nih.gov/pubmed/9986723?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=51[http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3927 [250]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3927 [250], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=40 [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=54 [http://www.ncbi.nlm.nih.gov/pubmed/9225282?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8380639?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3228 [http://www.ncbi.nlm.nih.gov/pubmed/9632349?dopt=AbstractPlus] – Gorilla, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=40 [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3928 [http://www.ncbi.nlm.nih.gov/pubmed/20855361?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=20 [http://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8422 [http://www.ncbi.nlm.nih.gov/pubmed/21422162?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=21 [http://www.ncbi.nlm.nih.gov/pubmed/9395253?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=77 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/15887956?dopt=AbstractPlus]	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=118 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=117 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3250 (Selective Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1738002?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8361548?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=131 (Selective Antagonist) (pK
d 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/10452531?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=119 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1608964?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8863519?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=151 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=261 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1328180?dopt=AbstractPlus] – Mouse	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=6
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5293, http://www.uniprot.org/uniprot/P28223
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5294, http://www.uniprot.org/uniprot/P41595
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5295, http://www.uniprot.org/uniprot/P28335
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=147 [http://www.ncbi.nlm.nih.gov/pubmed/2233697?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8534270?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11104741?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459568?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=147 [http://www.ncbi.nlm.nih.gov/pubmed/8078486?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=147 [http://www.ncbi.nlm.nih.gov/pubmed/10611640?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166 [http://www.ncbi.nlm.nih.gov/pubmed/14709324?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus]	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=161 [http://www.ncbi.nlm.nih.gov/pubmed/15466450?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=166[http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=229 [http://www.ncbi.nlm.nih.gov/pubmed/15705738?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2941 [http://www.ncbi.nlm.nih.gov/pubmed/18252809?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96 (Inverse agonist) (pK
i 9.3–10) [http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135 (pK
i 7.7–9.6) [http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15107597?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=59 (pK
i 8.8–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=185 (pIC50 6.5–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11562430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10188965?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7670 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/15686911?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=38 (Inverse agonist) (pK
i 7.6–9) [http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9732398?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15102927?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9880 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/29615471?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135 (pK
i 7.9–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/10455251?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459568?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=135 (Inverse agonist) (pK
i 8.3–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=134 (pK
i 8.6–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/10611640?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=59 (Inverse agonist) (pK
i 7.9–9) [http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=47 (Inverse agonist) (pK
i 8.1–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205 (Inverse agonist) (pK
i 7.8–8) [http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9825 (pK
i 10.6) [http://www.ncbi.nlm.nih.gov/pubmed/28943244?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88 (pK
i 8.1–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/8845011?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8423 (Inverse agonist) (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/17519387?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15102927?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8424 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/25666387?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=188 (pK
i 9–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/10455251?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=176 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/15107597?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3223 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/17074317?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=193 (pK
i 8.2–9) [http://www.ncbi.nlm.nih.gov/pubmed/9225286?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=187 (pK
i 8.3–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9225287?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3229 (Antagonist) (pK
d 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/8472747?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=197 (Antagonist) (pK
d 8.6–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3249 (Antagonist) [http://www.ncbi.nlm.nih.gov/pubmed/11044889?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3242 (Antagonist) [http://www.ncbi.nlm.nih.gov/pubmed/9027929?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8450835?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=232 (Antagonist, Inverse agonist) (pK
d 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=169 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=232 (Antagonist, Inverse agonist) (pK
d 8.7–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=169 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219 (Agonist)	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=10
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=648
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5299, http://www.uniprot.org/uniprot/Q13639
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5300, http://www.uniprot.org/uniprot/P47898
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16291, –	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=240 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7796807?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus]			
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8426 [http://www.ncbi.nlm.nih.gov/pubmed/23756062?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=235 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12801225?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9603189?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10821780?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3230 [http://www.ncbi.nlm.nih.gov/pubmed/8903510?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8427 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/25316608?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8425 [http://www.ncbi.nlm.nih.gov/pubmed/22959244?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18415081?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=234 [http://www.ncbi.nlm.nih.gov/pubmed/9351641?dopt=AbstractPlus]	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=250 (pK
i 8.7–12.2) [http://www.ncbi.nlm.nih.gov/pubmed/9351641?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15351779?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=256 (pK
i 9.8–10.4) [http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=247 (pKi 9.3–10.3) [http://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9603189?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15351779?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=264 (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/16002289?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=259 (Antagonist) (pK
d 9.7–10.3) [http://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10821780?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3243 (Antagonist) (pK
d 10.1) [251] – Pig, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=239 (Selective Antagonist) (pK
d 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/9225293?dopt=AbstractPlus] – Guinea pig, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3244 (Antagonist) (pK
d 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/21831646?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=261 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11343685?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11343685?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=261 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8450829?dopt=AbstractPlus] – Mouse, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9928243?dopt=AbstractPlus] – Mouse	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5301, http://www.uniprot.org/uniprot/P50406
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5302, http://www.uniprot.org/uniprot/P34969
	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3240 [http://www.ncbi.nlm.nih.gov/pubmed/17625499?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3217 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15771424?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8429 [http://www.ncbi.nlm.nih.gov/pubmed/19523834?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8428 [http://www.ncbi.nlm.nih.gov/pubmed/16055331?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8434 [http://www.ncbi.nlm.nih.gov/pubmed/17649988?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8435], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8436 [http://www.ncbi.nlm.nih.gov/pubmed/18800769?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8433 [http://www.ncbi.nlm.nih.gov/pubmed/23541835?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3929 [http://www.ncbi.nlm.nih.gov/pubmed/19118950?dopt=AbstractPlus]	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7461 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/20404009?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=90 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/7908055?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7351 (pK
i 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3241 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/17069795?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=276 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/9925723?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7356 (pK
i 8.9) [407], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3235 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/11140733?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=275 (pK
i 7.9–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9730917?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9647481?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3233 (pK
i 8.6–8.9) [http://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3237 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/12392747?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8431 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/12825922?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10052959?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8432 (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/22570363?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=281 (Inverse agonist) (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/9720804?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8430 (Antagonist) (pK
i 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/22223878?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3245 (Selective Antagonist) (pK
d 9) [http://www.ncbi.nlm.nih.gov/pubmed/17069795?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9284367?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3246 (Antagonist) (pK
d 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/9730917?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=262 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3248 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8226867?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9303561?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3247 (Selective Antagonist) (pK
d 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=219 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9303561?dopt=AbstractPlus]	



Comments
Tabulated pK
i and K
D values refer to binding to human 5‐HT receptors unless indicated otherwise. The nomenclature of 5‐HT1B/5‐HT1D receptors has been revised [http://www.ncbi.nlm.nih.gov/pubmed/8936345?dopt=AbstractPlus]. Only the non‐rodent form of the receptor was previously called 5‐HT1D: the human 5‐HT1B receptor (tabulated) displays a different pharmacology to the rodent forms of the receptor due to Thr335 of the human sequence being replaced by Asn in rodent receptors [http://www.ncbi.nlm.nih.gov/pubmed/18571247?dopt=AbstractPlus]. Wang et al. (2013) report X‐ray structures which reveal the binding modality of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=121 (DHE) to the 5‐HT1B receptor in comparison with the structure of the 5HT2B receptor [http://www.ncbi.nlm.nih.gov/pubmed/23519210?dopt=AbstractPlus]; some of these drugs adopt rather different conformations depending on the target receptor [http://www.ncbi.nlm.nih.gov/pubmed/29398112?dopt=AbstractPlus]. Various 5‐HT receptors have multiple partners in addition to G proteins, which may affect function and pharmacology [http://www.ncbi.nlm.nih.gov/pubmed/21777185?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3226 is a selective antagonist of the rodent 5‐HT1B receptor. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5434 (LSD) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88 bind with high affinity to dopamine D4 and histamine H1 receptors respectively, and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=88 is a potent α1 adrenoceptor antagonist, in addition to blocking 5‐HT2A receptors. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=139 (LSD) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=149 show a strong preference for arrestin recruitment over G protein coupling at the 5‐HT2B receptor, with no such preference evident at 5‐HT1B receptors, and they also antagonise 5‐HT7A receptors [http://www.ncbi.nlm.nih.gov/pubmed/23519215?dopt=AbstractPlus]. DHE (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=282), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=48 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=37 also show significant preference for arrestin recruitment over G protein coupling at 5‐HT2B receptors [http://www.ncbi.nlm.nih.gov/pubmed/23519215?dopt=AbstractPlus]. The 5‐HT2B (and other 5‐HT) receptors interact with immunocompetent cells [http://www.ncbi.nlm.nih.gov/pubmed/28265714?dopt=AbstractPlus]. The serotonin antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=206 was key to the discovery of the 5HT2C receptor [http://www.ncbi.nlm.nih.gov/pubmed/6519175?dopt=AbstractPlus], initially known as 5‐HT1C [http://www.ncbi.nlm.nih.gov/pubmed/28806488?dopt=AbstractPlus]. The human 5‐HT5A receptor may couple to several signal transduction pathways when stably expressed in C6 glioma cells [http://www.ncbi.nlm.nih.gov/pubmed/12558985?dopt=AbstractPlus] and rodent prefrontal cortex (layer V pyramidal neurons) [http://www.ncbi.nlm.nih.gov/pubmed/22539842?dopt=AbstractPlus]. The human orthologue of the mouse 5‐ht5b receptor is non‐functional (stop codons); the 5‐ht1e receptor has not been cloned from mouse, or rat, impeding definition of its function [http://www.ncbi.nlm.nih.gov/pubmed/18571247?dopt=AbstractPlus]. In addition to accepted receptors, an ’orphan’ receptor, unofficially termed5‐HT1P, has been described [http://www.ncbi.nlm.nih.gov/pubmed/10429737?dopt=AbstractPlus].

Further reading on 5‐Hydroxytryptamine receptors
Bockaert J et al. (2011) 5‐HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol
11: 87‐93 [https://www.ncbi.nlm.nih.gov/pubmed/21342787?dopt=AbstractPlus]

Hayes DJ et al. (2011) 5‐HT receptors and reward‐related behaviour: a review. Neurosci Biobehav Rev
35: 1419‐49 [https://www.ncbi.nlm.nih.gov/pubmed/21402098?dopt=AbstractPlus]

Hoyer D et al. (1994) International Union of Pharmacology classification of receptors for 5hydroxytryptamine (Serotonin). Pharmacol. Rev.
46: 157‐203 [https://www.ncbi.nlm.nih.gov/pubmed/7938165?dopt=AbstractPlus]

Leopoldo M et al. (2011)Serotonin 5‐HT7 receptor agents: Structure‐activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol. Ther.
129: 120‐48 [https://www.ncbi.nlm.nih.gov/pubmed/20923682?dopt=AbstractPlus]

Meltzer HY et al. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol
11: 59‐67 [https://www.ncbi.nlm.nih.gov/pubmed/21420906?dopt=AbstractPlus]

Roberts AJ et al. (2012) The 5‐HT(7) receptor in learning and memory. Hippocampus
22: 762‐71 [https://www.ncbi.nlm.nih.gov/pubmed/21484935?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2

Overview
Muscarinic acetylcholine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [http://www.ncbi.nlm.nih.gov/pubmed/9647869?dopt=AbstractPlus]) are GPCRs of the Class A, rhodopsin‐like family where the endogenous agonist is http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294. In addition to the agents listed in the table, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=289, its structural analogues http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=334 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3271, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=333, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3258 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5435 have been described as functionally selective agonists of the M1 receptor subtype via binding in a mode distinct from that utilized by non‐selective agonists [http://www.ncbi.nlm.nih.gov/pubmed/20413650?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18842902?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18454168?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16207821?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17525129?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20684563?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16959945?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12021390?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14595031?dopt=AbstractPlus]. There are two pharmacologically characterised allosteric sites on muscarinic receptors, one defined by it binding http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342, and the other defined by the binding of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=337, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=340, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=339 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=346 [http://www.ncbi.nlm.nih.gov/pubmed/10860942?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12435818?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=13
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=14
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1950, http://www.uniprot.org/uniprot/P11229
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1951, http://www.uniprot.org/uniprot/P08172
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298 [http://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297[http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298 [http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297[http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10259 [http://www.ncbi.nlm.nih.gov/pubmed/30276808?dopt=AbstractPlus]	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459 (pIC50 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586 (pK
i 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320 (pK
i 8.5–9.6) [http://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16439611?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=367 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=367 (pK
i 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320 (pK
i 7.8–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360 (Inverse agonist) (pK
i 8.4–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128 (pK
d 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3274 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/19407080?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3276 (pK
i 7.3–7.6) [http://www.ncbi.nlm.nih.gov/pubmed/10323493?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8813552?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=361 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/7805774?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=314 (Negative) (pK
i 11–11.1) [http://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8549 (Positive) (pKB 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/25326383?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=337 (Positive) (pK
d 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/10860942?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=342 (Positive) (pK
d 4.5–5.8) [http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9495826?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5436 (Positive) (pK
B 4–4.8) [http://www.ncbi.nlm.nih.gov/pubmed/25326383?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24443568?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22086918?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19717450?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3261 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/19047481?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3259 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/19047481?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=362 (Negative) (pK
d 6–7.5) [http://www.ncbi.nlm.nih.gov/pubmed/15163212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7634 (Negative) (pK
d 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/9890565?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=341 (Negative) (pK
d 6.1–6.9) [http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356 (Negative) (pK
d 5.9–6.3) [http://www.ncbi.nlm.nih.gov/pubmed/990587?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6938 (Positive) (pK
d 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/24807965?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24256733?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3262 (Positive) (pK
d 4.4) [http://www.ncbi.nlm.nih.gov/pubmed/21989256?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318 (Antagonist) (pK
d 10.6–10.8) [http://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8598 (Antagonist) (pK
d 10.5) [http://www.ncbi.nlm.nih.gov/pubmed/20133736?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317 (Antagonist) (pK
d 9.4–10.3) [http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16675658?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8594 (Antagonist) (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/2704371?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8600 (Antagonist) (pK
d 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/20133736?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3272 (Antagonist) (pK
d 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/6546354?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318 (Antagonist) (pK
d 10.1–10.6) [http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8598 (Antagonist) (pK
i 10.4) [http://www.ncbi.nlm.nih.gov/pubmed/23357106?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8592 (Antagonist) (pK
d 10.3) [http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317 (Antagonist) (pK
d 9.3–9.9) [http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16675658?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8600 (Antagonist) (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/23357106?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8593 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8595 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/6478115?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=364 (Allosteric modulator, Positive) (pK
d 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3266 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12668051?dopt=AbstractPlus] – Mouse	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=16
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1952, http://www.uniprot.org/uniprot/P20309
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1953, http://www.uniprot.org/uniprot/P08173
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1954, http://www.uniprot.org/uniprot/P08912
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298 [http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298[http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=297[http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=305 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/16002459?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=298 [http://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=367 (pK
i 9.5–11.1) [http://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586 (pKi 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=320 (pK
i 8.9–9.8) [http://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=325 (pK
i 9.3–9.8) [http://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7449 (pIC50 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/19653626?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459 (pIC50 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=359 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7128 (pK
d 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8583 (pKi 8.3–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7459 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8586 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=360 (pK
i 8.5–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321 (pK
i 7.9–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus]	
Selective antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8591 (pK
i 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/24692176?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=340 (Positive) (pK
d 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/12435818?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=344 (Positive) (pK
d 3.3) [http://www.ncbi.nlm.nih.gov/pubmed/9495826?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=313 (Negative) (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9862767?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3263 (Positive) (pEC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/18772318?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3256 (Positive) (pEC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/18772318?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6938 (Positive) (pK
d 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/24807965?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=348 (Positive) (pK
d 4) [http://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3262 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/18678919?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8687 (Positive) (pEC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/27461343?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25147929?dopt=AbstractPlus]	
Selective allosteric modulators	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7631 (Negative) (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/24164599?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8592 (Antagonist) (pK
d 10.7) [http://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318 (Antagonist) (pK
d 10.4) [http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317 (Antagonist) (pK
d 9.7–10.2) [http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=319 (Antagonist) (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318 (Antagonist) (pK
d 9.7–10.5) [http://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317 (Antagonist) (pK
d 9.9–10.2) [http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9862767?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8593 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=318 (Antagonist) (pK
d 10.2–10.7), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=317 (Antagonist) (pK
d 9.3–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus]	



Comments
The crystal structures of the M1‐M4 receptor subtypes have been reported [http://www.ncbi.nlm.nih.gov/pubmed/22278061?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26958838?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22358838?dopt=AbstractPlus]. Direct activation via an allosteric site has been reported for M1 receptors (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5436, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9228) and M4 receptors (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3262) [http://www.ncbi.nlm.nih.gov/pubmed/27275946?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21300722?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19940843?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19717450?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20406819?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18628403?dopt=AbstractPlus]. The allosteric site for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=356 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=347 on M2 receptors can be labelled by [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=364 [http://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=290 is a functionally selective partial agonist that appears to interact in a bitopic mode with both the orthosteric and an allosteric site on the M2 muscarinic receptor [http://www.ncbi.nlm.nih.gov/pubmed/18723515?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3255, hybrid 1 and hybrid 2, are multivalent (bitopic) ligands that also achieve selectivity for M2 receptors by binding both to the orthosteric and a nearby allosteric site [http://www.ncbi.nlm.nih.gov/pubmed/18842964?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17478612?dopt=AbstractPlus].

Although numerous ligands for muscarinic acetylcholine receptors have been described, relatively few selective antagonists have been described, so it is common to assess the rank order of affinity of a number of antagonists of limited selectivity (e.g.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=307, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=321, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=328) in order to identify the involvement of particular subtypes. It should be noted that the measured affinities of antagonists (and agonists) in radioligand binding studies are sensitive to ionic strength and can increase over 10‐fold at low ionic strength compared to their values at physiological ionic strengths [http://www.ncbi.nlm.nih.gov/pubmed/497538?dopt=AbstractPlus].

Further reading on Acetylcholine receptors (muscarinic)
Burger WAC et al. (2018) Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors. J Gen Physiol
150: 1360‐1372 [https://www.ncbi.nlm.nih.gov/pubmed/30190312?dopt=AbstractPlus]

Caulfield MP et al. (1998) International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev
50: 279‐290 [https://www.ncbi.nlm.nih.gov/pubmed/9647869?dopt=AbstractPlus]

Eglen RM. (2012) Overview of muscarinic receptor subtypes. Handb Exp Pharmacol 3‐28 [https://www.ncbi.nlm.nih.gov/pubmed/22222692?dopt=AbstractPlus]

Kruse AC et al. (2014) Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov
13: 549‐60 [https://www.ncbi.nlm.nih.gov/pubmed/24903776?dopt=AbstractPlus]

Leach K et al. (2012) Structure‐function studies of muscarinic acetylcholine receptors. Handb Exp Pharmacol 29‐48 [https://www.ncbi.nlm.nih.gov/pubmed/22222693?dopt=AbstractPlus]

Valant C et al. (2012) The best of both worlds? Bitopic orthosteric/allosteric ligands of g proteincoupled receptors. Annu Rev Pharmacol Toxicol
52: 153‐78 [https://www.ncbi.nlm.nih.gov/pubmed/21910627?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=3

Overview
Adenosine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Adenosine Receptors [http://www.ncbi.nlm.nih.gov/pubmed/11734617?dopt=AbstractPlus]) are activated by the endogenous ligand http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 (potentially http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554 also at A3 receptors). Crystal structures for the antagonist‐bound [http://www.ncbi.nlm.nih.gov/pubmed/22220592?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18832607?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22798613?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27312113?dopt=AbstractPlus], agonist‐bound [http://www.ncbi.nlm.nih.gov/pubmed/25762024?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21593763?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21393508?dopt=AbstractPlus] and G protein‐bound A2A adenosine receptors [http://www.ncbi.nlm.nih.gov/pubmed/27462812?dopt=AbstractPlus] have been described. The structures of an antagonist‐bound A1 receptor [http://www.ncbi.nlm.nih.gov/pubmed/28235198?dopt=AbstractPlus] and an adenosine‐bound A1 receptor‐Gi complex [http://www.ncbi.nlm.nih.gov/pubmed/29925945?dopt=AbstractPlus] have been resolved by cryo‐electronmicroscopy. Another structure of an antagonist‐bound A1 receptor obtained with X‐ray crystallography has also been reported [http://www.ncbi.nlm.nih.gov/pubmed/28712806?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=19
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:262, http://www.uniprot.org/uniprot/P30542
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:263, http://www.uniprot.org/uniprot/P29274
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:264, http://www.uniprot.org/uniprot/P29275
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:268, http://www.uniprot.org/uniprot/P0DMS8
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 [http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 [http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 [http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844 [http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377 [http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7798201?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8300561?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377 [http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377 [http://www.ncbi.nlm.nih.gov/pubmed/11093773?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10496952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16219300?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=377 [http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8234299?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=380 [http://www.ncbi.nlm.nih.gov/pubmed/9827575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15740718?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16444290?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7798201?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6560)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6560 [http://www.ncbi.nlm.nih.gov/pubmed/19317449?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5590 [http://www.ncbi.nlm.nih.gov/pubmed/12672250?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=374[http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10235 [http://www.ncbi.nlm.nih.gov/pubmed/30605331?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3290 [http://www.ncbi.nlm.nih.gov/pubmed/11406470?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8420 [http://www.ncbi.nlm.nih.gov/pubmed/22324512?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21393508?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9236 [http://www.ncbi.nlm.nih.gov/pubmed/22220592?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=375 [http://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5596[http://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3289 [http://www.ncbi.nlm.nih.gov/pubmed/17353435?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=422 [http://www.ncbi.nlm.nih.gov/pubmed/11705449?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8126704?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=457 [http://www.ncbi.nlm.nih.gov/pubmed/10731034?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7932588?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8421 [http://www.ncbi.nlm.nih.gov/pubmed/22559880?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404 (pK
d 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/19317449?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384 (pK
i 7.7–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404 (pK
i 8.4–9) [http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404 (pK
i 6.9–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/11093773?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10624567?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10496952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384 (pK
i 6–8.1) [http://www.ncbi.nlm.nih.gov/pubmed/19141710?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10624567?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=384 (pK
i 7–7.9) [http://www.ncbi.nlm.nih.gov/pubmed/8863790?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=404 (pK
i 7–7.4) [http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8234299?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3285 (pK
i 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/14563788?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386 (pKi 7.4–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/15740718?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8032613?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16902942?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3281 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/17558436?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8419 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/8632314?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9530 (pK
i 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/28235198?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3283 (pK
i 8.4–10.3) [http://www.ncbi.nlm.nih.gov/pubmed/20801028?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11087559?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=405 (pK
i 8.8–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6561 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/19569717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3284 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/19569717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=449 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10737749?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3286 (pK
i 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/11906291?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=448 (pK
i 8.2–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8863790?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11226132?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16553647?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3280 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10841801?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=474 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/9703464?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=470 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8917655?dopt=AbstractPlus, 1273]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9445 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/2174510?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9446 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/16722654?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9447 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/19161279?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=379 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=406 (Antagonist) (pK
d 8.4–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9827575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11705449?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8300561?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=455 (Antagonist) (pK
d 8.7–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/11164377?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10927024?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=424 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/2600819?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2213023?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=453 (Antagonist) (pK
d 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=436 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus]	



Comments
Adenosine inhibits many intracellular ATP‐utilising enzymes, including adenylyl cyclase (P‐site). A pseudogene exists for the A2B adenosine receptor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:265) with 79% identity to the A2B adenosine receptor cDNA coding sequence, but which is unable to encode a functional receptor [http://www.ncbi.nlm.nih.gov/pubmed/7558011?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=386 also exhibits antagonism at A2B receptors (pKi ca. 7,[http://www.ncbi.nlm.nih.gov/pubmed/8937736?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus]). Antagonists at A3 receptors exhibit marked species differences, such that only http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=474 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=470 are selective at the rat A3 receptor. In the absence of other adenosine receptors, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=406 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=455 can also be used to label A2B receptors (KD ca. 30 and 60 nM respectively). [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=436 also binds to A1 receptors [http://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus]. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=424 is relatively selective for A2A receptors, but may also bind to other sites in cerebral cortex [http://www.ncbi.nlm.nih.gov/pubmed/8692280?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7566470?dopt=AbstractPlus]. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=425 binds to other non‐receptor elements, which also recognise adenosine [http://www.ncbi.nlm.nih.gov/pubmed/8937447?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3279 has been described as a fluorescent antagonist for labelling A1 adenosine receptors in living cells, although activity at other adenosine receptors was not examined [http://www.ncbi.nlm.nih.gov/pubmed/15070776?dopt=AbstractPlus].

Further reading on Adenosine receptors
Borea PA et al. (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev
67: 74‐102 [https://www.ncbi.nlm.nih.gov/pubmed/25387804?dopt=AbstractPlus]

Cronstein BN et al. (2017) Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol
13: 41‐51 [https://www.ncbi.nlm.nih.gov/pubmed/27829671?dopt=AbstractPlus]

Fredholm BB et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev
63: 1‐34 [https://www.ncbi.nlm.nih.gov/pubmed/21303899?dopt=AbstractPlus]

Guo D et al. (2017) Kinetic Aspects of the Interaction between Ligand and G Protein‐Coupled Receptor: The Case of the Adenosine Receptors. Chem Rev
117: 38‐66 [https://www.ncbi.nlm.nih.gov/pubmed/27088232?dopt=AbstractPlus]

Göblyös A et al. (2011) Allosteric modulation of adenosine receptors. Biochim Biophys Acta
1808: 1309‐18 [https://www.ncbi.nlm.nih.gov/pubmed/20599682?dopt=AbstractPlus]

Lasley RD. (2011) Adenosine receptors and membrane microdomains. Biochim Biophys Acta
1808: 1284‐9 [https://www.ncbi.nlm.nih.gov/pubmed/20888790?dopt=AbstractPlus]

Mundell S et al. (2011) Adenosine receptor desensitization and trafficking. Biochim Biophys Acta
1808: 1319‐28 [https://www.ncbi.nlm.nih.gov/pubmed/20550943?dopt=AbstractPlus]

Vecchio EA et al. (2018) New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. Br J Pharmacol
175: 4036‐4046 [https://www.ncbi.nlm.nih.gov/pubmed/29679502?dopt=AbstractPlus]

Wei CJ etal. (2011)Normaland abnormalfunctions ofadenosine receptors inthecentral nervous system revealed by genetic knockout studies. Biochim Biophys Acta
1808: 1358‐79[https://www.ncbi.nlm.nih.gov/pubmed/21185258?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=17

Overview
Adhesion GPCRs are structurally identified on the basis of a large extracellular region, similar to the Class B GPCR, but which is linked to the 7TM region by a GPCR autoproteolysisinducing (GAIN) domain [http://www.ncbi.nlm.nih.gov/pubmed/22333914?dopt=AbstractPlus] containing a GPCR proteolytic site. The N‐terminus often shares structural homology with adhesive domains (e.g. cadherins, immunolobulin, lectins) facilitating inter‐ and matricellular interactions and leading to the term adhesion GPCR [http://www.ncbi.nlm.nih.gov/pubmed/12761335?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18789697?dopt=AbstractPlus]. Several receptors have been suggested to function as mechanosensors [http://www.ncbi.nlm.nih.gov/pubmed/26841242?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25695270?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25937282?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26499266?dopt=AbstractPlus]. The nomenclature of these receptors was revised in 2015 as recommended by
NC‐IUPHAR
and the
Adhesion GPCR Consortium [http://www.ncbi.nlm.nih.gov/pubmed/25713288?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=197
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=198
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=199
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=174
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=175
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=176
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13838, http://www.uniprot.org/uniprot/Q86SQ6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17849, http://www.uniprot.org/uniprot/Q96PE1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13839, http://www.uniprot.org/uniprot/Q8IWK6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:943, http://www.uniprot.org/uniprot/O14514
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:944, http://www.uniprot.org/uniprot/O60241
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:945, http://www.uniprot.org/uniprot/O60242
	
Endogenous agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3638 [http://www.ncbi.nlm.nih.gov/pubmed/17960134?dopt=AbstractPlus]	–	–	
Comments	–	Required to assemble higher‐order Reck/Gpr124/Frizzled/ Lrp5/6 complexes [http://www.ncbi.nlm.nih.gov/pubmed/30026314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25558062?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30304675?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26051822?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25373781?dopt=AbstractPlus].	–	Reported to mediate phagocytosis through binding of phosphatidylserine [http://www.ncbi.nlm.nih.gov/pubmed/17960134?dopt=AbstractPlus] and lipopolysaccharide [http://www.ncbi.nlm.nih.gov/pubmed/21245295?dopt=AbstractPlus].	–	Reported to bind C1q‐like molecules [http://www.ncbi.nlm.nih.gov/pubmed/21262840?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=178
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=179
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=180
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=202
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=204
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1850, http://www.uniprot.org/uniprot/Q9NYQ6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3231, http://www.uniprot.org/uniprot/Q9HCU4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3230, http://www.uniprot.org/uniprot/Q9NYQ7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19893, http://www.uniprot.org/uniprot/Q6QNK2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18651, http://www.uniprot.org/uniprot/Q7Z7M1
	
Comments	–	Mutated in Joubert syndrome patients [http://www.ncbi.nlm.nih.gov/pubmed/28052552?dopt=AbstractPlus].	High‐confidence risk gene for Tourette syndrome [http://www.ncbi.nlm.nih.gov/pubmed/30257206?dopt=AbstractPlus].	Is a Gs protein‐coupled receptor [http://www.ncbi.nlm.nih.gov/pubmed/22025619?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25533341?dopt=AbstractPlus] and highly expressed in glioblastoma [http://www.ncbi.nlm.nih.gov/pubmed/27775701?dopt=AbstractPlus].	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=182
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=183
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=184
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=185
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=177
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3336, http://www.uniprot.org/uniprot/Q14246
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3337, http://www.uniprot.org/uniprot/Q9UHX3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23647, http://www.uniprot.org/uniprot/Q9BY15
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19240, http://www.uniprot.org/uniprot/Q86SQ3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1711, http://www.uniprot.org/uniprot/P48960
	
Comments	–	A mutation destabilizing the GAIN domain sensitizes mast cells to IgE‐independent vibration‐induced degranulation [http://www.ncbi.nlm.nih.gov/pubmed/26841242?dopt=AbstractPlus]. Reported to bind chondroitin sulfate B [http://www.ncbi.nlm.nih.gov/pubmed/12829604?dopt=AbstractPlus].	–	–	Reported to bind CD55 [http://www.ncbi.nlm.nih.gov/pubmed/9064337?dopt=AbstractPlus], chondroitin sulfate B [http://www.ncbi.nlm.nih.gov/pubmed/12829604?dopt=AbstractPlus], α5β1 and αγβ3 integrins [http://www.ncbi.nlm.nih.gov/pubmed/15576472?dopt=AbstractPlus], and CD90 [http://www.ncbi.nlm.nih.gov/pubmed/22210915?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=190
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=191
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=193
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=195
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=196
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18990, http://www.uniprot.org/uniprot/Q5T601
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18991, http://www.uniprot.org/uniprot/Q8IZF7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18989, http://www.uniprot.org/uniprot/Q8IZF5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19011, http://www.uniprot.org/uniprot/Q8IZF3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19030, http://www.uniprot.org/uniprot/Q8IZF2
	
Comments	Synaptamide is an agonist at ADGRF1 supporting neurogenesis [http://www.ncbi.nlm.nih.gov/pubmed/27759003?dopt=AbstractPlus] and couples to Gs and Gq pathways [http://www.ncbi.nlm.nih.gov/pubmed/28154189?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25918380?dopt=AbstractPlus].	ADGRF2 is highly expressed in squamous epithelia and gene deficiency did not result in detectable defects [http://www.ncbi.nlm.nih.gov/pubmed/22837050?dopt=AbstractPlus].	ADGRF3 is highly expressed in gastrointestinal neuroendocrine tumors [http://www.ncbi.nlm.nih.gov/pubmed/23158174?dopt=AbstractPlus].	ADGRF4 couples to Gq/11 proteins [http://www.ncbi.nlm.nih.gov/pubmed/28154189?dopt=AbstractPlus], is highly expressed in squamous epithelia and gene deficiency did not result in detectable defects [http://www.ncbi.nlm.nih.gov/pubmed/22837050?dopt=AbstractPlus].	ADGRF5 controls alveolar surfactant secretion via Gq/11 pathway [http://www.ncbi.nlm.nih.gov/pubmed/28570277?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=186
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=187
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=188
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=192
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=194
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=200
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=201
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4512, http://www.uniprot.org/uniprot/Q9Y653
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4516, http://www.uniprot.org/uniprot/Q8IZP9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13728, http://www.uniprot.org/uniprot/Q86Y34
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18992, http://www.uniprot.org/uniprot/Q8IZF6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19010, http://www.uniprot.org/uniprot/Q8IZF4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13841, http://www.uniprot.org/uniprot/Q86SQ4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19241, http://www.uniprot.org/uniprot/Q96K78
	
Comments	Reported to bind tissue transglutaminase 2 [http://www.ncbi.nlm.nih.gov/pubmed/16757564?dopt=AbstractPlus] and collagen, which activates the G12/13 pathway [http://www.ncbi.nlm.nih.gov/pubmed/21768377?dopt=AbstractPlus].	ADGRG2 is coupled to Gq and Gs pathways [http://www.ncbi.nlm.nih.gov/pubmed/26188515?dopt=AbstractPlus] and gene deficiency causes congenital obstructive azoospermia [http://www.ncbi.nlm.nih.gov/pubmed/27476656?dopt=AbstractPlus].	ADGRG3 is expressed in immune cells [http://www.ncbi.nlm.nih.gov/pubmed/27089991?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24113187?dopt=AbstractPlus] and couples to Go proteins [http://www.ncbi.nlm.nih.gov/pubmed/22575658?dopt=AbstractPlus].	ADGRG4 is highly expressed in enterochromaffin cells and gastrointestinal neuroendocrine tumors [http://www.ncbi.nlm.nih.gov/pubmed/18953328?dopt=AbstractPlus].	ADGRG5 is a constitutively active Gs protein‐coupled receptor [http://www.ncbi.nlm.nih.gov/pubmed/22575658?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26499266?dopt=AbstractPlus], highly expressed in eosinophils and NK cells [http://www.ncbi.nlm.nih.gov/pubmed/21724806?dopt=AbstractPlus].	ADGRG6 is a key regulator of Schwann cell‐mediated myelination [http://www.ncbi.nlm.nih.gov/pubmed/19745155?dopt=AbstractPlus], and couples to Gs and Gi/o pathways [http://www.ncbi.nlm.nih.gov/pubmed/24227709?dopt=AbstractPlus].	ADGRG7 is expressed in interstine and involved in interstine contractility regulation [http://www.ncbi.nlm.nih.gov/pubmed/24574718?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=206
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=207
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=208
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=181
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=189
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20973, http://www.uniprot.org/uniprot/O94910
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18582, http://www.uniprot.org/uniprot/O95490
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20974, http://www.uniprot.org/uniprot/Q9HAR2
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20822, http://www.uniprot.org/uniprot/Q9HBW9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17416, http://www.uniprot.org/uniprot/Q8WXG9
	
Comments	Couples to Gs and Gq pathways [http://www.ncbi.nlm.nih.gov/pubmed/9261169?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26505631?dopt=AbstractPlus].	–	A LPHN3 gene variant in humans is associated with attention‐deficit‐hyperactivity disorder [http://www.ncbi.nlm.nih.gov/pubmed/20157310?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28472652?dopt=AbstractPlus].	–	Loss‐of‐function mutations are associated with Usher syndrome, a sensory deficit disorder [http://www.ncbi.nlm.nih.gov/pubmed/18463160?dopt=AbstractPlus].	



Further reading on Adhesion Class GPCRs
Hamann J et al. (2015) International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein‐coupled receptors. Pharmacol Rev
67: 338‐67 [https://www.ncbi.nlm.nih.gov/pubmed/25713288?dopt=AbstractPlus]

Langenhan T et al. (2013) Sticky signaling–adhesion class G protein‐coupled receptors take the stage. Sci Signal
6: re3 [https://www.ncbi.nlm.nih.gov/pubmed/23695165?dopt=AbstractPlus]

Liebscher I et al. (2016) Tethered Agonism: A Common Activation Mechanism of Adhesion GPCRs. Handb Exp Pharmacol
234: 111‐125 [https://www.ncbi.nlm.nih.gov/pubmed/27832486?dopt=AbstractPlus]

Monk KR et al. (2015) Adhesion G Protein‐Coupled Receptors: From In Vitro Pharmacology to In Vivo Mechanisms. Mol Pharmacol
88: 617‐23 [https://www.ncbi.nlm.nih.gov/pubmed/25956432?dopt=AbstractPlus]

Purcell RH et al. (2018) Adhesion G Protein‐Coupled Receptors as Drug Targets. Annu Rev Pharmacol Toxicol
58: 429‐449 [https://www.ncbi.nlm.nih.gov/pubmed/28968187?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=4

Overview

The nomenclature of the Adrenoceptors has been agreed by the
NC‐IUPHAR Subcommittee on Adrenoceptors [http://www.ncbi.nlm.nih.gov/pubmed/7938162?dopt=AbstractPlus], see also [http://www.ncbi.nlm.nih.gov/pubmed/7568329?dopt=AbstractPlus].


Adrenoceptors, α1

α1‐Adrenoceptors are activated by the endogenous agonists (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 and (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=483 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=515 are agonists and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=515 antagonists considered selective for α1‐ relative to α2‐adrenoceptors. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5385 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=482 (BE2254) are relatively selective radioligands. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=487 also has high affinity for L‐type Ca2+ channels. Fluorescent derivatives of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 (Bodipy PLprazosin‐ QAPB) are used to examine cellular localisation of α1‐adrenoceptors. Selective α1‐adrenoceptor agonists are used as nasal decongestants; antagonists to treat hypertension (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170) and benign prostatic hyperplasia (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488). The α1‐ and β2‐adrenoceptor antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551 is used to treat congestive heart failure, although the contribution of α1‐adrenoceptor blockade to the therapeutic effect is unclear. Several anti‐depressants and anti‐psychotic drugs are α1‐adrenoceptor antagonists contributing to side effects such as orthostatic hypotension and extrapyramidal effects.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=22
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=23
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=24
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:277, http://www.uniprot.org/uniprot/P35348
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:278, http://www.uniprot.org/uniprot/P35368
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:280, http://www.uniprot.org/uniprot/P25100
	
Endogenous agonists	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 [http://www.ncbi.nlm.nih.gov/pubmed/8564227?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus]	–	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 [http://www.ncbi.nlm.nih.gov/pubmed/8564227?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124 [http://www.ncbi.nlm.nih.gov/pubmed/8564227?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8719417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485 [http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=483[http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=485 [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7969082?dopt=AbstractPlus]	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=480 [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7616455?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3469 [http://www.ncbi.nlm.nih.gov/pubmed/14678390?dopt=AbstractPlus]	–	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 (Inverse agonist) (pK
i 9–9.9) [http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10334511?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170 (pK
i 9.3) [0795], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7302 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 (Inverse agonist) (pK
i 9.6–9.9) [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488 (Inverse agonist) (pK
i 9.5–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170 (pK
i 9.1) [0795], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/7658428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7302 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 (Inverse agonist) (pK
i 9.5–10.2) [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488 (pK
i 9.8–10.2) [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7170 (pKi 9.1) [0795], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7302 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7109 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7155 (pK
i 8.4) [0079], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=502 (Inverse agonist) (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7381 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7207 (pK
i 6.6) [0079]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=488 (pK
i 10–10.7) [http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10334511?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=493 (pK
i 10.4) [http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=487 (pK
i 9.1–10) [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7381 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=498 (pK
i 8.8–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9190863?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7752182?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6663‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6663 (pK
i 9.2–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/23935897?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20015090?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=495 (pK
i 9.2–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8632751?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8459 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/9190864?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=506 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/9548811?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8461 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/8764344?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9 (pK
i 8.7–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/11354357?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11459121?dopt=AbstractPlus]	



Comments
The α1C‐adrenoceptor corresponds to the pharmacologically defined α1A‐adrenoceptor [http://www.ncbi.nlm.nih.gov/pubmed/7568329?dopt=AbstractPlus]. Some tissues possess α1A‐adrenoceptors (α1L‐adrenoceptors [http://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17162094?dopt=AbstractPlus]) that display relatively low affinity in functional and binding assays for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 indicative of different receptor states or locations. α1A‐adrenoceptor C‐terminal splice variants form homo‐ and heterodimers, but fail to generate a functional α1L‐adrenoceptor [http://www.ncbi.nlm.nih.gov/pubmed/15266013?dopt=AbstractPlus]. α1D‐Adrenoceptors form heterodimers with α1B‐ or β2‐adrenoceptors that show increased cell‐surface expression [http://www.ncbi.nlm.nih.gov/pubmed/15615865?dopt=AbstractPlus]. Recombinant α1D‐adrenoceptors have been shown in some heterologous systems to be mainly located intracellularly but cell‐surface localization is encouraged by truncation of the Nterminus, or by co‐expression of α1B‐ or β2‐adrenoceptors [http://www.ncbi.nlm.nih.gov/pubmed/14718583?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14718583?dopt=AbstractPlus]. In blood vessels all three α1‐adrenoceptor subtypes are located on the surface and intracellularly [http://www.ncbi.nlm.nih.gov/pubmed/19572943?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19888965?dopt=AbstractPlus]. Signalling is predominantly via Gq/11 butα1‐adrenoceptors also couple toGi/o, Gs and G12/13. Several α1A‐adrenoceptor agonists display ligand directed signalling bias relative to noradrenaline [http://www.ncbi.nlm.nih.gov/pubmed/20978120?dopt=AbstractPlus]. There are also differences between subtypes in coupling efficiency to different pathways. In vascular smooth muscle, the potency of agonists is related to the predominant subtype, α1D‐ conveying greater agonist sensitivity than α1A‐adrenoceptors [http://www.ncbi.nlm.nih.gov/pubmed/23373597?dopt=AbstractPlus].


Adrenoceptors, α2

α2‐Adrenoceptors are activated by (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 and with lower potency by (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5442 are agonists and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=136 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102 antagonists selective for α2‐ relative to α1‐adrenoceptors. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=223, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5386 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=528 are relatively selective radioligands. There is species variation in the pharmacology of the α2A‐adrenoceptor. Multiple mutations of α2‐adrenoceptors have been described, some associated with alterations in function. Presynaptic α2‐adrenoceptors regulate many functions in the nervous system. The α2‐adrenoceptor agonists http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 affect central baroreflex control (hypotension and bradycardia), induce hypnotic effects and analgesia, and modulate seizure activity and platelet aggregation. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516 is an anti‐hypertensive and counteracts opioid withdrawal. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521 (also http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=523) is used as a sedative and analgesic in human and veterinary medicine with sympatholytic and anxiolytic properties. The α2‐adrenoceptor antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102 has been used to treat erectile dysfunction and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241 as an anti‐depressant. The α2B subtype appears to be involved in neurotransmission in the spinal cord and α2C in regulating catecholamine release from adrenal chromaffin cells.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=25
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=26
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=27
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:281, http://www.uniprot.org/uniprot/P08913
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:282, http://www.uniprot.org/uniprot/P18089
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:283, http://www.uniprot.org/uniprot/P18825
	
Endogenous agonists	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus]	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479[http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus]	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520[http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7117 [http://www.ncbi.nlm.nih.gov/pubmed/8784451?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443 [0079], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9283709?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521 [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=516 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443 [0079], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522[http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=521 [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7117 [http://www.ncbi.nlm.nih.gov/pubmed/8784451?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=522 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5443 [0079]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus]	–	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102 (pK
i 8.4–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102 (pK
i 7.9–8.9) [http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7268 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/1834671?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7310 (pK
i 5.5) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=102 (pK
i 8.5–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=499 (pKi 8.4–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=53 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7241 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7310 (pK
i 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=525 (pK
i 8.2–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2573535?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3470 (pK
i 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/1970500?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3930 (pK
B 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/17220913?dopt=AbstractPlus]	
Labelled ligands	–	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=527 (Antagonist) (pK
d 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus]	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=524 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 show selectivity for α2B‐ and α2C‐adrenoceptors over α2A‐adrenoceptors.http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=124 is a reduced efficacy imidazoline agonist but also binds to non‐GPCR binding sites for imidazolines, classified as I1, I2 and I3 sites [http://www.ncbi.nlm.nih.gov/pubmed/15224384?dopt=AbstractPlus]; catecholamines have a low affinity, while rilmenidine and moxonidine are selective ligands evoking hypotensive effects in vivo. I1‐imidazoline receptors cause central inhibition of sympathetic tone, I2‐imidazoline receptors are an allosteric binding site on monoamine oxidase B, and I3‐imidazoline receptors regulate insulin secretion from pancreatic β‐cells. α2A‐adrenoceptor stimulation reduces insulin secretion from β‐islets [http://www.ncbi.nlm.nih.gov/pubmed/22645144?dopt=AbstractPlus], with a polymorphism in the 5’‐UTR of the ADRA2A gene being associated with increased receptor expression in β‐islets and heightened susceptibility to diabetes [http://www.ncbi.nlm.nih.gov/pubmed/19965390?dopt=AbstractPlus]. α2A‐ and α2C‐adrenoceptors form homodimers [http://www.ncbi.nlm.nih.gov/pubmed/16605244?dopt=AbstractPlus]. Heterodimers between α2A‐ and either the α2C‐adrenoceptor or μ opioid peptide receptor exhibit altered signalling and trafficking properties compared to the individual receptors [http://www.ncbi.nlm.nih.gov/pubmed/16605244?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19126537?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18193048?dopt=AbstractPlus]. Signalling by α2‐adrenoceptors is primarily via Gi/o, although the α2A‐adrenoceptor also couples to Gs [http://www.ncbi.nlm.nih.gov/pubmed/7559592?dopt=AbstractPlus]. Imidazoline compounds display bias relative to each other at the α2A‐adrenoceptor [http://www.ncbi.nlm.nih.gov/pubmed/12649300?dopt=AbstractPlus]. The noradrenaline reuptake inhibitor desipramine acts directly on the α2A‐adrenoceptor to promote internalisation via recruitment of arrestin [http://www.ncbi.nlm.nih.gov/pubmed/21859713?dopt=AbstractPlus].

Adrenoceptors, β
β‐Adrenoceptors are activated by the endogenous agonists (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 and (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505. Isoprenaline is selective for β‐adrenoceptors relative to α1‐ and α2‐adrenoceptors, while http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564 (pKi 8.2‐9.2) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=132 (pKi 10.011.0) are relatively β1 and β2 adrenoceptor‐selective antagonists. (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=538 and (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5571 show selectivity for β1‐ relative to β2‐adrenoceptors. Pharmacological differences exist between human and mouse β3‐adrenoceptors, and the ’rodent selective’ agonists http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=567 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462 have low efficacy at the human β3‐adrenoceptor whereas http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931 activate human β3‐adrenoceptors [88]. β3‐Adrenoceptors are resistant to blockade by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564, but can be blocked by high concentrations of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547 has reasonably high affinity at β3‐adrenoceptors, but does not discriminate well between the three β‐ subtypes whereas http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931 is more selective. [125I]‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=132, [125I]‐hydroxy benzylpindolol and [3H]‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=563 are high affinity radioligands that label β1‐ and β2‐ adrenoceptors and β3‐adrenoceptors can be labelled with higher concentrations (nM) of [125I]‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=132 together with β1‐ and β2‐adrenoceptor antagonists. [3H]‐L748337 is a β3‐selective radioligand [http://www.ncbi.nlm.nih.gov/pubmed/24183974?dopt=AbstractPlus]. Fluorescent ligands such as BODIPY‐TMR‐CGP12177 can be used to track βadrenoceptors at the cellular level [8]. Somewhat selective β1adrenoceptor agonists (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=534, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=535) are used short term to treat cardiogenic shock but, chronically, reduce survival. β1‐Adrenoceptor‐preferring antagonists areused totreathypertension (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=549, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7129, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=553 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7246), cardiac arrhythmias (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548, bisoprolol, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7178) and cardiac failure (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=553, nebivolol). Cardiac failure is also treated with carvedilol that blocks β1‐ and β2‐adrenoceptors, as well as α1‐adrenoceptors. Short (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=558, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=560) and long (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3465, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=559) acting β2‐adrenoceptor‐selective agonists are powerful bronchodilators used to treat respiratory disorders. Many first generation β‐adrenoceptor antagonists (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564) block both β1‐ and β2‐adrenoceptors and there are no β2adrenoceptor‐selective antagonists used therapeutically. The β3‐adrenoceptor agonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7445 is used to control overactive bladder syndrome.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=28‐http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=28
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29‐http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30‐http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:285, http://www.uniprot.org/uniprot/P08588
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:286, http://www.uniprot.org/uniprot/P07550
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:288, http://www.uniprot.org/uniprot/P13945
	
Potency order of endogenous ligands	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 > (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479
	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 > (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505
	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 = (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479
	
Endogenous agonists	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 [http://www.ncbi.nlm.nih.gov/pubmed/2849109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=484]	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479 [http://www.ncbi.nlm.nih.gov/pubmed/2849109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9295336?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus]	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505 [http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9131260?dopt=AbstractPlus], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=91 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17804228?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=536 [http://www.ncbi.nlm.nih.gov/pubmed/2849109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=535 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=91 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17804228?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7479 [http://www.ncbi.nlm.nih.gov/pubmed/15324892?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=536 [http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=556 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9295336?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=569 [http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus]	
Selective agonists	(‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5571 [http://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=538 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=534 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7902433?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3465 [http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=559], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3466], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353 [http://www.ncbi.nlm.nih.gov/pubmed/20462258?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3464], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7455 [http://www.ncbi.nlm.nih.gov/pubmed/22932315?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=557 [http://www.ncbi.nlm.nih.gov/pubmed/24454993?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=558 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=560 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7250 [http://www.ncbi.nlm.nih.gov/pubmed/19168263?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3931 [http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3467 [http://www.ncbi.nlm.nih.gov/pubmed/9873496?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7445 [http://www.ncbi.nlm.nih.gov/pubmed/17293563?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3468 [http://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=567[http://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7912272?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462 [http://www.ncbi.nlm.nih.gov/pubmed/11249148?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550 (pK
i 7.3–9) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570 (pK
i 8.4) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7207 (pK
i 8.2) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=553 (pK
i 7–7.6) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7178 (pK
i 6.9) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=554 (pK
i 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=555 (pK
i 6.1–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561 (pK
i 6.7) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7297 (pK
i 6.1) [79]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551 (pK
i 9.4–9.9) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=565 (pK
i 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564 (pK
i 9.1–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12920204?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570 (pK
i 9.3) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550 (pK
i 8.3–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=563 (pKi 9) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=554 (pK
i 7–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7207 (pK
i 8) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2561 (pK
i 7.4) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7297 (pK
i 6.5) [79]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=547 (pK
i 6.9–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8730727?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550 (pK
i 6.8–7.3) [http://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=564 (pKi 6.3–7.2) [http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=570 (pK
i 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=541 (pK
i 8.5–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8035 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/11572462?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=549 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7246 (pIC50 8.1–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/2462161?dopt=AbstractPlus] – Rabbit, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=548 (pK
i 6.7–7.6) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15060759?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15060759?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7107 (pK
i 6.4) [79]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=543 (Inverse agonist) (pK
i 9.2–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12920204?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3932 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3463 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562 (Antagonist) (pK
d 10.4–11.3) [http://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562 (Antagonist) (pK
d 11.1) [http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9131260?dopt=AbstractPlus]	
Comments	The agonists indicated have less than two orders of magnitude selectivity [http://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus].	–	Agonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3468 has a pEC50 of 6.9 for the splice variant of the mouse β3 receptor, β3b [http://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus].	



Comments
[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562 can be used to define β1‐ or β2adrenoceptors when conducted in the presence of a β1‐ or β2adrenoceptor‐selective antagonist. A fluorescent analogue of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=532 can be used to study β2‐adrenoceptors in living cells [http://www.ncbi.nlm.nih.gov/pubmed/12770928?dopt=AbstractPlus]. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=562 at higher (nM) concentrations can be used to label β3‐adrenoceptors in systems with few if any other β‐adrenoceptor subtypes. The β3‐adrenoceptor has an intron in the coding region, but splice variants have only been described for the mouse [http://www.ncbi.nlm.nih.gov/pubmed/10455305?dopt=AbstractPlus], where the isoforms display different signalling characteristics [http://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus]. There are 3 β‐adrenoceptors in turkey (termed the tβ, tβ3c and tβ4c) that have a pharmacology that differs from the human β‐adrenoceptors [http://www.ncbi.nlm.nih.gov/pubmed/21152092?dopt=AbstractPlus]. Numerous polymorphisms have been described for the β‐adrenoceptors; some are associated with signalling and trafficking, altered susceptibility to disease and/or altered responses to pharmacotherapy [http://www.ncbi.nlm.nih.gov/pubmed/15090197?dopt=AbstractPlus]. All β‐adrenoceptors couple to Gs (activating adenylyl cyclase and elevating cAMP levels), but also activate Gi and β‐arrestin‐mediated signalling. Many β1‐ and β2‐adrenoceptor antagonists are agonists at β3adrenoceptors (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3462 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=569). Many ‘antagonists’ of cAMP accumulation, for example http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551 and bucindolol, weakly activate MAP kinase pathways [http://www.ncbi.nlm.nih.gov/pubmed/14645666?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20132209?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16901982?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18403719?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17717109?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18684840?dopt=AbstractPlus] and thus display ’protean agonism’. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=550 acts as a neutral antagonist in most systems so far examined. Agonists also display biased signalling at the β2‐adrenoceptor via Gs or arrestins [http://www.ncbi.nlm.nih.gov/pubmed/18086673?dopt=AbstractPlus]. X‐ray crystal structures have been described of the agonist bound [http://www.ncbi.nlm.nih.gov/pubmed/21228877?dopt=AbstractPlus] and antagonist bound forms of the β1[http://www.ncbi.nlm.nih.gov/pubmed/18594507?dopt=AbstractPlus], agonist‐bound [http://www.ncbi.nlm.nih.gov/pubmed/17962520?dopt=AbstractPlus] and antagonist‐bound forms of the β2‐adrenoceptor [http://www.ncbi.nlm.nih.gov/pubmed/21228869?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21228876?dopt=AbstractPlus], as well as a fully active agonistbound, Gs protein‐coupled β2‐adrenoceptor [http://www.ncbi.nlm.nih.gov/pubmed/21772288?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=551 and bucindolol bind to a site on the β1‐adrenoceptor involving contacts in TM2, 3, and 7 and extracellular loop 2 that may facilitate coupling to arrestins [http://www.ncbi.nlm.nih.gov/pubmed/18594507?dopt=AbstractPlus]. Compounds displaying arrestinbiased signalling at the β2‐adrenoceptor have a greater effect on the conformation of TM7, whereas full agonists for Gs coupling promote movement of TM5 and TM6 [http://www.ncbi.nlm.nih.gov/pubmed/22267580?dopt=AbstractPlus]. Recent studies using NMR spectroscopy demonstrate significant conformational flexibility in the β2‐adrenoceptor that is stabilized by both agonist and G proteins highlighting the dynamic nature of interactions with both ligand and downstreamsignalling partners [http://www.ncbi.nlm.nih.gov/pubmed/23721409?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25981665?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23374348?dopt=AbstractPlus]. Such flexibility likely has consequences for our understanding of biased agonism, and for the future therapeutic exploitation of this phenomenon.

Further reading on Adrenoceptors
Baker JG et al. (2011) Evolution of β‐blockers: from anti‐anginal drugs to ligand‐directed signalling. Trends Pharmacol. Sci.
32: 227‐34 [https://www.ncbi.nlm.nih.gov/pubmed/21429598?dopt=AbstractPlus]

Bylund DB et al. (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev.
46: 121‐136 [https://www.ncbi.nlm.nih.gov/pubmed/7938162?dopt=AbstractPlus]

Evans BA et al. (2010) Ligand‐directed signalling at beta‐adrenoceptors. Br. J. Pharmacol.
159: 1022‐38 [https://www.ncbi.nlm.nih.gov/pubmed/20132209?dopt=AbstractPlus]

Jensen BC et al. (2011) Alpha‐1‐adrenergic receptors: targets for agonist drugs to treat heart failure. J. Mol. Cell. Cardiol.
51: 518‐28 [https://www.ncbi.nlm.nih.gov/pubmed/21118696?dopt=AbstractPlus]

Kobilka BK. (2011) Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol. Sci.
32: 213‐8 [https://www.ncbi.nlm.nih.gov/pubmed/21414670?dopt=AbstractPlus]

Langer SZ. (2015) a2‐Adrenoceptors in the treatment of major neuropsychiatric disorders. Trends Pharmacol. Sci.
36: 196‐202 [https://www.ncbi.nlm.nih.gov/pubmed/25771972?dopt=AbstractPlus]

Michel MC et al. (2015) Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. Am. J. Physiol., Cell Physiol.
308: C505‐20 [https://www.ncbi.nlm.nih.gov/pubmed/25631871?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=6

Overview
The actions of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Angiotensin receptors [http://www.ncbi.nlm.nih.gov/pubmed/10977869?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26315714?dopt=AbstractPlus]), which have around 30% sequence similarity. The decapeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=583, http://www.uniprot.org/uniprot/P01019), the octapeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504, http://www.uniprot.org/uniprot/P01019) and the heptapeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=585, http://www.uniprot.org/uniprot/P01019) are endogenous ligands. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=587, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=592, etc. are clinically used AT1 receptor blockers.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=35
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:336, http://www.uniprot.org/uniprot/P30556
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:338, http://www.uniprot.org/uniprot/P50052
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) [466, http://www.ncbi.nlm.nih.gov/pubmed/10193788?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=585, http://www.uniprot.org/uniprot/P01019) [466], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5368, http://www.uniprot.org/uniprot/P01019) (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12006574?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=585 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) [http://www.ncbi.nlm.nih.gov/pubmed/8242249?dopt=AbstractPlus, 466, http://www.ncbi.nlm.nih.gov/pubmed/2775266?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504, http://www.uniprot.org/uniprot/P01019) [466, http://www.ncbi.nlm.nih.gov/pubmed/7850406?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2775266?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=582) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) [http://www.ncbi.nlm.nih.gov/pubmed/21542804?dopt=AbstractPlus]	
Agonists	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6903,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6903]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6903 [http://www.ncbi.nlm.nih.gov/pubmed/11901215?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10066768?dopt=AbstractPlus] – Rat	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3936 [http://www.ncbi.nlm.nih.gov/pubmed/7829475?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6895 [http://www.ncbi.nlm.nih.gov/pubmed/9383393?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3944 [http://www.ncbi.nlm.nih.gov/pubmed/21542804?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=595 [466, http://www.ncbi.nlm.nih.gov/pubmed/2194459?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6918 [http://www.ncbi.nlm.nih.gov/pubmed/22802221?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6899 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/7853190?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6913 (pIC50 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/22410249?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6917 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/22889560?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6910 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/11303957?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6902 (pK
d 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/20801892?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=598 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/2590220?dopt=AbstractPlus] – Rat	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=587 (pIC50 9.5–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/10193788?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=588 (pIC50 8.4–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/1309870?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590 (pIC50 7.4–8.7) [466, http://www.ncbi.nlm.nih.gov/pubmed/8372104?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=592 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9878991?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=591 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/11451212?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=596 (pIC50 8.5–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/2314387?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2590220?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8469774?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8374 (pIC50 8.5–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/24507378?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24507377?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23489258?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=597 (pK
d 8.7–9.2) [466, http://www.ncbi.nlm.nih.gov/pubmed/2402226?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1709220?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6907 (Antagonist) (pK
d 10.3) [http://www.ncbi.nlm.nih.gov/pubmed/10079018?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6897]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6897 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7759541?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6906,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6906]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6906 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7759541?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3940 (Antagonist) (pK
d 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/8463997?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3941 (Antagonist) (pK
d 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/8282008?dopt=AbstractPlus] – Rat	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=594 (Agonist) [466, http://www.ncbi.nlm.nih.gov/pubmed/2775266?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1764088?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6906,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6906]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6906 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10024318?dopt=AbstractPlus] – Rat	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=592 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=587 are also reported to be agonists of PPARγ [http://www.ncbi.nlm.nih.gov/pubmed/19021699?dopt=AbstractPlus].	–	



Comments
AT1 receptors are predominantly coupled to Gq/11, however they are also linked to arrestin recruitment and stimulate G protein‐independent arrestin signalling [http://www.ncbi.nlm.nih.gov/pubmed/20427692?dopt=AbstractPlus]. Most species express a single AGTR1 gene, but two related agtr1a and agtr1b receptor genes are expressed in rodents. The AT2 receptor counteracts several of the growth responses initiated by the AT1 receptors. The AT2 receptor is much less abundant than the AT1 receptor in adult tissues and is upregulated in pathological conditions. AT1 receptor antagonists bearing substituted 4‐phenylquinoline moieties have been synthesized, which bind to AT1 receptors with nanomolar affinity and are slightly more potent than http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=590 in functional studies [http://www.ncbi.nlm.nih.gov/pubmed/15115399?dopt=AbstractPlus]. The antagonist activity of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3944 at the AT2 receptor has also been reported [http://www.ncbi.nlm.nih.gov/pubmed/3071214?dopt=AbstractPlus]. The AT1 and bradykinin B2 receptors have been proposed to form a heterodimeric complex [http://www.ncbi.nlm.nih.gov/pubmed/10993080?dopt=AbstractPlus]. β‐Arrestin1 prevents AT1‐B2 receptor heteromerization[http://www.ncbi.nlm.nih.gov/pubmed/30503206?dopt=AbstractPlus]. There is also evidence for an AT4 receptor that specifically binds http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5368 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333, http://www.uniprot.org/uniprot/P01019) and is located in the brain and kidney. An additional putative endogenous ligand for the AT4 receptor has been described (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5353 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4827, http://www.uniprot.org/uniprot/P68871), a globin decapeptide) [http://www.ncbi.nlm.nih.gov/pubmed/9166749?dopt=AbstractPlus].

Further reading on Angiotensin receptors
Asada H et al. (2018) Crystal structure of the human angiotensin II type 2 receptor bound to an angiotensin II analog. Nat. Struct. Mol. Biol.
25: 570‐576 [https://www.ncbi.nlm.nih.gov/pubmed/29967536?dopt=AbstractPlus]

Karnik SS et al. (2015) International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol. Rev.
67: 754‐819 [https://www.ncbi.nlm.nih.gov/pubmed/26315714?dopt=AbstractPlus]

Singh KD et al. (2019) Mechanism of Hormone Peptide Activation of a GPCR: Angiotensin II Activated State of AT_1R Initiated by van der Waals Attraction. J Chem Inf Model
59: 373‐385 [https://www.ncbi.nlm.nih.gov/pubmed/30608150?dopt=AbstractPlus]

Wingler LM et al. (2019) Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations. Cell
176: 468‐478.e11 [https://www.ncbi.nlm.nih.gov/pubmed/30639099?dopt=AbstractPlus]

Wingler LM et al. (2019) Distinctive Activation Mechanism for Angiotensin Receptor Revealed by a Synthetic Nanobody. Cell
176: 479‐490.e12 [https://www.ncbi.nlm.nih.gov/pubmed/30639100?dopt=AbstractPlus]

Zhang H et al. (2015) Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. Cell
161: 833‐44 [https://www.ncbi.nlm.nih.gov/pubmed/25913193?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=7

Overview
The apelin receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the apelin receptor [http://www.ncbi.nlm.nih.gov/pubmed/20605969?dopt=AbstractPlus]) responds to apelin, a 36 amino‐acid peptide derived initially from bovine stomach. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=606 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=605, http://www.uniprot.org/uniprot/Q9ULZ1) and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) are the predominant endogenous ligands which are cleaved from a 77 amino‐acid precursor peptide (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665
http://www.uniprot.org/uniprot/Q9ULZ1) by a so far unidentified enzymatic pathway [http://www.ncbi.nlm.nih.gov/pubmed/9792798?dopt=AbstractPlus]. A second family of peptides discovered independently and named Elabela [http://www.ncbi.nlm.nih.gov/pubmed/24316148?dopt=AbstractPlus] or Toddler, that has little sequence similarity to apelin, is present, and functional at the apelin receptor in the adult cardiovascular system [http://www.ncbi.nlm.nih.gov/pubmed/24407481?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28137936?dopt=AbstractPlus]. Structure‐activity relationship Elabela analogues have been described [http://www.ncbi.nlm.nih.gov/pubmed/26986036?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=36
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:339, http://www.uniprot.org/uniprot/P35414
	
Potency order of endogenous ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=605 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=606 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) [http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9792798?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=605 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) [http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10777510?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7930 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:48925, http://www.uniprot.org/uniprot/P0DMC3) [http://www.ncbi.nlm.nih.gov/pubmed/25995451?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3556 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) [http://www.ncbi.nlm.nih.gov/pubmed/15341513?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15341513?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=599 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) [http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8525 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:48925, http://www.uniprot.org/uniprot/P0DMC3) [2378], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8524 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:48925, http://www.uniprot.org/uniprot/P0DMC3) [2378], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=606 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16665, http://www.uniprot.org/uniprot/Q9ULZ1) [http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8526 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:48925, http://www.uniprot.org/uniprot/Q9ULZ1) [2378]
	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9448 (Biased agonist) [http://www.ncbi.nlm.nih.gov/pubmed/27475715?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8523 (Biased agonist) [http://www.ncbi.nlm.nih.gov/pubmed/25712721?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6186 (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/21560248?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=603,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=603]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=603) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3761,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3761]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3761 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10777510?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=601)http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=601 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11250876?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=602 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=604)[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=604 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus]	



Comments
Potency order determined for heterologously expressed human apelin receptor (pD
2 values range from 9.5 to 8.6). The apelin receptor may also act as a co‐receptor with CD4 for isolates of human immunodeficiency virus, with apelin blocking this function [http://www.ncbi.nlm.nih.gov/pubmed/11090199?dopt=AbstractPlus]. A modified apelin‐13 peptide, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5354) was reported to block the hypotensive response to apelin in rat in vivo [http://www.ncbi.nlm.nih.gov/pubmed/15486224?dopt=AbstractPlus], however, this peptide exhibits agonist activity in HEK293 cells stably expressing the recombinant apelin receptor [http://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus]. The apelin receptor antagonist, MM54, was reported to suppress tumour growth and increase survival in an intracranial xenograft mouse model of glioblastoma [http://www.ncbi.nlm.nih.gov/pubmed/29053791?dopt=AbstractPlus].

Further reading on Apelin receptor
Cheng B et al. (2012) Neuroprotection of apelin and its signaling pathway. Peptides
37: 171‐3 [https://www.ncbi.nlm.nih.gov/pubmed/22820556?dopt=AbstractPlus]

Langelaan DN et al. (2009) Structural insight into G‐protein coupled receptor binding by apelin. Biochemistry
48: 537‐48 [https://www.ncbi.nlm.nih.gov/pubmed/19123778?dopt=AbstractPlus]

Mughal A et al. (2018) Vascular effects of apelin: Mechanisms and therapeutic potential. Pharmacol. Ther.
190: 139‐147 [https://www.ncbi.nlm.nih.gov/pubmed/29807055?dopt=AbstractPlus]

O’Carroll AM et al. (2013) The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J. Endocrinol.
219: R13‐35 [https://www.ncbi.nlm.nih.gov/pubmed/23943882?dopt=AbstractPlus]

Pitkin SL et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol. Rev.
62: 331‐42 [https://www.ncbi.nlm.nih.gov/pubmed/20605969?dopt=AbstractPlus]

Yang P et al. (2015) Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. Trends Pharmacol. Sci.
36: 560‐7 [https://www.ncbi.nlm.nih.gov/pubmed/26143239?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=8

Overview
The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718. Selective agonists are promising drugs for the treatment of metabolic disorders, such as type II diabetes, obesity and atherosclerosis.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=37
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19680, http://www.uniprot.org/uniprot/Q8TDU6
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=611 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=610 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=608, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=609 [http://www.ncbi.nlm.nih.gov/pubmed/12524422?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12419312?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7048 [http://www.ncbi.nlm.nih.gov/pubmed/20014870?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3945 [http://www.ncbi.nlm.nih.gov/pubmed/19911773?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3306 [http://www.ncbi.nlm.nih.gov/pubmed/17825251?dopt=AbstractPlus]	



Comments
The triterpenoid natural product http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3945 has also been reported to inhibit inflammatory signalling through the NFκB pathway [http://www.ncbi.nlm.nih.gov/pubmed/12960358?dopt=AbstractPlus]. Disruption of GPBA expression is reported to protect from cholesterol gallstone formation [http://www.ncbi.nlm.nih.gov/pubmed/16724960?dopt=AbstractPlus]. A new series of 5‐phenoxy‐1,3‐dimethyl‐1H‐pyrazole‐4‐carboxamides have been reported as highly potent agonists [http://www.ncbi.nlm.nih.gov/pubmed/23337601?dopt=AbstractPlus].

Further reading on Bile acid receptor
Duboc H et al. (2014) The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis
46: 302‐12 [https://www.ncbi.nlm.nih.gov/pubmed/24411485?dopt=AbstractPlus]

Lieu T et al. (2014) GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation. Br. J. Pharmacol.
171: 1156‐66 [https://www.ncbi.nlm.nih.gov/pubmed/24111923?dopt=AbstractPlus]

Lefebvre P et al. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev.
89: 147‐91 [https://www.ncbi.nlm.nih.gov/pubmed/19126757?dopt=AbstractPlus]

van Nierop FS et al. (2017) Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol
5: 224‐233 [https://www.ncbi.nlm.nih.gov/pubmed/27639537?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=9

Overview
Mammalian bombesin (Bn) receptors comprise 3 subtypes: BB1, BB2, BB3 (nomenclature recommended by the NC‐IUPHAR Subcommittee on bombesin receptors, [http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus]). BB1 and BB2 are activated by the endogenous ligands http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=612 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4605, http://www.uniprot.org/uniprot/P07492) (GRP), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=613 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7842, http://www.uniprot.org/uniprot/P08949) (NMB) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3582) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4605, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4605). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=616 is a tetradecapeptide, originally derived from amphibians. The three Bn receptor subtypes couple primarily to the Gq/11 and G12/13 family of G proteins [http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus]. Each of these receptors is widely distributed in the CNS and peripheral tissues [http://www.ncbi.nlm.nih.gov/pubmed/26066663?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15726424?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15203211?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22911445?dopt=AbstractPlus]. Activation of BB1 and BB2 receptors causes a wide range of physiological/pathophysiogical actions, including the stimulation of normal and neoplastic tissue growth, smoothmuscle contraction, feeding behavior, secretion and many central nervous system effects including regulation of circadian rhythm and mediation of pruritus [http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus, 991, 992, http://www.ncbi.nlm.nih.gov/pubmed/21042212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15134870?dopt=AbstractPlus,http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus]. A physiological role for the BB3 receptor has yet to be fully defined although recently studies suggest an important role in glucose and insulin regulation, metabolic homeostasis, feeding, regulation of body temperature, obesity, diabetes mellitus and growth of normal/neoplastic tissues [http://www.ncbi.nlm.nih.gov/pubmed/26066663?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22157398?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9367152?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27055378?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=39
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=39
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=40
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=40
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7843, http://www.uniprot.org/uniprot/P28336
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4609, http://www.uniprot.org/uniprot/P30550
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1113, http://www.uniprot.org/uniprot/P32247
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=613 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7842, http://www.uniprot.org/uniprot/P08949) [http://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21729729?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6178 [http://www.ncbi.nlm.nih.gov/pubmed/21729729?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6175]	–	
Selective agonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8509 [http://www.ncbi.nlm.nih.gov/pubmed/24412111?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8502 [http://www.ncbi.nlm.nih.gov/pubmed/24900461?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6170 [http://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24900253?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946) [http://www.ncbi.nlm.nih.gov/pubmed/15102928?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8507 [http://www.ncbi.nlm.nih.gov/pubmed/25497965?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6188 [http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8504 [http://www.ncbi.nlm.nih.gov/pubmed/20167483?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=635 (pIC50 6.2–6.6) [http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus]	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=626 (pIC50 9.3–9.8) [http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=621 (pIC50 9.3–9.6) [http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3871(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3871
	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3840, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3840, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3840,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3840) (pK
i 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3889 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/11463790?dopt=AbstractPlus] – Mouse, [(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627‐( (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8446610?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=624 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/10231715?dopt=AbstractPlus] – Mouse, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6183, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6183
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6183) (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6176 (pIC50 8.6–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8505 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/25554218?dopt=AbstractPlus] http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=627)	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3771) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=623]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=623 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=628]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=628 (Selective Antagonist) (pK
d 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/7684815?dopt=AbstractPlus] – Mouse, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=623]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=623 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7838118?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3788) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8506 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus] – Mouse, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=631) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9325344?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus]	



Comments
All three human subtypes may be activated by [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=632) [http://www.ncbi.nlm.nih.gov/pubmed/9325344?dopt=AbstractPlus]. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3946) has more than 200‐fold selectivity for BB3 receptors over BB1 and BB2 [http://www.ncbi.nlm.nih.gov/pubmed/15102928?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15102928?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26524625?dopt=AbstractPlus].

Further reading on Bombesin receptors
González N et al. (2015) Bombesin receptor subtype 3 as a potential target for obesity and diabetes. Expert Opin. Ther. Targets
19: 1153‐70 [https://www.ncbi.nlm.nih.gov/pubmed/26066663?dopt=AbstractPlus]

Jensen RT et al. (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev.
60: 1‐42 [https://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus]

Maina T et al. (2017) Theranostic Prospects of Gastrin‐Releasing Peptide Receptor‐Radioantagonists in Oncology. PET Clin
12: 297‐309 [https://www.ncbi.nlm.nih.gov/pubmed/28576168?dopt=AbstractPlus]

Moreno P et al. (2016) Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment. Expert Opin. Ther. Targets
20: 1055‐73 [https://www.ncbi.nlm.nih.gov/pubmed/26981612?dopt=AbstractPlus]

Qu X et al. (2018) Recent insights into biological functions of mammalian bombesin‐like peptides and their receptors. Curr Opin Endocrinol Diabetes Obes
25: 36‐41 [https://www.ncbi.nlm.nih.gov/pubmed/29120926?dopt=AbstractPlus]

Ramos‐Álvarez I et al. (2015) Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides
72: 128‐44 [https://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=10

Overview
Bradykinin (or kinin) receptors (nomenclature as agreed by the NC‐IUPHAR subcommittee on Bradykinin (kinin) Receptors [http://www.ncbi.nlm.nih.gov/pubmed/15734727?dopt=AbstractPlus]) are activated by the endogenous peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383, http://www.uniprot.org/uniprot/P01042) (BK), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383), Lys‐BK (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=650, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383)), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383), [Phospho‐Ser6]‐Bradykinin, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=639, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383) (Ile‐SerBK), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3578]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3578, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3580]‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3580, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383). Variation in pharmacology and activity of B1 and B2 receptor antagonists at species orthologs has been documented. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=667 (Hoe140, Firazir) is approved in North America and Europe for the treatment of acute attacks of hereditary angioedema.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=41
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=41
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=42
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=42
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1029, http://www.uniprot.org/uniprot/P46663
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1030, http://www.uniprot.org/uniprot/P30411
	
Potency order of endogenous ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383, http://www.uniprot.org/uniprot/P01042) > [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=650, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=650 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383, http://www.uniprot.org/uniprot/P01042) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383) [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=646, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383)	
Endogenous agonists	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=644 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383, http://www.uniprot.org/uniprot/P01042) [http://www.ncbi.nlm.nih.gov/pubmed/9111052?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9313952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8735629?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10422787?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=649 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6383, http://www.uniprot.org/uniprot/P01042)	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10254 [http://www.ncbi.nlm.nih.gov/pubmed/26565554?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=643,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=643]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=643 [http://www.ncbi.nlm.nih.gov/pubmed/10422787?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10255 [http://www.ncbi.nlm.nih.gov/pubmed/19111586?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23362191?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3841,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3841)http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3841]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3841, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3846,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3846(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3846‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3846]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3846, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=672, http://www.ncbi.nlm.nih.gov/pubmed/19111586?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=655 (pK
i 9.2–10.3) [http://www.ncbi.nlm.nih.gov/pubmed/16368899?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9650825?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=642,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=642]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=642 (pK
i 9.1–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/9111052?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9313952?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=662 (pK
i 9.1–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/14747609?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3906 (pA
2 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/24361511?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=661 (pA
2 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/8901831?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=667 (pK
i 10.2) [http://www.ncbi.nlm.nih.gov/pubmed/10514288?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=674 (pA
2 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/9095082?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=679 (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/10596852?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3791 (pK
d 10), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3825]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3825 (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3826][http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3826]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3826 (Antagonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3812) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9333122?dopt=AbstractPlus] – Mouse, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3831 (Antagonist) (pK
d 9.1–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/9651119?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11379050?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3765]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3765 (Agonist)	



Further reading on Bradykinin receptors
Campos MM et al. (2006) Non‐peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends Pharmacol. Sci.
27: 646‐51 [https://www.ncbi.nlm.nih.gov/pubmed/17056130?dopt=AbstractPlus]

Duchene J et al. (2009) The kinin B(1) receptor and inflammation: new therapeutic target for cardiovascular disease. Curr Opin Pharmacol
9: 125‐31 [https://www.ncbi.nlm.nih.gov/pubmed/19124274?dopt=AbstractPlus]

Marceau F et al. (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov
3: 845‐52 [https://www.ncbi.nlm.nih.gov/pubmed/15459675?dopt=AbstractPlus]

Paquet JL et al. (1999) Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses. Br. J. Pharmacol.
126: 1083‐90 [https://www.ncbi.nlm.nih.gov/pubmed/10204994?dopt=AbstractPlus]

Thornton E et al. (2010) Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules
15: 6598‐618 [https://www.ncbi.nlm.nih.gov/pubmed/20877247?dopt=AbstractPlus]

Whalley ET et al. (2012) Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov
7: 1129‐48 [https://www.ncbi.nlm.nih.gov/pubmed/23095011?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=11

Overview
This receptor family comprises a group of receptors for the calcitonin/CGRP family of peptides. The calcitonin (CT), amylin (AMY), calcitonin gene‐related peptide (CGRP) and adrenomedullin (AM) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on CGRP, AM, AMY, and CT receptors [http://www.ncbi.nlm.nih.gov/pubmed/18552275?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12037140?dopt=AbstractPlus]) are generated by the genes https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1440 (which codes for the CT receptor) and https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16709 (which codes for the calcitonin receptor‐like receptor, CLR, previously known as CRLR). Their function and pharmacology are altered in the presence of RAMPs (receptor activity‐modifying proteins), which are single TM domain proteins of ca. 130 amino acids, identified as a family of three members; RAMP1, RAMP2 and RAMP3. There are splice variants of the CT receptor; these in turn produce variants of the AMY receptor [http://www.ncbi.nlm.nih.gov/pubmed/12037140?dopt=AbstractPlus], some of which can be potently activated by CGRP. The endogenous agonists are the peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P01258), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681, http://www.uniprot.org/uniprot/P06881) (formerly known as CGRP‐I), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) (formerly known as CGRP‐II), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) (occasionally called islet‐amyloid polypeptide, diabetes‐associated polypeptide), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4). There are species differences in peptide sequences, particularly for the CTs. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5369 {Pig} (CRSP) is another member of the family with selectivity for the CT receptor but it is not expressed in humans [http://www.ncbi.nlm.nih.gov/pubmed/12556539?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702 (also known as BIBN4096BS, pKi10.5) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=703 (also known as MK0974, pKi9) are the most selective antagonists available, showing selectivity for CGRP receptors, with a particular preference for those of primate origin. CLR (calcitonin receptor‐like receptor) by itself binds no known endogenous ligand, but in the presence of RAMPs it gives receptors for CGRP, adrenomedullin and adrenomedullin 2/intermedin.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=44
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=45
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=46
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1440, http://www.uniprot.org/uniprot/P30988
	–	–	–	
Subunits	–	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=51 (Accessory protein), http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=52 (Accessory protein)	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=43, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=53 (Accessory protein)	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P01258) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681, http://www.uniprot.org/uniprot/P06881), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) ≥http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685, http://www.uniprot.org/uniprot/P01258) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318)	Poorly defined	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881),http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685, http://www.uniprot.org/uniprot/P01258) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318)	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P01258) [http://www.ncbi.nlm.nih.gov/pubmed/7588285?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11033437?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565884?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11023820?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10342886?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881) [http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14722252?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565884?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11023820?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26125036?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) [http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) [http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) [http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus]	
Sub/family‐selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7482 [http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7482 [http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7482 [http://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus]	
Sub/family‐selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=690) (pK
d 9) [http://www.ncbi.nlm.nih.gov/pubmed/10856900?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=689 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=689 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=690) (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702 (pK
d 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/26125036?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=690) (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=689 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3776) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3777) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3766) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3770) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3770) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3770) (Agonist)	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=48
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=49
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=50
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16709, http://www.uniprot.org/uniprot/Q16602
	–	–	–	
Subunits	–	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=51 (Accessory protein)	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=52 (Accessory protein)	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=47, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=53 (Accessory protein)	
Potency order of endogenous ligands	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4) >http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28898, http://www.uniprot.org/uniprot/Q7Z4H4) ≥http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=687 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5329, http://www.uniprot.org/uniprot/P10997) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6973)	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1438, http://www.uniprot.org/uniprot/P10092) [http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P06881) http://www.uniprot.org/uniprot/P06881, http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) [http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:259, http://www.uniprot.org/uniprot/P35318) [http://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10347248?dopt=AbstractPlus]	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702 (pK
i 10.7–11) [http://www.ncbi.nlm.nih.gov/pubmed/10711339?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16959943?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24405707?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11847213?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=703 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/18039958?dopt=AbstractPlus]	–	–	
Selective antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=706) (pK
i 7–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=706)	
Labelled ligands	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3766) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6567) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3768) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3768) (Agonist)	



Comments
It is important to note that a complication with the interpretation of pharmacological studies with AMY receptors in transfected cells is that most of this work has likely used a mixed population of receptors, encompassing RAMP‐coupled CTR as well as CTR alone. This means that although in binding assays human http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=685 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1437, http://www.uniprot.org/uniprot/P01258) has low affinity for 125I‐AMY binding sites, cells transfected with CTR and RAMPs can display potent CT functional responses. Transfection of human CTR with any RAMP can generate receptors with a high affinity for both salmon CT and AMY and varying affinity for different antagonists [http://www.ncbi.nlm.nih.gov/pubmed/10385705?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16959943?dopt=AbstractPlus]. The major human CTR splice variant (hCT(a), which does not contain an insert) with RAMP1 (i.e. the AMY1(a) receptor) has a high affinity for CGRP [http://www.ncbi.nlm.nih.gov/pubmed/26125036?dopt=AbstractPlus], unlike hCT(a)‐RAMP3 (i.e. AMY3(a) receptor) [http://www.ncbi.nlm.nih.gov/pubmed/10385705?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus]. However, the AMY receptor phenotype is RAMP‐type, splice variant and cell‐line‐dependent [http://www.ncbi.nlm.nih.gov/pubmed/18599553?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22946511?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10871296?dopt=AbstractPlus]. Emerging data suggests that AMY1 could be a second CGRP receptor [http://www.ncbi.nlm.nih.gov/pubmed/29797087?dopt=AbstractPlus].

The ligands described have limited selectivity. Adrenomedullin has appreciable affinity for CGRP receptors. CGRP can show significant cross‐reactivity at AMY receptors and AM2 receptors. Adrenomedullin 2/intermedin also has high affinity for the AM2 receptor [http://www.ncbi.nlm.nih.gov/pubmed/21658025?dopt=AbstractPlus]. CGRP‐(8‐37) acts as an antagonist of CGRP (pKi 8) and inhibits some AM and AMY responses (pKi 6‐7). It is weak at CT receptors. HumanAM‐(22‐52)has some selectivity towardsAM receptors, but with modest potency (pKi 7), limiting its use [http://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=702 shows the greatest selectivity between receptors but still has significant affinity for AMY1 receptors [http://www.ncbi.nlm.nih.gov/pubmed/26125036?dopt=AbstractPlus].

Gs is a prominent route for effector coupling for CLR and CTR but other pathways (e.g. Ca2+, ERK, Akt), and G proteins can be activated [http://www.ncbi.nlm.nih.gov/pubmed/20633935?dopt=AbstractPlus]. There is evidence that CGRP‐RCP (a 148 amino‐acid hydrophilic protein, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:746 (http://www.uniprot.org/uniprot/P04424) is important for the coupling of CLR to adenylyl cyclase [http://www.ncbi.nlm.nih.gov/pubmed/10903324?dopt=AbstractPlus].

[125I]‐Salmon CT is the most common radioligand for CT receptors but it has high affinity for AMY receptors and is also poorly reversible.

Further reading on Calcitonin receptors
Hay DL et al. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br. J. Pharmacol.
175: 3‐17 [https://www.ncbi.nlm.nih.gov/pubmed/29059473?dopt=AbstractPlus]

Russell FA et al. (2014) Calcitonin gene‐related peptide: physiology and pathophysiology. Physiol. Rev.
94: 1099‐142 [https://www.ncbi.nlm.nih.gov/pubmed/25287861?dopt=AbstractPlus]

Hay DL et al. (2016) Receptor Activity‐Modifying Proteins (RAMPs): New Insights and Roles. Annu. Rev. Pharmacol. Toxicol.
56: 469‐87 [https://www.ncbi.nlm.nih.gov/pubmed/26514202?dopt=AbstractPlus]

Russo AF. (2015) Calcitonin gene‐related peptide (CGRP): a new target for migraine. Annu. Rev. Pharmacol. Toxicol.
55: 533‐52 [https://www.ncbi.nlm.nih.gov/pubmed/25340934?dopt=AbstractPlus]

Kato J et al. (2015) Bench‐to‐bedside pharmacology of adrenomedullin. Eur. J. Pharmacol.
764: 140‐8 [https://www.ncbi.nlm.nih.gov/pubmed/26144371?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=12

Overview
The calcium‐sensing receptor (CaS, provisional nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) responds to multiple endogenous ligands, including extracellular calcium and other divalent/trivalent cations, polyamines and polycationic peptides, L‐amino acids (particularly L‐Trp and L‐Phe), glutathione and various peptide analogues, ionic strength and extracellular pH (reviewed in [http://www.ncbi.nlm.nih.gov/pubmed/24111791?dopt=AbstractPlus]). While divalent/trivalent cations, polyamines and polycations are CaS receptor agonists [http://www.ncbi.nlm.nih.gov/pubmed/8255296?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9357776?dopt=AbstractPlus], L‐amino acids, glutamyl peptides, ionic strength and pH are allosteric modulators of agonist function [http://www.ncbi.nlm.nih.gov/pubmed/10781086?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10781086?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7493018?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15201280?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9677383?dopt=AbstractPlus]. Indeed, L‐amino acids have been identified as "co‐agonists", with both concomitant calcium and L‐amino acid binding required for full receptor activation [http://www.ncbi.nlm.nih.gov/pubmed/27434672?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27746744?dopt=AbstractPlus]. The sensitivity of the CaS receptor to primary agonists is increased by elevated extracellular pH [http://www.ncbi.nlm.nih.gov/pubmed/25556167?dopt=AbstractPlus] or decreased extracellular ionic strength [http://www.ncbi.nlm.nih.gov/pubmed/9677383?dopt=AbstractPlus]. This receptor bears no sequence or structural relation to the plant calcium receptor, also called CaS.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=54
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1514, http://www.uniprot.org/uniprot/P41180
	
Amino‐acid rank order of potency	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=720 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3314, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309 (not L‐lysine, L‐arginine, L‐leucine and L‐isoleucine) [http://www.ncbi.nlm.nih.gov/pubmed/10781086?dopt=AbstractPlus]	
Cation rank order of potency	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708 [http://www.ncbi.nlm.nih.gov/pubmed/8255296?dopt=AbstractPlus]	
Glutamyl peptide rank order of potency	S‐methylglutathione ≈ γGlu‐Val‐Gly > glutathione >γGlu‐Cys [http://www.ncbi.nlm.nih.gov/pubmed/21187282?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19892707?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16455645?dopt=AbstractPlus]	
Polyamine rank order of potency	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2390 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388 [http://www.ncbi.nlm.nih.gov/pubmed/9357776?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9475 (Negative) (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/20158186?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9474 (Negative) (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/24900301?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9476 (Negative) (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/19786130?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9473 (Negative) (pIC50 6.5–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/19442519?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=716 (Negative) (pK
B 6.2–6.7) [http://www.ncbi.nlm.nih.gov/pubmed/22210744?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27002221?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23372019?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3308 (Positive) (pK
B 5.9–6.6) [http://www.ncbi.nlm.nih.gov/pubmed/25220431?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22210744?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27002221?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=718 (Positive) (pK
B 6.2–6.6) [http://www.ncbi.nlm.nih.gov/pubmed/25220431?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25220431?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3947 (Positive) (pK
B 6.3–6.4) [http://www.ncbi.nlm.nih.gov/pubmed/25220431?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27002221?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=714 (Negative) (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/14506236?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=719 (Positive) (pK
B 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/25220431?dopt=AbstractPlus]	



Comments
The CaS receptor has a number of physiological functions, but it is best known for its central role in parathyroid and renal regulation of extracellular calcium homeostasis [http://www.ncbi.nlm.nih.gov/pubmed/27647839?dopt=AbstractPlus]. This is seen most clearly in patients with loss‐of‐function CaS receptor mutations who develop familial hypocalciuric hypercalcaemia (heterozygous mutations) or neonatal severe hyperparathyroidism (heterozygous, compound heterozygous or homozygous mutations) [http://www.ncbi.nlm.nih.gov/pubmed/27647839?dopt=AbstractPlus] and in Casr null mice [http://www.ncbi.nlm.nih.gov/pubmed/18765830?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7493018?dopt=AbstractPlus], which exhibit similar increases in PTH secretion and blood calcium levels. Gain‐of‐function CaS mutations are associated with autosomal dominant hypocalcaemia and Bartter syndrome type V [http://www.ncbi.nlm.nih.gov/pubmed/27647839?dopt=AbstractPlus].

The CaS receptor primarily couples to Gq/11, G12/13 and Gi/o [http://www.ncbi.nlm.nih.gov/pubmed/22210744?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16247029?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12954603?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22192592?dopt=AbstractPlus], but in some cell types can couple to Gs [http://www.ncbi.nlm.nih.gov/pubmed/20032198?dopt=AbstractPlus]. However, the CaS receptor can form heteromers with Class C GABAB [http://www.ncbi.nlm.nih.gov/pubmed/17591780?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17615148?dopt=AbstractPlus] and mGlu1/5 receptors [http://www.ncbi.nlm.nih.gov/pubmed/11489900?dopt=AbstractPlus], which may introduce further complexity in its signalling capabilities.

Multiple other small molecule chemotypes are positive and negative allosteric modulators of the CaS receptor [http://www.ncbi.nlm.nih.gov/pubmed/21406038?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24050279?dopt=AbstractPlus]. Further, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8375 is a novel peptide positive allosteric modulator of the receptor [http://www.ncbi.nlm.nih.gov/pubmed/23674604?dopt=AbstractPlus]. Agonists and positive allosteric modulators of the CaS receptor are termed Type I and II calcimimetics, respectively, and can suppress parathyroid hormone (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9606, http://www.uniprot.org/uniprot/P01270)) secretion [http://www.ncbi.nlm.nih.gov/pubmed/9520489?dopt=AbstractPlus]. Negative allosteric modulators are called calcilytics and can act to increase http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9606) secretion [http://www.ncbi.nlm.nih.gov/pubmed/11561095?dopt=AbstractPlus].

Where functional pKB values are provided for allosteric modulators, this refers to ligand affinity determined in an assay that measures a functional readout of receptor activity (i.e. a receptor signalling assay), as opposed to affinity determined in a radioligand binding assay. The functional pKB may differ depending on the signalling pathway studied. Consult the http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=54&familyId=12&familyType=GPCR#Allosterics for the assay description, as well as other functional readouts.

Further reading on Calcium‐sensing receptor
Brown EM. (2013) Role of the calcium‐sensing receptor in extracellular calcium homeostasis. Best Pract. Res. Clin. Endocrinol. Metab.
27: 333‐43 [https://www.ncbi.nlm.nih.gov/pubmed/23856263?dopt=AbstractPlus]

Hannan FM et al. (2018) The calcium‐sensing receptor in physiology and in calcitropic and noncal citropic diseases. Nat Rev Endocrinol
15: 33‐51 [https://www.ncbi.nlm.nih.gov/pubmed/30443043?dopt=AbstractPlus]

Conigrave AD et al. (2013) Calcium‐sensing receptor (CaSR): pharmacological properties and signaling pathways. Best Pract. Res. Clin. Endocrinol. Metab.
27: 315‐31 [https://www.ncbi.nlm.nih.gov/pubmed/23856262?dopt=AbstractPlus]

Nemeth EF et al. (2018) Discovery and Development of Calcimimetic and Calcilytic Compounds. Prog Med Chem
57: 1‐86 [https://www.ncbi.nlm.nih.gov/pubmed/29680147?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=13

Overview
Cannabinoid receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Cannabinoid Receptors [http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus]) are activated by endogenous ligands that include N‐arachidonoylethanolamine (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5444‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5444, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5445 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [http://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus].

There are currently three licenced cannabinoid medicines each of which contains a compound that can activate CB1 and CB2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/23108552?dopt=AbstractPlus]. Two of these medicines were developed to suppress nausea and vomiting produced by chemotherapy. These are http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9071 (Cesamet®), a synthetic CB1/CB2 receptor agonist, and synthetic http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 (Marinol®; dronabinol), which can also be used as an appetite stimulant. The third medicine, Sativex®, contains mainly http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4150, both extracted from cannabis, and is used to treat multiple sclerosis and cancer pain.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2159, http://www.uniprot.org/uniprot/P21554
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2160, http://www.uniprot.org/uniprot/P34972
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731 [http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=730, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733, http://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=740 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=731 [http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9379442?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733, http://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=730, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8626625?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8626625?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9379442?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=738 [http://www.ncbi.nlm.nih.gov/pubmed/10336536?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=739] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=732 [http://www.ncbi.nlm.nih.gov/pubmed/11181068?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2506 [http://www.ncbi.nlm.nih.gov/pubmed/8893848?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=747 [http://www.ncbi.nlm.nih.gov/pubmed/10658595?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11060760?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=748 [0663, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3316 [http://www.ncbi.nlm.nih.gov/pubmed/16894349?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=749 [0663, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=746 [http://www.ncbi.nlm.nih.gov/pubmed/10588688?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=743 (pK
i 7.9–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/9435190?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8070571?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12663689?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10029 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/25535367?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/10052983?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=741 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/11741201?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=742 (pK
i 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/9435190?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=751 (pK
i 8.3–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9454810?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=750 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9237 (Negative) (pEC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/26529344?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9239 (Positive) (pEC50 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/26052038?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10272 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/28103441?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4150 (Negative) [http://www.ncbi.nlm.nih.gov/pubmed/26218440?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9188 (Positive) (pKi ∼7.3) [http://www.ncbi.nlm.nih.gov/pubmed/28842619?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10273 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/29990428?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=745 (Antagonist) (pK
d 8.9–10) [http://www.ncbi.nlm.nih.gov/pubmed/9316881?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8981483?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8978752?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8733746?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8614277?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8987831?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9536023?dopt=AbstractPlus] – Rat	–	



Comments
Both CB1 and CB2 receptors may be labelled with [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=734 (0.5 nM;[http://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus]) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=736 (2‐2.4 nM; [http://www.ncbi.nlm.nih.gov/pubmed/7651369?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8622639?dopt=AbstractPlus]). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 is also an agonist at vanilloid receptors (http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=78%23show_object_507)and http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=86 [http://www.ncbi.nlm.nih.gov/pubmed/17704824?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10440374?dopt=AbstractPlus]. There is evidence for an allosteric site on the CB1 receptor [http://www.ncbi.nlm.nih.gov/pubmed/16113085?dopt=AbstractPlus]. All of the compounds listed as antagonists behave as inverse agonists in some bioassay systems [http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus]. For some cannabinoid receptor ligands, additional pharmacological targets that include GPR55 and GPR119 have been identified [http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus]. Moreover, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114 although showing little structural similarity to CB1 and CB2 receptors, respond to endogenous agents that are structurally similar to the endogenous cannabinoid ligands [http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus].

Further reading on Cannabinoid receptors
Howlett AC et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev.
54: 161‐202 [https://www.ncbi.nlm.nih.gov/pubmed/12037135?dopt=AbstractPlus]

Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev.
62: 588‐631 [https://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus]

Pertwee RG. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem.
17: 1360‐81 [https://www.ncbi.nlm.nih.gov/pubmed/20166927?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=338

Overview
Nomenclature for the chemerin receptors is presented as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/29279348?dopt=AbstractPlus]). The chemoattractant protein and adipokine, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2945 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9868, http://www.uniprot.org/uniprot/Q99969), has been shown to be the endogenous ligand for both chemerin family receptors. Chemerin1 was the founding family member, and when GPR1 was de‐orphanised it was re‐named Chermerin2 [http://www.ncbi.nlm.nih.gov/pubmed/29279348?dopt=AbstractPlus]. Chemerin1 is also activated by the lipid‐derived, antiinflammatory ligand http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333 (RvE1), which is formed via the sequential metabolism of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362 by aspirin‐modified cyclooxygenase and lipoxygenase [http://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17339491?dopt=AbstractPlus]. In addition, two GPCRs for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 (RvD1) have been identified: FPR2/ALX, the lipoxin A4 receptor, and GPR32, an orphan receptor [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=79
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=82
	
Common abbreviation	Chemerin1
	Chemerin2
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2121, http://www.uniprot.org/uniprot/Q99788
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4463, http://www.uniprot.org/uniprot/P46091
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3422 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3400 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362 [http://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus]	–	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2945 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9868, http://www.uniprot.org/uniprot/Q99969) [http://www.ncbi.nlm.nih.gov/pubmed/18165312?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333
	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2901 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17339491?dopt=AbstractPlus]	–	
Comments	–	Reported to act as a co‐receptor for HIV [http://www.ncbi.nlm.nih.gov/pubmed/10233994?dopt=AbstractPlus]. See review [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] for discussion of pairing with chemerin.	



Comments
CCX832 (structure not disclosed) is a selective antagonist, pKi=9.2 [http://www.ncbi.nlm.nih.gov/pubmed/27742615?dopt=AbstractPlus].

Further reading on Chemerin receptors
Kennedy AJ et al. (2018) International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function. Pharmacol. Rev.
70: 174‐196 [https://www.ncbi.nlm.nih.gov/pubmed/29279348?dopt=AbstractPlus]

Shin WJ et al. (2018) Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention. Front Immunol
9: 2772 [https://www.ncbi.nlm.nih.gov/pubmed/30555465?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=14

Overview
Chemokine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Chemokine Receptors [http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12037138?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10699158?dopt=AbstractPlus]) comprise a large subfamily of 7TM proteins that bind one or more chemokines, a large family of small cytokines typically possessing chemotactic activity for leukocytes. Additional hematopoietic and non‐hematopoietic roles have been identified for many chemokines in the areas of embryonic development, immune cell proliferation, activation and death, viral infection, and as antibiotics, among others. Chemokine receptors can be divided by function into two main groups: G protein‐coupled chemokine receptors, which mediate leukocyte trafficking, and "Atypical chemokine receptors", which may signal through non‐G protein‐coupled mechanisms and act as chemokine scavengers to downregulate inflammation or shape chemokine gradients [http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus].

Chemokines in turn can be divided by structure into four subclasses by the number and arrangement of conserved cysteines. CC (also known as β‐chemokines; n= 28), CXC (also known as α‐chemokines; n= 17) and CX3C (n= 1) chemokines all have four conserved cysteines, with zero, one and three amino acids separating the first two cysteines respectively. C chemokines (n= 2) have only the second and fourth cysteines found in other chemokines. Chemokines can also be classified by function into homeostatic and inflammatory subgroups. Most chemokine receptors are able to bind multiple high‐affinity chemokine ligands, but the ligands for a given receptor are almost always restricted to the same structural subclass. Most chemokines bind to more than one receptor subtype. Receptors for inflammatory chemokines are typically highly promiscuous with regard to ligand specificity, and may lack a selective endogenous ligand. G protein‐coupled chemokine receptors are named acccording to the class of chemokines bound, whereas ACKR is the root acronym for atypical chemokine receptors [http://www.ncbi.nlm.nih.gov/pubmed/25958743?dopt=AbstractPlus]. There can be substantial cross‐species differences in the sequences of both chemokines and chemokine receptors, and in the pharmacology and biology of chemokine receptors. Endogenous and microbial non‐chemokine ligands have also been identified for chemokine receptors. Many chemokine receptors function as HIV co‐receptors, but CCR5 is the only one demonstrated to play an essential role in HIV/AIDS pathogenesis. The tables include bothstandard chemokine receptor names [http://www.ncbi.nlm.nih.gov/pubmed/10714678?dopt=AbstractPlus] and aliases.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=58
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=60
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1602, http://www.uniprot.org/uniprot/P32246
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1603, http://www.uniprot.org/uniprot/P41597
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1604, http://www.uniprot.org/uniprot/P51677
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10627, http://www.uniprot.org/uniprot/P10147) [http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9624164?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11170631?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=755 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10622, http://www.uniprot.org/uniprot/P55773) http://www.uniprot.org/uniprot/P55773], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10632, http://www.uniprot.org/uniprot/P13501) [http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098) http://www.uniprot.org/uniprot/P80098, http://www.ncbi.nlm.nih.gov/pubmed/11994538?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=754 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10613, http://www.uniprot.org/uniprot/Q16663) [http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10612, http://www.uniprot.org/uniprot/Q16627) http://www.uniprot.org/uniprot/Q16627], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10611, http://www.uniprot.org/uniprot/Q99616), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10635, http://www.uniprot.org/uniprot/P80075)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10618, http://www.uniprot.org/uniprot/P13500) [http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10770925?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10611, http://www.uniprot.org/uniprot/Q99616) [http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098) http://www.uniprot.org/uniprot/P80098, http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10610, http://www.uniprot.org/uniprot/P51671) (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1272 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10614, http://www.uniprot.org/uniprot/O15467)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10611, http://www.uniprot.org/uniprot/Q99616) [http://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=775 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10623, http://www.uniprot.org/uniprot/O00175) http://www.uniprot.org/uniprot/O00175, http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10632, http://www.uniprot.org/uniprot/P13501) [http://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098) [http://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10610, http://www.uniprot.org/uniprot/P51671) [http://www.ncbi.nlm.nih.gov/pubmed/12761559?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10854442?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=776 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10625, http://www.uniprot.org/uniprot/Q9Y258) [http://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=754 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10613, http://www.uniprot.org/uniprot/Q16663) [http://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3649 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17700, http://www.uniprot.org/uniprot/Q9NRJ3), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10635, http://www.uniprot.org/uniprot/P80075)	
Agonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=787 {Mouse} [http://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus]	
Endogenous antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10630, http://www.uniprot.org/uniprot/P13236) (pK
i 7.1–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=776 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10625, http://www.uniprot.org/uniprot/Q9Y258) (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=835 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10637, http://www.uniprot.org/uniprot/P02778), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10638, http://www.uniprot.org/uniprot/O14625), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=837 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7098, http://www.uniprot.org/uniprot/Q07325)	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=767 (pK
i 8.2–9) [http://www.ncbi.nlm.nih.gov/pubmed/10748002?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3696 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/12614873?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3536 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/10854442?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3497 (pK
d 8) [http://www.ncbi.nlm.nih.gov/pubmed/12909630?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3502 (pK
i 7.6)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=796) (Inverse agonist) (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/12450563?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3530 (pKi 8.4), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3492 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/12067561?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=765) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7545673?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=763) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7545673?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9115216?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9336350?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=764) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9336350?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=762) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=765) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=794) (Antagonist) (pK
d 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/12450563?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=764) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=765) (Agonist)	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=62
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=63
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=64
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=65
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=66
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=67
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1605, http://www.uniprot.org/uniprot/P51679
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1606, http://www.uniprot.org/uniprot/P51681
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1607, http://www.uniprot.org/uniprot/P51684
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1608, http://www.uniprot.org/uniprot/P32248
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1609, http://www.uniprot.org/uniprot/P51685
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1610, http://www.uniprot.org/uniprot/P51686
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4474, http://www.uniprot.org/uniprot/P46092
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=798 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10621, http://www.uniprot.org/uniprot/O00626) [http://www.ncbi.nlm.nih.gov/pubmed/9430724?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10615, http://www.uniprot.org/uniprot/Q92583) http://www.uniprot.org/uniprot/Q92583]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10632, http://www.uniprot.org/uniprot/P13501) [http://www.ncbi.nlm.nih.gov/pubmed/10318947?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10630, http://www.uniprot.org/uniprot/P13236 [http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10635, http://www.uniprot.org/uniprot/P80075) [http://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10627, http://www.uniprot.org/uniprot/P10147)[http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11170631?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10610, http://www.uniprot.org/uniprot/P51671) [http://www.ncbi.nlm.nih.gov/pubmed/10477718?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10618, http://www.uniprot.org/uniprot/P13500 [http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10612, http://www.uniprot.org/uniprot/Q16627 [http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1272 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10614, http://www.uniprot.org/uniprot/O15467)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=808 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10619, http://www.uniprot.org/uniprot/P78556) [http://www.ncbi.nlm.nih.gov/pubmed/12081481?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9169459?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9294137?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3648 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2767
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30193, http://www.uniprot.org/uniprot/O15263) [http://www.ncbi.nlm.nih.gov/pubmed/10521347?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=811 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10620, http://www.uniprot.org/uniprot/O00585) [http://www.ncbi.nlm.nih.gov/pubmed/9507024?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10617, http://www.uniprot.org/uniprot/Q99731) [http://www.ncbi.nlm.nih.gov/pubmed/16904643?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9153236?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9153236?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=812 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10609, http://www.uniprot.org/uniprot/P22362) [http://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16221874?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4415 {Mouse}	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=817 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10624, http://www.uniprot.org/uniprot/O15444)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3646 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10626, http://www.uniprot.org/uniprot/Q9Y4X3) [http://www.ncbi.nlm.nih.gov/pubmed/10725697?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3649 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17700, http://www.uniprot.org/uniprot/Q9NRJ3)	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4359
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3910
	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=815 [http://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus]	–	–	
Endogenous antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098) (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus]	–	–	–	–	–	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=807 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/16304152?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=804 (pK
i 7.8–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11585437?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11585437?dopt=AbstractPlus]	–	–	–	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9478 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/19081254?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3500 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/11454872?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=805 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=806 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=783 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3651 [http://www.ncbi.nlm.nih.gov/pubmed/12604693?dopt=AbstractPlus] – Rat	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=816 (pIC50 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus]	–	–	
Selective allosteric modulators	–	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9046 (Antagonist) (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/20660125?dopt=AbstractPlus]	–	
Antibodies	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6477 (Inhibition) [http://www.ncbi.nlm.nih.gov/pubmed/21154168?dopt=AbstractPlus, 1962]	–	–	–	–	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3652) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3653) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=799) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=763) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=764) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=766) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3654) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9294138?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3655) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3656) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10201891?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=814) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9211859?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3657) (Agonist)	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=68
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=69
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=70
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=72
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=73
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=74
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6026, http://www.uniprot.org/uniprot/P25024
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6027, http://www.uniprot.org/uniprot/P25025
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4540, http://www.uniprot.org/uniprot/P49682
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2561, http://www.uniprot.org/uniprot/P61073
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1060, http://www.uniprot.org/uniprot/P32302
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16647, http://www.uniprot.org/uniprot/O00574
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2558, http://www.uniprot.org/uniprot/P49238
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6025, http://www.uniprot.org/uniprot/P10145) [http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15946947?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10643, http://www.uniprot.org/uniprot/P80162) [http://www.ncbi.nlm.nih.gov/pubmed/9692902?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=819 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4602, http://www.uniprot.org/uniprot/P09341) [http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6025, http://www.uniprot.org/uniprot/P10145) [http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15946947?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=830 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9240, http://www.uniprot.org/uniprot/P02775) [http://www.ncbi.nlm.nih.gov/pubmed/8702798?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=828 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4604, http://www.uniprot.org/uniprot/P19876) http://www.uniprot.org/uniprot/P19876], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=827 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4603, http://www.uniprot.org/uniprot/P19875) http://www.uniprot.org/uniprot/P19875], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=829 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10642, http://www.uniprot.org/uniprot/P42830) http://www.uniprot.org/uniprot/P42830], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10643, http://www.uniprot.org/uniprot/P80162) [http://www.ncbi.nlm.nih.gov/pubmed/9692902?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10638, http://www.uniprot.org/uniprot/O14625) [http://www.ncbi.nlm.nih.gov/pubmed/15761110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=835 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10637, http://www.uniprot.org/uniprot/P02778) http://www.uniprot.org/uniprot/P02778, http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=837 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7098, http://www.uniprot.org/uniprot/Q07325) http://www.uniprot.org/uniprot/Q07325, http://www.ncbi.nlm.nih.gov/pubmed/15761110?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4358 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10672, http://www.uniprot.org/uniprot/P48061) [http://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9712844?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=845 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10672, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10672) [http://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3645 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10639, http://www.uniprot.org/uniprot/O43927) [http://www.ncbi.nlm.nih.gov/pubmed/22913878?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=855 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16642, http://www.uniprot.org/uniprot/Q9H2A7) [http://www.ncbi.nlm.nih.gov/pubmed/11290797?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=856 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10647, http://www.uniprot.org/uniprot/P78423) [http://www.ncbi.nlm.nih.gov/pubmed/14607932?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8496 [http://www.ncbi.nlm.nih.gov/pubmed/20044480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8495 [http://www.ncbi.nlm.nih.gov/pubmed/22262769?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8496 [http://www.ncbi.nlm.nih.gov/pubmed/20044480?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8495 [http://www.ncbi.nlm.nih.gov/pubmed/22262769?dopt=AbstractPlus]	–	–	–	–	–	
Selective agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=607 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11923301?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3919
	–	–	–	
Endogenous antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10610, http://www.uniprot.org/uniprot/P51671) (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098) (pK
i 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus]	–	–	–	–	
Antagonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=844 (pK
i 7) [http://www.ncbi.nlm.nih.gov/pubmed/11923301?dopt=AbstractPlus]	–	–	–	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8497 (pIC50 10.3) [http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17181143?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8500 (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/26092545?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=833 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/9553055?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8499 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8501 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/25254640?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=852 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9918823?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8580 (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/20297846?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=773
	–	–	–	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8498 (Negative) (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8498 (Negative) (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus]	–	–	–	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=822) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12626541?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=822) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12626541?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3677) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3659) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3658) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3660) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3661) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=849 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=849) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11104827?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8631) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/24190631?dopt=AbstractPlus] – Mouse	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3662) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3664) (Agonist)	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=75
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=316
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=314
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=80
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=315
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=78
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1625, http://www.uniprot.org/uniprot/P46094
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4035, http://www.uniprot.org/uniprot/Q16570
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1565, http://www.uniprot.org/uniprot/O00590
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23692, http://www.uniprot.org/uniprot/P25106
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1611, http://www.uniprot.org/uniprot/Q9NPB9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1612, http://www.uniprot.org/uniprot/O00421
	
Endogenous ligands	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=829 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10642, http://www.uniprot.org/uniprot/P42830), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=820 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10643, http://www.uniprot.org/uniprot/P80162), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=821 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6025, http://www.uniprot.org/uniprot/P10145), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10638, http://www.uniprot.org/uniprot/O14625), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10618, http://www.uniprot.org/uniprot/P13500), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10632, http://www.uniprot.org/uniprot/P13501), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10610, http://www.uniprot.org/uniprot/P51671), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10612, http://www.uniprot.org/uniprot/Q16627), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10615, http://www.uniprot.org/uniprot/Q92583)	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3422, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10617, http://www.uniprot.org/uniprot/Q99731) [http://www.ncbi.nlm.nih.gov/pubmed/18165312?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3647 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10645, http://www.uniprot.org/uniprot/P47992) [http://www.ncbi.nlm.nih.gov/pubmed/25497737?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4370 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10646, http://www.uniprot.org/uniprot/Q9UBD3) http://www.uniprot.org/uniprot/Q9UBD3]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=771 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10618, http://www.uniprot.org/uniprot/P13500), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=756 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10627, http://www.uniprot.org/uniprot/P10147), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=757 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10630, http://www.uniprot.org/uniprot/P13236), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=758 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10632, http://www.uniprot.org/uniprot/P13501), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=759 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10634, http://www.uniprot.org/uniprot/P80098), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=772 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10635, http://www.uniprot.org/uniprot/P80075), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=769 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10610, http://www.uniprot.org/uniprot/P51671), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=770 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10611, http://www.uniprot.org/uniprot/Q99616), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=753 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10612, http://www.uniprot.org/uniprot/Q16627), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=797 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10615, http://www.uniprot.org/uniprot/Q92583), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=798 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10621, http://www.uniprot.org/uniprot/O00626)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4358 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10672, http://www.uniprot.org/uniprot/P48061) [http://www.ncbi.nlm.nih.gov/pubmed/20956518?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=836 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10638, http://www.uniprot.org/uniprot/O14625)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=810 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10617, http://www.uniprot.org/uniprot/Q99731) [http://www.ncbi.nlm.nih.gov/pubmed/23341447?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=817 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10624, http://www.uniprot.org/uniprot/O15444) http://www.uniprot.org/uniprot/O15444], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=811 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10620, http://www.uniprot.org/uniprot/O00585) http://www.uniprot.org/uniprot/O00585]	–	
Comments	XCL1 cannot be iodinated, but a secreted alkaline phophatase (SEAP)‐XCL1 fusion peptide can be used as a probe at XCR1.	ACKR1 is used by Plasmodium vivax and Plasmodium knowlsei for entering erythrocytes.	–	Several lines of evidence have suggested that CGRP and adrenomedullin could be ligands for ACKR3; however, classical direct binding to the receptor has not yet been convincingly demonstrated [http://www.ncbi.nlm.nih.gov/pubmed/29530506?dopt=AbstractPlus].	–	–	



Comments
Specific chemokine receptors facilitate cell entry by microbes, such as ACKR1 for Plasmodium vivax, and CCR5 and CXCR4 for HIV‐1. Virally encoded chemokine receptors are known (e.g. US28, a homologue of CCR1 from human cytomegalovirus and ORF74, which encodes a homolog of CXCR2 in Herpesvirus saimiri and gamma‐Herpesvirus‐68), but their role in viral life cycles is not established. Viruses can exploit or subvert the chemokine system by producing chemokine antagonists and scavengers. Three chemokine receptor antagonists have now been approved by the FDA: 1) the CCR5 antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=806 (Pfizer) for treatment of HIV/AIDS in patients with CCR5‐using strains; and 2) the CXCR4 antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=844 (Sanofi) for hematopoietic stem cell mobilization with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4934 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2438, http://www.uniprot.org/uniprot/P09919) in patients undergoing transplantation in the context of chemotherapy for Hodgkins’ Disease and multiple myeloma; and 3) the CCR4 blocking antibody Poteligeo (mogamulizumab‐kpkc, Kyowa Kirin, Inc.) for mycosis fungoides or Sezary syndrome.

Further reading on Chemokine receptors
Bachelerie F et al. (2015) An atypical addition to the chemokine receptor nomenclature: IUPHAR Review 15. Br. J. Pharmacol.
172: 3945‐9 [https://www.ncbi.nlm.nih.gov/pubmed/25958743?dopt=AbstractPlus]

Murphy PM et al. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev.
52: 145‐176 [https://www.ncbi.nlm.nih.gov/pubmed/10699158?dopt=AbstractPlus]

Koelink PJ et al. (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol. Ther.
133: 1‐18 [https://www.ncbi.nlm.nih.gov/pubmed/21839114?dopt=AbstractPlus]

Scholten DJ et al. (2012) Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol.
165: 1617‐43 [https://www.ncbi.nlm.nih.gov/pubmed/21699506?dopt=AbstractPlus]

Murphy PM. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev.
54: 227‐9 [https://www.ncbi.nlm.nih.gov/pubmed/12037138?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=15

Overview
Cholecystokinin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on CCK receptors [http://www.ncbi.nlm.nih.gov/pubmed/10581329?dopt=AbstractPlus) are activated by the endogenous peptides cholecystokinin‐8 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569, http://www.uniprot.org/uniprot/P06307)), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=860, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3552, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569) and gastrin (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164, http://www.uniprot.org/uniprot/P01350)). There are only two distinct subtypes of CCK receptors, CCK1 and CCK2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/1373504?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1313582?dopt=AbstractPlus], with some alternatively spliced forms most often identified in neoplastic cells. The CCK receptor subtypes are distinguished by their peptide selectivity, with the CCK1 receptor requiring the carboxyl‐terminal heptapeptide‐amide that includes a sulfated tyrosine for high affinity and potency, while the CCK2 receptor requires only the carboxyl‐terminal tetrapeptide shared by each CCK and gastrin peptides. These receptors have characteristic and distinct distributions, with both present in both the central nervous system and peripheral tissues.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=77
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1570, http://www.uniprot.org/uniprot/P32238
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1571, http://www.uniprot.org/uniprot/P32239
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569, http://www.uniprot.org/uniprot/P06307), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3552, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10221), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=860, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569) http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164, http://www.uniprot.org/uniprot/P01350), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3725 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=861, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569, http://www.uniprot.org/uniprot/P06307), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10221), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=860, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3552, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164, http://www.uniprot.org/uniprot/P01350), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3725, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=861, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569)	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=860 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569, http://www.uniprot.org/uniprot/P06307), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10221), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3552, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=864, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3725 [http://www.ncbi.nlm.nih.gov/pubmed/7681836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3559 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164, http://www.uniprot.org/uniprot/P01350) [http://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=861 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1569, http://www.uniprot.org/uniprot/P06307) [http://www.ncbi.nlm.nih.gov/pubmed/8349705?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3558, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8408, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8409, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8410, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8411, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3562, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3566, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4164)	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=858 [http://www.ncbi.nlm.nih.gov/pubmed/1636779?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3888 [http://www.ncbi.nlm.nih.gov/pubmed/7654246?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=865 [http://www.ncbi.nlm.nih.gov/pubmed/9276016?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=900 [http://www.ncbi.nlm.nih.gov/pubmed/14698161?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3948 [http://www.ncbi.nlm.nih.gov/pubmed/8720482?dopt=AbstractPlus] – Rat	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=890 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/10988332?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=878 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=884 (pIC50 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/8813597?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=904 (pIC50 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/8605955?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=891 (pIC50 6.7–8.2) [http://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2437574?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=887 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/22607579?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9042983?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3503 (pIC50 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/11020274?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=881 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=888 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6665 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/21493750?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=879 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/7681836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3523 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/10385255?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3509 (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/21228869?dopt=AbstractPlus] – Rat	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3476 (Antagonist) (pK
d 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/3018478?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6666 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/3410633?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3478 (Antagonist) (pK
i 9.7–10) [http://www.ncbi.nlm.nih.gov/pubmed/8474432?dopt=AbstractPlus] – Guinea pig, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3472 (Antagonist) (pK
d 9.6) [0905] – Guinea pig, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6666 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/3410633?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3781 (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3821 (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3477 (Antagonist) (pK
d 8.2–8.5) [http://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6667 (Antagonist) (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/19271701?dopt=AbstractPlus]	



Comments
While a cancer‐specific CCK receptor has been postulated to exist, which also might be responsive to incompletely processed forms of CCK (Gly‐extended forms), this has never been isolated. An alternatively spliced form of the CCK2 receptor in which intron 4 is retained, adding 69 amino acids to the intracellular loop 3 (ICL3) region, has been described to be present particularly in certain neoplasms where mRNA mis‐splicing has been commonly observed [http://www.ncbi.nlm.nih.gov/pubmed/12429993?dopt=AbstractPlus], but it is not clear that this receptor splice form plays a special role in carcinogenesis. Another alternative splicing event for the CCK2 receptor was reported [http://www.ncbi.nlm.nih.gov/pubmed/8415658?dopt=AbstractPlus], with alternative donor sites in exon 4 resulting in long (452 amino acids) and short (447 amino acids) forms of the receptor differing by five residues in ICL3, however, no clear functional differences have been observed.

Further reading on Cholecystokinin receptors
Ballaz S. (2017) The unappreciated roles of the cholecystokinin receptor CCK(1) in brain functioning. Rev Neurosci
28: 573‐585 [https://www.ncbi.nlm.nih.gov/pubmed/28343167?dopt=AbstractPlus]

Dockray GJ. (2009) Cholecystokinin and gut‐brain signalling. Regul. Pept.
155: 6‐10 [https://www.ncbi.nlm.nih.gov/pubmed/19345244?dopt=AbstractPlus]

Cawston EE et al. (2010) Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor. Br. J. Pharmacol.
159: 1009‐21 [https://www.ncbi.nlm.nih.gov/pubmed/19922535?dopt=AbstractPlus]

Dufresne M et al. (2006) Cholecystokinin and gastrin receptors. Physiol. Rev.
86: 805‐47 [https://www.ncbi.nlm.nih.gov/pubmed/16816139?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=25

Overview
Receptors of the Class Frizzled (FZD, nomenclature as agreed by the NC‐IUPHAR subcommittee on the Class Frizzled GPCRs [http://www.ncbi.nlm.nih.gov/pubmed/21079039?dopt=AbstractPlus]), are GPCRs originally identified in Drosophila [http://www.ncbi.nlm.nih.gov/pubmed/1334084?dopt=AbstractPlus], which are highly conserved across species. While SMO shows structural resemblance to the 10 FZDs, it is functionally separated as it mediates effects in the Hedgehog signaling pathway [http://www.ncbi.nlm.nih.gov/pubmed/21079039?dopt=AbstractPlus]. FZDs are activated by WNTs, which are cysteine‐rich lipoglycoproteins withfundamentalfunctions inontogeny and tissue homeostasis. FZD signalling was initially divided into two pathways, being either dependent on the accumulation of the transcription regulator http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5371 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2514, http://www.uniprot.org/uniprot/P35222) or being β‐catenin‐independent (often referred to as canonical vs. non‐canonical WNT/FZD signalling, respectively). WNT stimulation of FZDs can, in cooperation with the low density lipoprotein receptors https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6697 (http://www.uniprot.org/uniprot/O75197) and https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6698 (http://www.uniprot.org/uniprot/O75581), lead to the inhibition of a constitutively active destruction complex, which results in the accumulation of β‐catenin and subsequently its translocation to the nucleus. β‐Catenin, in turn, modifies gene transcription by interacting with TCF/LEF transcription factors. βCatenin‐independent FZD signalling is far more complex with regard to the diversity of the activated pathways. WNT/FZD signalling can lead to the activation of heterotrimeric G proteins [http://www.ncbi.nlm.nih.gov/pubmed/24032637?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28790300?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30049420?dopt=AbstractPlus], the elevation of intracellular calcium [http://www.ncbi.nlm.nih.gov/pubmed/9389482?dopt=AbstractPlus], activation of cGMP‐specific PDE6 [http://www.ncbi.nlm.nih.gov/pubmed/12471263?dopt=AbstractPlus] and elevation of cAMP as well as RAC‐1, JNK, Rho and Rho kinase signalling [http://www.ncbi.nlm.nih.gov/pubmed/19651774?dopt=AbstractPlus]. Novel resonance energy transfer‐based tools have allowed the study of the GPCR‐like nature of FZDs in greater detail. Upon ligand stimulation, FZDs undergo conformational changes and signal via heterotrimeric G proteins [http://www.ncbi.nlm.nih.gov/pubmed/30514810?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30737406?dopt=AbstractPlus]. Furthermore, the phosphoprotein Dishevelled constitutes a key player in WNT/FZD signalling. Importantly, FZDs exist in at least two distinct conformational states that regulate the pathway selection [http://www.ncbi.nlm.nih.gov/pubmed/30737406?dopt=AbstractPlus]. As with other GPCRs, members of the Frizzled family are functionally dependent on the arrestin scaffolding protein for internalization [http://www.ncbi.nlm.nih.gov/pubmed/12958365?dopt=AbstractPlus], as well as for β‐catenin‐dependent [http://www.ncbi.nlm.nih.gov/pubmed/17426148?dopt=AbstractPlus] and ‐independent [http://www.ncbi.nlm.nih.gov/pubmed/18953287?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17476309?dopt=AbstractPlus] signalling. The pattern of cell signalling is complicated by the presence of additional ligands, which can enhance or inhibit FZD signalling (secreted Frizzled‐related proteins (sFRP), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5372 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18081, http://www.uniprot.org/uniprot/Q9Y5W5) (WIF), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3704 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13771, http://www.uniprot.org/uniprot/Q9BQB4) or Dickkopf (DKK)), as well as modulatory (co)‐receptors with http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#Type XV RTKs: RYK, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#Type VIII RTKs: ROR1, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304#Type VIII RTKs: ROR2 and Kremen, which may also function as independent signalling proteins.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=229
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=230
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=231
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=232
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=233
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4038, http://www.uniprot.org/uniprot/Q9UP38
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4040, http://www.uniprot.org/uniprot/Q14332
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4041, http://www.uniprot.org/uniprot/Q9NPG1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4042, http://www.uniprot.org/uniprot/Q9ULV1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4043, http://www.uniprot.org/uniprot/Q13467
	
Allosteric modulators	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10321 (Negative) (pIC50 5.5–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/25751279?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10321 (Positive) (pEC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/29293331?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10322 (Negative) (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/25751279?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25751279?dopt=AbstractPlus]	–	
Antibodies	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10197 (Antagonist) (pIC50 ∼9.1) [http://www.ncbi.nlm.nih.gov/pubmed/22753465?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10197 (Antagonist) (pIC50 ∼9) [http://www.ncbi.nlm.nih.gov/pubmed/22753465?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10197 (Antagonist) (pIC50 ∼9) [http://www.ncbi.nlm.nih.gov/pubmed/22753465?dopt=AbstractPlus]	
Comments	–	–	–	–	IgG‐2919 and IgG‐2921 are FZD5 antibodies that have exhibited antitumour activities in vitro and in vivo (inhibiting the growth of RNF43‐mutant pancreatic ductal adenocarcinoma cells/xenograft tumours), by blocking autocrine Wnt‐β‐catenin signalling in these mutant, FZD5‐dependent cells [http://www.ncbi.nlm.nih.gov/pubmed/27869803?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=234
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=235
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=236
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=237
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=238
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4044, http://www.uniprot.org/uniprot/O60353
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4045, http://www.uniprot.org/uniprot/O75084
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4046, http://www.uniprot.org/uniprot/Q9H461
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4047, http://www.uniprot.org/uniprot/O00144
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4039, http://www.uniprot.org/uniprot/Q9ULW2
	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10324 (pIC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/29632413?dopt=AbstractPlus]	–	–	–	
Antibodies	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10197 (Antagonist) (pIC50 ∼9) [http://www.ncbi.nlm.nih.gov/pubmed/22753465?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10197 (Antagonist) (pIC50 ∼8) [http://www.ncbi.nlm.nih.gov/pubmed/22753465?dopt=AbstractPlus]	–	–	
Comments	–	–	FZD8‐Fc/OMP‐54F28 is a FZD8 antagonist [http://www.ncbi.nlm.nih.gov/pubmed/17545618?dopt=AbstractPlus].	–	Radio‐labelled murine monoclonal antibody MAb 92‐13 has been used to demonstrate the therapeutic potential of targeting FZD10‐positive tumours [http://www.ncbi.nlm.nih.gov/pubmed/18271942?dopt=AbstractPlus].	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=239
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11119, http://www.uniprot.org/uniprot/Q99835
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10327) [http://www.ncbi.nlm.nih.gov/pubmed/12391318?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10356 [http://www.ncbi.nlm.nih.gov/pubmed/16408088?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10332 (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/25636740?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10330 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/12391318?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10329 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/10984056?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10328 (pIC50 ∼7) [http://www.ncbi.nlm.nih.gov/pubmed/27338657?dopt=AbstractPlus] – Mouse	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6975 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/23063522?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10326 (Positive) (pEC50 5.9) [http://www.ncbi.nlm.nih.gov/pubmed/23448715?dopt=AbstractPlus]	
Comments	SANT‐3 and SANT‐4 are SMO antagonists [http://www.ncbi.nlm.nih.gov/pubmed/12391318?dopt=AbstractPlus].	



Comments
There is limited knowledge about WNT/FZD specificity and which molecular entities determine the signalling outcome of a specific WNT/FZD pair. Understanding of theFZD and SMO coupling to G proteins is incomplete, but progress have been made [http://www.ncbi.nlm.nih.gov/pubmed/27458145?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24032637?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24873871?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26179037?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16885213?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23292797?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22179044?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30514810?dopt=AbstractPlus]. There is also a scarcity of information on basic pharmacological characteristics of FZDs, such as binding constants, ligand specificity or concentration‐response relationships [http://www.ncbi.nlm.nih.gov/pubmed/19208479?dopt=AbstractPlus]. Development of pharmacological tools for SMO has been faciliated by successful crystalization of several SMO structures [http://www.ncbi.nlm.nih.gov/pubmed/27437577?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/29804838?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25008467?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23636324?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24525480?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28513578?dopt=AbstractPlus]. The recently solved FZD4 in apo state has provided first insight into FZD transmembranous organization [http://www.ncbi.nlm.nih.gov/pubmed/30135577?dopt=AbstractPlus].

Ligands associated with FZD signalling

WNTs: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3672 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12774, http://www.uniprot.org/uniprot/P04628), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3673 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12780, http://www.uniprot.org/uniprot/P09544) (also known as Int‐1‐related protein), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3674 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12781, http://www.uniprot.org/uniprot/Q93097) (also known as WNT‐13), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3675 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12782, http://www.uniprot.org/uniprot/P56703), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3549 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15983, http://www.uniprot.org/uniprot/P56704), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3547 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12783, http://www.uniprot.org/uniprot/P56705), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3548 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12784, http://www.uniprot.org/uniprot/P41221) (pEC50 7.7‐8.9 [http://www.ncbi.nlm.nih.gov/pubmed/30514810?dopt=AbstractPlus]), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3676 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16265, http://www.uniprot.org/uniprot/Q9H1J7), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3678 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12785, http://www.uniprot.org/uniprot/Q9Y6F9), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3679 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12786, http://www.uniprot.org/uniprot/O00755), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12787, http://www.uniprot.org/uniprot/P56706), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3682 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12788, http://www.uniprot.org/uniprot/Q9H1J5), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3683 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12789, http://www.uniprot.org/uniprot/Q93098), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3684 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12778, http://www.uniprot.org/uniprot/O14904) (also known as WNT‐14), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3686 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12779, http://www.uniprot.org/uniprot/O14905) (also known as WNT‐15 or WNT14b), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3687(https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13829, http://www.uniprot.org/uniprot/Q9GZT5), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3688 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12775, http://www.uniprot.org/uniprot/O00744) (also known as WNT‐12), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3689 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12776, http://www.uniprot.org/uniprot/O96014) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3690 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16267, http://www.uniprot.org/uniprot/Q9UBV4).


Extracellular proteins that interact with FZDs:
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1063 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7678, http://www.uniprot.org/uniprot/Q00604), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3700 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16175, http://www.uniprot.org/uniprot/Q2I0M5), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3691 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10776, http://www.uniprot.org/uniprot/Q8N474), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3692 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10777, http://www.uniprot.org/uniprot/Q96HF1), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3693 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3959,http://www.uniprot.org/uniprot/Q92765), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3694 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10778, http://www.uniprot.org/uniprot/Q6FHJ7), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3695 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10779, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10779).


Extracellular proteins that interact with WNTs or LRPs:
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3701 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2891, http://www.uniprot.org/uniprot/O94907), https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18081 (http://www.uniprot.org/uniprot/Q9Y5W5), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3704 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13771, http://www.uniprot.org/uniprot/Q9BQB4), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3702 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17550, http://www.uniprot.org/uniprot/Q96MU8) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3703 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18797, http://www.uniprot.org/uniprot/Q8NCW0)


Small exogenous ligands: Foxy‐5 [http://www.ncbi.nlm.nih.gov/pubmed/18927296?dopt=AbstractPlus], Box‐5 [http://www.ncbi.nlm.nih.gov/pubmed/19901340?dopt=AbstractPlus], UM206 [http://www.ncbi.nlm.nih.gov/pubmed/21931076?dopt=AbstractPlus], and XWnt8 (http://www.uniprot.org/uniprot/P28026) also known as mini‐Wnt8.


Ligands associated with SMO signalling:
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718, oxysterols [http://www.ncbi.nlm.nih.gov/pubmed/27437577?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27705744?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30340023?dopt=AbstractPlus].

Further reading on Class Frizzled GPCRs
Angers S et al. (2009) Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol.
10: [https://www.ncbi.nlm.nih.gov/pubmed/22935904?dopt=AbstractPlus]

van Amerongen R. (2012) Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol
4: 468‐77 [https://www.ncbi.nlm.nih.gov/pubmed/19536106?dopt=AbstractPlus]

Schulte G.(2015)Frizzleds and WNT/β‐cateninsignaling–The black boxof ligand‐receptor selectivity, 113‐39 [https://www.ncbi.nlm.nih.gov/pubmed/26969975?dopt=AbstractPlus]

Wang Y et al. (2016) Frizzled Receptors in Development and Disease. Curr. Top. Dev. Biol.
117: complex stoichiometry and activation kinetics. Eur. J. Pharmacol.
763: 191‐5 [https://www.ncbi.nlm.nih.gov/pubmed/26003275?dopt=AbstractPlus]

Schulte G et al. (2018) Frizzleds as GPCRs ‐ More Conventional Than We Thought! Trends Pharmacol. Sci.
39: 828‐842 [https://www.ncbi.nlm.nih.gov/pubmed/30049420?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=5

Overview
Complement peptide receptors (nomenclature as agreed by the NC‐IUPHAR subcommittee on Complement peptide receptors [http://www.ncbi.nlm.nih.gov/pubmed/23383423?dopt=AbstractPlus]) are activated by the endogenous 75 amino‐acid anaphylatoxin polypeptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1318, http://www.uniprot.org/uniprot/P01024) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1331, http://www.uniprot.org/uniprot/P01031), generated upon stimulation of the complement cascade. C3a and C5a exert their functions through binding to their receptors (C3aR and C5aR), causing cell activation and triggering cellular degranulation that contributes to the local inflammation.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=31
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=32
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=33
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1319, http://www.uniprot.org/uniprot/Q16581
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1338, http://www.uniprot.org/uniprot/P21730
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4527, http://www.uniprot.org/uniprot/Q9P296
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1318, http://www.uniprot.org/uniprot/P01024) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1331, http://www.uniprot.org/uniprot/P01031) [http://www.ncbi.nlm.nih.gov/pubmed/8898085?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1331, http://www.uniprot.org/uniprot/P01031), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=574) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1318, http://www.uniprot.org/uniprot/P01024) [http://www.ncbi.nlm.nih.gov/pubmed/8898085?dopt=AbstractPlus]	–	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3728 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10402, http://www.uniprot.org/uniprot/P39019) [http://www.ncbi.nlm.nih.gov/pubmed/11107061?dopt=AbstractPlus]	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9449 [http://www.ncbi.nlm.nih.gov/pubmed/24257095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8381 [http://www.ncbi.nlm.nih.gov/pubmed/25259874?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10224 [http://www.ncbi.nlm.nih.gov/pubmed/9145417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26297549?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10226
2086, http://www.ncbi.nlm.nih.gov/pubmed/26297549?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10227 [http://www.ncbi.nlm.nih.gov/pubmed/11179594?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7804141?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9746 (Inverse agonist) [http://www.ncbi.nlm.nih.gov/pubmed/18753409?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=572 [http://www.ncbi.nlm.nih.gov/pubmed/1732540?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7930622?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10228 [2276, http://www.ncbi.nlm.nih.gov/pubmed/26297549?dopt=AbstractPlus]	–	
Selective agonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9385 (Biased agonist) [http://www.ncbi.nlm.nih.gov/pubmed/27108698?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9384 (Biased agonist) [http://www.ncbi.nlm.nih.gov/pubmed/27108698?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3529 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/11342658?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8384 (pIC50 5.9) [http://www.ncbi.nlm.nih.gov/pubmed/25259874?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9450 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/27768695?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=581 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/12384495?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9451 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/25385614?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3853 (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/9719594?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=576 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/7930622?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3773) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10092660?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3774) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/4020139?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3774) (Agonist)	
Comments	C3a‐C3aR signalling plays a crucial role in inhibiting neural progenitor cell proliferation during neurodevelopment, playing a critical role in the normal development of the mammalian brain [http://www.ncbi.nlm.nih.gov/pubmed/30449309?dopt=AbstractPlus].	–	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3529 has also been reported to have agonist properties at the C3a receptor [http://www.ncbi.nlm.nih.gov/pubmed/16154494?dopt=AbstractPlus]. The putative chemoattractant receptor termed C5a2 (also known as GPR77, C5L2) binds [125I]C5a with no clear signalling function, but has a putative role opposing inflammatory responses [http://www.ncbi.nlm.nih.gov/pubmed/11773063?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15784721?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15715664?dopt=AbstractPlus]. Binding to this site may be displaced with the rank order http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=574 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1331)> http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=573 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1331, http://www.uniprot.org/uniprot/P01031[http://www.ncbi.nlm.nih.gov/pubmed/11773063?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12899627?dopt=AbstractPlus] while there is controversy over the ability of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3640 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1318, http://www.uniprot.org/uniprot/P01024) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5367 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1318, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1318) to compete [http://www.ncbi.nlm.nih.gov/pubmed/15990859?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12540846?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15833747?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12899627?dopt=AbstractPlus]. C5a2 appears to lack G protein signalling and has been termed a decoy receptor [http://www.ncbi.nlm.nih.gov/pubmed/19100624?dopt=AbstractPlus]. However, C5a2 does recruit arrestin after ligand binding, which might provide a signaling pathway for this receptor [http://www.ncbi.nlm.nih.gov/pubmed/20044484?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19641221?dopt=AbstractPlus], and forms heteromers with C5a1. C5a, but not C5a‐des Arg, induces upregulation of heteromer formation between complement C5a receptors C5a1 and C5a2 [http://www.ncbi.nlm.nih.gov/pubmed/24060963?dopt=AbstractPlus]. There are also reports of pro‐inflammatory activity of C5a2, mediated by HMGB1, but the signaling pathway that underlies this is currently unclear (reviewed in [http://www.ncbi.nlm.nih.gov/pubmed/23239822?dopt=AbstractPlus]). More recently, work in T cells has shown that C5a1 and C5a2 act in opposition to each other and that altering the equilibrium between the two receptors, by differential expression or production of C5a‐des Arg (which favours C5a2), can affect the final cellular response [http://www.ncbi.nlm.nih.gov/pubmed/27313051?dopt=AbstractPlus].

Further reading on Complement peptide receptors
Arbore G et al. (2016) A novel "complement‐metabolism‐inflammasome axis" as a key regulator of immune cell effector function. Eur. J. Immunol.
46: 1563‐73 [https://www.ncbi.nlm.nih.gov/pubmed/27184294?dopt=AbstractPlus]

Coulthard LG et al. (2018) Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance. Mol. Immunol.
101: 176‐181 [https://www.ncbi.nlm.nih.gov/pubmed/30449309?dopt=AbstractPlus]

Laumonnier Y et al. (2017) Novel insights into the expression pattern of anaphylatoxin receptors in mice and men. Mol. Immunol.
89: 44‐58 [https://www.ncbi.nlm.nih.gov/pubmed/28600003?dopt=AbstractPlus]

Li R et al. (2013) C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J.
27: 855‐64 [https://www.ncbi.nlm.nih.gov/pubmed/23239822?dopt=AbstractPlus]

Monk PN et al. (2007) Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol.
152: 429‐48 [https://www.ncbi.nlm.nih.gov/pubmed/17603557?dopt=AbstractPlus]

Reichhardt MP et al. (2018) Intracellular complement activation‐An alarm raising mechanism? Semin. Immunol.
38: 54‐62 [https://www.ncbi.nlm.nih.gov/pubmed/29631809?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=19

Overview
Corticotropin‐releasing factor (CRF, nomenclature as agreed by the NC‐IUPHAR subcommittee on Corticotropin‐releasing Factor Receptors [http://www.ncbi.nlm.nih.gov/pubmed/12615952?dopt=AbstractPlus]) receptors are activated by the endogenous peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2355, http://www.uniprot.org/uniprot/P06850), a 41 aminoacid peptide, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=919 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12516, http://www.uniprot.org/uniprot/P55089), 40 amino‐acids, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=921 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18414, http://www.uniprot.org/uniprot/Q96RP3), 38 amino‐acids and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=928 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17781, http://www.uniprot.org/uniprot/Q969E3), 38 amino‐acids. CRF1 and CRF2 receptors are activated non‐selectively by CRH and UCN. CRF2 receptors are selectively activated by UCN2 and UCN3. Binding to CRF receptors can be conducted using radioligands [125I]Tyr0‐CRF or [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5389‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5389 with K
d values of 0.1‐0.4 nM. CRF1 and CRF2 receptors are non‐selectively antagonized by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=923, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3865) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=925. CRF1 receptors are selectively antagonized by small molecules http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3512, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3520, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3489, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3495, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3496. CRF2 receptors are selectively antagonized by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=931 and astressin 2B.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=212
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=213
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2357, http://www.uniprot.org/uniprot/P34998
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2358, http://www.uniprot.org/uniprot/Q13324
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=919 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12516, http://www.uniprot.org/uniprot/P55089) [http://www.ncbi.nlm.nih.gov/pubmed/15450949?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11123370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8612563?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2355, http://www.uniprot.org/uniprot/P06850) [http://www.ncbi.nlm.nih.gov/pubmed/7692441?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9326293?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11123370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9851694?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7477349?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=921 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18414, http://www.uniprot.org/uniprot/Q96RP3) [http://www.ncbi.nlm.nih.gov/pubmed/15450949?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=928 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17781, http://www.uniprot.org/uniprot/Q969E3)http://www.uniprot.org/uniprot/Q969E3]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3533 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/11907190?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=925 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/24269930?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=925 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/12361401?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3495 (pIC50 9.3–10.4) [http://www.ncbi.nlm.nih.gov/pubmed/8874139?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3499 (pK
i 8.3–9) [http://www.ncbi.nlm.nih.gov/pubmed/10669572?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3512 (pKi 8.3–9) [http://www.ncbi.nlm.nih.gov/pubmed/8893829?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3520 (pK
i 8.3–9) [http://www.ncbi.nlm.nih.gov/pubmed/10867111?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3489 (pK
i 8.3–9) [http://www.ncbi.nlm.nih.gov/pubmed/8940412?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3496 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/18288792?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3498 (pIC50 6.4–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/10357258?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=931 (pK
d 8.8–9.6) [http://www.ncbi.nlm.nih.gov/pubmed/11123370?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3891 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/12110614?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10335 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/12361401?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3890 (pK
i 8.7–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/11835994?dopt=AbstractPlus]	



Comments
A CRF binding protein has been identified (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2356, http://www.uniprot.org/uniprot/P24387) to which both http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2355, http://www.uniprot.org/uniprot/P06850) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=919 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12516, http://www.uniprot.org/uniprot/P55089) bind with high affinities, which has been suggested to bind and inactivate circulating http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=912, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2355) [http://www.ncbi.nlm.nih.gov/pubmed/7595134?dopt=AbstractPlus].

Further reading on Corticotropin‐releasing factor receptors
Deussing JM et al. (2018) The Corticotropin‐Releasing Factor Family: Physiology of the Stress Response. Physiol. Rev.
98: 2225‐2286 [https://www.ncbi.nlm.nih.gov/pubmed/30109816?dopt=AbstractPlus]

Hauger RL et al. (2003) International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin‐releasing factor and their ligands. Pharmacol Rev.
55: 21‐26 [https://www.ncbi.nlm.nih.gov/pubmed/12615952?dopt=AbstractPlus]

Grammatopoulos DK. (2012) Insights into mechanisms of corticotropin‐releasing hormone receptor signal transduction. Br. J. Pharmacol.
166: 85‐97 [https://www.ncbi.nlm.nih.gov/pubmed/21883143?dopt=AbstractPlus]

Liapakis G et al. (2011) Members of CRF family and their receptors: from past to future. Curr. Med. Chem.
18: 2583‐600 [https://www.ncbi.nlm.nih.gov/pubmed/21568890?dopt=AbstractPlus]

Slater PG et al. (2016) Corticotropin‐Releasing Factor Receptors and Their Interacting Proteins: Functional Consequences. Mol. Pharmacol.
90: 627‐632 [https://www.ncbi.nlm.nih.gov/pubmed/27612874?dopt=AbstractPlus]

Zelenay V et al. (2017) Structures of the First Extracellular Domain of CRF Receptors. Curr Mol Pharmacol
10: 318‐324 [https://www.ncbi.nlm.nih.gov/pubmed/28103782?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=20

Overview
Dopamine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Dopamine Receptors [1906]) are commonly divided into D1‐like (D1 and D5) and D2‐like (D2, D3 and D4) families, where the endogenous agonist is http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=214
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=214
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3020, http://www.uniprot.org/uniprot/P21728
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3023, http://www.uniprot.org/uniprot/P14416
	
Sub/family‐selective labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=945 (Antagonist) (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/2144334?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=946 (Antagonist) (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/2168520?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3300 (Antagonist) (pK
d 10.2) [http://www.ncbi.nlm.nih.gov/pubmed/2974511?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10882389?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20122961?dopt=AbstractPlus] – Rat	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=939 [http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=941 [http://www.ncbi.nlm.nih.gov/pubmed/12086487?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=37 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=34 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/23279866?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=35 [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8369 (Biased agonist) [http://www.ncbi.nlm.nih.gov/pubmed/24755247?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7295 [http://www.ncbi.nlm.nih.gov/pubmed/9057850?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=33 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=953 [http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7124 [http://www.ncbi.nlm.nih.gov/pubmed/22711801?dopt=AbstractPlus]	
Sub/family‐selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6077 [http://www.ncbi.nlm.nih.gov/pubmed/16318870?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=935 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2 [http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8443 (Biased agonist) [http://www.ncbi.nlm.nih.gov/pubmed/25660762?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9637 [http://www.ncbi.nlm.nih.gov/pubmed/17067639?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=938 [http://www.ncbi.nlm.nih.gov/pubmed/1973652?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3949 [http://www.ncbi.nlm.nih.gov/pubmed/15980060?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=948 (pK
i 7–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7670 (pK
i 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/15686911?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7557 (pK
i 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/1586393?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=209 (pKi 8.9–9.6) [http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus, 1920], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=96 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/1060115?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=214 (pK
i 8.9–9) [http://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=50 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus]	
Sub/family‐selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943 (pK
i 7.4–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3304 (pKi 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86 (pK
i 7.4–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7907989?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus]	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=177 (pK
i 7.9–8.5) [http://www.ncbi.nlm.nih.gov/pubmed/17095222?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8642550?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=965 (pK
i 7.9–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=94 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8368 (pK
i 7) [http://www.ncbi.nlm.nih.gov/pubmed/24260782?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24666157?dopt=AbstractPlus]	
Labelled ligands	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3299 (Antagonist) (pK
d 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/4015674?dopt=AbstractPlus] – Rat	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=216
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=216
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=218
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=218
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3024, http://www.uniprot.org/uniprot/P35462
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3025, http://www.uniprot.org/uniprot/P21917
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3026, http://www.uniprot.org/uniprot/P21918
	
Sub/family‐selective labelled ligands	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3300 (Antagonist) (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/7777184?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=946 (Antagonist) (pK
d 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/8051291?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=953 [http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=35 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7295 [http://www.ncbi.nlm.nih.gov/pubmed/9057850?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=33 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=33 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus]	–	
Sub/family‐selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2 [http://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2 [http://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6077 [http://www.ncbi.nlm.nih.gov/pubmed/16318870?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=952 [http://www.ncbi.nlm.nih.gov/pubmed/8531103?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=975 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15448188?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3301 [http://www.ncbi.nlm.nih.gov/pubmed/16153699?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3301]	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98 (pK
i 8–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus, 1920], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7279 (pK
i 8.4) [79], (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=958 (pK
i 6.7–7.7) [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8301592?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205 (pK
i 7.7) [1920], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=965 (pK
i 7.1–7.6) [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7281 (pK
i 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/16135699?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7556 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/9577836?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=98 (pK
i 7.8–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/16135699?dopt=AbstractPlus, 1920, http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=980 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/9098699?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=205 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus]	–	
Sub/family‐selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86 (pK
i 7.5–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=86 (pK
i 8.7–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/8102973?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=943 (pK
i 7.5–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3304 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=129 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/10869410?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=44 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/8531087?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6675 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/17672446?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6674 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/17627675?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=143 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/10945872?dopt=AbstractPlus], (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=955 (pK
i 6.9–7.9) [http://www.ncbi.nlm.nih.gov/pubmed/7988633?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3303 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/8642550?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8441 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/15992586?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3302 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/8642551?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8440 (pK
i 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/25221667?dopt=AbstractPlus]	–	
Selective allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7694 (Negative) (pKi ∼9) [http://www.ncbi.nlm.nih.gov/pubmed/25583363?dopt=AbstractPlus]	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3300 (Antagonist) (pK
d 9.9) [http://www.ncbi.nlm.nih.gov/pubmed/10882389?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20122961?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3296 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7759603?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3298 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7674830?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3295 (Antagonist) (pK
d 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3297 (Antagonist) (pK
d 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/9262371?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=945 (Antagonist) (pK
d 9.1)	



Comments
The selectivity of many of these agents is less than two orders of magnitude. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3299 exhibits similar high affinity for D2 and D3 receptors (low affinity for D4), but has been used to label D2 receptors in the presence of a D3‐selective antagonist. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3296 has similar affinity for D2 and D3 receptors, but labels only D3 receptors in the absence of divalent cations. The pharmacological profile of the D5 receptor is similar to, yet distinct from, that of the D1 receptor. The splice variants of the D2 receptor are commonly termed D2S and D2L (short and long). The DRD4 gene encoding the D4 receptor is highly polymorphic in humans, with allelic variations of the protein from amino acid 387 to 515.

Further reading on Dopamine receptors
Beaulieu JM et al. (2015) Dopamine receptors ‐ IUPHAR Review 13. Br. J. Pharmacol.
172: 1‐23 [https://www.ncbi.nlm.nih.gov/pubmed/25671228?dopt=AbstractPlus]

Beaulieu JM et al. (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev.
63: 182‐217 [https://www.ncbi.nlm.nih.gov/pubmed/21303898?dopt=AbstractPlus]

Cumming P. (2011) Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review. Synapse
65: 892‐909 [https://www.ncbi.nlm.nih.gov/pubmed/21308799?dopt=AbstractPlus]

Maggio R et al. (2010) Dopamine D2‐D3 receptor heteromers: pharmacological properties and therapeutic significance. Curr Opin Pharmacol
10: 100‐7 [https://www.ncbi.nlm.nih.gov/pubmed/19896900?dopt=AbstractPlus]

Ptácek R et al. (2011) Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. Med. Sci. Monit.
17: RA215‐20 [https://www.ncbi.nlm.nih.gov/pubmed/21873960?dopt=AbstractPlus]

Schwartz J‐C et al. (1998) Dopamine Receptors. In The IUPHAR Compendium of Receptor Characterization and Classification Edited by Girdlestone D: IUPHAR Media: 141‐151

Undieh AS. (2010) Pharmacology of signaling induced by dopamine D(1)‐like receptor activation. Pharmacol. Ther.
128: 37‐60 [https://www.ncbi.nlm.nih.gov/pubmed/20547182?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=21

Overview
Endothelin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Endothelin Receptors [http://www.ncbi.nlm.nih.gov/pubmed/12037137?dopt=AbstractPlus]) are activated by the endogenous 21 amino‐acid peptides endothelins 1‐3 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3176, http://www.uniprot.org/uniprot/P05305), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3177, http://www.uniprot.org/uniprot/P20800) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3178, http://www.uniprot.org/uniprot/P14138)).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3179, http://www.uniprot.org/uniprot/P25101
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3180, http://www.uniprot.org/uniprot/P24530
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3176, http://www.uniprot.org/uniprot/P05305) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3177, http://www.uniprot.org/uniprot/P20800) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3178, http://www.uniprot.org/uniprot/P14138) [http://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3176, http://www.uniprot.org/uniprot/P05305) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3177, http://www.uniprot.org/uniprot/P20800), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3178, http://www.uniprot.org/uniprot/P14138) [http://www.ncbi.nlm.nih.gov/pubmed/2175397?dopt=AbstractPlus]	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1008 [http://www.ncbi.nlm.nih.gov/pubmed/8587419?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3859 [http://www.ncbi.nlm.nih.gov/pubmed/7733918?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3837]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3837 [http://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3886 [http://www.ncbi.nlm.nih.gov/pubmed/1320877?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3528 (pK
B 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/8201588?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3913 (pA
2 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/7780649?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3494 (pA
2 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8035319?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3528 (pK
B 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/8201588?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3913 (pA
2 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/7780649?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3494 (pKi 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/12502366?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7352 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/22862294?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3950 (pA
2 8) [http://www.ncbi.nlm.nih.gov/pubmed/9171878?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=998 (Inverse agonist) (pIC50 7.3–7.9) [http://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=997 (pA
2 6.9–7.4) [http://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3951 (pA
2 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/15139756?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9651 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/28805809?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1009 (pK
d 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/10479298?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1010 (pK
d 7.9–8) [http://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3887 (pK
d 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1011 (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/8612786?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1002 (Antagonist) (pK
d 9.6–9.8) [http://www.ncbi.nlm.nih.gov/pubmed/9489609?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3479 (Antagonist) (pK
d 9.2), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1001 (Antagonist) (pK
d 9–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/8012722?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1003 (Antagonist) (pK
d 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/7768260?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1007 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8301559?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1005 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8587429?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7881728?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3760]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3760 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus]	



Comments
Splice variants of the ETA receptor have been identified in rat pituitary cells; one of these, ETAR‐C13, appeared to show loss of function with comparable plasma membrane expression to wild type receptor [http://www.ncbi.nlm.nih.gov/pubmed/17312275?dopt=AbstractPlus]. Subtypes of the ETB receptor have been proposed, although gene disruption studies in mice suggest that only a single gene product exists [http://www.ncbi.nlm.nih.gov/pubmed/9113361?dopt=AbstractPlus]. Crystal structures of the ETB receptor bound to the antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3494 and ETB selective analogue http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9651 [http://www.ncbi.nlm.nih.gov/pubmed/28805809?dopt=AbstractPlus] and selective ETB agonists http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1004 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3178, http://www.uniprot.org/uniprot/P14138) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3886 [http://www.ncbi.nlm.nih.gov/pubmed/30413709?dopt=AbstractPlus] have been reported.

Further reading on Endothelin receptors
Clozel M et al. (2013) Endothelin receptor antagonists. Handb Exp Pharmacol
218: 199‐227 https://www.ncbi.nlm.nih.gov/pubmed/24092342?dopt=AbstractPlus


Davenport AP. (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev.
54: 219‐26 https://www.ncbi.nlm.nih.gov/pubmed/12037137?dopt=AbstractPlus


Davenport AP et al. (2016) Endothelin. Pharmacol. Rev.
68: 357‐418 https://www.ncbi.nlm.nih.gov/pubmed/26956245?dopt=AbstractPlus


Davenport AP et al. (2018) New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine. Physiol Res
67: S37‐S54 https://www.ncbi.nlm.nih.gov/pubmed/29947527?dopt=AbstractPlus


Maguire JJ et al. (2014) Endothelin@25 ‐ new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br. J. Pharmacol.
171: 5555‐72 https://www.ncbi.nlm.nih.gov/pubmed/25131455?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=22

Overview
The G protein‐coupled estrogen receptor (GPER, nomenclature as agreed by the NC‐IUPHAR Subcommittee on the G protein‐coupled estrogen receptor [http://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus]) was identified following observations of estrogen‐evoked http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352 signalling in breast cancer cells [http://www.ncbi.nlm.nih.gov/pubmed/8078914?dopt=AbstractPlus], which mirrored the differential expression of an orphan 7‐transmembrane receptor GPR30 [http://www.ncbi.nlm.nih.gov/pubmed/9367686?dopt=AbstractPlus]. There are observations of both cell‐surface and intracellular expression of the GPER receptor [http://www.ncbi.nlm.nih.gov/pubmed/15705806?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus]. Selective agonist/ antagonists for GPER have been characterized [http://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus]. Antagonists of the nuclear estrogen receptor, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1015 [http://www.ncbi.nlm.nih.gov/pubmed/11043579?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016 [http://www.ncbi.nlm.nih.gov/pubmed/15705806?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820 [http://www.ncbi.nlm.nih.gov/pubmed/24379833?dopt=AbstractPlus], as well as the flavonoid ’phytoestrogens’ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5346 [http://www.ncbi.nlm.nih.gov/pubmed/15090535?dopt=AbstractPlus], are agonists of GPER. A complete review of GPER pharmacology has been recently published [http://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus]. The roles of GPER in physiological systems throughout the body (cardiovascular, metabolic, endocrine, immune, reproductive) and in cancer have also been reviewed [http://www.ncbi.nlm.nih.gov/pubmed/28595943?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28249728?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28343901?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26189910?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=221
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4485, http://www.uniprot.org/uniprot/Q99527
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1015 [http://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820 [http://www.ncbi.nlm.nih.gov/pubmed/24379833?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2817 [http://www.ncbi.nlm.nih.gov/pubmed/15705806?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1014 [http://www.ncbi.nlm.nih.gov/pubmed/16520733?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6480 (pIC50 6.8–6.9) [http://www.ncbi.nlm.nih.gov/pubmed/21782022?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3320 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/19430488?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1012 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus]	



Comments
Antagonists at the nuclear estrogen receptor, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1015, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016 [http://www.ncbi.nlm.nih.gov/pubmed/11043579?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2820 [http://www.ncbi.nlm.nih.gov/pubmed/24379833?dopt=AbstractPlus], as well as the flavonoid ‘phytoestrogens’ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2826 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5346 [http://www.ncbi.nlm.nih.gov/pubmed/15090535?dopt=AbstractPlus], are agonists at GPER receptors. A complete review of GPER pharmacology has been recently published [http://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus].

Further reading on G protein‐coupled estrogen receptor
Barton M et al. (2018) Twenty years of the G protein‐coupled estrogen receptor GPER: Historical and personal perspectives. J. Steroid Biochem. Mol. Biol.
176: 4‐15 https://www.ncbi.nlm.nih.gov/pubmed/28347854?dopt=AbstractPlus


Gaudet HM et al. (2015) The G‐protein coupled estrogen receptor, GPER: The inside and inside‐out story. Mol. Cell. Endocrinol.
418 Pt 3: 207‐19 https://www.ncbi.nlm.nih.gov/pubmed/26190834?dopt=AbstractPlus


Prossnitz ER et al. (2015) International Union of Basic and Clinical Pharmacology. XCVII. G Protein‐Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol. Rev.
67: 505‐40 https://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus


Prossnitz ER et al. (2015) What have we learned about GPER function in physiology and disease from knockout mice? J. Steroid Biochem. Mol. Biol.
153: 114‐26 https://www.ncbi.nlm.nih.gov/pubmed/26189910?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=23

Overview
The http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00510000502765 (nomenclature agreed by the NC‐IUPHAR Subcommittee on the formylpeptide receptor family [http://www.ncbi.nlm.nih.gov/pubmed/19498085?dopt=AbstractPlus]) respond to exogenous ligands such as the bacterial product http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022 (fMLP) and endogenous ligands such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:533, http://www.uniprot.org/uniprot/P04083), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3570 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2532, http://www.uniprot.org/uniprot/P08311), amyloid β42, serum amyloid A and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1026, derived from http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5370 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4827, http://www.uniprot.org/uniprot/P68871).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=222
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=224
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3826, http://www.uniprot.org/uniprot/P21462
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3827, http://www.uniprot.org/uniprot/P25090
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3828, http://www.uniprot.org/uniprot/P25089
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3570 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2532, http://www.uniprot.org/uniprot/P08311) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:533, http://www.uniprot.org/uniprot/P04083) [http://www.ncbi.nlm.nih.gov/pubmed/12401407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15210802?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3402
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022 [http://www.ncbi.nlm.nih.gov/pubmed/10393980?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8527441?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11141472?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9151906?dopt=AbstractPlus]	–	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6239 [http://www.ncbi.nlm.nih.gov/pubmed/22449948?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3935 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17176, http://www.uniprot.org/uniprot/Q9NRV9) [http://www.ncbi.nlm.nih.gov/pubmed/15623572?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022 [http://www.ncbi.nlm.nih.gov/pubmed/7387981?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1262785?dopt=AbstractPlus]	–	–	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383 [http://www.ncbi.nlm.nih.gov/pubmed/15056011?dopt=AbstractPlus]	–	
Endogenous antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1026 (pIC50 4.3) [http://www.ncbi.nlm.nih.gov/pubmed/11714831?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1373134?dopt=AbstractPlus]	–	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1030 (pK
i 6–6.5) [http://www.ncbi.nlm.nih.gov/pubmed/8387097?dopt=AbstractPlus]	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1025 (pK
i 6.1–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/8387097?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17082621?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1040 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/15210823?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1030 (pIC50 4.3–6) [http://www.ncbi.nlm.nih.gov/pubmed/6280748?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17687636?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10882119?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1018 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/6285921?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3411 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1322894?dopt=AbstractPlus]	–	
Comments	A FITC‐conjugated fMLP analogue has been used for binding to the mouse recombinant receptor [http://www.ncbi.nlm.nih.gov/pubmed/23160941?dopt=AbstractPlus].	–	–	



Comments
Note that the data for FPR2/ALX are also reproduced on the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35 receptor page.

Further reading on Formylpeptide receptors
Dorward DA et al. (2015) The Role of Formylated Peptides and Formyl Peptide Receptor 1 in Governing Neutrophil Function during Acute Inflammation. Am. J. Pathol.
185: 1172‐1184 https://www.ncbi.nlm.nih.gov/pubmed/25791526?dopt=AbstractPlus


Dufton N et al. (2010) Therapeutic anti‐inflammatory potential of formyl‐peptide receptor agonists. Pharmacol. Ther.
127: 175‐88 https://www.ncbi.nlm.nih.gov/pubmed/20546777?dopt=AbstractPlus


Liu M et al. (2012) G protein‐coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Int. Immunopharmacol.
14: 283‐8 https://www.ncbi.nlm.nih.gov/pubmed/22863814?dopt=AbstractPlus


Rabiet MJ et al. (2011) N‐formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX receptor with regard to the major processes governing chemoattractant receptor regulation, expression at the cell surface, and phosphorylation. J. Biol. Chem.
286: 26718‐31 https://www.ncbi.nlm.nih.gov/pubmed/21543323?dopt=AbstractPlus


Yazid S et al. (2012) Anti‐inflammatory drugs, eicosanoids and the annexin A1/FPR2 anti‐inflammatory system. Prostaglandins Other Lipid Mediat.
98: 94‐100 https://www.ncbi.nlm.nih.gov/pubmed/22123264?dopt=AbstractPlus


Ye RD et al. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev.
61: 119‐61 https://www.ncbi.nlm.nih.gov/pubmed/19498085?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=24

Overview
Free fatty acid receptors (FFA, nomenclature as agreed by the NC‐IUPHAR Subcommittee on free fatty acid receptors [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19047536?dopt=AbstractPlus]) are activated by free fatty acids. Long‐chain saturated and unsaturated fatty acids (including C14.0 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806), C16:0 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1055), C18:1 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054), C18:2 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052), C18:3, (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049), C20:4 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391), C20:5,n‐3 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362) and C22:6,n‐3 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051)) activate FFA1 [http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus] and FFA4 receptors [http://www.ncbi.nlm.nih.gov/pubmed/15619630?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22343897?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20813258?dopt=AbstractPlus], while short chain fatty acids (C2 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058), C3 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062), C4 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059) and C5 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1061)) activate FFA2 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus] and FFA3 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus] receptors. The crystal structure for agonist bound FFA1 has been described [http://www.ncbi.nlm.nih.gov/pubmed/25043059?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=225
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=226
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4498, http://www.uniprot.org/uniprot/O14842
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4501, http://www.uniprot.org/uniprot/O15552
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051 [http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 [http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 [http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806 [http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6499 [http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6500 [http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6485 [http://www.ncbi.nlm.nih.gov/pubmed/22859723?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9148 [http://www.ncbi.nlm.nih.gov/pubmed/27074625?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6483 [http://www.ncbi.nlm.nih.gov/pubmed/23687558?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9149 [http://www.ncbi.nlm.nih.gov/pubmed/22724451?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1050 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6484 [http://www.ncbi.nlm.nih.gov/pubmed/25787200?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24900210?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25043059?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21752941?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10107 [http://www.ncbi.nlm.nih.gov/pubmed/30247908?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1057 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17200419?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8417 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/26852904?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25380412?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6487 (pIC50 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/23066016?dopt=AbstractPlus]	
Comments	A wide range of both saturated and unsaturated fatty acids containing from 6 to 22 carbons have been shown to act as agonists at FFA1 [http://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus]. Antagonist GW1100 is also an oxytocin receptor antagonist [http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus]. Fasiglifam, TUG‐770 and GW9508 are approximately 100 fold selective for FFA1 over FFA4 [http://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23687558?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24900210?dopt=AbstractPlus]. AMG‐837 and the related analogue AM6331 have been suggested to have an allosteric mechanism of action at FFA1, with respect to the orthosteric fatty acid binding site [http://www.ncbi.nlm.nih.gov/pubmed/22859723?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23403053?dopt=AbstractPlus].	–	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=227
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=127
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=228
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4499, http://www.uniprot.org/uniprot/O14843
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19061, http://www.uniprot.org/uniprot/Q5NUL3
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4500, http://www.uniprot.org/uniprot/O15529
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1062 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6500 [http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 [http://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806 [http://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1049 [http://www.ncbi.nlm.nih.gov/pubmed/18320172?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054 [http://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus]	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058 [http://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus]	–	–	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8418 [http://www.ncbi.nlm.nih.gov/pubmed/24997608?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6490 [http://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5587 [http://www.ncbi.nlm.nih.gov/pubmed/19007110?dopt=AbstractPlus]	–	
Comments	Beta‐hydroxybutyrate has been reported to antagonise FFA3 responses to short chain fatty acids [http://www.ncbi.nlm.nih.gov/pubmed/21518883?dopt=AbstractPlus]. A range of FFA3 selective molecules with agonist and antagonist properties, but which bind at sites distinct from the short chain fatty acid binding site (i.e. allosteric modulators), have been described [http://www.ncbi.nlm.nih.gov/pubmed/27385588?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24870406?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26808470?dopt=AbstractPlus].	A wide range of both saturated and unsaturated fatty acids containing from 6 to 22 carbons have been shown to act as agonists at FFA4 [http://www.ncbi.nlm.nih.gov/pubmed/25916176?dopt=AbstractPlus] with a small subset listed above. Compound A [PMID 24997608] exhibits more than 1000 fold selectivity [http://www.ncbi.nlm.nih.gov/pubmed/24997608?dopt=AbstractPlus], and TUG‐891 50‐1000 fold selectivity for FFA4 over FFA1 [http://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus], dependent on the assay. NGC21 exhibits approximately 15 fold selectivity for FFA4 over FFA1 [http://www.ncbi.nlm.nih.gov/pubmed/20685848?dopt=AbstractPlus].	–	



Comments
Short (361 amino acids) and long (377 amino acids) splice variants of human FFA4 have been reported [http://www.ncbi.nlm.nih.gov/pubmed/19723586?dopt=AbstractPlus], which differ by a 16 amino acid insertion in intracellular loop 3, and exhibit differences in intracellular signalling properties in recombinant systems [http://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus]. The long FFA4 splice variant has not been identified in other primates or rodents to date [http://www.ncbi.nlm.nih.gov/pubmed/15619630?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19723586?dopt=AbstractPlus].


https://www.genenames.org/data/gene‐symbol‐report/%23!/hgnc_id/HGNC:4500 was originally described as a pseudogene within the family (http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000002583), but the discovery of several polymorphisms suggests that some versions of GPR42 may be functional [http://www.ncbi.nlm.nih.gov/pubmed/19630535?dopt=AbstractPlus]. https://www.genenames.org/data/gene‐symbol‐report/%23!/hgnc_id/HGNC:4535 is a structurally‐unrelated G protein‐coupled receptor which has been found to respond to medium chain fatty acids [http://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus].

Further reading on Free fatty acid receptors
Bolognini D et al. (2016) The Pharmacology and Function of Receptors for Short‐Chain Fatty Acids. Mol. Pharmacol.
89: 388‐98 https://www.ncbi.nlm.nih.gov/pubmed/26719580?dopt=AbstractPlus


Mancini AD et al. (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol. Metab.
24: 398‐407 https://www.ncbi.nlm.nih.gov/pubmed/23631851?dopt=AbstractPlus


Milligan G et al. (2017) Complex Pharmacology of Free Fatty Acid Receptors. Chem. Rev.
117: 67‐110 https://www.ncbi.nlm.nih.gov/pubmed/27299848?dopt=AbstractPlus


Moniri NH. (2016) Free‐fatty acid receptor‐4 (GPR120): Cellular and molecular function and its role in metabolic disorders. Biochem. Pharmacol.
110‐111: 1‐15 https://www.ncbi.nlm.nih.gov/pubmed/26827942?dopt=AbstractPlus


Stoddart LA et al. (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, ‐2, and ‐3: pharmacology and pathophysiological functions. Pharmacol. Rev.
60: 405‐17 [https://www.ncbi.nlm.nih.gov/pubmed/19047536?dopt=AbstractPlus]

Watterson KR et al. (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front Endocrinol (Lausanne)
5: 137 [https://www.ncbi.nlm.nih.gov/pubmed/25221541?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=26

Overview
Functional GABAB receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on GABAB receptors [http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17329545?dopt=AbstractPlus]) are formed from the heterodimerization of two similar 7TM subunits termed GABAB1 and GABAB2 [http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17499108?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17329545?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17433877?dopt=AbstractPlus]. GABAB receptors are widespread in the CNS and regulate both pre‐ and postsynaptic activity. The GABAB1 subunit, when expressed alone, binds both antagonists and agonists, but the affinity of the latter is generally 10‐100fold less than for the native receptor. Co‐expression of GABAB1 and GABAB2 subunits allows transport of GABAB1 to the cell surface and generates a functional receptor that can couple to signal transduction pathways such as high‐voltage‐activated Ca2+ channels (Cav2.1, Cav2.2), or inwardly rectifying potassium channels (Kir3) [http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10604925?dopt=AbstractPlus]. The GABAB1 subunit harbours the GABA (orthosteric)‐binding site within an extracellular domain (ECD) venus flytrap module (VTM), whereas the GABAB2 subunit mediates G protein‐coupled signalling [http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24305054?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22660477?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus]. The two subunits interact by direct allosteric coupling [http://www.ncbi.nlm.nih.gov/pubmed/21063387?dopt=AbstractPlus], such that GABAB2 increases the affinity of GABAB1 for agonists and reciprocally GABAB1 facilitates the coupling of GABAB2 to G proteins [http://www.ncbi.nlm.nih.gov/pubmed/24305054?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15922585?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus]. GABAB1 and GABAB2 subunits assemble in a 1:1 stoichiometry by means of a coiled‐coil interaction between α‐helices within their carboxy‐termini that masks an endoplasmic reticulum retention motif (RXRR) within the GABAB1 subunit but other domains of the proteins also contribute to their heteromerization [http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24778228?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus]. Recent evidence indicates that higher order assemblies of GABAB receptor comprising dimers of heterodimers occur in recombinant expression systems and in vivo and that such complexes exhibit negative functional cooperativity between heterodimers [http://www.ncbi.nlm.nih.gov/pubmed/21552208?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19723778?dopt=AbstractPlus]. Adding further complexity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b and 16 associate as tetramers with the carboxy terminus of the GABAB2 subunit to impart altered signalling kinetics and agonist potency to the receptor complex [http://www.ncbi.nlm.nih.gov/pubmed/20406808?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20400944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24836506?dopt=AbstractPlus] and are reviewed by [http://www.ncbi.nlm.nih.gov/pubmed/20655485?dopt=AbstractPlus]. The molecular complexity of GABAB receptors is further increased through association with trafficking and effector proteins [Schwenk et al., 2016, Nature Neuroscience 19(2): 233‐42] and reviewed by [http://www.ncbi.nlm.nih.gov/pubmed/27905440?dopt=AbstractPlus]. Four isoforms of the human GABAB1 subunit have been cloned. The predominant GABAB1a and GABAB1b isoforms, which are most prevalent in neonatal and adult brain tissue respectively, differ in their ECD sequences as a result of the use of alternative transcription initiation sites. GABAB1a‐containing heterodimers localise todistal axonsand mediate inhibition of glutamate release in the CA3‐CA1 terminals, and GABA release onto the layer 5 pyramidal neurons, whereas GABAB1b‐containing receptors occur within dendritic spines and mediate slow postsynaptic inhibition [http://www.ncbi.nlm.nih.gov/pubmed/16701210?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16701209?dopt=AbstractPlus]. Only the 1a and 1b variants are identified as components of native receptors [http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus]. Additional GABAB1 subunit isoforms have been described in rodents and humans [http://www.ncbi.nlm.nih.gov/pubmed/21124972?dopt=AbstractPlus] and reviewed by [http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242
	
Subunits	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=240, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241,http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1919 (Accessory protein), http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1920 (Accessory protein), http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1918 (Accessory protein), http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1917 (Accessory protein)	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1082 [635] – Rat, (‐)‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1064 [635] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1081 [http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1084 [http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1080 [http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1072 (pK
i 8.5–8.9) [http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1088 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1075 (pK
i 5.5–6) [http://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1069 (pK
i 4.4) [http://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1068 (pIC50 4.1) [http://www.ncbi.nlm.nih.gov/pubmed/9069281?dopt=AbstractPlus] – Rat	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10267 (Positive) (pEC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/18536733?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446 (Positive) (pK
B 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/29514854?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12954816?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8539 (Negative) (pIC50 4.4) [http://www.ncbi.nlm.nih.gov/pubmed/25050158?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/11641424?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1090 (Antagonist) (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/9872315?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3429 (Antagonist) (pK
d 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/10521582?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1076 (Antagonist) (pK
d 9) [http://www.ncbi.nlm.nih.gov/pubmed/10692480?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1077 (Antagonist) (pK
d 9) [http://www.ncbi.nlm.nih.gov/pubmed/9069281?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3428 (Agonist)	




Subunits
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=240
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4070, http://www.uniprot.org/uniprot/Q9UBS5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4507, http://www.uniprot.org/uniprot/O75899
	



Comments
Potencies of agonists and antagonists listed in the table, quantified as IC50 values for the inhibition of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5381 binding to rat cerebral cortex membranes, are from [http://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus, 635]. Radioligand K
D values relate to binding to rat brain membranes. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1074 is a photoaffinity ligand for the GABAB1 subunit [http://www.ncbi.nlm.nih.gov/pubmed/10658574?dopt=AbstractPlus]. CGP27492 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1081), CGP35024 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1080) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1082 act as antagonists at human GABAA
ρ1 receptors, with potencies in the low micromolar range [http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus]. In addition to the ligands listed in the table, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707 binds to the VTM of the GABAB1 subunit to act as a positive allosteric modulator of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067 [http://www.ncbi.nlm.nih.gov/pubmed/10692480?dopt=AbstractPlus]. Synthetic positive allosteric modulators with low, or no, intrinsic activity include http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5503 [http://www.ncbi.nlm.nih.gov/pubmed/21181127?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5504 [http://www.ncbi.nlm.nih.gov/pubmed/17894647?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15126507?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus]. The site of action of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446 appears to be on the heptahelical domain of the GABAB2 subunit [http://www.ncbi.nlm.nih.gov/pubmed/16966477?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus]. In the presence of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1079 or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5446, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1069 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1068 behave as partial agonists [http://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus]. A negative allosteric modulator of GABAB activity has been reported [http://www.ncbi.nlm.nih.gov/pubmed/25050158?dopt=AbstractPlus]. Knock‐out of the GABAB1 subunit in C57B mice causes the development of severe tonic‐clonic convulsions that prove fatal within a month of birth, whereas GABAB1
‐/‐ BALB/c mice, although also displaying spontaneous epileptiform activity, are viable. The phenotype of the latter animals additionally includes hyperalgesia, hyperlocomotion (in a novel, but not familiar, environment), hyperdopaminergia, memory impairment and behaviours indicative of anxiety [http://www.ncbi.nlm.nih.gov/pubmed/15451397?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16606363?dopt=AbstractPlus]. A similar phenotype has been found for GABAB2
‐/‐ BALB/c mice [http://www.ncbi.nlm.nih.gov/pubmed/15240800?dopt=AbstractPlus].

Further reading on GABAB receptors
Bowery NG et al. (2002) International Union of Pharmacology. XXXIII. Mammalian gammaaminobutyricacid(B) receptors: structure and function. Pharmacol Rev.
54: 247‐264 [https://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus]

Froestl W. (2011) An historical perspective on GABAergic drugs. Future Med Chem
3: 163‐75 [https://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus]

Gassmann M et al. (2012) Regulation of neuronal GABA(B) receptor functions by subunit composition. Nat. Rev. Neurosci.
13: 380‐94 [https://www.ncbi.nlm.nih.gov/pubmed/22595784?dopt=AbstractPlus]

Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature
540: 60‐68 [https://www.ncbi.nlm.nih.gov/pubmed/27905440?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=27

Overview
Galanin receptors (provisional nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4114, http://www.uniprot.org/uniprot/P22466) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24840, http://www.uniprot.org/uniprot/Q9UBC7). Human http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4114, http://www.uniprot.org/uniprot/P22466) is a 30 amino‐acid non‐amidated peptide [http://www.ncbi.nlm.nih.gov/pubmed/1714839?dopt=AbstractPlus]; in other species, it is 29 amino acids long and C‐terminally amidated. Amino acids 1–14 of galanin are highly conserved in mammals, birds, reptiles, amphibia and fish. Shorter peptide species (e.g. human galanin‐1–19 [http://www.ncbi.nlm.nih.gov/pubmed/1710578?dopt=AbstractPlus] and porcine galanin‐5–29 [http://www.ncbi.nlm.nih.gov/pubmed/1283627?dopt=AbstractPlus]) and N‐terminally extended forms (e.g. N‐terminally seven and nine residue elongated forms of porcine galanin [http://www.ncbi.nlm.nih.gov/pubmed/1718731?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1283627?dopt=AbstractPlus]) have been reported.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=243
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=244
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=245
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4132, http://www.uniprot.org/uniprot/P47211
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4133, http://www.uniprot.org/uniprot/O43603
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4134, http://www.uniprot.org/uniprot/O60755
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4114, http://www.uniprot.org/uniprot/P22466) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24840, http://www.uniprot.org/uniprot/Q9UBC7) [http://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24840, http://www.uniprot.org/uniprot/Q9UBC7) ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4114, http://www.uniprot.org/uniprot/P22466) [http://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3594 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24840, http://www.uniprot.org/uniprot/Q9UBC7) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3592 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4114, http://www.uniprot.org/uniprot/P22466) [http://www.ncbi.nlm.nih.gov/pubmed/15944009?dopt=AbstractPlus]	
Agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3876) [http://www.ncbi.nlm.nih.gov/pubmed/9832122?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9742938?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9405385?dopt=AbstractPlus] – Rat	–	
Selective agonists	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3866) [http://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus] – Rat	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3486 (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/10896115?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3900 (pK
i 7.9) [2010]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6125 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/16789730?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16730981?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16287967?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6126 (pK
i 7.8–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/16789730?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16730981?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16287967?dopt=AbstractPlus]	
Selective allosteric modulators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8547 (Positive) (pEC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/20660766?dopt=AbstractPlus] – Rat	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5391 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5391 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5391 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6117 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9880084?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus]	
Comments	–	The CYM2503 PAM potentiates the anticonvulsant activity of endogenous galanin in mouse seizure models [http://www.ncbi.nlm.nih.gov/pubmed/20660766?dopt=AbstractPlus].	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5356) is a high‐affinity agonist at GAL1/GAL2 (pKi 9), and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5357) is selective for GAL2 and GAL3 compared with GAL1 [http://www.ncbi.nlm.nih.gov/pubmed/15944007?dopt=AbstractPlus]. [125I]‐[Tyr26]galanin binds to all three subtypes with K
d values generally reported to range from 0.05 to 1 nM, depending on the assay conditions used [http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2436195?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus]. Porcine galanin‐(3‐29) does not bind to cloned GAL1, GAL2 or GAL3 receptors, but a receptor that is functionally activated by porcine galanin‐(3–29) has been reported in pituitary and gastric smooth muscle cells [http://www.ncbi.nlm.nih.gov/pubmed/7529309?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7683428?dopt=AbstractPlus]. Additional galanin receptor subtypes are also suggested from studies with chimeric peptides (e.g. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3896, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3898 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3899), which act as antagonists in functional assays in the cardiovascular system [http://www.ncbi.nlm.nih.gov/pubmed/7693918?dopt=AbstractPlus], spinal cord [http://www.ncbi.nlm.nih.gov/pubmed/1373497?dopt=AbstractPlus], locus coeruleus, hippocampus [http://www.ncbi.nlm.nih.gov/pubmed/1720557?dopt=AbstractPlus] and hypothalamus [http://www.ncbi.nlm.nih.gov/pubmed/7504301?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1283559?dopt=AbstractPlus], but exhibit agonist activity at some peripheral sites [http://www.ncbi.nlm.nih.gov/pubmed/7504301?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7529309?dopt=AbstractPlus]. The chimeric peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3896, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3897, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3898, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3899 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3861 are agonists at GAL1 receptors expressed endogenously in Bowes human melanoma cells [http://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus], and at heterologously expressed recombinant GAL1, GAL2 and GAL3 receptors [http://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus]. Recent studies have described the synthesis of a series of novel, systemically‐active, galanin analogues, with modest preferential binding at the GAL2 receptor. Specific chemical modifications to the galanin backbone increased brain levels of these peptides after i.v. injection and several of these peptides exerted a potent antidepressant‐like effect in mouse models of depression [http://www.ncbi.nlm.nih.gov/pubmed/23600864?dopt=AbstractPlus].

Further reading on Galanin receptors
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288 [https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Lang R et al. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol. Rev.
67: 118‐75 [https://www.ncbi.nlm.nih.gov/pubmed/25428932?dopt=AbstractPlus]

Lang R et al. (2011) The galanin peptide family in inflammation. Neuropeptides
45: 1‐8 [https://www.ncbi.nlm.nih.gov/pubmed/21087790?dopt=AbstractPlus]

Lawrence C et al. (2011) Galanin‐like peptide (GALP) is a hypothalamic regulator of energy homeostasis and reproduction. Front Neuroendocrinol
32: 1‐9 [https://www.ncbi.nlm.nih.gov/pubmed/20558195?dopt=AbstractPlus]

Webling KE et al. (2012) Galanin receptors and ligands. Front Endocrinol (Lausanne)
3: 146 [https://www.ncbi.nlm.nih.gov/pubmed/23233848?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=28

Overview
The ghrelin receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee for the Ghrelin receptor [http://www.ncbi.nlm.nih.gov/pubmed/16382107?dopt=AbstractPlus]) is activated by a 28 amino‐acid peptide originally isolated from rat stomach, where it is cleaved from a 117 aminoacid precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3). The human gene encoding the precursor peptide has 83% sequence homology to rat preproghrelin, although the mature peptides from rat and human differ by only two amino acids [http://www.ncbi.nlm.nih.gov/pubmed/11549267?dopt=AbstractPlus]. Alternative splicing results in the formation of a second peptide, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3600 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3) with equipotent biological activity [http://www.ncbi.nlm.nih.gov/pubmed/10801861?dopt=AbstractPlus]. A unique post‐translational modification (octanoylation of Ser3, catalysed by ghrelin O‐acyltransferase (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32311, http://www.uniprot.org/uniprot/Q96T53) [http://www.ncbi.nlm.nih.gov/pubmed/18267071?dopt=AbstractPlus] occurs in both peptides, essential for full activity in binding to ghrelin receptors in the hypothalamus and pituitary, and for the release of growth hormone from the pituitary [http://www.ncbi.nlm.nih.gov/pubmed/10604470?dopt=AbstractPlus]. Structure activity studies showed the first five N‐terminal amino acids to be the minimum required for binding [http://www.ncbi.nlm.nih.gov/pubmed/11087562?dopt=AbstractPlus], and receptor mutagenesis has indicated overlap of the ghrelin binding site with those for small molecule agonists and allosteric modulators of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1099 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3) function [http://www.ncbi.nlm.nih.gov/pubmed/18923064?dopt=AbstractPlus]. In cell systems, the ghrelin receptor is constitutively active [http://www.ncbi.nlm.nih.gov/pubmed/15383539?dopt=AbstractPlus], but this is abolished by a naturally occurring mutation (A204E) that results in decreased cell surface receptor expression and is associated with familial short stature [http://www.ncbi.nlm.nih.gov/pubmed/16511605?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4267, http://www.uniprot.org/uniprot/Q92847
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1099 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3) = [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3600 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3) [http://www.ncbi.nlm.nih.gov/pubmed/12969753?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11549267?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9734 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29571, http://www.uniprot.org/uniprot/Q969E1) (pIC50 8.2) [675]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5870 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/20593439?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5870 (pK
B 8) [http://www.ncbi.nlm.nih.gov/pubmed/21034740?dopt=AbstractPlus] – Rat	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1094) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11522606?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1096) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11314756?dopt=AbstractPlus]	



Comments
[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1098 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3) has been shown to bind (as [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3810) and have effects in the cardiovascular system [http://www.ncbi.nlm.nih.gov/pubmed/12969753?dopt=AbstractPlus], which raises the possible existence of different receptor subtypes in peripheral tissues and the central nervous system. A potent inverse agonist has been identified ([http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1102, pD
2 8.3; [http://www.ncbi.nlm.nih.gov/pubmed/12907757?dopt=AbstractPlus]). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3535, described as a ghrelin receptor agonist (pKi 7.8 and pD
2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacologically discriminating the orexigenic and gastrointestinal actions of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1099 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18129, http://www.uniprot.org/uniprot/Q9UBU3) from the release of growth hormone [http://www.ncbi.nlm.nih.gov/pubmed/18719021?dopt=AbstractPlus]. A number of selective antagonists have been reported, including peptidomimetic [http://www.ncbi.nlm.nih.gov/pubmed/22798076?dopt=AbstractPlus] and non‐peptide small molecules including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5870 [http://www.ncbi.nlm.nih.gov/pubmed/21034740?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20593439?dopt=AbstractPlus].

Further reading on Ghrelin receptor
Andrews ZB. (2011) The extra‐hypothalamic actions of ghrelin on neuronal function. Trends Neurosci.
34: 31‐40 [https://www.ncbi.nlm.nih.gov/pubmed/21035199?dopt=AbstractPlus]

Angelidis G et al. (2010) Current and potential roles of ghrelin in clinical practice. J. Endocrinol. Invest.
33: 823‐38 [https://www.ncbi.nlm.nih.gov/pubmed/21293171?dopt=AbstractPlus]

Briggs DI et al. (2011) Metabolic status regulates ghrelin function on energy homeostasis. Neuroendocrinology
93: 48‐57 [https://www.ncbi.nlm.nih.gov/pubmed/21124019?dopt=AbstractPlus]

Callaghan B et al. (2014) Novel and conventional receptors for ghrelin, desacyl‐ghrelin, and pharmacologically related compounds. Pharmacol. Rev.
66: 984‐1001 [https://www.ncbi.nlm.nih.gov/pubmed/25107984?dopt=AbstractPlus]

Davenport AP et al. (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol. Rev.
57: 541‐6 [https://www.ncbi.nlm.nih.gov/pubmed/16382107?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=29

Overview
The glucagon family of receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the Glucagon receptor family [http://www.ncbi.nlm.nih.gov/pubmed/12615957?dopt=AbstractPlus]) are activated by the endogenous peptide (27‐44 aa) hormones http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1136 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1140 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275), glucose‐dependent insulinotropic polypeptide (also known as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3542 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4270, http://www.uniprot.org/uniprot/P09681)), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4265, http://www.uniprot.org/uniprot/P01286) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10607, http://www.uniprot.org/uniprot/P09683). One common precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191) generates http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1136 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1140 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275) peptides [http://www.ncbi.nlm.nih.gov/pubmed/11179772?dopt=AbstractPlus]. For a recent review on review the current understanding of the structures of GLP‐1 and GLP‐1R, the molecular basis of their interaction, and the signaling events associated with it, see de Graaf et al., 2016 [http://www.ncbi.nlm.nih.gov/pubmed/27630114?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=247
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=248
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4266, http://www.uniprot.org/uniprot/Q02643
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4271, http://www.uniprot.org/uniprot/P48546
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4324, http://www.uniprot.org/uniprot/P43220
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4265, http://www.uniprot.org/uniprot/P01286)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3542 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4270, http://www.uniprot.org/uniprot/P09681) [http://www.ncbi.nlm.nih.gov/pubmed/7589426?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1132 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275) [http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3544) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191) [http://www.ncbi.nlm.nih.gov/pubmed/8404634?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6523 [http://www.ncbi.nlm.nih.gov/pubmed/24373935?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6998
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1133 [http://www.ncbi.nlm.nih.gov/pubmed/10794683?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7387 [http://www.ncbi.nlm.nih.gov/pubmed/20570597?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8544 [http://www.ncbi.nlm.nih.gov/pubmed/25176008?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3857 [http://www.ncbi.nlm.nih.gov/pubmed/8993400?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6959
	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9724 [http://www.ncbi.nlm.nih.gov/pubmed/26308095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135 [http://www.ncbi.nlm.nih.gov/pubmed/18412318?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135 [http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3730 (http://www.uniprot.org/uniprot/P20394) [http://www.ncbi.nlm.nih.gov/pubmed/1704369?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1107 (pK
i 10.1–10.4) [http://www.ncbi.nlm.nih.gov/pubmed/10542394?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9892695?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14755056?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1109 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/10542394?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9892695?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14755056?dopt=AbstractPlus] – Rat	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3847]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3847 [http://www.ncbi.nlm.nih.gov/pubmed/12627321?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1138) (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6524) (pIC50 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/9261127?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=884 (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/11498540?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3783) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11814616?dopt=AbstractPlus] – Rat	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1131) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8795084?dopt=AbstractPlus] – Rat	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1134 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1137) (Antagonist) (pK
d 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3784) (Agonist)	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=250
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=252
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4325, http://www.uniprot.org/uniprot/O95838
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4192, http://www.uniprot.org/uniprot/P47871
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10608, http://www.uniprot.org/uniprot/P47872
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1140 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275) [http://www.ncbi.nlm.nih.gov/pubmed/11738243?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1136 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191, http://www.uniprot.org/uniprot/P01275) [http://www.ncbi.nlm.nih.gov/pubmed/4305077?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10607, http://www.uniprot.org/uniprot/P09683) [http://www.ncbi.nlm.nih.gov/pubmed/7612008?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7049 [http://www.ncbi.nlm.nih.gov/pubmed/25859983?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9760 [http://www.ncbi.nlm.nih.gov/pubmed/29300013?dopt=AbstractPlus]	–	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3505 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/10085108?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9479 (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/26681715?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25656305?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1150 (pA
2 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/3035568?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2560175?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3515 (pK
i 5) [http://www.ncbi.nlm.nih.gov/pubmed/9857085?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3491 [http://www.ncbi.nlm.nih.gov/pubmed/11719833?dopt=AbstractPlus]	[(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3755 (pK
i 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/1702423?dopt=AbstractPlus]	
Labelled ligands	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3785) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3759) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9843782?dopt=AbstractPlus] – Rat	



Comments
The glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), specifically http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=52, in heterologous expression systems [http://www.ncbi.nlm.nih.gov/pubmed/12446722?dopt=AbstractPlus], although the physiological significance of this has yet to be established.

Further reading on Glucagon receptor family
Ahrén B. (2019) Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development. J Diabetes Investig
10: 196‐201 [https://www.ncbi.nlm.nih.gov/pubmed/30099845?dopt=AbstractPlus]

Andersen A et al. (2018) Glucagon‐like peptide 1 in health and disease. Nat Rev Endocrinol
14: 390‐403 [https://www.ncbi.nlm.nih.gov/pubmed/29728598?dopt=AbstractPlus]

Gentilella R et al. (2019) Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes Metab. Res. Rev.
35: e3070 [https://www.ncbi.nlm.nih.gov/pubmed/30156747?dopt=AbstractPlus]

Graaf Cd et al. (2016) Glucagon‐Like Peptide‐1 and Its Class B G Protein‐Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol. Rev.
68: 954‐1013 [https://www.ncbi.nlm.nih.gov/pubmed/27630114?dopt=AbstractPlus]

Romera I et al. (2019) A Review of Practical Issues on the Use of Glucagon‐Like Peptide‐1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Ther
10: 5‐19 [https://www.ncbi.nlm.nih.gov/pubmed/30506340?dopt=AbstractPlus]

Trujillo JM et al. (2014) GLP‐1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy
34: 1174‐86 [https://www.ncbi.nlm.nih.gov/pubmed/25382096?dopt=AbstractPlus]

Zhang Y et al. (2017) Cryo‐EM structure of the activated GLP‐1 receptor in complex with a G protein. Nature
546: 248‐253 [https://www.ncbi.nlm.nih.gov/pubmed/28538729?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=30

Overview
Glycoprotein hormone receptors (provisional nomenclature [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by a non‐covalent heterodimeric glycoprotein made up of a common α chain

(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3731 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885, http://www.uniprot.org/uniprot/P01215) https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885, http://www.uniprot.org/uniprot/P01215), with a unique β chain that confers the biological specificity to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1157 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3964, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01225), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1159 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6584, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01229), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1160 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1886, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01233) or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3920 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12372, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01222). There is binding cross‐reactivity across the endogenous agonists for each of the glycoprotein hormone receptors. The deglycosylated hormones appear to exhibit reduced efficacy at these receptors [http://www.ncbi.nlm.nih.gov/pubmed/2542111?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=255
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3969, http://www.uniprot.org/uniprot/P23945
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6585, http://www.uniprot.org/uniprot/P22888
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12373, http://www.uniprot.org/uniprot/P16473
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1157 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3964, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01225)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1159 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6584, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01229), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1160 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1886, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01233) [http://www.ncbi.nlm.nih.gov/pubmed/1922095?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12727981?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3920 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1885
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12372, http://www.uniprot.org/uniprot/P01215
http://www.uniprot.org/uniprot/P01222)	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3780 (Agonist)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3793 (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3775 (Agonist)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3806 (Agonist)	



Further reading on Glycoprotein hormone receptors
Jiang X et al. (2012) Structure of follicle‐stimulating hormone in complex with the entire ectodomain of its receptor. Proc. Natl. Acad. Sci. U.S.A.
109: 12491‐6 https://www.ncbi.nlm.nih.gov/pubmed/22802634?dopt=AbstractPlus


Kleinau G et al. TSH receptor mutations and disease. http://www.thyroidmanager.org/chapter/tsh‐receptor‐mutations‐and‐diseases/. Accessed on 2017‐02‐23.

Tao YX et al. (2009) Follicle stimulating hormone receptor mutations and reproductive disorders. Prog Mol Biol Transl Sci
89: 115‐31 https://www.ncbi.nlm.nih.gov/pubmed/20374735?dopt=AbstractPlus


Troppmann B et al. (2013) Structural and functional plasticity of the luteinizing hormone/choriogonadotrophin receptor. Hum. Reprod. Update
19: 583‐602 https://www.ncbi.nlm.nih.gov/pubmed/23686864?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=31

Overview
GnRH1 and GnRH2 receptors (provisonal nomenclature [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus], also called Type I and Type II GnRH receptor, respectively [http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus]) have been cloned from numerous species, most of which express two or three types of GnRH receptor [http://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus, http:http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148) (p‐Glu‐His‐Trp‐Ser‐Tyr‐Gly‐LeuArg‐Pro‐Gly‐NH2) is a hypothalamic decapeptide also known as luteinizing hormone‐releasing hormone, gonadoliberin, luliberin, gonadorelin or simply as GnRH. It is a member of a family of similar peptides found in many species [http://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus] including http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) (pGlu‐His‐Trp‐Ser‐His‐Gly‐Trp‐Tyr‐Pro‐Gly‐NH2 (which is also known as chicken GnRH‐II). Receptors for three forms of GnRH exist in some species but only GnRH I and GnRH II and their cognate receptors have been found in mammals [http://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus]. GnRH1 receptors are expressed by pituitary gonadotrophs, where they mediate the effects of GnRH on gonadotropin hormone synthesis and secretion that underpin central control of mammalian reproduction. GnRH analogues are used in assisted reproduction and to treat steroid hormone‐dependent conditions [http://www.ncbi.nlm.nih.gov/pubmed/12072036?dopt=AbstractPlus]. Notably, agonists cause desensitization of GnRH‐stimulated gonadotropin secretion and the consequent reduction in circulating sex steroids is exploited to treat hormone‐dependent cancers of the breast, ovary and prostate [http://www.ncbi.nlm.nih.gov/pubmed/12072036?dopt=AbstractPlus]. GnRH1 receptors are selectively activated by GnRH I and all lack the COOH‐terminal tails found in other GPCRs. GnRH2 receptors do have COOH‐terminal tails and (where tested) are selective for GnRH II over GnRH I. GnRH2 receptors are expressed by some primates but not by humans [http://www.ncbi.nlm.nih.gov/pubmed/12538601?dopt=AbstractPlus]. Phylogenetic classifications divide GnRH receptors into three [http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus] or five groups [http://www.ncbi.nlm.nih.gov/pubmed/25344287?dopt=AbstractPlus] and highlight examples of gene loss through evolution, with humans retaining only one ancient gene.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=257
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4421, http://www.uniprot.org/uniprot/P30968
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16341, http://www.uniprot.org/uniprot/Q96P88
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) [http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148) (Monkey) [http://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148) [http://www.ncbi.nlm.nih.gov/pubmed/17452338?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) [http://www.ncbi.nlm.nih.gov/pubmed/19638591?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17452338?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17942747?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) [http://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus] – Monkey, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148) [http://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus] – Monkey	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3860 [http://www.ncbi.nlm.nih.gov/pubmed/26774084?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3860 [http://www.ncbi.nlm.nih.gov/pubmed/26398856?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3860 [http://www.ncbi.nlm.nih.gov/pubmed/26398856?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1177 [http://www.ncbi.nlm.nih.gov/pubmed/11726197?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1175 [http://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3879, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3902
	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3854 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/1850267?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1190 (pK
i 9.3–10) [http://www.ncbi.nlm.nih.gov/pubmed/7649152?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9300077?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1188 (pK
i 9.1–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5585 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/21188095?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3877
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3916 [http://www.ncbi.nlm.nih.gov/pubmed/14651258?dopt=AbstractPlus] – Monkey	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1186 (Antagonist) (pK
d 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/10894158?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1168 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9484907?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1167 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8013367?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3786 (Agonist)	–	



Comments
GnRH1 and GnRH2 receptors couple primarily to Gq/11 [http://www.ncbi.nlm.nih.gov/pubmed/10734055?dopt=AbstractPlus] but coupling to Gs and Gi is evident in some systems [http://www.ncbi.nlm.nih.gov/pubmed/12591945?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8013367?dopt=AbstractPlus]. GnRH2 receptors may also mediate (heterotrimeric) G protein‐independent signalling to protein kinases [http://www.ncbi.nlm.nih.gov/pubmed/15059960?dopt=AbstractPlus]. There is increasing evidence for expression of GnRH receptors on hormone‐dependent cancer cells where they can exert antiproliferative and/or proapoptotic effects and mediate effects of cytotoxins conjugated to GnRH analogues [http://www.ncbi.nlm.nih.gov/pubmed/15561800?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15613448?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14726258?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15350601?dopt=AbstractPlus]. In some human cancer cell models http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) is more potent than http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148), implying mediation by GnRH2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/12237622?dopt=AbstractPlus], but GnRH2 receptors are not expressed by humans because the human GNRHR2 gene contains a frame shift and internal stop codon [http://www.ncbi.nlm.nih.gov/pubmed/12538601?dopt=AbstractPlus]. The possibility remains that this gene generates GnRH2 receptor‐related proteins (other than the full‐length receptor) that mediate responses to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1164 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4420, http://www.uniprot.org/uniprot/O43555) (see [http://www.ncbi.nlm.nih.gov/pubmed/11861490?dopt=AbstractPlus]). Alternatively, evidence for multiple active GnRH receptor conformations [http://www.ncbi.nlm.nih.gov/pubmed/15059960?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22808094?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20009083?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15492280?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus] raises the possibility that GnRH1 receptor‐mediated proliferation inhibition in hormone‐dependent cancer cells is dependent upon a conformation that couples to Gi rather than Gq/11 proteins as in pituitary cells [http://www.ncbi.nlm.nih.gov/pubmed/22808094?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15492280?dopt=AbstractPlus]. Loss‐of‐function mutations in the GnRH1 receptor and deficiency of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1162 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4419, http://www.uniprot.org/uniprot/P01148) are associated with hypogonadotropic hypogonadism although some ’loss of function’ mutations may actually prevent trafficking of ’functional’ GnRH1 receptors to the cell surface, as evidenced by recovery of function by nonpeptide antagonists [http://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus]. Human GnRH1 receptors are poorly expressed at the cell surface because of failure to meet structural quality control criteria for endoplasmic reticulum exit [http://www.ncbi.nlm.nih.gov/pubmed/19888967?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus], and this increases susceptibility to point mutations that further impair trafficking [http://www.ncbi.nlm.nih.gov/pubmed/19888967?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus]. GnRH receptor signalling may require receptor oligomerisation [http://www.ncbi.nlm.nih.gov/pubmed/6282571?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11278883?dopt=AbstractPlus].

Further reading on Gonadotrophin‐releasing hormone receptors
Desaulniers AT et al. (2017) Expression and Role of Gonadotropin‐Releasing Hormone 2 and Its Receptor in Mammals. Front Endocrinol (Lausanne)
8: 269 https://www.ncbi.nlm.nih.gov/pubmed/29312140?dopt=AbstractPlus


Limonta P et al. (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr. Rev.
33: 784‐811 https://www.ncbi.nlm.nih.gov/pubmed/22778172?dopt=AbstractPlus


McArdle CA and Roberson MS.. (2015) Gonadotropes and gonadotropin‐releasing hormone signaling. In Knobil and Neill's Physiology of Reproduction (4th edition). Edited by Plant TM and Zeleznik AJ.: Elsevier Inc.: [ISBN: 9780123971753]

Millar RP et al. (2004) Gonadotropin‐releasing hormone receptors. Endocr Rev
25: 235‐275 https://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus


Tao YX et al. (2014) Chaperoning G protein‐coupled receptors: from cell biology to therapeutics. Endocr. Rev.
35: 602‐47 https://www.ncbi.nlm.nih.gov/pubmed/24661201?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=114

Overview
GPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB1 and CB2 cannabinoid receptors, respond to endogenous agents analogous to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands [http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus]. Although there are multiple reports to indicate that GPR18, GPR55 and GPR119 can be activated in vitro by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3635, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4028 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661, respectively, there is a lack of evidence for activation by these lipid messengers in vivo. As such, therefore, these receptors retain their orphan status.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=89
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=109
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4472, http://www.uniprot.org/uniprot/Q14330
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4511, http://www.uniprot.org/uniprot/Q9Y2T6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19060, http://www.uniprot.org/uniprot/Q8TDV5
	
Potency order of endogenous ligands	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 is ineffective) [http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3635 [http://www.ncbi.nlm.nih.gov/pubmed/16844083?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4028 [http://www.ncbi.nlm.nih.gov/pubmed/20136841?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17765871?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4029 [http://www.ncbi.nlm.nih.gov/pubmed/18845565?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661 [http://www.ncbi.nlm.nih.gov/pubmed/19901198?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621
	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317 [http://www.ncbi.nlm.nih.gov/pubmed/20136841?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19723626?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17876302?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4027 [http://www.ncbi.nlm.nih.gov/pubmed/20804735?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3319 [http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3318 [http://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus]	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6577 (apparent pA2) (pA
2 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/23639801?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9967 (plC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/22091481?dopt=AbstractPlus]	–	
Comments	The pairing of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3635 with GPR18 was not replicated in two studies based on arrestin assays [http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus]. See [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] for discussion.	See reviews [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus] and [http://www.ncbi.nlm.nih.gov/pubmed/25926795?dopt=AbstractPlus].	In addition to those shown above, further small molecule agonists have been reported [http://www.ncbi.nlm.nih.gov/pubmed/26048791?dopt=AbstractPlus].	



Comments
GPR18 failed to respond to a variety of lipid‐derived agents in an in vitro screen [http://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus], but has been reported to be activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 [http://www.ncbi.nlm.nih.gov/pubmed/21595653?dopt=AbstractPlus]. GPR55 responds to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3317 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=743 at micromolar concentrations, compared to their nanomolar affinity as CB1 receptor antagonists/inverse agonists [http://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus]. It has been reported that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4028 acts at other sites in addition to GPR55 [http://www.ncbi.nlm.nih.gov/pubmed/23714700?dopt=AbstractPlus]. N‐Arachidonoylserine has been suggested to act as a low efficacy agonist/antagonist at GPR18 in vitro [http://www.ncbi.nlm.nih.gov/pubmed/20346144?dopt=AbstractPlus]. It has also been suggested http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3623 acts, at least in part, through GPR119 [http://www.ncbi.nlm.nih.gov/pubmed/18724386?dopt=AbstractPlus]. Although http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3318 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3319 produce GPR119‐dependent responses in heterologous expression systems, comparison with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661‐mediated responses suggests additional mechanisms of action [http://www.ncbi.nlm.nih.gov/pubmed/18724386?dopt=AbstractPlus].

Further reading on GPR18, GPR55 and GPR119
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein‐coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev.
65: 967‐86 https://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus


Hassing HA et al. (2016) Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochem. Pharmacol.
119: 66‐75 https://www.ncbi.nlm.nih.gov/pubmed/27569424?dopt=AbstractPlus


Irving A et al. (2017) Cannabinoid Receptor‐Related Orphan G Protein‐Coupled Receptors. Adv Pharmacol
80: 223‐247 https://www.ncbi.nlm.nih.gov/pubmed/28826536


Liu B et al. (2015) GPR55: from orphan to metabolic regulator? Pharmacol. Ther.
145: 35‐42 https://www.ncbi.nlm.nih.gov/pubmed/24972076?dopt=AbstractPlus


Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev.
62: 588‐631 https://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=33

Overview
Histamine receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Histamine Receptors [http://www.ncbi.nlm.nih.gov/pubmed/9311023?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus]) are activated by the endogenous ligand http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204. Marked species differences exist between histamine receptor orthologues [http://www.ncbi.nlm.nih.gov/pubmed/9311023?dopt=AbstractPlus]. The human and rat H3 receptor genes are subject to significant splice variance [http://www.ncbi.nlm.nih.gov/pubmed/16415177?dopt=AbstractPlus]. The potency order of histamine at histamine receptor subtypes is H3 = H4 > H2 > H1 [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus]. Some agonists at the human H3 receptor display significant ligand bias [http://www.ncbi.nlm.nih.gov/pubmed/27864425?dopt=AbstractPlus]. Antagonists of all 4 histamine receptors have clinical uses: H1 antagonists for allergies (e.g.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1222), H2 antagonists for acid‐reflux diseases (e.g.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1234), H3 antagonists for narcolepsy (e.g.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8924/WAKIX; Registered) and H4 antagonists for atopic dermatitis (e.g.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8985; Phase IIa) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus] and vestibular neuritis (AUV) (SENS‐111 (Seliforant, previously UR‐63325), entered and completed vestibular neuritis (AUV) Phase IIa efficacy and safety trials, respectively) [http://www.ncbi.nlm.nih.gov/pubmed/27673668?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30152527?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=262
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=263
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5182, http://www.uniprot.org/uniprot/P35367
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5183, http://www.uniprot.org/uniprot/P25021
	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1205 [http://www.ncbi.nlm.nih.gov/pubmed/12626648?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4026 [http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4025 [http://www.ncbi.nlm.nih.gov/pubmed/19072936?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=277 (pK
i 10.2) [http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7282 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/16782354?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1227 (Inverse agonist) (pK
i 8.7–9) [http://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15206929?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1222 (Inverse agonist) (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1224 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6063 (pK
i 10.3) [79], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7157 (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/15482930?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1228 (pK
i 8.5–9) [http://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7121 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/21381763?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2603 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/12747773?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1235 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/9384502?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1234 (pK
i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/7921611?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1231 (pK
i 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/23466604?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1220 (Antagonist, Inverse agonist) (pK
d 8.4–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/9794809?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12626648?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3958 (Antagonist) (pK
d 9) [http://www.ncbi.nlm.nih.gov/pubmed/15093820?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3957 (Antagonist, Inverse agonist)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1230 (Antagonist) (pK
d 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/8961278?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3959 (Antagonist) (pK
d 7.7–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/12869657?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=265
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5184, http://www.uniprot.org/uniprot/Q9Y5N1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17383, http://www.uniprot.org/uniprot/Q9H3N8
	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4024 [http://www.ncbi.nlm.nih.gov/pubmed/15115383?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1254 [http://www.ncbi.nlm.nih.gov/pubmed/15771452?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7346 (Inverse agonist) [http://www.ncbi.nlm.nih.gov/pubmed/18598020?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11561071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11181941?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1269 [http://www.ncbi.nlm.nih.gov/pubmed/16432504?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8983 [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1274 [http://www.ncbi.nlm.nih.gov/pubmed/17154494?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1266 (pK
i 8.2–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/11714875?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8924 (pK
i 8.1–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19329325?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4023 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/15033391?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8981 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7346 (pK
i 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1267 (Selective for H3/H4 compared to H1 and H3.) (pK
i 7.1–7.7) [http://www.ncbi.nlm.nih.gov/pubmed/11284713?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15294456?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10869375?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11714875?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1265 (pK
i 6.7–7.3) [http://www.ncbi.nlm.nih.gov/pubmed/11284713?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15294456?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8985 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8982 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1278 (pK
i 7.8–8.3) [http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16854056?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14722321?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8984 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24495018?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1267 (Selective for H3/H4 compared to H1 and H3.) (pK
i 6.3–7.6) [http://www.ncbi.nlm.nih.gov/pubmed/15294456?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11561071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11181941?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11179436?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1264 (Antagonist) (pK
d 10.2) [http://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3960 (Antagonist) (pK
d 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/7834183?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1237 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1240 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12706455?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1279 (Antagonist) (pK
d 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/14722321?dopt=AbstractPlus]	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4026 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1205 are reduced efficacy agonists. The H4 receptor appears to exhibit broadly similar pharmacology to the H3 receptor for imidazole‐containing ligands, although http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1236 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1239 are less potent, while http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1223 acts as a reduced efficacy agonist at the H4 receptor and an antagonist at the H3 receptor [http://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11118334?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11179435?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10973974?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11179436?dopt=AbstractPlus]. Moreover, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1269 is identified as a high affinity, full agonist for the human H4 receptor [http://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1247 has been used to label the H4 receptor heterologous expression systems.

Further reading on Histamine receptors
Gbahou F et al. (2012) The histamine autoreceptor is a short isoform of the H_3 receptor. Br. J.
Pharmacol.
166: 1860‐71 https://www.ncbi.nlm.nih.gov/pubmed/22356432?dopt=AbstractPlus


Nieto‐Alamilla G et al. (2016) The Histamine H3 Receptor: Structure, Pharmacology, and Function. Mol. Pharmacol.
90: 649‐673 https://www.ncbi.nlm.nih.gov/pubmed/27563055?dopt=AbstractPlus


Panula P et al. (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol. Rev.
67: 601‐55 https://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus


van Rijn RM et al. (2008) Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor. Biochem. J.
414: 121‐31 [https://www.ncbi.nlm.nih.gov/pubmed/18452403?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=48

Overview
The hydroxycarboxylic acid family of receptors (http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00500000271913, nomenclature as agreed by the
NC‐IUPHAR
Subcommittee on Hydroxycarboxylic acid receptors [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21454438?dopt=AbstractPlus]) respond to organic acids, including the endogenous hydroxy carboxylic acids 3‐hydroxy butyric acid and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932, as well as the lipid lowering agents http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588 (niacin), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1596 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1595 [http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus]. These receptors were provisionally described as nicotinic acid receptors, although nicotinic acid shows submicromolar potency at HCA2 receptors only and is unlikely to be the natural ligand [http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus, https://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=311
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=312
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=313
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4532, http://www.uniprot.org/uniprot/Q9BXC0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24827, http://www.uniprot.org/uniprot/Q8TDS4
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16824, http://www.uniprot.org/uniprot/P49019
	
Potency order of endogenous ligands	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1593 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059
	–	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2932 [http://www.ncbi.nlm.nih.gov/pubmed/20374963?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18952058?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19047060?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1593 [http://www.ncbi.nlm.nih.gov/pubmed/15929991?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1059
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2933 [http://www.ncbi.nlm.nih.gov/pubmed/19561068?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8467 [http://www.ncbi.nlm.nih.gov/pubmed/24486398?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5783 [http://www.ncbi.nlm.nih.gov/pubmed/22434674?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8469 [http://www.ncbi.nlm.nih.gov/pubmed/24900372?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8470 [http://www.ncbi.nlm.nih.gov/pubmed/25773497?dopt=AbstractPlus]	–	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5788 [http://www.ncbi.nlm.nih.gov/pubmed/20184326?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5785 [http://www.ncbi.nlm.nih.gov/pubmed/22435740?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1588 [http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1596 [https://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5786 [http://www.ncbi.nlm.nih.gov/pubmed/18722346?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5800 [http://www.ncbi.nlm.nih.gov/pubmed/19524438?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1597 [http://www.ncbi.nlm.nih.gov/pubmed/16480258?dopt=AbstractPlus]	
Labelled ligands	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1594 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus]	–	



Comments
Further closely‐related GPCRs include the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24884, http://www.uniprot.org/uniprot/Q8TDS5)and https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4486 (http://www.uniprot.org/uniprot/O00270). Lactate activates HCA1 on adipocytes in an autocrine manner. It inhibits lipolysis and thereby promotes anabolic effects. HCA2 and HCA3 regulate adipocyte lipolysis and immune functions under conditions of increased FFA formation through lipolysis (e.g., during fasting). HCA2 agonists acting mainly through the receptor on immune cells exert antiatherogenic and anti‐inflammatory effects. HCA2 is also a receptor for butyrate and mediates some of the beneficial effects of short‐chain fatty acids produced by gut microbiota. HCA3 has been shown to be activated by aromatic D‐amino acids.

Further reading on Hydroxycarboxylic acid receptors
Boatman PD et al. (2008) Nicotinic acid receptor agonists. J. Med. Chem.
51: 7653‐62 https://www.ncbi.nlm.nih.gov/pubmed/18983141?dopt=AbstractPlus


Graff EC et al. (2016) Anti‐inflammatory effects of the hydroxycarboxylic acid receptor 2. Metab. Clin. Exp.
65: 102‐13 https://www.ncbi.nlm.nih.gov/pubmed/26773933?dopt=AbstractPlus


Kamanna VS et al. (2013) Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol.
24: 239‐45 [https://www.ncbi.nlm.nih.gov/pubmed/23619367?dopt=AbstractPlus]

Offermanns S. (2017) Hydroxy‐Carboxylic Acid Receptor Actions in Metabolism. Trends Endocrinol.
Metab.
28: 227‐236 https://www.ncbi.nlm.nih.gov/pubmed/28087125?dopt=AbstractPlus


Offermanns S et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy‐carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev.
63: 269‐90 https://www.ncbi.nlm.nih.gov/pubmed/21454438?dopt=AbstractPlus


Offermanns S et al. (2015) Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation. Trends Mol Med
21: 245‐55 https://www.ncbi.nlm.nih.gov/pubmed/25766751?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=34

Overview
The kisspeptin receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the kisspeptin receptor [http://www.ncbi.nlm.nih.gov/pubmed/21079036?dopt=AbstractPlus]), like neuropeptide FF (NPFF), prolactin‐releasing peptide (PrP) and QRFP receptors (provisional nomenclature) responds to endogenous peptides with an arginine‐phenylalanine amide (RFamide) motif. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1288 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341, http://www.uniprot.org/uniprot/Q15726) (KP54, originally named metastin), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1284 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341, http://www.uniprot.org/uniprot/Q15726) (KP13) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1283 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341) (KP10) are biologically‐active peptides cleaved from the https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341 (http://www.uniprot.org/uniprot/Q15726) gene product. Kisspeptins have roles in, for example, cancer metastasis, fertility/puberty regula tion and glucose homeostasis.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=266
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4510, http://www.uniprot.org/uniprot/Q969F8
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1283 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341) [http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1288 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341, http://www.uniprot.org/uniprot/Q15726) [http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1285 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341, http://www.uniprot.org/uniprot/Q15726) [http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1284 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6341, http://www.uniprot.org/uniprot/Q15726) [http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4014 [http://www.ncbi.nlm.nih.gov/pubmed/18302161?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4015 [http://www.ncbi.nlm.nih.gov/pubmed/19934405?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10222 [http://www.ncbi.nlm.nih.gov/pubmed/27589480?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4012 [http://www.ncbi.nlm.nih.gov/pubmed/19321788?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1280 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3792) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17023533?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1281) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4013) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17023533?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10223 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/30044673?dopt=AbstractPlus]	



Comments
2‐acylamino‐4,6‐diphenylpyridine derivatives have been described and are the first small molecule kisspeptin receptor antagonists reported with potential for treatment of sex‐hormone dependent diseases such as prostate cancer and endometriosis [http://www.ncbi.nlm.nih.gov/pubmed/20580563?dopt=AbstractPlus] .

Further reading on Kisspeptin receptor
Harter CJL et al. (2018) The role of kisspeptin neurons in reproduction and metabolism. J. Endocrinol.
238: R173‐R183 https://www.ncbi.nlm.nih.gov/pubmed/30042117?dopt=AbstractPlus


Kanda S et al. (2013) Structure, synthesis, and phylogeny of kisspeptin and its receptor. Adv. Exp. Med. Biol.
784: 9‐26 https://www.ncbi.nlm.nih.gov/pubmed/23550000?dopt=AbstractPlus


Kirby HR et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function. Pharmacol. Rev.
62: 565‐78 https://www.ncbi.nlm.nih.gov/pubmed/21079036?dopt=AbstractPlus


Oakley AE et al. (2009) Kisspeptin signaling in the brain. Endocr. Rev.
30: 713‐43 https://www.ncbi.nlm.nih.gov/pubmed/19770291?dopt=AbstractPlus


Pasquier J et al. (2014) Molecular evolution of GPCRs: Kisspeptin/kisspeptin receptors. J. Mol. Endocrinol.
52: T101‐17 https://www.ncbi.nlm.nih.gov/pubmed/24577719?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35

Overview
The leukotriene receptors (nomenclature as agreed by the NC‐IUPHAR subcommittee on Leukotriene Receptors [http://www.ncbi.nlm.nih.gov/pubmed/21771892?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus]) are activated by the endogenous ligands leukotrienes (LT), synthesized from lipoxygenase metabolism of arachidonic acid. The human BLT1 receptor is the high affinity LTB4 receptor whereas the BLT2 receptor in addition to being a low‐affinity LTB4 receptor also binds several other lipoxygenase‐products, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401, and the thromboxane synthase product http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6159. The BLT receptors mediate chemotaxis and immunomodulation in several leukocyte populations and are in addition expressed on non‐myeloid cells, such as vascular smooth muscle and endothelial cells. In addition to BLT receptors, LTB4 has been reported to bind to the peroxisome proliferator activated receptor (PPAR) α [http://www.ncbi.nlm.nih.gov/pubmed/9890897?dopt=AbstractPlus] and the vanilloid TRPV1 ligand‐gated nonselective cation channel [http://www.ncbi.nlm.nih.gov/pubmed/16207832?dopt=AbstractPlus]. The receptors for the cysteinyl‐leukotrienes (i.e.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352) aretermed CysLT1 and CysLT2 and exhibit distinct expression patterns in human tissues, mediating for example smooth muscle cell contraction, regulation of vascular permeability, and leukocyte activation. There is also evidence in the literature for additional CysLT receptor subtypes, derived from functional in vitro studies, radioligand binding and in mice lacking both CysLT1 and CysLT2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus]. Cysteinyl‐leukotrienes have also been suggested to signal through the P2Y12 receptor [http://www.ncbi.nlm.nih.gov/pubmed/20702811?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16185654?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19822647?dopt=AbstractPlus], GPR17 [http://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus] and GPR99 [http://www.ncbi.nlm.nih.gov/pubmed/23504326?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=267
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=268
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=269
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=271
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6713, http://www.uniprot.org/uniprot/Q15722
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19260, http://www.uniprot.org/uniprot/Q9NPC1
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17451, http://www.uniprot.org/uniprot/Q9Y271
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18274, http://www.uniprot.org/uniprot/Q9NS75
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24884, http://www.uniprot.org/uniprot/Q8TDS5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3827, http://www.uniprot.org/uniprot/P25090
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487 >http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3399 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3405 [http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6159 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3404 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3401 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3405 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3399 [http://www.ncbi.nlm.nih.gov/pubmed/18378794?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352 [http://www.ncbi.nlm.nih.gov/pubmed/10391245?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10462554?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 ≥ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352 [http://www.ncbi.nlm.nih.gov/pubmed/10851239?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11093801?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10913337?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3391, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3392, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6164 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6167 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2483 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3390 [http://www.ncbi.nlm.nih.gov/pubmed/19450703?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12065583?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9829988?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18292294?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1326548?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7797484?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3402 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1022 [http://www.ncbi.nlm.nih.gov/pubmed/10393980?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8527441?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11141472?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9151906?dopt=AbstractPlus]	
Endogenous agonists	–	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034 [http://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3934 [https://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6239 [http://www.ncbi.nlm.nih.gov/pubmed/22449948?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933
	
Selective agonists	–	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3383 [http://www.ncbi.nlm.nih.gov/pubmed/15056011?dopt=AbstractPlus]	
Endogenous antagonists	–	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6171 (pIC50 6.3) [http://www.ncbi.nlm.nih.gov/pubmed/9920859?dopt=AbstractPlus]	–	
Antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3634 (pK
i 7.1–8.8) [http://www.ncbi.nlm.nih.gov/pubmed/9504401?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11996896?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3334 (pKi 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/9547367?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3634 (pA
2 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/25839425?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3334 (pA
2 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/25839425?dopt=AbstractPlus]	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6154 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/11259574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17170051?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3368 (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/7714764?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3325 (pK
i 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/10513580?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3351 (pIC50 6–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/1316967?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3358 (pK
i 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/2170649?dopt=AbstractPlus] – Guinea pig, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3322 (zafirlukast is only about 100‐fold selective for CysLT1) (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/9504401?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11996896?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3340 (pKi 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/11996896?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10346 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/10391245?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6196 (pA
2 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/21753081?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6196 (pA
2 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/21753081?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6197 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/20423349?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1040 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/15210823?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1030 (pIC50 4.3–6) [http://www.ncbi.nlm.nih.gov/pubmed/6280748?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17687636?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10882119?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3413 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9177352?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3415 (Antagonist) (pK
d 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/1320692?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3413 (pK
d 7.6–9.7)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3412 (Agonist), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3414 (Antagonist) (pK
d 10.6) [http://www.ncbi.nlm.nih.gov/pubmed/1329767?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3412 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10851239?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3416 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9829988?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3411 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1322894?dopt=AbstractPlus]	



Comments
The FPR2/ALX receptor (nomenclatureas agreed by the NC‐IUPHAR subcommittee on Leukotriene and Lipoxin Receptors [http://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus]) is activated by the endogenous lipidderived, anti‐inflammatory ligands lipoxin A4 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034) and 15‐epiLXA4 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3933, ATL). The FPR2/ALX receptor also interacts with endogenous peptide and protein ligands, such as MHC binding peptide [http://www.ncbi.nlm.nih.gov/pubmed/10748237?dopt=AbstractPlus] as well as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1031 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:533, http://www.uniprot.org/uniprot/P04083) (ANXA1) and its N‐terminal peptides [http://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12368905?dopt=AbstractPlus]. In addition, a soluble hydrolytic product of protease action on the urokinase‐type plasminogen activator receptor has been reported to activate the FPR2/ALX receptor [http://www.ncbi.nlm.nih.gov/pubmed/11818541?dopt=AbstractPlus]. Furthermore, FPR2/ALX has been suggested to act as a receptor mediating the proinflammatory actions of the acute‐phase reactant, serum amyloid A [http://www.ncbi.nlm.nih.gov/pubmed/15171815?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9892621?dopt=AbstractPlus]. The agonist activity of the lipid mediators described has been questioned [http://www.ncbi.nlm.nih.gov/pubmed/23643932?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23607720?dopt=AbstractPlus], which may derive from batchto‐batch differences, partial agonism or biased agonism. Results from Cooray et al. (2013) [http://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus] have addressed this issue and the role of homodimers and heterodimers in intracellular signaling. A receptor selective for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216 has been suggested from functional studies [http://www.ncbi.nlm.nih.gov/pubmed/12794159?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8551217?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8757340?dopt=AbstractPlus]. Note that the data for FPR2/ALX are also reproduced on the http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=23.

Oxoeicosanoid receptors (OXE, nomenclature agreed by the
NC‐IUPHAR subcommittee on Oxoeicosanoid Receptors [http://www.ncbi.nlm.nih.gov/pubmed/15001665?dopt=AbstractPlus]) are activated by endogenous chemotactic eicosanoid ligands oxidised at the C‐5 position, with http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3391 the most potent agonist identified for this receptor. Initial characterization of the heterologously expressed OXE receptor suggested that polyunsaturated fatty acids, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3362, acted as receptor antagonists [http://www.ncbi.nlm.nih.gov/pubmed/12065583?dopt=AbstractPlus].

Further reading on Leukotriene receptors
Brink C et al. (2004) International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor. Pharmacol. Rev.
56: 149‐157 https://www.ncbi.nlm.nih.gov/pubmed/15001665?dopt=AbstractPlus


Brink C et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev.
55: 195‐227 https://www.ncbi.nlm.nih.gov/pubmed/12615958?dopt=AbstractPlus


Bäck M et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol. Rev.
63: 539‐84 https://www.ncbi.nlm.nih.gov/pubmed/21771892?dopt=AbstractPlus


Bäck M et al. (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J. Pharmacol.
171: 3551‐74 https://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus


Laidlaw TM et al. (2012) Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin. Exp. Allergy
42: 1313‐20 https://www.ncbi.nlm.nih.gov/pubmed/22925317?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=36

Overview
Lysophosphatidic acid (LPA) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Lysophospholipid (LPA) receptors Lysophospholipid Receptors [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24602016?dopt=AbstractPlus]) are activated by the endogenous phospholipid http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906. The first receptor, LPA1, was identified as ventricular zone gene‐1 (vzg‐1) [http://www.ncbi.nlm.nih.gov/pubmed/8922387?dopt=AbstractPlus], leading to deorphanisation of members of the endothelial differentiation gene (edg) family as other LPA receptors along with sphingosine 1phosphate (S1P) receptors. Additional LPA receptor GPCRs were later identified. Gene names have been codified as LPAR1, etc. to reflect the receptor function of proteins. The crystal structure of LPA1 was solved and demonstrates extracellular LPA access to the binding pocket, consistent with proposed delivery via autotaxin [http://www.ncbi.nlm.nih.gov/pubmed/26091040?dopt=AbstractPlus]. These studies have also implicated cross‐talk with endocannabinoids via phosphorylated intermediates that can also activate these receptors. The identified receptors can account for most, although not all, LPA‐induced phenomena in the literature, indicating that a majority of LPA‐dependent phenomena are receptor‐mediated. Binding affinities of unlabeled, natural LPA and AEApto LPA1 weremeasured using backscattering interferometry (pKd = 9) [http://www.ncbi.nlm.nih.gov/pubmed/30463988?dopt=AbstractPlus]. Binding affinities were 77‐fold lower than than values obtained using radioactivity [http://www.ncbi.nlm.nih.gov/pubmed/19386608?dopt=AbstractPlus]. Targeted deletion of LPA receptors has clarified signalling pathways and identified physiological and pathophysiological roles. Independent validation by multiple groups has been reported in the peer‐reviewed literature for all six LPA receptors described in the tables, including further validation using a distinct read‐out via a novel TGFα “shedding” assay [http://www.ncbi.nlm.nih.gov/pubmed/22983457?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906 has also been described as an agonist for the transient receptor potential (Trp) ion channel TRPV1 [http://www.ncbi.nlm.nih.gov/pubmed/22101604?dopt=AbstractPlus] and TRPA1 [http://www.ncbi.nlm.nih.gov/pubmed/28176353?dopt=AbstractPlus]. LPA was originally proposed to be a ligand for GPCR35, but data show that in fact it is a receptor for http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6479 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19232, http://www.uniprot.org/uniprot/Q6UXB2) [http://www.ncbi.nlm.nih.gov/pubmed/25411203?dopt=AbstractPlus]. All of these proposed non‐GPCR receptor identities require confirmation and are not currently recognized as bona fide LPA receptors.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=272
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=273
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=274
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=94
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=124
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=163
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3166, http://www.uniprot.org/uniprot/Q92633
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3168, http://www.uniprot.org/uniprot/Q9HBW0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14298, http://www.uniprot.org/uniprot/Q9UBY5
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4478, http://www.uniprot.org/uniprot/Q99677
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13307, http://www.uniprot.org/uniprot/Q9H1C0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15520, http://www.uniprot.org/uniprot/P43657
	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4031 [http://www.ncbi.nlm.nih.gov/pubmed/12695531?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4030 [https://www.ncbi.nlm.nih.gov/pubmed/12695531?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6580 [http://www.ncbi.nlm.nih.gov/pubmed/22968304?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2912 [http://www.ncbi.nlm.nih.gov/pubmed/12554733?dopt=AbstractPlus]	–	–	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2907 (pIC50 6.6–6.9) [http://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2909 (pK
i 5.2–6.9) [http://www.ncbi.nlm.nih.gov/pubmed/11723223?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5450 [http://www.ncbi.nlm.nih.gov/pubmed/15125924?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2909 (pK
i 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/11723223?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5450 [http://www.ncbi.nlm.nih.gov/pubmed/15125924?dopt=AbstractPlus]	–	–	–	
Sub/family‐selective antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2907 (pK
i 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus]	–	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9498 (pIC50 8.9), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2905 (pIC50 6.7–7.8) [http://www.ncbi.nlm.nih.gov/pubmed/21159750?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9499 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/27774128?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6988 (pIC50 6–6.1) [http://www.ncbi.nlm.nih.gov/pubmed/21159750?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2916 (pK
i 5.5–7) [http://www.ncbi.nlm.nih.gov/pubmed/11562440?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10230 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/28859883?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9500 (pIC50 6.1) [http://www.ncbi.nlm.nih.gov/pubmed/22801643?dopt=AbstractPlus]	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2907 [http://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2909 [http://www.ncbi.nlm.nih.gov/pubmed/11723223?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5450 [http://www.ncbi.nlm.nih.gov/pubmed/15125924?dopt=AbstractPlus] have dual antagonist activity at LPA1 and LPA3 receptors. There is growing evidence for in vivo efficacy of these chemical antagonists in several disorders, including fetal hydrocephalus [http://www.ncbi.nlm.nih.gov/pubmed/21900594?dopt=AbstractPlus], fetal hypoxia [http://www.ncbi.nlm.nih.gov/pubmed/21878565?dopt=AbstractPlus], lung fibrosis [http://www.ncbi.nlm.nih.gov/pubmed/25959255?dopt=AbstractPlus], systemic sclerosis [http://www.ncbi.nlm.nih.gov/pubmed/25959255?dopt=AbstractPlus] and atherosclerosis progression [http://www.ncbi.nlm.nih.gov/pubmed/27883026?dopt=AbstractPlus]. The LPA2 selective agonist, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6580, also shows efficacy in an animal model of multiple sclerosis [http://www.ncbi.nlm.nih.gov/pubmed/28578681?dopt=AbstractPlus]. The LPA5 selective antagonist, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10230, is effective in pain models [http://www.ncbi.nlm.nih.gov/pubmed/29208511?dopt=AbstractPlus].

Further reading on Lysophospholipid (LPA) receptors
Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev.
62: 579‐87 https://www.ncbi.nlm.nih.gov/pubmed/21079037?dopt=AbstractPlus


Kihara Y et al. (2014) Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br. J. Pharmacol.
171: 3575‐94 https://www.ncbi.nlm.nih.gov/pubmed/24602016?dopt=AbstractPlus


Yung YC et al. (2015) Lysophosphatidic Acid signaling in the nervous system. Neuron
85: 669‐82 https://www.ncbi.nlm.nih.gov/pubmed/25695267?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=135

Overview
Sphingosine 1‐phosphate (S1P) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Lysophospholipid receptors [http://www.ncbi.nlm.nih.gov/pubmed/24602016?dopt=AbstractPlus]) are activated by the endogenous lipid http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 (S1P). Originally cloned as orphan members of the endothelial differentiation gene (edg) family, current gene names have been designated as S1P1R through S1P5R [http://www.ncbi.nlm.nih.gov/pubmed/2160972?dopt=AbstractPlus]. S1PRs, particularly S1P1, are expressed throughout all mammalian organ systems. Ligand delivery occurs via two known carriers (or “chaperones”): albumin and HDLbound apolipoprotein M (ApoM), the latter of which elicits biased agonist signaling by S1P1 in multiple cell types [http://www.ncbi.nlm.nih.gov/pubmed/26053123?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26268607?dopt=AbstractPlus]. The five S1PRs, two chaperones, and active cellular metabolism have complicated analyses of receptor ligand binding in native systems. Signaling pathways and physiological roles have been characterized through radioligand binding in heterologous expression systems, targeted deletion of the different S1PRs, and most recently, mouse models that report in vivo S1P1R activation [http://www.ncbi.nlm.nih.gov/pubmed/29079828?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24667638?dopt=AbstractPlus]. A crystal structure of an S1P1‐T4 fusion protein confirmed aspects and binding, specificity, and receptor activation determined previously through biochemical and genetic studies [http://www.ncbi.nlm.nih.gov/pubmed/30343728?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22344443?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407 (FTY720), the first drug to target any of the lysophospholipid receptors, binds to four of the five S1PRs, and was the first oral therapy for multiple sclerosis [http://www.ncbi.nlm.nih.gov/pubmed/30625282?dopt=AbstractPlus]. The mechanisms of action of fingolimod and other S1PR modulating drugs in development include binding S1PRs in multiple organ systems, e.g., immune and nervous systems, although the precise nature of their receptor interactions requires clarification [http://www.ncbi.nlm.nih.gov/pubmed/21520239?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23518370?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30255127?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25831442?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=276
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=277
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=278
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=279
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3165, http://www.uniprot.org/uniprot/P21453
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3169, http://www.uniprot.org/uniprot/O95136
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3167, http://www.uniprot.org/uniprot/Q99500
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3170, http://www.uniprot.org/uniprot/O95977
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14299, http://www.uniprot.org/uniprot/Q9H228
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921 [http://www.ncbi.nlm.nih.gov/pubmed/10383399?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921 [http://www.ncbi.nlm.nih.gov/pubmed/10383399?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921 [http://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921 [http://www.ncbi.nlm.nih.gov/pubmed/10753843?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921 [http://www.ncbi.nlm.nih.gov/pubmed/10799507?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2924 [http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14747617?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9289 [http://www.ncbi.nlm.nih.gov/pubmed/29735753?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24900670?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9331 [http://www.ncbi.nlm.nih.gov/pubmed/25516790?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2924 [http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14747617?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2924 [http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14747617?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2924 [http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14747617?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17114004?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14732717?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25347187?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9331 [http://www.ncbi.nlm.nih.gov/pubmed/12110609?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25516790?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2924 [http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14747617?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17114004?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9289 [http://www.ncbi.nlm.nih.gov/pubmed/9735753?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22646698?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24125884?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9331 [http://www.ncbi.nlm.nih.gov/pubmed/25516790?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10309 [http://www.ncbi.nlm.nih.gov/pubmed/21445057?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9320 [http://www.ncbi.nlm.nih.gov/pubmed/20446681?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9824 [http://www.ncbi.nlm.nih.gov/pubmed/29226621?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2928 [http://www.ncbi.nlm.nih.gov/pubmed/18708635?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2926 [http://www.ncbi.nlm.nih.gov/pubmed/14732717?dopt=AbstractPlus] – Mouse	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9494 [http://www.ncbi.nlm.nih.gov/pubmed/22971058?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10311 [http://www.ncbi.nlm.nih.gov/pubmed/21982495?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9496 [http://www.ncbi.nlm.nih.gov/pubmed/29688337?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26509640?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3324 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/15590668?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6992 (pK
i 7.6–7.7) [http://www.ncbi.nlm.nih.gov/pubmed/21632869?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2930 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/17113298?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2930 (pK
i 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/17113298?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3324 (pK
i 5.9) [http://www.ncbi.nlm.nih.gov/pubmed/15590668?dopt=AbstractPlus]	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6997 (pIC50 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/22999882?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2931 (pK
i 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/16829954?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2917 (pIC50 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/12445827?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10310 (pK
i 7) [http://www.ncbi.nlm.nih.gov/pubmed/20097776?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10312 (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/23913862?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21570287?dopt=AbstractPlus]	–	



Comments
The FDA‐approved immunomodulator http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407 (FTY720) is phosphorylated in vivo [http://www.ncbi.nlm.nih.gov/pubmed/16078855?dopt=AbstractPlus] to generatean agonist with activity at S1P1, S1P3, S1P4 and S1P5 receptors [http://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11923495?dopt=AbstractPlus]. Many of the physiological consequences of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2924 administration, as well as those of other currently described S1P1 agonists, may involve functional antagonism via ubiquitination and subsequent degradation of S1P1 [http://www.ncbi.nlm.nih.gov/pubmed/17237497?dopt=AbstractPlus]. Additionally, receptor specificities of the different compounds may depend on the functional assay system utilized and from which species the receptor sequence originated.

Further reading on Lysophospholipid (S1P) receptors
Chew WS et al. (2016) To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling. Pharmacol. Res.
113: 521‐532 https://www.ncbi.nlm.nih.gov/pubmed/27663260?dopt=AbstractPlus


Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev.
62: 579‐87 https://www.ncbi.nlm.nih.gov/pubmed/21079037?dopt=AbstractPlus


Cyster JG et al. (2012) Sphingosine‐1‐phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol.
30: 69‐94 https://www.ncbi.nlm.nih.gov/pubmed/22149932?dopt=AbstractPlus


Pyne NJ et al. (2017) Sphingosine 1‐Phosphate Receptor 1 Signaling in Mammalian Cells. Molecules
22: https://www.ncbi.nlm.nih.gov/pubmed/28241498?dopt=AbstractPlus


Rosen H et al. (2013) Sphingosine‐1‐phosphate and its receptors: structure, signaling, and influence. Annu. Rev. Biochem.
82: 637‐62 https://www.ncbi.nlm.nih.gov/pubmed/23527695?dopt=AbstractPlus


Yanagida K et al. (2017) Vascular and Immunobiology of the Circulatory Sphingosine 1‐Phosphate Gradient. Annu. Rev. Physiol.
79: 67‐91 https://www.ncbi.nlm.nih.gov/pubmed/27813829?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=37

Overview
Melanin‐concentrating hormone (MCH) receptors (provisional nomenclature as recommended by
NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by an endogenous nonadecameric cyclic peptide identical in humans and rats (DFDMLRCMLGRVYRPCWQV; mammalian MCH) generated from a precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9109, http://www.uniprot.org/uniprot/P20382), which also produces http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5374 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9109, http://www.uniprot.org/uniprot/P20382) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5375 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9109, http://www.uniprot.org/uniprot/P20382).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=280
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=281
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4479, http://www.uniprot.org/uniprot/Q99705
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20867, http://www.uniprot.org/uniprot/Q969V1
	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4033 (pIC50 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/16870432?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1313 (pA
2 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/12118247?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1314 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/11909603?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1305 (pIC50 7.9–8.1) [http://www.ncbi.nlm.nih.gov/pubmed/15677346?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1317
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1317 (Antagonist) (pK
d 9.2–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/11375253?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3844
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3844,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3844]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3844 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9434758?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3827
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3827) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9434758?dopt=AbstractPlus]	–	



Comments
The MCH2 receptor appears to be a non‐functional pseudogene in rodents [http://www.ncbi.nlm.nih.gov/pubmed/12036292?dopt=AbstractPlus].

Further reading on Melanin‐concentrating hormone receptors
Chung S et al. (2011) Recent updates on the melanin‐concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists. J. Mol. Neurosci.
43: 115‐21 [https://www.ncbi.nlm.nih.gov/pubmed/20582487?dopt=AbstractPlus]

Eberle AN et al. (2010) Cellular models for the study of the pharmacology and signaling of melaninconcentrating hormone receptors. J. Recept. Signal Transduct. Res.
30: 385‐402 [https://www.ncbi.nlm.nih.gov/pubmed/21083507?dopt=AbstractPlus]

Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288 [https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Takase K et al. (2014) Meta‐analysis of melanin‐concentrating hormone signaling‐deficient mice on behavioral and metabolic phenotypes. PLoS ONE
9: e99961 [https://www.ncbi.nlm.nih.gov/pubmed/24924345?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=38

Overview
Melanocortin receptors (provisional nomenclature as recommended by
NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by members of the melanocortin family (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606, http://www.uniprot.org/uniprot/P01189) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333, http://www.uniprot.org/uniprot/P01189) forms; δ form is not found in mammals) and adrenocorticotrophin (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633, http://www.uniprot.org/uniprot/P01189)). Endogenous antagonists include http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3609 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:745, http://www.uniprot.org/uniprot/P42127) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1335 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:330, http://www.uniprot.org/uniprot/O00253). ACTH(1‐24) was approved by the US FDA as a diagnostic agent for adrenal function test, whilst NDP‐MSH was approved by EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=282
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=283
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=284
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=286
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6929, http://www.uniprot.org/uniprot/Q01726
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6930, http://www.uniprot.org/uniprot/Q01718
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6931, http://www.uniprot.org/uniprot/P41968
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6932, http://www.uniprot.org/uniprot/P32245
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6933, http://www.uniprot.org/uniprot/P33032
	
Potency order of endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333, http://www.uniprot.org/uniprot/P01189)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320, http://www.uniprot.org/uniprot/P01189)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333, http://www.uniprot.org/uniprot/P01189)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1320 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3606, http://www.uniprot.org/uniprot/P01189) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3633, http://www.uniprot.org/uniprot/P01189) >http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1333, http://www.uniprot.org/uniprot/P01189)	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6967
	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1334]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1334‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1334 [http://www.ncbi.nlm.nih.gov/pubmed/11150170?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1338 [http://www.ncbi.nlm.nih.gov/pubmed/12361385?dopt=AbstractPlus]	–	
Antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6546 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/17482720?dopt=AbstractPlus]	–	–	
Selective antagonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1339 (pIC50 10) [http://www.ncbi.nlm.nih.gov/pubmed/11606131?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1321 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/9630346?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3767
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3767) (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3804
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3804 (Antagonist) [http://www.ncbi.nlm.nih.gov/pubmed/12604699?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3804
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3804 (Antagonist) (pK
d 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/12604699?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7774675?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1326 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus]	



Comments
Polymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deficiency. Polymorphisms of the MC4 receptor have been linked to obesity [http://www.ncbi.nlm.nih.gov/pubmed/9392003?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18779842?dopt=AbstractPlus].

Further reading on Melanocortin receptors
Caruso V et al. (2014) Synaptic changes induced by melanocortin signalling. Nat. Rev. Neurosci.
15: 98‐110 [https://www.ncbi.nlm.nih.gov/pubmed/24588018?dopt=AbstractPlus]

Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288 [https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Renquist BJ et al. (2011) Physiological roles of the melanocortin MC_3 receptor. Eur. J. Pharmacol.
660: 13‐20 [https://www.ncbi.nlm.nih.gov/pubmed/21211527?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=39

Overview
Melatonin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Melatonin Receptors [http://www.ncbi.nlm.nih.gov/pubmed/20605968?dopt=AbstractPlus]) are activated by the endogenous ligands http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224 and clinically used drugs like http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=287
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7463, http://www.uniprot.org/uniprot/P48039
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7464, http://www.uniprot.org/uniprot/P49286
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224 [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2991499?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224 [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2991499?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356 [http://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198 [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9618428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 [http://www.ncbi.nlm.nih.gov/pubmed/19054552?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198 [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9618428?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356 [http://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21182402?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 [http://www.ncbi.nlm.nih.gov/pubmed/19054552?dopt=AbstractPlus]	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9226 [http://www.ncbi.nlm.nih.gov/pubmed/26334942?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1350 [http://www.ncbi.nlm.nih.gov/pubmed/10737738?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10420436?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1364 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus]	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1358 (pK
i 8.8–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9737724?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1359 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/10737738?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10420436?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3366 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/9840420?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7770
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7770 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1344
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1344 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10696085?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7770
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7770 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1344
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1344 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7771
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7771 (Agonist, Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1357 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10696085?dopt=AbstractPlus]	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1343, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=198, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1349, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1351 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1356 [http://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus] are nonselective agonists for MT1 and MT2 receptors. (‐)‐AMMTC displays an ˜400‐fold greater agonist potency than (+)‐AMMTC at rat MT1 receptors (see http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3385 for structure) [http://www.ncbi.nlm.nih.gov/pubmed/10433507?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1363 is an MT1/MT2 non‐selective competitive melatonin receptor antagonist with about 15‐25 fold selectivity for the MT2 receptor [http://www.ncbi.nlm.nih.gov/pubmed/9737724?dopt=AbstractPlus]. MT1/MT2 heterodimers present differentpharmacological profiles from MT1 and MT2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/15266022?dopt=AbstractPlus]. The MT3 binding site of hamster brain and peripheral tissues such as kidney and testis, also termed the ML2 receptor, binds selectively http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5396
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5396 [http://www.ncbi.nlm.nih.gov/pubmed/8773460?dopt=AbstractPlus]. Pharmacological investigations of MT3 binding sites have primarily been conducted in hamster tissues. At this site, The endogenous ligand http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5451 [http://www.ncbi.nlm.nih.gov/pubmed/8246675?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9283717?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9283717?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7798906?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3393 [http://www.ncbi.nlm.nih.gov/pubmed/7798906?dopt=AbstractPlus] appear to function as agonists, while http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=503 [http://www.ncbi.nlm.nih.gov/pubmed/9283717?dopt=AbstractPlus] functions as an antagonist. The MT3 binding site of hamster kidney was also identified as the hamster homologue of human quinone reductase 2 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7856, http://www.uniprot.org/uniprot/P16083 [http://www.ncbi.nlm.nih.gov/pubmed/10913150?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11331072?dopt=AbstractPlus]). The MT3 binding site activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3393 in eye ciliary body is positively coupled to adenylyl cyclase and regulates chloride secretion [http://www.ncbi.nlm.nih.gov/pubmed/25344385?dopt=AbstractPlus]. Xenopus melanophores and chick brain express a distinct receptor (x420, P49219; c346, P49288, initially termed Mel1C) coupled to the Gi/o family of G proteins, for which GPR50 has recently been suggested to be a mammalian counterpart [http://www.ncbi.nlm.nih.gov/pubmed/18400093?dopt=AbstractPlus] although http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=224 does not bind to GPR50 receptors. Several variants of the MTNR1B gene have been associated with increased type 2 diabetes risk [http://www.ncbi.nlm.nih.gov/pubmed/30531911?dopt=AbstractPlus].

Further reading on Melatonin receptors
Cecon E et al. (2018) Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br. J. Pharmacol.
175: 3263‐3280 [https://www.ncbi.nlm.nih.gov/pubmed/28707298?dopt=AbstractPlus]

Dubocovich ML et al. (2010) International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein‐coupled melatonin receptors. Pharmacol. Rev.
62: 343‐80 [https://www.ncbi.nlm.nih.gov/pubmed/20605968?dopt=AbstractPlus]

Jockers R et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br. J. Pharmacol.
173: 2702‐25 [https://www.ncbi.nlm.nih.gov/pubmed/27314810?dopt=AbstractPlus]

Karamitri A et al. (2019) Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol
15: 105‐125 [https://www.ncbi.nlm.nih.gov/pubmed/30531911?dopt=AbstractPlus]

Liu J et al. (2016) MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu. Rev. Pharmacol. Toxicol.
56: 361‐83 [https://www.ncbi.nlm.nih.gov/pubmed/26514204?dopt=AbstractPlus]

Zlotos DP et al. (2014) MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J. Med. Chem.
57: 3161‐85 [https://www.ncbi.nlm.nih.gov/pubmed/24228714?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=40

Overview
Metabotropic glutamate (mGlu) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Metabotropic Glutamate Receptors[1899]) area family of G protein‐coupled receptors activated by the neurotransmitter glutamate. The mGlu family is composed of eight members (named mGlu1 to mGlu8) which are divided in three groups based on similarities of agonist pharmacology, primary sequence and G protein coupling to effector: Group‐I (mGlu1 and mGlu5), Group‐II (mGlu2 and mGlu3) and Group‐III (mGlu4, mGlu6, mGlu7 and mGlu8) (see Further reading).

Structurally, mGlu are composed of three juxtaposed domains: a core G protein‐activating seven‐transmembrane domain (TM), common to all GPCRs, is linked via a rigid cysteine‐rich domain (CRD) to the Venus Flytrap domain (VFTD), a large bi‐lobed extracellular domain where glutamate binds. The structures of the VFTD of mGlu1, mGlu2, mGlu3, mGlu5 and mGlu7 have been solved [http://www.ncbi.nlm.nih.gov/pubmed/11069170?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25602126?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17360426?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11867751?dopt=AbstractPlus]. The structure of the 7 transmembrane (TM) domains of both mGlu1 and mGlu5 have been solved, and confirm a general helical organization similar to that of other GPCRs, although the helices appear more compacted [http://www.ncbi.nlm.nih.gov/pubmed/29455526?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25042998?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24603153?dopt=AbstractPlus]. mGlu form constitutive dimers crosslinked by a disulfide bridge. Recent studies revealed the possible formation of heterodimers between either group‐I receptors, or within and between group‐II and ‐III receptors [http://www.ncbi.nlm.nih.gov/pubmed/20826542?dopt=AbstractPlus]. Although well characterized in transfected cells, co‐localization and specific pharmacological properties also suggest the existence of such heterodimers in the brain [http://www.ncbi.nlm.nih.gov/pubmed/28661401?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24381270?dopt=AbstractPlus].

The endogenous ligands of mGlu are http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411, N‐acetylaspartylglutamate (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5447. Group‐I mGlu receptors may be activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1367 and (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1366)http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1366 [http://www.ncbi.nlm.nih.gov/pubmed/8532171?dopt=AbstractPlus] and antagonized by (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5448 [http://www.ncbi.nlm.nih.gov/pubmed/15996690?dopt=AbstractPlus]. Group‐II mGlu receptors may be activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3349 [http://www.ncbi.nlm.nih.gov/pubmed/10090786?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1394], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1393 [http://www.ncbi.nlm.nih.gov/pubmed/9144636?dopt=AbstractPlus
http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1377 and (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1392,http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1392)http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1392 [http://www.ncbi.nlm.nih.gov/pubmed/9076745?dopt=AbstractPlus, and antagonised by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1400 [http://www.ncbi.nlm.nih.gov/pubmed/9121605?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3350 [http://www.ncbi.nlm.nih.gov/pubmed/9871538?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8632404?dopt=AbstractPlus]. Group‐III mGlu receptors may be activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410 and (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1406)http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1406 [http://www.ncbi.nlm.nih.gov/pubmed/10336568?dopt=AbstractPlus]. An example of an antagonist selective for mGlu receptors is http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1378, which blocks mGlu2 and mGlu3 at low nanomolar concentrations, mGlu8 at high nanomolar concentrations, and mGlu4, mGlu5, and mGlu7 in the micromolar range [http://www.ncbi.nlm.nih.gov/pubmed/9680254?dopt=AbstractPlus]. In addition to orthosteric ligands that directly interact with the glutamate recognition site, allosteric modulators that bind within the TM domain have been described. Negative allosteric modulators are listed separately. The positive allosteric modulators most often act as ‘potentiators’ of an orthosteric agonist response, without significantly activating the receptor in the absence of agonist.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=290
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=291
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4593, http://www.uniprot.org/uniprot/Q13255
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4594, http://www.uniprot.org/uniprot/Q14416
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4595, http://www.uniprot.org/uniprot/Q14832
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4596, http://www.uniprot.org/uniprot/Q14833
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4597, http://www.uniprot.org/uniprot/P41594
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405 [http://www.ncbi.nlm.nih.gov/pubmed/10884552?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
Agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410 [http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411]	–	
Selective agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6706 [http://www.ncbi.nlm.nih.gov/pubmed/22223752?dopt=AbstractPlus]	(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3421 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10428410?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1417 [http://www.ncbi.nlm.nih.gov/pubmed/11080213?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1379 (pIC50 5.1) [400]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1414 (pK
i 4.6) [http://www.ncbi.nlm.nih.gov/pubmed/10187777?dopt=AbstractPlus] – Rat	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3396 (pIC50 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/12015200?dopt=AbstractPlus] – Rat, (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3421 (pIC50 4.2) [http://www.ncbi.nlm.nih.gov/pubmed/10428410?dopt=AbstractPlus] – Rat, (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3419 (pIC50 4.2) [http://www.ncbi.nlm.nih.gov/pubmed/11249114?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1376 (pA
2 4.2) [http://www.ncbi.nlm.nih.gov/pubmed/9152378?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3335 (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/8667369?dopt=AbstractPlus] – Rat	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3388 (pIC50 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/15686941?dopt=AbstractPlus]	
Allosteric modulators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3372 (Positive) (pEC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/15717213?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1402 (Positive) (pIC50 5.8) [http://www.ncbi.nlm.nih.gov/pubmed/15149652?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12852748?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12852748?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14500736?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6221 (Negative) (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/17416742?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10237 (Negative) (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/26335039?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1432 (Positive) (pEC50 6.3–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/12684257?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1426 (Positive) (pEC50 6.3–6.6) [http://www.ncbi.nlm.nih.gov/pubmed/12684257?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1416 (Positive) (pEC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/14573382?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8543 (Negative) (pIC50 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/25173999?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1422 (Positive) (pEC50 7.6–8) [http://www.ncbi.nlm.nih.gov/pubmed/15608073?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15537338?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3336 (Negative) (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/12473093?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1426 (Negative) (pIC50 7.4–7.7) [http://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10530811?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1434 (Negative) (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/16040814?dopt=AbstractPlus]	
Selective allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1381 (Negative) (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/11306677?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1385 (Negative) (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/15555631?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1386 (Positive) (pK
i 7.5–7.7) [http://www.ncbi.nlm.nih.gov/pubmed/11606768?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3346 (Negative) (pIC50 6.9) [1270], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1382 (Negative) (pIC50 5.2–5.8) [http://www.ncbi.nlm.nih.gov/pubmed/10051528?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3955 (Negative) (pIC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/10465539?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3954 (Positive) (pEC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/16046122?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8765 (Negative) (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/23718281?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3956 (Positive) (pEC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/19469556?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3323 (Positive) (pEC50 6.1) [http://www.ncbi.nlm.nih.gov/pubmed/18664603?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4059 (Positive) (pEC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/16722652?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=295
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=296
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4598, http://www.uniprot.org/uniprot/O15303
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4599, http://www.uniprot.org/uniprot/Q14831
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4600, http://www.uniprot.org/uniprot/O00222
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411 [http://www.ncbi.nlm.nih.gov/pubmed/10216218?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369 [http://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus]	
Agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6706 [http://www.ncbi.nlm.nih.gov/pubmed/22223752?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1411 [http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410]	(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1407)http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1407 [http://www.ncbi.nlm.nih.gov/pubmed/11166323?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1410 [http://www.ncbi.nlm.nih.gov/pubmed/10216218?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1436 [2158] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3359 [http://www.ncbi.nlm.nih.gov/pubmed/8759641?dopt=AbstractPlus]	–	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1414 (pIC50 3.5) [http://www.ncbi.nlm.nih.gov/pubmed/12769621?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3326 [http://www.ncbi.nlm.nih.gov/pubmed/9144637?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1415 (pIC50 4.3) [http://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus]	
Allosteric modulators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3341 (Negative) (pIC50 6.1–7.6) [http://www.ncbi.nlm.nih.gov/pubmed/20026717?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17609420?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6217 (Negative) (pIC50 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/23257312?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1441 (Positive) (pEC50 6.5–6.8) [http://www.ncbi.nlm.nih.gov/pubmed/16339898?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8545 (Negative) (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/24596089?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10239 (Positive) (pK
B 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/25225882?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10238 (Positive) (pK
B 5) [http://www.ncbi.nlm.nih.gov/pubmed/25225882?dopt=AbstractPlus]	



Comments
The activity of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1405 as an agonist at mGlu3 receptors was questioned on the basis of contamination with glutamate [http://www.ncbi.nlm.nih.gov/pubmed/19389924?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19285517?dopt=AbstractPlus], but this has been refuted [http://www.ncbi.nlm.nih.gov/pubmed/21740441?dopt=AbstractPlus].

Radioligand binding using a variety of radioligands has been conducted on recombinant receptors (for example, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1391
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1391 [http://www.ncbi.nlm.nih.gov/pubmed/12695537?dopt=AbstractPlus] and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5392
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5392 [http://www.ncbi.nlm.nih.gov/pubmed/15976016?dopt=AbstractPlus] at mGlu1 receptors and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1425
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1425 [http://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus] and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5394
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5394 [http://www.ncbi.nlm.nih.gov/pubmed/12438526?dopt=AbstractPlus] at mGlu5 receptors; [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1399
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1399 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1396
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1396 for mGlu2 and mGlu3 receptors [http://www.ncbi.nlm.nih.gov/pubmed/10530814?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10884552?dopt=AbstractPlus]). Although a number of radioligands have been used to examine binding in native tissues, correlation with individual subtypes is limited. Many pharmacological agents have not been fully tested across all known subtypes of mGlu receptors and may have unappreciated biased or neutral activity at other subtypes [http://www.ncbi.nlm.nih.gov/pubmed/29514854?dopt=AbstractPlus]. Potential differences linked to the species (e.g. human versus rat or mouse) of the receptors and the receptor splice variants are generally not known. The influence of receptor expression level on pharmacology and selectivity has not been controlled for in most studies, particularly those involving functional assays of receptor coupling.

(http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3421 is an antagonist at mGlu1, but is an agonist (albeit of reduced efficacy) at mGlu5 receptors. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1377 also exhibits agonist activity at NMDA glutamate receptors [http://www.ncbi.nlm.nih.gov/pubmed/9106476?dopt=AbstractPlus], and is an antagonist at all Group‐III mGluRs with an IC50 of 30μM. A potential novel metabotropic glutamate receptor coupled to phosphoinositide turnover has been observed in rat brain; it is activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5449 (ineffective as an agonist at recombinant Group I metabotropic glutamate receptors), but is resistant to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1378 [http://www.ncbi.nlm.nih.gov/pubmed/9353394?dopt=AbstractPlus]. There are also reports of a distinct metabotropic glutamatereceptor coupled tophospholipase D in ratbrain, which does not readily fit into the current classification [http://www.ncbi.nlm.nih.gov/pubmed/9175608?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8799579?dopt=AbstractPlus]

A related class C receptor composed of two distinct subunits, T1R1 + T1R3 is also activated by glutamate and is responsible for umami taste detection.

All selective antagonists at metabotropic glutamate receptors are competitive.

Further reading on Metabotropic glutamate receptors
Conn PJ et al. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol.
37: 205‐237 [https://www.ncbi.nlm.nih.gov/pubmed/9131252?dopt=AbstractPlus]

Ferraguti F et al. (2006) Metabotropic glutamate receptors. Cell Tissue Res.
326: 483‐504 [https://www.ncbi.nlm.nih.gov/pubmed/16847639?dopt=AbstractPlus]

Nicoletti F et al. (2011) Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology
60: 1017‐41 [https://www.ncbi.nlm.nih.gov/pubmed/21036182?dopt=AbstractPlus]

Niswender CM et al. (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol.
50: 295‐322 [https://www.ncbi.nlm.nih.gov/pubmed/20055706?dopt=AbstractPlus]

Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature
540: 60‐68 [https://www.ncbi.nlm.nih.gov/pubmed/27905440?dopt=AbstractPlus]

Rondard P et al. (2011) The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein‐coupled receptors. Neuropharmacology
60: 82‐92 [https://www.ncbi.nlm.nih.gov/pubmed/20713070?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=41

Overview
Motilin receptors (provisional nomenclature) are activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1458 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7141, http://www.uniprot.org/uniprot/P12872), a 22 amino‐acid peptide derived from a precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7141, http://www.uniprot.org/uniprot/P12872), which may also generate a http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5376 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7141, http://www.uniprot.org/uniprot/P12872). These receptors promote gastrointestinal motility and are suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics (often called motilides; e.g. erythromycin), although for many of these molecules the evidence is sparse.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4495, http://www.uniprot.org/uniprot/O43193
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1458 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7141, http://www.uniprot.org/uniprot/P12872) [http://www.ncbi.nlm.nih.gov/pubmed/11461914?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15677347?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11781320?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16531413?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1444 [http://www.ncbi.nlm.nih.gov/pubmed/15764739?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1456 [http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6510 [http://www.ncbi.nlm.nih.gov/pubmed/23190027?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4035 [http://www.ncbi.nlm.nih.gov/pubmed/25341626?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19374732?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3511 [1123, http://www.ncbi.nlm.nih.gov/pubmed/17183187?dopt=AbstractPlus] – Rabbit	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4036 (pA
2 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/18164286?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1466 (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/11806718?dopt=AbstractPlus] – Rabbit	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3794 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus]	



Comments
In terms of structure, the motilin receptor has closest homology with the ghrelin receptor. Thus, the human motilin receptor shares 52% overall amino acid identity with the ghrelin receptor and 86% in the transmembrane regions [http://www.ncbi.nlm.nih.gov/pubmed/19696113?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17183187?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15764739?dopt=AbstractPlus]. However, differences between the N‐terminus regions of these receptors means that their cognate peptide ligands do not readily activate each other [http://www.ncbi.nlm.nih.gov/pubmed/14504130?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19374732?dopt=AbstractPlus]. In laboratory rodents, the gene encoding the motilin percursor appears to be absent, while the receptor appears to be a pseudogene [http://www.ncbi.nlm.nih.gov/pubmed/19696113?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21531468?dopt=AbstractPlus]. Functions of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1458 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7141, http://www.uniprot.org/uniprot/P12872) are not usually detected in rodents, although brain and other responses to motilin and the macrolide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1444 have been reported and the mechanism of these actions is obscure [http://www.ncbi.nlm.nih.gov/pubmed/9441746?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10092986?dopt=AbstractPlus]. Notably, in some non‐laboratory rodents (e.g. the North American kangaroo rat (Dipodomys) and mouse (Microdipodops) a functional form of motilin may exist but the motilin receptor is non‐functional [http://www.ncbi.nlm.nih.gov/pubmed/15027861?dopt=AbstractPlus]. Marked differences in ligand affinities for the motilin receptor in dogs and humans may be explained by significant differences in receptor structure [http://www.ncbi.nlm.nih.gov/pubmed/23189978?dopt=AbstractPlus]. Note that for the complex macrolide structures, selectivity of action has often not been rigorously examined and other actions are possible (e.g. P2X inhibition by erythromycin; [http://www.ncbi.nlm.nih.gov/pubmed/10749750?dopt=AbstractPlus]). Small molecule motilin receptor agonists are now described [http://www.ncbi.nlm.nih.gov/pubmed/15027861?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19374732?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21544957?dopt=AbstractPlus]. The motilin receptor does not appear to have constitutive activity [http://www.ncbi.nlm.nih.gov/pubmed/12907757?dopt=AbstractPlus]. Although not proven, the existence of biased agonism at the receptor has been suggested [http://www.ncbi.nlm.nih.gov/pubmed/16531413?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17074305?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24438586?dopt=AbstractPlus]. A truncated 5‐transmembrane structure has been identified but this is without activity when transfected into a host cell [http://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus]. Receptor dimerisation has not been reported.

Further reading on Motilin receptor
De Smet B et al. (2009) Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther.
123: 207‐23 [https://www.ncbi.nlm.nih.gov/pubmed/19427331?dopt=AbstractPlus]

Marrinan SL etal. (2018) A randomized, double‐blind, placebo‐controlled trial of camicinal in Parkinson's disease. Mov. Disord.
33: 329‐332 [https://www.ncbi.nlm.nih.gov/pubmed/29278279?dopt=AbstractPlus]

Sanger GJ et al. (2016) Ghrelin and motilin receptors as drug targets for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol
13: 38‐48 [https://www.ncbi.nlm.nih.gov/pubmed/26392067?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=42

Overview
Neuromedin U receptors (provisional nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous 25 amino acid peptide neuromedin U (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1470 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7859, http://www.uniprot.org/uniprot/P48645), NmU‐25), a peptide originally isolated from pig spinal cord [http://www.ncbi.nlm.nih.gov/pubmed/3839674?dopt=AbstractPlus]. In humans, NmU‐25 appears to be the sole product of a precursor gene (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7859, http://www.uniprot.org/uniprot/P48645) showing a broad tissue distribution, but which is expressed at highest levels in the upper gastrointestinal tract, CNS, bone marrow and fetal liver. Much shorter versions of NmU are found in some species, but not in human, and are derived at least in some instances from the proteolytic cleavage of the longer NmU. Despite species differences in NmU structure, the C‐terminal region (particularly the C‐terminal pentapeptide) is highly conserved and contains biological activity. Neuromedin S (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1468 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32203, http://www.uniprot.org/uniprot/Q5H8A3)) has also been identified as an endogenous agonist [http://www.ncbi.nlm.nih.gov/pubmed/15635449?dopt=AbstractPlus]. NmS33 is, as its name suggests, a 33 amino‐acid product of a precursor protein derived from a single gene and contains an amidated Cterminal heptapeptide identical to NmU. NmS‐33 appears to activate NMU receptors with equivalent potency to NmU‐25.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=298
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=299
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4518, http://www.uniprot.org/uniprot/Q9HB89
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16454, http://www.uniprot.org/uniprot/Q9GZQ4
	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3524 (pK
B 7) [http://www.ncbi.nlm.nih.gov/pubmed/19369576?dopt=AbstractPlus]	



Comments
NMU1 and NMU2 couple predominantly to Gq/11 although there is evidence of good coupling to Gi/o [http://www.ncbi.nlm.nih.gov/pubmed/15331768?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10887190?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17652154?dopt=AbstractPlus]. NMU1 and NMU2 can be labelled with [125I]‐NmU and [125I]‐NmS (of various species, e.g. [http://www.ncbi.nlm.nih.gov/pubmed/18358099?dopt=AbstractPlus]), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3858 or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3863 [http://www.ncbi.nlm.nih.gov/pubmed/15331768?dopt=AbstractPlus]. A range of radiolabelled ( 125I‐), fluorescently labelled (e.g. Cy3, Cy5, rhodamine and FAM) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787 labelled versions of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1470 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7859, http://www.uniprot.org/uniprot/P48645) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1468 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32203, http://www.uniprot.org/uniprot/Q5H8A3) are now commercially available.

Further reading on Neuromedin U receptors
Brighton PJ et al. (2004) Neuromedin U and its receptors: structure, function, and physiological roles. Pharmacol. Rev.
56: 231‐48 [https://www.ncbi.nlm.nih.gov/pubmed/15169928?dopt=AbstractPlus]

Budhiraja S et al. (2009) Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin Pharmacol
23: 149‐57 [https://www.ncbi.nlm.nih.gov/pubmed/19645813?dopt=AbstractPlus]

Mitchell JD et al. (2009) Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br. J. Pharmacol.
158: 87‐103 [https://www.ncbi.nlm.nih.gov/pubmed/19519756?dopt=AbstractPlus]

Novak CM. (2009) Neuromedin S and U. Endocrinology
150: 2985‐7 [https://www.ncbi.nlm.nih.gov/pubmed/19549882?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=43

Overview
The Neuropeptide FF receptor family contains two subtypes, NPFF1 and NPFF2 (provisional nomenclature [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]), which exhibit high affinities for neuropeptide FF (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) and RFamide related peptides (RFRP: precursor genesymbol https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7). NPFF1 is broadly distributed in the central nervous system with the highest levels found in the limbic system and the hypothalamus. NPFF2 is present in high density in the superficial layers of the mammalian spinal cord where it is involved in nociception and modulation of opioid functions.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=300
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=301
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17425, http://www.uniprot.org/uniprot/Q9GZQ6
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4525, http://www.uniprot.org/uniprot/Q9Y5X5
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5340 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4016 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7) > FMRFhttp://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3735 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3736 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29982, http://www.uniprot.org/uniprot/P83859), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) [http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3735 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) > FMRF, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29982, http://www.uniprot.org/uniprot/P83859) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3736 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) [http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) [http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4016 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7 [http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17337079?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1479 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130) [http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11325787?dopt=AbstractPlus]	
Selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1489 [http://www.ncbi.nlm.nih.gov/pubmed/16129413?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4020 [http://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1486 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/16407169?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4017 (pK
i 7.7–8.1) [http://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4018 (pK
i 7.4–8.1) [http://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1484 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4019 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/19682524?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3797 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1488 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4021 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/19682524?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3797 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus]	



Comments
An orphan receptor https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4523 (http://www.uniprot.org/uniprot/Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1486 is selective for NPFF receptors, but does not distinguish between the NPFF1 and NPFF2 subtypes (pKi 7.1 and 7.2, respectively, [http://www.ncbi.nlm.nih.gov/pubmed/16407169?dopt=AbstractPlus]).

Further reading on Neuropeptide FF/neuropeptide AF receptors
Moulédous L et al. (2010) Opioid‐modulating properties of the neuropeptide FF system. Biofactors
36: 423‐9 [https://www.ncbi.nlm.nih.gov/pubmed/20803521?dopt=AbstractPlus]

Vyas N et al. (2006) Structure‐activity relationships of neuropeptide FF and related peptidic and non‐peptidic derivatives. Peptides
27: 990‐6 [https://www.ncbi.nlm.nih.gov/pubmed/16490282?dopt=AbstractPlus]

Yang HY et al. (2008) Modulatory role of neuropeptide FF system in nociception and opiate analgesia. Neuropeptides
42: 1‐18 [https://www.ncbi.nlm.nih.gov/pubmed/17854890?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=44

Overview
The neuropeptide S receptor (NPS, provisional nomenclature [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) responds to the 20 amino‐acid peptide neuropeptide S derived from a precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33940, http://www.uniprot.org/uniprot/P0C0P6).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=302
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23631, http://www.uniprot.org/uniprot/Q6W5P4
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1490 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33940, http://www.uniprot.org/uniprot/P0C0P6) [http://www.ncbi.nlm.nih.gov/pubmed/15312648?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9167 [http://www.ncbi.nlm.nih.gov/pubmed/25692025?dopt=AbstractPlus] – Mouse	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9168 (pA
2 9) [http://www.ncbi.nlm.nih.gov/pubmed/23761908?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5813 (pA
2 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/20172007?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7929 [http://www.ncbi.nlm.nih.gov/pubmed/18555684?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1493 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15312648?dopt=AbstractPlus]	



Comments
Multiple single‐nucleotide polymorphisms (SNP) and several splice variants have been identified in the human NPS receptor. The most interesting of these is an Asn‐Ile exchange at position 107 (Asn107Ile). The human NPS receptor Asn107Ile displayed similar binding affinity buthigher NPSpotency (by approx. 10‐fold) than human NPS receptor Asn107 [http://www.ncbi.nlm.nih.gov/pubmed/16144971?dopt=AbstractPlus]. Several epidemiological studies reported an association between Asn107Ile receptor variant and susceptibility to panic disorders [http://www.ncbi.nlm.nih.gov/pubmed/20603625?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20705147?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17669576?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20628342?dopt=AbstractPlus]. The SNP Asn107Ile has also been linked to sleep behavior [http://www.ncbi.nlm.nih.gov/pubmed/17903308?dopt=AbstractPlus], inflammatory bowel disease [http://www.ncbi.nlm.nih.gov/pubmed/17854592?dopt=AbstractPlus], schizophrenia [http://www.ncbi.nlm.nih.gov/pubmed/22078257?dopt=AbstractPlus], increased impulsivity and ADHD symptoms [http://www.ncbi.nlm.nih.gov/pubmed/23325374?dopt=AbstractPlus]. Interestingly, a carboxy‐terminal splice variant of human NPS receptor was found to be overexpressed in asthmatic patients [http://www.ncbi.nlm.nih.gov/pubmed/15073379?dopt=AbstractPlus].

Further reading on Neuropeptide S receptor
Grund T et al. (2019) Brain neuropeptide S: via GPCR activation to a powerful neuromodulator of socio‐emotional behaviors. Cell Tissue Res.
375: 123‐132 [https://www.ncbi.nlm.nih.gov/pubmed/30112573?dopt=AbstractPlus]

Guerrini R et al. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev
30: 751‐77 [https://www.ncbi.nlm.nih.gov/pubmed/19824051?dopt=AbstractPlus]

Ruzza C et al. (2017) Neuropeptide S receptor ligands: a patent review (2005‐2016). Expert Opin Ther Pat
27: 347‐362 [https://www.ncbi.nlm.nih.gov/pubmed/27788040?dopt=AbstractPlus]

Xu YL et al. (2004) Neuropeptide S: a neuropeptide promoting arousal and anxiolytic‐like effects. Neuron
43: 487‐497 [https://www.ncbi.nlm.nih.gov/pubmed/15312648?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=45

Overview
The neuropeptide BW receptor 1 (NPBW1, provisional nomenclature [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) is activated by two 23‐amino‐acid peptides, neuropeptide W (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1495 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30509, http://www.uniprot.org/uniprot/Q8N729)) and neuropeptide B (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1501 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41)) [http://www.ncbi.nlm.nih.gov/pubmed/12118011?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12130646?dopt=AbstractPlus]. C‐terminally extended forms of the peptides (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1496 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30509, http://www.uniprot.org/uniprot/Q8N729) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1502 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41)) also activate NPBW1[http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus]. Unique to both forms of neuropeptide B is the N‐terminal bromination of the first tryptophan residue, and it is from this post‐translational modification that the nomenclature NPB is derived. These peptides were first identified from bovine hypothalamus and therefore are classed as neuropeptides. Endogenous variants of the peptides without the N‐terminal bromination, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1499 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1500 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41), were not found to be major components of bovine hypothalamic tissue extracts. The NPBW2 receptor is activated by the short and C‐terminal extended forms of neuropeptide W and neuropeptide B [http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=303
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=304
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4522, http://www.uniprot.org/uniprot/P48145
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4530, http://www.uniprot.org/uniprot/P48146
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1502 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1501 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1495 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30509, http://www.uniprot.org/uniprot/Q8N729) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1496 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30509, http://www.uniprot.org/uniprot/Q8N729) [http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1495 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30509, http://www.uniprot.org/uniprot/Q8N729) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1496 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30509, http://www.uniprot.org/uniprot/Q8N729) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1502 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1501 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30099, http://www.uniprot.org/uniprot/Q8NG41) [http://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3855 [http://www.ncbi.nlm.nih.gov/pubmed/17486669?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3856 [http://www.ncbi.nlm.nih.gov/pubmed/17486669?dopt=AbstractPlus]	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1497 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15261118?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1497 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12130646?dopt=AbstractPlus]	



Comments
Potency measurements were conducted with heterologously‐expressed receptors with a range of 0.14‐0.57 nM (NPBW1) and 0.98‐21 nM (NPBW2).

NPBW1‐/‐ mice show changes in social behavior, suggesting that the NPBW1pathway may have animportant role in theemotional responses of social interaction [http://www.ncbi.nlm.nih.gov/pubmed/21390312?dopt=AbstractPlus].

For a review of the contribution of neuropeptide B/W to social dominance, see Watanabe and Yamamoto, 2015 [http://www.ncbi.nlm.nih.gov/pubmed/26136644?dopt=AbstractPlus]. It has been reported that neuropeptide W may have a key role in the gating of stressful stimuli when mice are exposed to novel environments [http://www.ncbi.nlm.nih.gov/pubmed/27140610?dopt=AbstractPlus].

Two antagonists have been discovered and reported to have affinity for NPBW1, ML181 and ML250, the latter exhibiting improved selectivity (100 fold) for NPBW1 compared to MCH1 receptors [http://www.ncbi.nlm.nih.gov/pubmed/23762933?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22834040?dopt=AbstractPlus]. Computational insights into the binding of antagonists to this receptor have also been described [http://www.ncbi.nlm.nih.gov/pubmed/24938207?dopt=AbstractPlus].

Further reading on Neuropeptide W/neuropeptide B receptors
Sakurai T. (2013) NPBWR1 and NPBWR2: Implications in Energy Homeostasis, Pain, and Emotion. Front Endocrinol (Lausanne)
4: 23 [https://www.ncbi.nlm.nih.gov/pubmed/23515889?dopt=AbstractPlus]

Singh G et al. (2006) Neuropeptide B and W: neurotransmitters in an emerging G‐protein‐coupled receptor system. Br. J. Pharmacol.
148: 1033‐41 [https://www.ncbi.nlm.nih.gov/pubmed/16847439?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=46

Overview
Neuropeptide Y (NPY) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Neuropeptide Y Receptors [http://www.ncbi.nlm.nih.gov/pubmed/9549761?dopt=AbstractPlus]) are activated by the endogenous peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7955, http://www.uniprot.org/uniprot/P01303), neuropeptide Y‐(3‐36), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1514 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9748, http://www.uniprot.org/uniprot/P10082), PYY‐(3‐36) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1512 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9327, http://www.uniprot.org/uniprot/P01298) (PP). The receptor originally identified as the Y3 receptor has been identified as the http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 (originally named LESTR, [http://www.ncbi.nlm.nih.gov/pubmed/8276799?dopt=AbstractPlus]). The y6 receptor is a functional gene product in mouse, absent in rat, but contains a frame‐shift mutation in primates producing a truncated non‐functional gene [http://www.ncbi.nlm.nih.gov/pubmed/8641440?dopt=AbstractPlus]. Many of the agonists exhibit differing degrees of selectivity dependent on the species examined. For example, the potency of PP is greater at the rat Y4 receptor than at the human receptor [http://www.ncbi.nlm.nih.gov/pubmed/9802391?dopt=AbstractPlus]. In addition, many agonists lack selectivity for individual subtypes, but can exhibit comparable potency against pairs of NPY receptor subtypes, or have not been examined for activity at all subtypes. [125I]‐PYY or [125I]‐NPY can be used to label Y1, Y2, Y5 and y6 subtypes non‐selectively, while [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3921 may be used to label Y5 receptors preferentially (note that cPP denotes chicken peptide sequence and hPP is the human sequence).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=305
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=307
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=308
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=683
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7956, http://www.uniprot.org/uniprot/P25929
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7957, http://www.uniprot.org/uniprot/P49146
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9329, http://www.uniprot.org/uniprot/P50391
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7958, http://www.uniprot.org/uniprot/Q15761
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7959, http://www.uniprot.org/uniprot/Q99463
	
Potency order of endogenous ligands	neuropeptide Y = peptide YY ≫ pancreatic polypeptide	peptide YY = peptide YY(3‐36) = neuropeptide Y = neuropeptide Y(3‐36) ≫ pancreatic polypeptide	pancreatic polypeptide ≫ neuropeptide Y = peptide YY	neuropeptide Y > peptide YY > pancreatic polypeptide	neuropeptide Y = peptide YY > pancreatic polypeptide	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7955, http://www.uniprot.org/uniprot/P01303), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1514 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9748, http://www.uniprot.org/uniprot/P10082)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1517) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9748, http://www.uniprot.org/uniprot/P10082) [http://www.ncbi.nlm.nih.gov/pubmed/8632753?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7592910?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7955, http://www.uniprot.org/uniprot/P01303), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3627) (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7955, http://www.uniprot.org/uniprot/P01303), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1514 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9748, http://www.uniprot.org/uniprot/P10082)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1512 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9327, http://www.uniprot.org/uniprot/P01298) [http://www.ncbi.nlm.nih.gov/pubmed/7592911?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7493937?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16807358?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8643460?dopt=AbstractPlus]	–	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1545 [http://www.ncbi.nlm.nih.gov/pubmed/8590988?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1527, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3848, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1546
	–	–	–	–	
Selective agonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1522 [http://www.ncbi.nlm.nih.gov/pubmed/12069595?dopt=AbstractPlus]	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1528 (pIC50 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/9806339?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1485 (pK
i 8.1–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/7562541?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7562543?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1547 (pIC50 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/10611450?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3504 (pIC50 6.9–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/14617685?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1565 (pK
i 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/10872822?dopt=AbstractPlus]	–	
Selective allosteric modulators	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8494 (Positive) [http://www.ncbi.nlm.nih.gov/pubmed/27294784?dopt=AbstractPlus]	–	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3474 (Antagonist) (pK
d 8.7), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3762 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3802 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3800 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3921 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15337369?dopt=AbstractPlus] – Rat		
Comments	Note that Pro34‐containing NPY and PYY can also bind Y4 and Y5 receptors, so strictly speaking are not selective, but are the ’preferred’ agonists.	–	–	–	–	



Comments
The Y1 agonists indicated are selective relative to Y2 receptors. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1485 is selective relative to Y2, Y4 and Y5 receptors [http://www.ncbi.nlm.nih.gov/pubmed/8700207?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3903) is Y2 selective relative to Y1 and Y5 receptors. PYY‐(3‐36) is Y2 selective relative to Y1 receptors. Note that Pro34‐containing NPY and PYY can also bind Y4 and Y5, thus they are selective only relative to Y2. The y6 receptor is a pseudogene in humans, but is functional in mouse, rabbit and some other mammals.

Further reading on Neuropeptide Y receptors
Bowers ME et al. (2012) Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol. Behav.
107: 699‐710 [https://www.ncbi.nlm.nih.gov/pubmed/22429904?dopt=AbstractPlus]

Michel MC et al. (1998) XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol. Rev.
50: 143‐150 [https://www.ncbi.nlm.nih.gov/pubmed/9549761?dopt=AbstractPlus]

Pedragosa‐Badia X et al. (2013) Neuropeptide Y receptors: how to get subtype selectivity. Front En docrinol (Lausanne)
4: 5 [https://www.ncbi.nlm.nih.gov/pubmed/23382728?dopt=AbstractPlus]

Zhang L et al. (2011) The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther.
131: 91‐113 [https://www.ncbi.nlm.nih.gov/pubmed/21439311?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=47

Overview
Neurotensin receptors (nomenclature as recommended by
NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous tridecapeptide neurotensin (pGlu‐Leu‐Tyr‐Glu‐Asn‐Lys‐Pro‐Arg‐Arg‐Pro‐Tyr‐Ile‐Leu) derived from a precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8038, http://www.uniprot.org/uniprot/30990), which also generates neuromedin N, an agonist at the NTS2 receptor. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3830) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1574) may be used to label NTS1 and NTS2 receptors at 0.1‐0.3 and 3‐5 nM concentrations respectively.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=309
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=310
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8039, http://www.uniprot.org/uniprot/P30989
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8040, http://www.uniprot.org/uniprot/O95665
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1579 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8038, http://www.uniprot.org/uniprot/P30990) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1578 {Mouse, Rat} [http://www.ncbi.nlm.nih.gov/pubmed/9283723?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1579 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8038, http://www.uniprot.org/uniprot/P30990) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1578 {Mouse, Rat} [http://www.ncbi.nlm.nih.gov/pubmed/8795617?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1570 [http://www.ncbi.nlm.nih.gov/pubmed/12869647?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1586 [http://www.ncbi.nlm.nih.gov/pubmed/8795617?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11723247?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1582 (pIC50 7.5–8.2) [http://www.ncbi.nlm.nih.gov/pubmed/9023294?dopt=AbstractPlus]	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1583 (Antagonist) (pK
d 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/7746272?dopt=AbstractPlus] – Rat	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1579 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8038, http://www.uniprot.org/uniprot/P30990) appears to be a lowefficacy agonist at the NTS2 receptor [http://www.ncbi.nlm.nih.gov/pubmed/9851594?dopt=AbstractPlus], while the NTS1 receptor antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1582 is an agonist at NTS2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/9851594?dopt=AbstractPlus]. An additional protein, provisionally termed NTS3 (also known as NTR3, gp95 and sortilin; http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134243;r=1:109852192‐109940573), has been suggested to bind lipoprotein lipase and mediate its degradation [http://www.ncbi.nlm.nih.gov/pubmed/10085125?dopt=AbstractPlus]. It has been reported to interact with the NTS1 receptor [http://www.ncbi.nlm.nih.gov/pubmed/12360476?dopt=AbstractPlus] and the NTS2 receptor [http://www.ncbi.nlm.nih.gov/pubmed/19891061?dopt=AbstractPlus], and has beenimplicated in hormone trafficking and/or neurotensin uptake. A splice variant of the NTS2 receptor bearing 5 transmembrane domains has been identified in mouse [http://www.ncbi.nlm.nih.gov/pubmed/9001400?dopt=AbstractPlus] and later in rat [http://www.ncbi.nlm.nih.gov/pubmed/15637074?dopt=AbstractPlus].

Further reading on Neurotensin receptors
Boules M et al. (2013) Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne)
4: 36 https://www.ncbi.nlm.nih.gov/pubmed/23526754?dopt=AbstractPlus


Mazella J et al. (2012) Neurotensin and its receptors in the control of glucose homeostasis. Front Endocrinol (Lausanne)
3: 143 https://www.ncbi.nlm.nih.gov/pubmed/23230428?dopt=AbstractPlus


Myers RM et al. (2009) Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. ACS Chem. Biol.
4: 503‐25 https://www.ncbi.nlm.nih.gov/pubmed/19462983?dopt=AbstractPlus


Ouyang Q et al. (2017) Oncogenic role of neurotensin and neurotensin receptors in various cancers. Clin. Exp. Pharmacol. Physiol.
44: 841‐846 https://www.ncbi.nlm.nih.gov/pubmed/28556374?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=50

Overview
Opioid and opioid‐like receptors are activated by a variety of endogenous peptides including [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210) (met), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1613 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210) (leu), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189) (β‐end), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3737 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8820, http://www.uniprot.org/uniprot/P01213), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1620 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8820, http://www.uniprot.org/uniprot/P01213) (dynA), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1622 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8820, http://www.uniprot.org/uniprot/P01213) (dynB), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3669 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8820, http://www.uniprot.org/uniprot/P01213) (Big dyn), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9163, http://www.uniprot.org/uniprot/Q13519) (N/OFQ); http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668 are also potential endogenous peptides. The Greek letter nomenclature for the opioid receptors, μ, δ and κ, is well established, and NC‐IUPHAR considers this nomenclature appropriate, along with the symbols spelled out (mu, delta, and kappa), and the acronyms, MOP, DOP, and KOP. [http://www.ncbi.nlm.nih.gov/pubmed/24528283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8981566?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]. The human N/OFQ receptor, NOP, is considered ’opioid‐related’ rather than opioid because, while it exhibits a high degree of structural homology with the conventional opioid receptors [http://www.ncbi.nlm.nih.gov/pubmed/8137918?dopt=AbstractPlus], it displays a distinct pharmacology. Currently there are numerous clinically used drugs, such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1627 and many other opioid analgesics, as well as antagonists such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1638, however only for the μ receptor.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8153, http://www.uniprot.org/uniprot/P41143
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8154, http://www.uniprot.org/uniprot/P41145
	
Principal endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1613 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3669 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8820, http://www.uniprot.org/uniprot/P01213), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1620 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8820, http://www.uniprot.org/uniprot/P01213)	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1607 [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1625 [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1602 [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus]	–	
Sub/family‐selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9294 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21177476?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9294 [http://www.ncbi.nlm.nih.gov/pubmed/21177476?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9006 [http://www.ncbi.nlm.nih.gov/pubmed/18069089?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9002 [http://www.ncbi.nlm.nih.gov/pubmed/18788723?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9004 [http://www.ncbi.nlm.nih.gov/pubmed/18788723?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1608 [http://www.ncbi.nlm.nih.gov/pubmed/6310598?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4060 [http://www.ncbi.nlm.nih.gov/pubmed/2544892?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9003 [http://www.ncbi.nlm.nih.gov/pubmed/19694468?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1611 [http://www.ncbi.nlm.nih.gov/pubmed/8035418?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9178661?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1652 [http://www.ncbi.nlm.nih.gov/pubmed/14718611?dopt=AbstractPlus, 1671, http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/6129321?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1646 [http://www.ncbi.nlm.nih.gov/pubmed/2178014?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14613319?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1655 [http://www.ncbi.nlm.nih.gov/pubmed/2986999?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2986999?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1666 [http://www.ncbi.nlm.nih.gov/pubmed/15869877?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12192085?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9838 (pK
i 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/22194444?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/29524334?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1639 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1638 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1670 (pK
i 9.1–10.2) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1639 (pK
i 8.4–9.4) [1671, http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1638 (pK
i 7.6–8.6) [1671, http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus]	
Sub/family‐selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8870 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12801588?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8870 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25635572?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1640 (pK
i 10) [http://www.ncbi.nlm.nih.gov/pubmed/1851833?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1641 (pK
i 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/2832195?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1637 (Inverse agonist) (pK
i 9) [http://www.ncbi.nlm.nih.gov/pubmed/8230106?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1642 (pK
i 8.9–11) [1671, http://www.ncbi.nlm.nih.gov/pubmed/2444704?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1669 (pK
i 9.7–9.9) [http://www.ncbi.nlm.nih.gov/pubmed/10822054?dopt=AbstractPlus, 1671, http://www.ncbi.nlm.nih.gov/pubmed/10893314?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7362 (pK
i 9–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/23976952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11495579?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25635572?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3829 (Antagonist) (pK
d 10.4) [http://www.ncbi.nlm.nih.gov/pubmed/1313133?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9065 (Selective Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1329092?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1612 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1313812?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3819 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/2986120?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3816 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1313131?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3828 (Antagonist) [http://www.ncbi.nlm.nih.gov/pubmed/9696425?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1612 (Antagonist) (pK
d 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/1313812?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1656 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/2986999?dopt=AbstractPlus, 1671, http://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3475 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11239918?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8156, http://www.uniprot.org/uniprot/P35372
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8155, http://www.uniprot.org/uniprot/P41146
	
Potential endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668
	–	
Principal endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9201, http://www.uniprot.org/uniprot/P01189), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1614 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1613 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8831, http://www.uniprot.org/uniprot/P01210)	–	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1681 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9163, http://www.uniprot.org/uniprot/Q13519) [http://www.ncbi.nlm.nih.gov/pubmed/9413015?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12070757?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369464?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7595 [http://www.ncbi.nlm.nih.gov/pubmed/12502358?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7082 [http://www.ncbi.nlm.nih.gov/pubmed/19282177?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1626 [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1670 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5458 [http://www.ncbi.nlm.nih.gov/pubmed/11585443?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9838 [http://www.ncbi.nlm.nih.gov/pubmed/22194444?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/29524334?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1671 [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7477 [http://www.ncbi.nlm.nih.gov/pubmed/17656655?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7221 [http://www.ncbi.nlm.nih.gov/pubmed/11585443?dopt=AbstractPlus]	–	
Sub/family‐selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9294 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21177476?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8866 [http://www.ncbi.nlm.nih.gov/pubmed/24713140?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9294 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21177476?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3534 [http://www.ncbi.nlm.nih.gov/pubmed/21215785?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1647 [http://www.ncbi.nlm.nih.gov/pubmed/6263640?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7215 [http://www.ncbi.nlm.nih.gov/pubmed/15454210?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1627 [http://www.ncbi.nlm.nih.gov/pubmed/2549383?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1671 [http://www.ncbi.nlm.nih.gov/pubmed/6313901?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1682 [http://www.ncbi.nlm.nih.gov/pubmed/12070757?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9191955?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12967935?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10369464?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1680 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9353393?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12967935?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8868 [http://www.ncbi.nlm.nih.gov/pubmed/18492950?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1684 [http://www.ncbi.nlm.nih.gov/pubmed/10758169?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11006485?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9747 [http://www.ncbi.nlm.nih.gov/pubmed/29232769?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1639 (pK
i 9.1–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/24973897?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1628 (pK
i 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1629 (pKi 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1638 (pK
i 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7563 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/19282177?dopt=AbstractPlus]	–	
Sub/family‐selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8870 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25635572?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8870 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/25635572?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7471 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/18313920?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7209 (pK
i 8.8–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/21621410?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1635 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/6313901?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1694 (pK
i 10.2) [http://www.ncbi.nlm.nih.gov/pubmed/12010780?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9462 (pK
i 10) [http://www.ncbi.nlm.nih.gov/pubmed/24678969?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7361 (pK
i 9.6) [http://www.ncbi.nlm.nih.gov/pubmed/19445927?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1693 (pK
i 9.2–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/17329552?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14593080?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1691 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/10602690?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9159 (Neutral) (pK
B 6) [http://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9156 (Positive) (pK
B 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9160 (Neutral) (pK
B 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9157 (Positive) (pK
B 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus]	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1612 (Antagonist) (pK
d 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/8114680?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3815 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/8114680?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3832 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/3030778?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1688 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9353393?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8849681?dopt=AbstractPlus]	



Comments
Three naloxone‐sensitive opioid receptor genes havebeen identified in humans, and while the μ‐receptor in particular may be subject to extensive alternative splicing [http://www.ncbi.nlm.nih.gov/pubmed/24076545?dopt=AbstractPlus], these putative isoforms have not been correlated with any of the subtypesof receptor proposed inyears past. Opioid receptors may heterodimerize with each other or with other 7TM receptors [http://www.ncbi.nlm.nih.gov/pubmed/10385123?dopt=AbstractPlus], and give rise to complexes with a unique pharmacology, however, evidence for such heterodimers in native cells is equivocal and the consequences of this heterodimerization for signalling remains largely unknown. For μ‐opioid receptors at least, dimerization does not seem to be required for signalling [http://www.ncbi.nlm.nih.gov/pubmed/19542234?dopt=AbstractPlus]. A distinct met‐enkephalin receptor lacking structural resemblance to the opioid receptors listed has been identified (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15768, http://www.uniprot.org/uniprot/9NZT2) and termed an opioid growth factor receptor [http://www.ncbi.nlm.nih.gov/pubmed/11890982?dopt=AbstractPlus].


http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1623 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3668 have been identified as highly selective, putative endogenous agonists for the μ‐opioid receptor. At present, however, the mechanisms for endomorphin synthesis in vivo have not been established, and there is no gene identified that encodes for either. Thus, the status of these peptides as endogenous ligands remains unproven.

Two areas of increasing importance in defining opioid receptor function are the presence of functionally relevant single nucleotide polymorphisms in human μ‐receptors [http://www.ncbi.nlm.nih.gov/pubmed/19116204?dopt=AbstractPlus] and the identification of biased signalling by opioid receptor ligands, in particular, compounds previously characterized as antagonists [http://www.ncbi.nlm.nih.gov/pubmed/17702750?dopt=AbstractPlus]. Pathway bias for agonists makes general rank orders of potency and efficacy somewhat obsolete, so these do not appear in the table. As ever, the mechanisms underlying the acute and long term regulation of opiod receptor function are the subject of intense investigation and debate.

The richness of opioid receptor pharmacology has been enhanced with the recent discovery of allosteric modulators of μ and δ receptors, notably thepositive allosteric modulators and silent allosteric “antagonists” outlined in [http://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25901762?dopt=AbstractPlus]. Negative allosteric modulation of opioid receptors has been previously suggested [http://www.ncbi.nlm.nih.gov/pubmed/16489449?dopt=AbstractPlus], whether all compounds are acting at a similar site remains to be established.

Further reading on Opioid receptors
Butelman ER et al. (2012) κ‐opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci.
35: 587‐96 https://www.ncbi.nlm.nih.gov/pubmed/22709632?dopt=AbstractPlus


Cox BM et al. (2015) Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br. J. Pharmacol.
172: 317‐23 https://www.ncbi.nlm.nih.gov/pubmed/24528283?dopt=AbstractPlus


Pradhan AA et al. (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol. Sci.
32: 581‐90 https://www.ncbi.nlm.nih.gov/pubmed/21925742?dopt=AbstractPlus


Williams JT et al. (2013) Regulation of μ‐opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev.
65: 223‐54 https://www.ncbi.nlm.nih.gov/pubmed/23321159?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=51

Overview
Orexin receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Orexin receptors [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous polypeptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697 (https://www.genenames.org/data/gene‐symbol‐report/%23!/hgnc_id/HGNC:4847, http://www.uniprot.org/uniprot/O43612)and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699 (https://www.genenames.org/data/gene‐symbol‐report/%23!/hgnc_id/HGNC:4847,http://www.uniprot.org/uniprot/O43612) (also known as hypocretin‐1 and ‐2; 33 and 28 aa) derived from a common precursor, https://www.genenames.org/data/gene‐symbol‐report/%23!/hgnc_id/HGNC:4847, by proteolytic cleavage and some typical peptide modifications [http://www.ncbi.nlm.nih.gov/pubmed/9491897?dopt=AbstractPlus]. Currently the only orexin receptor ligand in clinical use is http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2890,whichisused as a hypnotic. Orexin receptor crystal structures have been solved [http://www.ncbi.nlm.nih.gov/pubmed/26950369?dopt=AbstractPlus,http://www.ncbi.nlm.nih.gov/pubmed/25533960?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=321
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=322
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4848, http://www.uniprot.org/uniprot/O43613
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4849, http://www.uniprot.org/uniprot/O43614
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4847, http://www.uniprot.org/uniprot/O43612) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699, http://www.uniprot.org/uniprot/O43612)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4847, http://www.uniprot.org/uniprot/O43612) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699, http://www.uniprot.org/uniprot/O43612)	
Selective agonists	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700 [http://www.ncbi.nlm.nih.gov/pubmed/12467628?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21362456?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9305 [http://www.ncbi.nlm.nih.gov/pubmed/26267383?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30194937?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10277 [http://www.ncbi.nlm.nih.gov/pubmed/28507129?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28507129?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4461 (pK
i 9.3–9.6) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20565075?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2890 (pK
i 8.7–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23692283?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4460 (pK
i 8.4–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22019562?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9304 (pK
i 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/18207395?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2886 (pK
i 7.8–8.5) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22796453?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10280 (pK
i 7.6–8) [http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4461 (pK
i 8.9–9.8) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20565075?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9304 (pK
i 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/18207395?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2890 (pK
i 8.9–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23692283?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10280 (pK
i 8.5–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4460 (pKi 8.9–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22019562?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9136 (70–300‐fold selective) (pK
i 8.7–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1703 (50–150‐fold selective) (pK
i 7.2–7.9) [http://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11459658?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22079339?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11250867?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1704 (60–80‐fold selective) (pK
i 7.2–7.9) [http://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23692283?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4037 (300–3000‐fold selective) (pK
i 8.4–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23692283?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21679703?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1701 (200–800‐fold selective) (pK
i 7.7–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/20565075?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15261275?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4038 (pK
i 6.9–7.5) [http://www.ncbi.nlm.nih.gov/pubmed/18207395?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14643355?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1706
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1706 (Antagonist) (pK
d 8.3–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9465
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9465 (Antagonist) (pK
d 8.6–8.9) [http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9464
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9464 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/26582739?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25132134?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9491897?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9465
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9465 (Selective Antagonist) (pK
d 8.9–9.8) [http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9466
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9466 (Selective Antagonist) (pK
d 9.2–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9467
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9467 (Selective Antagonist) (pK
d 8.6–9) [http://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9464
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9464 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/26582739?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25132134?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9491897?dopt=AbstractPlus]	



Comments
The primary coupling of orexin receptors to Gq/11 proteins is rather speculative and based on the strong activation of phospholipase C, though recent studies in recombinant cells also stress the importance of Gq/11 [http://www.ncbi.nlm.nih.gov/pubmed/27237973?dopt=AbstractPlus]. Coupling of both receptors to Gi/o and Gs has also been reported [http://www.ncbi.nlm.nih.gov/pubmed/15687100?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23902572?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23848055?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11600545?dopt=AbstractPlus]. For most native cellular responses observed, the G protein pathway is unknown. The relative potency order of endogenous ligands depends on the cellular signal transduction machinery [http://www.ncbi.nlm.nih.gov/pubmed/23034387?dopt=AbstractPlus]. Similarly, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700]http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1700, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9305 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10277 may show variable selectivity for OX2 receptors and are also likely to activate OX1 receptors [http://www.ncbi.nlm.nih.gov/pubmed/21362456?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30194937?dopt=AbstractPlus]. Many antagonists and radioligands are not well‐characterized, and thus the affinities are uncertain. Among radioligands, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1706
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1706, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9467
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9467 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9465
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9465 are commercially available. [3H]‐TCS 1102 (pKd/OX1 8.2, pKd/OX2 9.0) [http://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus] and Rhodamine Green‐orexinA [http://www.ncbi.nlm.nih.gov/pubmed/11266181?dopt=AbstractPlus] are also useful radioligand tools. Orexin receptors have been reported to be able to form complexes with each other and some other GPCRs as well as σ1 receptors, which might affect the signaling and pharmacology [http://www.ncbi.nlm.nih.gov/pubmed/27909990?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25926444?dopt=AbstractPlus]. Loss‐of‐function mutations in the gene encoding the OX2 receptor underlie canine hereditary narcolepsy [http://www.ncbi.nlm.nih.gov/pubmed/10458611?dopt=AbstractPlus]. Antagonists of the orexin receptors are the focus of major drug discovery efforts for their potential to treat insomnia and other disorders of wakefulness [http://www.ncbi.nlm.nih.gov/pubmed/26317591?dopt=AbstractPlus], while agonists would likely be useful in human narcolepsy.

Further reading on Orexin receptors
Baimel C et al. (2015) Orexin/hypocretin role in reward: implications for opioid and other addictions. Br. J. Pharmacol.
172: 334‐48 [https://www.ncbi.nlm.nih.gov/pubmed/24641197?dopt=AbstractPlus]

Burdakov D. (2018) Reactive and predictive homeostasis: Roles of orexin/hypocretin neurons. Neuropharmacology [https://www.ncbi.nlm.nih.gov/pubmed/30347195?dopt=AbstractPlus]

Kukkonen JP. (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am. J. Physiol., Cell Physiol.
304: C2‐32 [https://www.ncbi.nlm.nih.gov/pubmed/23034387?dopt=AbstractPlus]

Li SB et al. (2016) Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders. Curr Psychiatry Rep
18: 7 [https://www.ncbi.nlm.nih.gov/pubmed/26733323?dopt=AbstractPlus]

Mahler SV et al. (2014) Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat. Neurosci.
17: 1298‐303 [https://www.ncbi.nlm.nih.gov/pubmed/25254979?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=447

Overview

Nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=162
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4531, http://www.uniprot.org/uniprot/Q96P68
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636 [http://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus]	



Further reading on Oxoglutarate receptor
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein‐coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev.
65: 967‐86 [https://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus]

Grimm PR and Welling PA (2017) alpha‐Ketoglutarate drives electroneutral NaCl reabsorption in intercalated cells by activating a G‐protein coupled receptor. Oxgr1. Curr. Opin. Nephrol. Hypertens.
26: 426‐433 [https://www.ncbi.nlm.nih.gov/pubmed/28771454]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=52

Overview
P2Y receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on P2Y Receptors [http://www.ncbi.nlm.nih.gov/pubmed/12559763?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16968944?dopt=AbstractPlus]) are activated by the endogenous ligands http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as ’http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734‐preferring (or http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713‐, etc.) P2Y receptor’ or ’P2Y1‐like’, etc., until further, as yet undefined, corroborative criteria can be applied [271, http://www.ncbi.nlm.nih.gov/pubmed/21586366?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23597047?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21586365?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22963441?dopt=AbstractPlus]. Clinically used drugs acting on these receptors include the dinucleoside polyphosphate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1736, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [http://www.ncbi.nlm.nih.gov/pubmed/24511227?dopt=AbstractPlus], and the P2Y12 receptor antagonists http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7562, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1765 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1776, all approved as antiplatelet drugs [http://www.ncbi.nlm.nih.gov/pubmed/23809135?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27886821?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=323
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=324
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=325
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=326
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8539, http://www.uniprot.org/uniprot/P47900
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8541, http://www.uniprot.org/uniprot/P41231
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8542, http://www.uniprot.org/uniprot/P51582
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8543, http://www.uniprot.org/uniprot/Q15077
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 [http://www.ncbi.nlm.nih.gov/pubmed/8564228?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 (at rat recombinant receptors, UTP = ATP)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734 [http://www.ncbi.nlm.nih.gov/pubmed/11754592?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8564228?dopt=AbstractPlus]	–	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755 [http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1710 [http://www.ncbi.nlm.nih.gov/pubmed/9154346?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus]	–	–	–	
Sub/family‐selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1736 [http://www.ncbi.nlm.nih.gov/pubmed/11206448?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1737 [http://www.ncbi.nlm.nih.gov/pubmed/8825364?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8825364?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12183642?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1735
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1735 [http://www.ncbi.nlm.nih.gov/pubmed/8564228?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1736 [http://www.ncbi.nlm.nih.gov/pubmed/16475938?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1737 [http://www.ncbi.nlm.nih.gov/pubmed/12183642?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1735
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1735 [http://www.ncbi.nlm.nih.gov/pubmed/8825364?dopt=AbstractPlus]	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3338 [http://www.ncbi.nlm.nih.gov/pubmed/15345752?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8447‐http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8447) [http://www.ncbi.nlm.nih.gov/pubmed/23751098?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1733 [http://www.ncbi.nlm.nih.gov/pubmed/17302398?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3398 [http://www.ncbi.nlm.nih.gov/pubmed/17125260?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5902 (EC50 value determined using an IP3 functional assay) [http://www.ncbi.nlm.nih.gov/pubmed/17125260?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21417463?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17088057?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4044 [http://www.ncbi.nlm.nih.gov/pubmed/21528910?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6199], (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1740 [http://www.ncbi.nlm.nih.gov/pubmed/11754592?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5910
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5910 [http://www.ncbi.nlm.nih.gov/pubmed/22901672?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24970757?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5903 [http://www.ncbi.nlm.nih.gov/pubmed/20446735?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1747 [http://www.ncbi.nlm.nih.gov/pubmed/16942026?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728 (pK
i 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1725 (pKi 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus]	–	–	–	
Sub/family‐selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1739 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/10401562?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728 (pIC50 4.3) [http://www.ncbi.nlm.nih.gov/pubmed/10401562?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9154346?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1725 (pEC50 2–5) [http://www.ncbi.nlm.nih.gov/pubmed/18600475?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1739 (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/9647463?dopt=AbstractPlus] – Rat	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1739 (pK
B 6) [http://www.ncbi.nlm.nih.gov/pubmed/26519900?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1725 (pK
B 4) [http://www.ncbi.nlm.nih.gov/pubmed/26519900?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728 (pK
B 4) [http://www.ncbi.nlm.nih.gov/pubmed/26519900?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1724 (pK
i 8.8–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/15476670?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14584948?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1721 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1720 (pK
i 7–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/8913364?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5907 (pIC50 ∼6) [http://www.ncbi.nlm.nih.gov/pubmed/15231488?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1738 (pEC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/17302398?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9468 (pIC50 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/19419204?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713 (pK
d 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/10779375?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1753 (pIC50 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/15081875?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1752 (pIC50 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/15081875?dopt=AbstractPlus]	
Selective allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5808 (Negative) (pK
i 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/25822790?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1729 (Negative) (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/15193995?dopt=AbstractPlus]	–	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1727
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1727 (Antagonist) (pK
d 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1763
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1763 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3408
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3408
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3408 (Agonist)	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9469 (Selective Antagonist) (pEC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/24712832?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=327
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=329
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=330
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8540, http://www.uniprot.org/uniprot/Q96G91
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18124, http://www.uniprot.org/uniprot/Q9H244
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4537, http://www.uniprot.org/uniprot/Q9BPV8
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16442, http://www.uniprot.org/uniprot/Q15391
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783 [http://www.ncbi.nlm.nih.gov/pubmed/19759354?dopt=AbstractPlus]	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 [http://www.ncbi.nlm.nih.gov/pubmed/15199474?dopt=AbstractPlus]	–	–	
Sub/family‐selective agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1710 [http://www.ncbi.nlm.nih.gov/pubmed/15199474?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755 [http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1710 [http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1711], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1755]	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1756 [http://www.ncbi.nlm.nih.gov/pubmed/15893764?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10578132?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4046 [http://www.ncbi.nlm.nih.gov/pubmed/19815812?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1714
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1714 [http://www.ncbi.nlm.nih.gov/pubmed/10578132?dopt=AbstractPlus]	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6203.http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6203 [http://www.ncbi.nlm.nih.gov/pubmed/19902968?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5908 [http://www.ncbi.nlm.nih.gov/pubmed/21484092?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6202]	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1776 (pIC50 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1764 (pIC50 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1776 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1732 (pIC50 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1764 (pIC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus]	–	
Sub/family‐selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728 (pIC50 4.8–6) [http://www.ncbi.nlm.nih.gov/pubmed/10578132?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1739 (pIC50 5) [http://www.ncbi.nlm.nih.gov/pubmed/10578132?dopt=AbstractPlus]	–	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1761 (pK
i 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/16250663?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1762 (pIC50 6.4–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/19815812?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7360 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/24215345?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24670650?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3384 (pIC50 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/7582510?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7858849?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1765 (pKi 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/22984835?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1778 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/15913566?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1777 (pIC50 6) [http://www.ncbi.nlm.nih.gov/pubmed/15913566?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5802 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/23592514?dopt=AbstractPlus]	
Labelled ligands	–	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1763
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1763 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6147
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6147 (Antagonist) (pK
d 8.3–8.5) [http://www.ncbi.nlm.nih.gov/pubmed/16213725?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22892887?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1774
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1774 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9470 (Selective Antagonist) (pKi 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/25299434?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9471 (Selective Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/26303895?dopt=AbstractPlus]	



Comments
A series of 4‐alkyloxyimino derivatives of uridine5’‐triphosphate which could be useful for derivatization as fluorescent P2Y2/4/6 receptor probes has been recently synthesized [http://www.ncbi.nlm.nih.gov/pubmed/24712832?dopt=AbstractPlus].

Single nucleotide polymorphisms of the P2YR1 gene have been associated to different platelet reactivity to ADP http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712 [http://www.ncbi.nlm.nih.gov/pubmed/15514209?dopt=AbstractPlus]. Three frequent nonsynonymous P2Y2 receptor polymorphisms have been identified, one of which was significantly more common in cystic fibrosis patients. This polymorphism is linked to increases in Ca2+ influx in transfected cells, and might therefore play a role in disease development [http://www.ncbi.nlm.nih.gov/pubmed/16495779?dopt=AbstractPlus]. Although http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1734 (UTP) was also shown to be a biased agonist at P2Y11, this is still under debate [http://www.ncbi.nlm.nih.gov/pubmed/25015314?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12761346?dopt=AbstractPlus]. A group of single nucleotide polymorphisms in the P2Y12 gene, forming the so called P2Y12 H2 haplotype, has been associated with increased platelet responsiveness to ADP, increased risk of peripheral arterial disease and with coronary artery disease [http://www.ncbi.nlm.nih.gov/pubmed/17803810?dopt=AbstractPlus]. The platelet‐type bleeding disorder due to P2Y12 receptor defects is an autosomal recessive condition characterized by mild to moderate mucocutaneous bleeding and excessive bleeding after surgery or trauma. The defect is due to the inability of ADP to induce platelet aggregation [http://www.ncbi.nlm.nih.gov/pubmed/12578987?dopt=AbstractPlus]. The P2Y13 receptor Met‐158‐Thr polymorphism, which is in linkage disequilibrium with the P2Y12 locus, is not associated with acute myocardial infarction, diabetes mellitus or related risk factors [http://www.ncbi.nlm.nih.gov/pubmed/18213371?dopt=AbstractPlus]. The P2Y14 receptor was previously considered to exclusively bind sugar nucleotides such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1782 [http://www.ncbi.nlm.nih.gov/pubmed/10753868?dopt=AbstractPlus]. However, more recent evidence with several cell lines has demonstrated that http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749 (UDP) is 5‐fold more potent than http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783 [http://www.ncbi.nlm.nih.gov/pubmed/19759354?dopt=AbstractPlus]. UDP was also shown to competitively antagonise the UDP‐glucose response at the human recombinant P2Y14 receptor [http://www.ncbi.nlm.nih.gov/pubmed/18252808?dopt=AbstractPlus].

Further reading on P2Y receptors
Abbracchio MP et al. (2006) International Union of Pharmacology LVIII: update on the P2Y G protein‐coupled nucleotide receptors: frommolecular mechanisms andpathophysiology totherapy. Pharmacol. Rev.
58: 281‐341 [https://www.ncbi.nlm.nih.gov/pubmed/16968944?dopt=AbstractPlus]

Jacobson KA et al. (2015) Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. Mol. Pharmacol.
88: 220‐30 [https://www.ncbi.nlm.nih.gov/pubmed/25837834?dopt=AbstractPlus]

von Kügelgen I et al. (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology
104: 50‐61 [https://www.ncbi.nlm.nih.gov/pubmed/26519900?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=53

Overview
The parathyroid hormone receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Parathyroid Hormone Receptors [http://www.ncbi.nlm.nih.gov/pubmed/25713287?dopt=AbstractPlus]) are family B G protein‐coupled receptors. The parathyroid hormone (PTH)/parathyroid hormone‐related peptide (PTHrP) receptor (PTH1 receptor) is activated by precursor‐derived peptides: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9606, http://www.uniprot.org/uniprot/P01270) (84 amino acids), and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3738 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9607, http://www.uniprot.org/uniprot/P12272) (141 amino‐acids) and related peptides (PTH‐(1‐34), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1790, http://www.uniprot.org/uniprot/P12272)). The parathyroid hormone 2 receptor (PTH2 receptor) is activated by the precursor‐derived peptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30828, http://www.uniprot.org/uniprot/Q96A98) (39 amino acids). [125I]PTH may be used to label both PTH1 and PTH2 receptors.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=331
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9608, http://www.uniprot.org/uniprot/Q03431
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9609, http://www.uniprot.org/uniprot/P49190
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9606, http://www.uniprot.org/uniprot/P01270) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3738 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9607, http://www.uniprot.org/uniprot/P12272)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30828, http://www.uniprot.org/uniprot/Q96A98), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9606, http://www.uniprot.org/uniprot/P01270) ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3738 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9607, http://www.uniprot.org/uniprot/P12272)	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4448 [http://www.ncbi.nlm.nih.gov/pubmed/8702701?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30828, http://www.uniprot.org/uniprot/Q96A98) [http://www.ncbi.nlm.nih.gov/pubmed/11602681?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10854439?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1822) [http://www.ncbi.nlm.nih.gov/pubmed/7896796?dopt=AbstractPlus] – Rat	–	



Comments
The parathyroid hormone type 1 receptor (PTHR) is the canonical GPCR for PTH and PTHrP. It is coupled to Gs and Gq and regulates the development of bone, heart, mammary glands and other tissues in response to PTHrP, and blood concentrations of calcium and phosphate ions, as well as vitamin D, in response to PTH. Another important action of the PTH/PTHR system is to stimulate bone formation when the hormone is intermittently administrated (daily injection).

Although http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1785 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9606, http://www.uniprot.org/uniprot/P01270) is an agonist at human PTH2 receptors, it fails to activate the rodent orthologues. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1815 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30828, http://www.uniprot.org/uniprot/Q96A98) is a weak antagonist at PTH1 receptors [http://www.ncbi.nlm.nih.gov/pubmed/11159842?dopt=AbstractPlus].

Further reading on Parathyroid hormone receptors
Cheloha RW et al. (2015) PTH receptor‐1 signalling‐mechanistic insights and therapeutic prospects. Nat Rev Endocrinol
11: 712‐24 [https://www.ncbi.nlm.nih.gov/pubmed/26303600?dopt=AbstractPlus]

Gardella TJ et al. (2015) International Union of Basic and Clinical Pharmacology. XCIII. The Parathyroid Hormone Receptors‐Family B G Protein‐Coupled Receptors. Pharmacol. Rev.
67: 310‐37 [https://www.ncbi.nlm.nih.gov/pubmed/25713287?dopt=AbstractPlus]

Vilardaga JP et al. (2014) Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol.
10: 700‐6 [https://www.ncbi.nlm.nih.gov/pubmed/25271346?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=55

Overview
Platelet‐activating factor (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1831, 1‐O‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inflammatory roles. The PAF receptor (provisional nomenclature recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) is activated by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1831 and other suggested endogenous ligands are oxidized phosphatidylcholine [http://www.ncbi.nlm.nih.gov/pubmed/10497200?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508 [http://www.ncbi.nlm.nih.gov/pubmed/9038918?dopt=AbstractPlus]. It may also be activated by bacterial lipopolysaccharide [http://www.ncbi.nlm.nih.gov/pubmed/1333988?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=334
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9582, http://www.uniprot.org/uniprot/P25105
	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3427
	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1856 (pK
i 10.3) [http://www.ncbi.nlm.nih.gov/pubmed/8395255?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1850 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9151941?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1852 (pIC50 8.1–8.3) [http://www.ncbi.nlm.nih.gov/pubmed/15922596?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1657923?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3426 (pK
i 7.8) [http://www.ncbi.nlm.nih.gov/pubmed/2841449?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1860 (pK
i 5.2–7.5) [http://www.ncbi.nlm.nih.gov/pubmed/8798529?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8380690?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1833 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11560941?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1657923?dopt=AbstractPlus]	



Comments
Note that a previously recommended radioligand (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1859 Kd 44.6 nM) is currently unavailable.

Further reading on Platelet‐activating factor receptor
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288 [https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Ishii S et al. (2000) Platelet‐activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog. Lipid Res.
39: 41‐82 [https://www.ncbi.nlm.nih.gov/pubmed/10729607?dopt=AbstractPlus]

Prescott SM et al. (2000) Platelet‐activating factor and related lipid mediators. Annu. Rev. Biochem.
69: 419‐45 [https://www.ncbi.nlm.nih.gov/pubmed/10966465?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=56

Overview
Prokineticin receptors, PKR1 and PKR2 (provisional nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) respond to the cysteine‐rich 81‐86 amino‐acid peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18454, http://www.uniprot.org/uniprot/Q9HC23) (also known as endocrine glandderived vascular endothelial growth factor, mambakine) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18455, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18455) (protein Bv8 homologue). An orthologue of PROK1 from black mamba (Dendroaspis polylepis) venom, mamba intestinal toxin 1 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1865, [http://www.ncbi.nlm.nih.gov/pubmed/10567694?dopt=AbstractPlus]) is a potent, nonselective agonist at prokineticin receptors [http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus], while http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5362, an orthologue of PROK2 from amphibians (Bombina sp., [http://www.ncbi.nlm.nih.gov/pubmed/10422759?dopt=AbstractPlus]), is equipotent at recombinant PKR1 and PKR2 [http://www.ncbi.nlm.nih.gov/pubmed/16113687?dopt=AbstractPlus], and has high potency in macrophagechemotaxis assays, which arelost in PKR1null mice.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=335
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=336
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4524, http://www.uniprot.org/uniprot/Q8TCW9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15836, http://www.uniprot.org/uniprot/Q8NFJ6
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18455, http://www.uniprot.org/uniprot/Q9HC23) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18454, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18454) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18455) [http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11886876?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12427552?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1867 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18455, http://www.uniprot.org/uniprot/Q9HC23) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1866 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18454, https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18454) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1868 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18455) [http://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11886876?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12427552?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1865 [http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1865 [http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8518 [http://www.ncbi.nlm.nih.gov/pubmed/25831128?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8517 [http://www.ncbi.nlm.nih.gov/pubmed/25831128?dopt=AbstractPlus]	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8522 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8522 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus]	



Comments
Genetic mutations in PROKR1 are associated with Hirschsprung's disease [http://www.ncbi.nlm.nih.gov/pubmed/21858136?dopt=AbstractPlus], while genetic mutations in PROKR2 are associated with hypogonadotropic hypogonadism with anosmia [http://www.ncbi.nlm.nih.gov/pubmed/23596439?dopt=AbstractPlus], hypopituitarism with pituitary stalk interruption [http://www.ncbi.nlm.nih.gov/pubmed/22466334?dopt=AbstractPlus] and Hirschsprung's disease [http://www.ncbi.nlm.nih.gov/pubmed/21858136?dopt=AbstractPlus]. PKR2 has been recently identified as a receptor for T. cruzi natural infection [http://www.ncbi.nlm.nih.gov/pubmed/25324134?dopt=AbstractPlus].

Further reading on Prokineticin receptors
Boulberdaa M et al. (2011) Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney functions. Cardiovasc. Res.
92: 191‐8 [https://www.ncbi.nlm.nih.gov/pubmed/21856786?dopt=AbstractPlus]

Negri L et al. (2018) The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell‐Dependent Angiogenesis. Physiol. Rev.
98: 1055‐1082 [https://www.ncbi.nlm.nih.gov/pubmed/29537336?dopt=AbstractPlus]

Negri L et al. (2012) Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr Opin Pharmacol
12: 62‐6 [https://www.ncbi.nlm.nih.gov/pubmed/22136937?dopt=AbstractPlus]

Negri L et al. (2007) Bv8/Prokineticin proteins and their receptors. Life Sci.
81: 1103‐16 [https://www.ncbi.nlm.nih.gov/pubmed/17881008?dopt=AbstractPlus]

Ngan ES et al. (2008) Prokineticin‐signaling pathway. Int. J. Biochem. Cell Biol.
40: 1679‐84 [https://www.ncbi.nlm.nih.gov/pubmed/18440852?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=57

Overview
The precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) for PrRP generates 31 and 20‐amino‐acid versions. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3665 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29982, http://www.uniprot.org/uniprot/P83859) (named after a pyroglutamylated arginine‐phenylalanine‐amide peptide) is a 43 amino acid peptide derived from https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29982 (http://www.uniprot.org/uniprot/P83859) and is also known as P518 or 26RFa. RFRP is an RF amide‐related peptide [http://www.ncbi.nlm.nih.gov/pubmed/11025660?dopt=AbstractPlus] derived from a FMRFamide‐related peptide precursor (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7), which is cleaved to generate http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3736 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7901, http://www.uniprot.org/uniprot/O15130), neuropeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5340 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7), neuropeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5373 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7) and neuropeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4016 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13782, http://www.uniprot.org/uniprot/Q9HCQ7) (neuropeptide NPVF).
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=337
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4464, http://www.uniprot.org/uniprot/P49683
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1871 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) [http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus]	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1871 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) [http://www.ncbi.nlm.nih.gov/pubmed/12606605?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1873 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17945, http://www.uniprot.org/uniprot/P81277) [http://www.ncbi.nlm.nih.gov/pubmed/12606605?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus]	
Endogenous antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1504 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7955, http://www.uniprot.org/uniprot/P01303) (pK
i 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/15885496?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1875 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4022 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15752583?dopt=AbstractPlus]	



Comments
The orphan receptor https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4523 (http://www.uniprot.org/uniprot/Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.

Further reading on Prolactin‐releasing peptide receptor
Samson WK et al. (2006) Prolactin releasing peptide (PrRP): an endogenous regulator of cell growth. Peptides
27: 1099‐103 [https://www.ncbi.nlm.nih.gov/pubmed/16500730?dopt=AbstractPlus]

Takayanagi Y et al. (2010) Roles of prolactin‐releasing peptide and RFamide related peptides in the control of stress and food intake. FEBS J.
277: 4998‐5005 [https://www.ncbi.nlm.nih.gov/pubmed/21126313?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=58

Overview
Prostanoid receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Prostanoid Receptors [http://www.ncbi.nlm.nih.gov/pubmed/21752876?dopt=AbstractPlus]) are activated by the endogenous ligands prostaglandins http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483, prostacyclin [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482. Measurement of the potency of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482 is hampered by their instability in physiological salt solution; they are often replaced by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1917 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1888, respectively, in receptor characterization studies.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9591, http://www.uniprot.org/uniprot/Q13258
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4502, http://www.uniprot.org/uniprot/Q9Y5Y4
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5820 [http://www.ncbi.nlm.nih.gov/pubmed/25542069?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus]	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1878 [http://www.ncbi.nlm.nih.gov/pubmed/7642548?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10448933?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1879 [http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10448933?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1902 [http://www.ncbi.nlm.nih.gov/pubmed/12721327?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12490611?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16256979?dopt=AbstractPlus]	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8995 (pK
d 9) [2072, http://www.ncbi.nlm.nih.gov/pubmed/26916831?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911 (pK
i 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/16256979?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3356 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/17300164?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1897 (pK
i 8.6–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/7642548?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2924081?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8537 (pK
i 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/21819041?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15388164?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18178816?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1905 (pIC50 8.9) [http://www.ncbi.nlm.nih.gov/pubmed/17714552?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15715457?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1891 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1891 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/16418339?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12975488?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=340
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=340
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=342
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9593, http://www.uniprot.org/uniprot/P34995
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9594, http://www.uniprot.org/uniprot/P43116
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9595, http://www.uniprot.org/uniprot/P43115
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9596, http://www.uniprot.org/uniprot/P35408
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10462542?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 (EP3‐III isoform) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus]	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1912 [http://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5820 [http://www.ncbi.nlm.nih.gov/pubmed/25542069?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 [http://www.ncbi.nlm.nih.gov/pubmed/8163486?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1936) (EP3‐III isoform) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1912 [http://www.ncbi.nlm.nih.gov/pubmed/27664754?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1914 [http://www.ncbi.nlm.nih.gov/pubmed/10746663?dopt=AbstractPlus] – Mouse	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1932 [http://www.ncbi.nlm.nih.gov/pubmed/10746663?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10315 [http://www.ncbi.nlm.nih.gov/pubmed/29332128?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1892 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10462542?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1919 (EP3‐III isoform) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1931 [http://www.ncbi.nlm.nih.gov/pubmed/21323896?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22342278?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3357 [http://www.ncbi.nlm.nih.gov/pubmed/18516068?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/19584306?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1933 [http://www.ncbi.nlm.nih.gov/pubmed/21323896?dopt=AbstractPlus]	
Antagonists	–	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1952 (pK
i 7.6–8.5) [http://www.ncbi.nlm.nih.gov/pubmed/11408598?dopt=AbstractPlus, 2406]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1920 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/10537280?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1924 (pK
i 7.9) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5817 (PF‐04418948 has weaker affinity at the EP2‐receptor in guinea‐pigs) (pK
B 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/21595651?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22747912?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9283 (pK
B 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/23914286?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5844 (EP3‐III isoform (pKi=8.04 in the presence of HSA)) (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/11504634?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1943 (pIC50 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/12538661?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5822 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/19486006?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1942 (pK
i 8.5), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1953 (pK
i 7–7.1) [http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15655509?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1916 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10952683?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=346
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9600, http://www.uniprot.org/uniprot/P43088
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9602, http://www.uniprot.org/uniprot/P43119
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11608, http://www.uniprot.org/uniprot/P21731
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482
	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483 ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915
	
Endogenous agonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915 [http://www.ncbi.nlm.nih.gov/pubmed/372237?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1882 [http://www.ncbi.nlm.nih.gov/pubmed/11454473?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17704830?dopt=AbstractPlus]	–	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9875 [http://www.ncbi.nlm.nih.gov/pubmed/25788650?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5820 [http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus]	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1940 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1960 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1917 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5852 [http://www.ncbi.nlm.nih.gov/pubmed/23850788?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17545310?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1888 [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus]	
Antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1911 (pK
i 8) [http://www.ncbi.nlm.nih.gov/pubmed/1387312?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3424 (pK
i 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/17618756?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1969 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/16331286?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4042 (pA
2 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/16331286?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1976 (pK
i 8.3–9.4) [http://www.ncbi.nlm.nih.gov/pubmed/8242228?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2527074?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1980 (pK
i 8.1–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2975605?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1957 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8300593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3417 (Agonist)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1966 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7512962?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1982 (Antagonist) (pK
d 7.7–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/1386885?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1973 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/2530338?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1985 (Antagonist) (pK
d 7.4–8.2) [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus]	



Comments
Whilst http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1917 is selective for IP receptors, it does exhibit moderate agonist potency at EP4 receptors [http://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus]. Apart from IP receptors, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1895 also binds to EP1 receptors.

The EP1 agonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1912 also shows agonist activity at EP3 and EP4 receptors [http://www.ncbi.nlm.nih.gov/pubmed/21323896?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/27664754?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3379 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3331 may require de‐esterification within tissues to attain full agonist potency. There is evidence for subtypes of FP [http://www.ncbi.nlm.nih.gov/pubmed/7830272?dopt=AbstractPlus] and TP receptors [http://www.ncbi.nlm.nih.gov/pubmed/8882612?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8034687?dopt=AbstractPlus]. mRNA for the EP3 receptor undergoes alternative splicing to produce variants which can interfere with signalling [http://www.ncbi.nlm.nih.gov/pubmed/8940129?dopt=AbstractPlus] or generate complex patterns of G‐protein (Gi/o, Gq/11, Gs and G12,13) coupling (e.g. [http://www.ncbi.nlm.nih.gov/pubmed/7476918?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7608175?dopt=AbstractPlus]). The number of EP3 receptor (protein) variants are variable depending on species, with five in human, three in rat and three in mouse. Putative receptor(s) for prostamide F (which as yet lack molecular correlates) and which preferentially recognize http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5456 and its analogues (e.g. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1958) have been identified, together with moderate‐potency antagonists (e.g.
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5455) [http://www.ncbi.nlm.nih.gov/pubmed/18700152?dopt=AbstractPlus].

The free acid form of AL‐12182, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3386, used in in vitro studies, has a EC50 of 15nM which is the concentration of the compound giving half‐maximal stimulation of inositol phosphate turnover in HEK‐293 cells expressing the human FP receptor [http://www.ncbi.nlm.nih.gov/pubmed/17076623?dopt=AbstractPlus].

References given alongside the TP receptor agonists I‐BOP [http://www.ncbi.nlm.nih.gov/pubmed/1830308?dopt=AbstractPlus] and STA2 [http://www.ncbi.nlm.nih.gov/pubmed/8242228?dopt=AbstractPlus] use human platelets as the source of TP receptors for competition radio‐ligand binding assays to determine the indicated activity values.

Pharmacological evidence for a second IP receptor, denoted IP2, in the central nervous system [http://www.ncbi.nlm.nih.gov/pubmed/8621463?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10349870?dopt=AbstractPlus] and in the BEAS‐2B human airway epithelial cell line [http://www.ncbi.nlm.nih.gov/pubmed/21173040?dopt=AbstractPlus] is available. This receptor is selectively activated by 15R‐17,18,19,20‐tetranor‐16‐m‐tolylisocarbacyclin (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5864) and 15R‐Deoxy 17,18,19,20‐tetranor‐16m‐tolyl‐isocarbacyclin (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5865). However, molecular biological evidence for an IP2 subtype is currently lacking.

Further reading on Prostanoid receptors
Woodward DF et al. (2011) International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev.
63: 471‐538 [https://www.ncbi.nlm.nih.gov/pubmed/21752876?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=59

Overview
Proteinase‐activated receptors (PARs, nomenclature as agreed by the NC‐IUPHAR Subcommittee on Proteinase‐activated Receptors [http://www.ncbi.nlm.nih.gov/pubmed/12037136?dopt=AbstractPlus]) are unique members of the GPCR superfamily activated by proteolytic cleavage of their amino terminal exodomains. Agonist proteinase‐induced hydrolysis unmasks a tethered ligand (TL) at the exposed amino terminus, which acts intramolecularly at the binding site in the body of the receptor to effect transmembrane signalling. TL sequences at human PAR1‐4 are http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5361, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3740, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5360 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3739, respectively. With the exception of PAR3, synthetic peptides with these sequences (as carboxyl terminal amides) are able to act as agonists at their respective receptors. Several proteinases, including neutrophil elastase, cathepsin G and chymotrypsin can have inhibitory effects at PAR1 and PAR2 such that they cleave the exodomain of the receptor without inducing activation of Gαq‐coupled calcium signalling, thereby preventing activation by activating proteinases but not by agonist peptides. Neutrophil elastase (NE) cleavage of PAR1 and PAR2 can however activate MAP kinase signaling by exposing a TL that is different from the one revealed by trypsin [http://www.ncbi.nlm.nih.gov/pubmed/22212680?dopt=AbstractPlus]. PAR2 ectivation by NE regulates inflammation and pain responses [http://www.ncbi.nlm.nih.gov/pubmed/26140667?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25878251?dopt=AbstractPlus] and triggers mucin secretion from airway epithelial cells [http://www.ncbi.nlm.nih.gov/pubmed/23392769?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=347
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=348
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=349
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=350
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3537, http://www.uniprot.org/uniprot/P25116
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3538, http://www.uniprot.org/uniprot/P55085
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3539, http://www.uniprot.org/uniprot/O00254
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3540, http://www.uniprot.org/uniprot/Q96RI0
	
Agonist proteases	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734), activated http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4473 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9451, http://www.uniprot.org/uniprot/P04070), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6655 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7155, http://www.uniprot.org/uniprot/P45452), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6656 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7159, http://www.uniprot.org/uniprot/P45452) [http://www.ncbi.nlm.nih.gov/pubmed/23086754?dopt=AbstractPlus]	Trypsin, tryptase, TF/VIIa, Xa; http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 [http://www.ncbi.nlm.nih.gov/pubmed/30012612?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21576245?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734), trypsin, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3570 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2532, http://www.uniprot.org/uniprot/P08311)	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9255
	–	–	–	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3742 [http://www.ncbi.nlm.nih.gov/pubmed/11877318?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9455 [http://www.ncbi.nlm.nih.gov/pubmed/26819675?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6657 [http://www.ncbi.nlm.nih.gov/pubmed/20873792?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3851 [http://www.ncbi.nlm.nih.gov/pubmed/14976230?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3740 [http://www.ncbi.nlm.nih.gov/pubmed/18179608?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3741 [http://www.ncbi.nlm.nih.gov/pubmed/18179608?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4061, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3883, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3739
	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4047 (pK
i 8.1) [http://www.ncbi.nlm.nih.gov/pubmed/18447380?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4048 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/21300059?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3525 (pIC50 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/10535908?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10268 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/29263243?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9585 (pK
d 6.5) [http://www.ncbi.nlm.nih.gov/pubmed/28445455?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6658 (pIC50 5.7) [http://www.ncbi.nlm.nih.gov/pubmed/21806599?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6659 [http://www.ncbi.nlm.nih.gov/pubmed/21536878?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10269 (pK
d 10) [http://www.ncbi.nlm.nih.gov/pubmed/28053157?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9458 (pIC50 6.9) [http://www.ncbi.nlm.nih.gov/pubmed/25176330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9459 (pIC50 6.8) [http://www.ncbi.nlm.nih.gov/pubmed/25176330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10270 [http://www.ncbi.nlm.nih.gov/pubmed/12357249?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10271 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/28126849?dopt=AbstractPlus]	
Allosteric modulators	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9560 (Negative) (pIC50 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/28445455?dopt=AbstractPlus]	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3823 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9203642?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4050 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/18477767?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4049 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/18477767?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6660 (Selective Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15765104?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3914 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10411588?dopt=AbstractPlus]	–	–	
Comments	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3742 is selective relative to the PAR2 receptor [http://www.ncbi.nlm.nih.gov/pubmed/8663335?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9862790?dopt=AbstractPlus].	2‐Furoyl‐LIGRLO‐NH2 activity was measured via calcium mobilisation in HEK 293 cells which constitutively coexpress human PAR1 and PAR2.	–	–	



Comments
Endogenous serine proteases (EC 3.4.21.) active at the proteinase‐activated receptors include: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734), generated by the action of Factor X (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3528, http://www.uniprot.org/uniprot/P00742) on liver‐derived prothrombin (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734); trypsin, generated by the action of enterokinase (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9490, http://www.uniprot.org/uniprot/P98073) on pancreatic‐derived trypsinogen (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9475, http://www.uniprot.org/uniprot/P07477); tryptase, a family of enzymes (α/β1 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12019, http://www.uniprot.org/uniprot/Q15661; γ1 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14134, http://www.uniprot.org/uniprot/Q9NRR2
δ1 https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14118, http://www.uniprot.org/uniprot/Q9BZJ3) secreted from mast cells; cathepsin G (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2532, http://www.uniprot.org/uniprot/P08311) generated from leukocytes; liver‐derived protein C (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9451, http://www.uniprot.org/uniprot/P04070) generated in plasma by http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4453 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535, http://www.uniprot.org/uniprot/P00734) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6655 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7155, http://www.uniprot.org/uniprot/P45452).

Further reading on Proteinase‐activated receptors
Adams MN et al. (2011) Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther.
130: 248‐82 https://www.ncbi.nlm.nih.gov/pubmed/21277892?dopt=AbstractPlus


Canto I et al. (2012) Allosteric modulation of protease‐activated receptor signaling. Mini Rev Med Chem
12: 804‐11 https://www.ncbi.nlm.nih.gov/pubmed/22681248?dopt=AbstractPlus


García PS et al. (2010) The role of thrombin and protease‐activated receptors in pain mechanisms. Thromb. Haemost.
103: 1145‐51 https://www.ncbi.nlm.nih.gov/pubmed/20431855?dopt=AbstractPlus


Hollenberg MD et al. (2002) International Union of Pharmacology. XXVIII. Proteinase‐activated receptors. Pharmacol. Rev.
54: 203‐17 https://www.ncbi.nlm.nih.gov/pubmed/12037136?dopt=AbstractPlus


Ramachandran R et al. (2012) Targeting proteinase‐activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov
11: 69‐86 https://www.ncbi.nlm.nih.gov/pubmed/22212680?dopt=AbstractPlus


Soh UJ et al. (2010) Signal transduction by protease‐activated receptors. Br. J. Pharmacol.
160: 191‐203 https://www.ncbi.nlm.nih.gov/pubmed/20423334?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=54

Overview
The human gene encoding the QRFP receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee on the QRFP receptor [http://www.ncbi.nlm.nih.gov/pubmed/28613414?dopt=AbstractPlus]; QRFPR, formerly known as the Peptide P518 receptor), previously designated as an orphan GPCR receptor was identified in 2001 by Lee et al. from a hypothalamus cDNA library [http://www.ncbi.nlm.nih.gov/pubmed/11574155?dopt=AbstractPlus]. However, the reported cDNA (AF411117) is a chimera with bases 1‐127 derived from chromosome 1 and bases 155‐1368 derived from chromosome 4. When corrected, QRFPR (also referred to as SP9155 or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the transmembrane spanning regions with other peptide receptors. These include neuropeptide FF2 (38%), neuropeptide Y2 (37%) and galanin Gal1 (35%) receptors.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=333
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15565, http://www.uniprot.org/uniprot/Q96P65
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5895 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29982) [http://www.ncbi.nlm.nih.gov/pubmed/14657341?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12714592?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10252 [http://www.ncbi.nlm.nih.gov/pubmed/30358997?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9442 [http://www.ncbi.nlm.nih.gov/pubmed/22800498?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9443 (pIC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/24937104?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25875054?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3803) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12960173?dopt=AbstractPlus, 1164, http://www.ncbi.nlm.nih.gov/pubmed/16648250?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10253) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/17534937?dopt=AbstractPlus]	



Comments
The orphan receptor http://www.guidetopharmacology.org/GRAC/ (http://www.uniprot.org/uniprot/9NYM4) shows sequence similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP receptors.

Further reading on QRFP receptor
Chartrel N et al. (2011) The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions. Front Neuroendocrinol
32: 387‐97 https://www.ncbi.nlm.nih.gov/pubmed/21530572?dopt=AbstractPlus


Fukusumi S et al. (2006) Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. Peptides
27: 1073‐86 https://www.ncbi.nlm.nih.gov/pubmed/16500002?dopt=AbstractPlus


Leprince J et al. (2017) The Arg‐Phe‐amide peptide 26RFa/glutamine RF‐amide peptide and its receptor: IUPHAR Review 24. Br. J. Pharmacol.
174: 3573‐3607 https://www.ncbi.nlm.nih.gov/pubmed/28613414?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=60

Overview
Relaxin family peptide receptors (RXFP, nomenclature as agreed by the NC‐IUPHAR Subcommittee on Relaxin family peptide receptors [http://www.ncbi.nlm.nih.gov/pubmed/16507880?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25761609?dopt=AbstractPlus]) may be divided into two pairs, RXFP1/2 and RXFP3/4. Endogenous agonists at these receptors are heterodimeric peptide hormones structurally related to insulin: http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1988 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10026, http://www.uniprot.org/uniprot/P04808), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) (also known as INSL7), insulin‐like peptide 3 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6086, http://www.uniprot.org/uniprot/P51460)) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6). Species homologues of relaxin have distinct pharmacology and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) interacts with RXFP1, RXFP2 and RXFP3, whereas mouse and rat relaxin selectively bind to and activate RXFP1 [http://www.ncbi.nlm.nih.gov/pubmed/15956680?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) is the ligand for RXFP3 but it also binds to RXFP1 and RXFP4 and has differential affinity for RXFP2 between species [http://www.ncbi.nlm.nih.gov/pubmed/15956681?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6) is the ligand for RXFP4 but is a weak antagonist of RXFP3. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6086, http://www.uniprot.org/uniprot/P51460) have multiple complex binding interactions with RXFP1 [http://www.ncbi.nlm.nih.gov/pubmed/27088579?dopt=AbstractPlus] and RXFP2 [http://www.ncbi.nlm.nih.gov/pubmed/30594862?dopt=AbstractPlus] which direct the N‐terminal LDLa modules of the receptors together with a linker domain to act as a tethered ligand to direct receptor signaling [http://www.ncbi.nlm.nih.gov/pubmed/16963451?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) interact with their receptors using distinct residues in their B‐chains for binding, and activation, respectively [http://www.ncbi.nlm.nih.gov/pubmed/28274616?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30131340?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=351
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=352
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=353
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=354
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19718, http://www.uniprot.org/uniprot/Q9HBX9
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17318, http://www.uniprot.org/uniprot/Q8WXD0
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24883, http://www.uniprot.org/uniprot/Q9NSD7
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14666, http://www.uniprot.org/uniprot/Q8TDU9
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1988 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10026, http://www.uniprot.org/uniprot/P04808) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) [http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6086, http://www.uniprot.org/uniprot/P51460) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) [http://www.ncbi.nlm.nih.gov/pubmed/12114498?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1997 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) [http://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6) = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1997 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) [http://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/14522967?dopt=AbstractPlus]	
Endogenous antagonists	–	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6) (pK
i 7) [http://www.ncbi.nlm.nih.gov/pubmed/18582868?dopt=AbstractPlus]	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4371 (pEC50 5.7–6.7) [http://www.ncbi.nlm.nih.gov/pubmed/20043231?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24812057?dopt=AbstractPlus]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3907 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/17606621?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3907 (pIC50 8–8.6) [http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17606621?dopt=AbstractPlus]	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8329 (pK
i 9.1) [http://www.ncbi.nlm.nih.gov/pubmed/18434306?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8330 (pK
i 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/18434306?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8331 (pK
i 8.6) [http://www.ncbi.nlm.nih.gov/pubmed/20570702?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4372 (pKi 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/20560146?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8332 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/20570702?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8333 (pKi 6.7) [http://www.ncbi.nlm.nih.gov/pubmed/17120268?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3885 (pKi 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/16547350?dopt=AbstractPlus], (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3754 [http://www.ncbi.nlm.nih.gov/pubmed/15708846?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8326 (pK
i 7.6) [http://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4373 (pK
i 7.4) [http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8326 (pIC50 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus]	
Allosteric modulators	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8322 (Agonist) (pEC50 7) [http://www.ncbi.nlm.nih.gov/pubmed/23905199?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23764525?dopt=AbstractPlus]	–	–	–	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1991 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3874 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/22425984?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5398 (Agonist)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1996 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/16051677?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1991 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1999) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3789 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4374 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1999) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/14522967?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3789 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6522 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21866895?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4374 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4375 (pK
d 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus]	
Comments	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3875 is a fluorescent ligand for this receptor (K
d=1nM) [http://www.ncbi.nlm.nih.gov/pubmed/18529069?dopt=AbstractPlus].	–	–	



Comments

http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) is the cognate peptide ligand for RXFP1 and is in extended Phase III clinical trials for the treatment of acute heart failure [http://www.ncbi.nlm.nih.gov/pubmed/23273292?dopt=AbstractPlus]. Relaxin has vasodilatory, anti‐fibrotic, angiogenic, anti‐apoptotic and anti‐inflammatory effects. A small molecule allosteric agonists http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8322 has been developed [http://www.ncbi.nlm.nih.gov/pubmed/18854305?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23764525?dopt=AbstractPlus], and a relaxin B‐chain mimetic peptide B7‐33 has been developed which that has cell specific signaling properties [http://www.ncbi.nlm.nih.gov/pubmed/30155023?dopt=AbstractPlus]. The antifibrotic actions of relaxin are dependent on the angiotensin receptor AT2 [http://www.ncbi.nlm.nih.gov/pubmed/24429402?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1995 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6086, http://www.uniprot.org/uniprot/P51460) is the cognate peptide for RXFP2 and is a circulating hormone that in males is essential for testicular descent in utero [http://www.ncbi.nlm.nih.gov/pubmed/10391220?dopt=AbstractPlus] and in females has important roles in ovarian follicle function [http://www.ncbi.nlm.nih.gov/pubmed/30204868?dopt=AbstractPlus]. In adults, INSL3 has potential roles in testicular function [http://www.ncbi.nlm.nih.gov/pubmed/20952422?dopt=AbstractPlus] and the musculoskeletal system [http://www.ncbi.nlm.nih.gov/pubmed/30625346?dopt=AbstractPlus]. RXFP2 is also present in brain, associated with cortico‐thalamic motor circuits [http://www.ncbi.nlm.nih.gov/pubmed/18706979?dopt=AbstractPlus]. cAMP elevation is the major signalling pathway for both RXFP1 and RXFP2 [http://www.ncbi.nlm.nih.gov/pubmed/10935549?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11809971?dopt=AbstractPlus], but RXFP1 also activates MAP kinases, nitric oxide signalling, and tyrosine kinase phosphorylation; and relaxin can interact with glucocorticoid receptors [http://www.ncbi.nlm.nih.gov/pubmed/17293890?dopt=AbstractPlus]. Receptor expression profiles suggest that RXFP3 is a brain neuropeptide receptor and RXFP4 a gut hormone receptor. The brain relaxin‐3/RXFP3 system modulates feeding [http://www.ncbi.nlm.nih.gov/pubmed/23135160?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22854307?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/21899720?dopt=AbstractPlus] via effects in hypothalamus [http://www.ncbi.nlm.nih.gov/pubmed/28864207?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23135160?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28098344?dopt=AbstractPlus], anxiety [http://www.ncbi.nlm.nih.gov/pubmed/24297931?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/26057358?dopt=AbstractPlus], reward and motivated, goal‐directed behaviours [http://www.ncbi.nlm.nih.gov/pubmed/25257104?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/24297931?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25849482?dopt=AbstractPlus], and spatial and social memory [http://www.ncbi.nlm.nih.gov/pubmed/30368554?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/28100033?dopt=AbstractPlus]. Of the other relaxin peptides, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3)is anagonist atRXFP3 and RXFP4 whereashttp://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6) is an agonist at RXFP4 and a weak antagonist at RXFP3. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2000 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6088, http://www.uniprot.org/uniprot/Q9Y5Q6) is secreted from enteroendocrine L cells and the INSL5/RXFP4 system affects food intake [http://www.ncbi.nlm.nih.gov/pubmed/25028498?dopt=AbstractPlus] and glucose homeostasis [http://www.ncbi.nlm.nih.gov/pubmed/25514935?dopt=AbstractPlus]. RXFP3 and RXFP4 couple to Gi/o and inhibit adenylyl cyclase [http://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus], and also cause Erk1/2 phosphorylation [http://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus]. RXFP4 also causes phosphorylation of p38MAPK, Akt and S6RP [http://www.ncbi.nlm.nih.gov/pubmed/27243554?dopt=AbstractPlus] and GLP‐1 secretion in vitro [http://www.ncbi.nlm.nih.gov/pubmed/29535183?dopt=AbstractPlus]. There is evidence that at RXFP3, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1989 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10027, http://www.uniprot.org/uniprot/P04090) is a biased ligand compared to the cognate ligand http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1990 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17135, http://www.uniprot.org/uniprot/Q8WXF3) [http://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus].

Further reading on Relaxin family peptide receptors
Bathgate RA et al. (2013) Relaxin family peptides and their receptors. Physiol. Rev.
93: 405‐80 https://www.ncbi.nlm.nih.gov/pubmed/23303914?dopt=AbstractPlus


Du XJ et al. (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol
7: 48‐58 https://www.ncbi.nlm.nih.gov/pubmed/19935741?dopt=AbstractPlus


Halls ML et al. (2015) International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1‐4, the receptors for relaxin family peptides. Pharmacol. Rev.
67: 389‐440 https://www.ncbi.nlm.nih.gov/pubmed/25761609?dopt=AbstractPlus


Ivell R etal. (2011) Relaxin family peptides in the male reproductive system‐a critical appraisal. Mol. Hum. Reprod.
17: 71‐84 https://www.ncbi.nlm.nih.gov/pubmed/20952422?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=61

Overview
Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (SST1‐SST5; nomenclature as agreed by the NC‐IUPHAR Subcommittee on Somatostatin Receptors [http://www.ncbi.nlm.nih.gov/pubmed/30232095?dopt=AbstractPlus]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of secretion of many hormones. Endogenous ligands for these receptors are somatostatin‐14 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2019 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11329, http://www.uniprot.org/uniprot/P61278)) and somatostatin‐28 (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2020 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11329, http://www.uniprot.org/uniprot/P61278)). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2007 {Mouse, Rat} has also been suggested to be an endogenous ligand for somatostatin receptors [http://www.ncbi.nlm.nih.gov/pubmed/8622767?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=358
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11330, http://www.uniprot.org/uniprot/P30872
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11331, http://www.uniprot.org/uniprot/P30874
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11332, http://www.uniprot.org/uniprot/P32745
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11333, http://www.uniprot.org/uniprot/P31391
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11334, http://www.uniprot.org/uniprot/P35346
	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018 [http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018 [http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8487 [http://www.ncbi.nlm.nih.gov/pubmed/11145612?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018 [http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3513 [http://www.ncbi.nlm.nih.gov/pubmed/9822540?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8487 [http://www.ncbi.nlm.nih.gov/pubmed/11145612?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2018 [http://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8487 [http://www.ncbi.nlm.nih.gov/pubmed/11145612?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2015 [http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2010 [http://www.ncbi.nlm.nih.gov/pubmed/15658864?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2046 [http://www.ncbi.nlm.nih.gov/pubmed/9724791?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2033 [http://www.ncbi.nlm.nih.gov/pubmed/8646408?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2050 [http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2055 [http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9724791?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2031 [http://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2073 [http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2082 [http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10115 [http://www.ncbi.nlm.nih.gov/pubmed/15333679?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2004 [http://www.ncbi.nlm.nih.gov/pubmed/9600011?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2016 [http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2030 (pK
d 8–8.1) [http://www.ncbi.nlm.nih.gov/pubmed/15135911?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10113 [http://www.ncbi.nlm.nih.gov/pubmed/18543899?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10114 (pIC50 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/24900499?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2076 (pK
i 7.9) [917]	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10116 (pK
i 9.3) [http://www.ncbi.nlm.nih.gov/pubmed/28938487?dopt=AbstractPlus]	



Comments
[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2060, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2023, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2022 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2024 may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype‐selective agonists have been synthesised [http://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus]. Octreotide and lanreotide are being used in the treatment of SST2‐expressing neuroendocrine tumors and pasireotide for SST5‐expressing neuroendocrine tumors. A novel peptide somatostatin analogue, veldoreotide (COR‐005), has affinity for SST2, SST4 and SST5 receptors and is a potent inhibitor of GH secretion [http://www.ncbi.nlm.nih.gov/pubmed/22065857?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15636423?dopt=AbstractPlus].

Further reading on Somatostatin receptors
Colao A et al. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev.
32: 247‐71 https://www.ncbi.nlm.nih.gov/pubmed/21123741?dopt=AbstractPlus


Günther T et al. (2018) International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol. Rev.
70: 763‐835 https://www.ncbi.nlm.nih.gov/pubmed/30232095?dopt=AbstractPlus


Hoyer D et al. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR Media: 354‐364

Schulz S et al. (2014) Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol.
171: 1591‐9 https://www.ncbi.nlm.nih.gov/pubmed/24328848?dopt=AbstractPlus


Weckbecker G et al. (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov
2: 999‐1017 https://www.ncbi.nlm.nih.gov/pubmed/14654798?dopt=AbstractPlus



http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=446

Overview

Nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus]. The Succinate receptor has been identified as being activated by physiological levels of the Kreb's cycle intermediate succinate and other dicarboxylic acids such as maleate in 2004. Since its pairing with its endogenous ligand, the receptor has been the focus of intensive research and its role has been evidenced in various (patho)physiological processes such as regulation of renin production, retinal angiogenesis, inflammation or immune response.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=166
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4542, http://www.uniprot.org/uniprot/Q9BXA5
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637 [http://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9630 [http://www.ncbi.nlm.nih.gov/pubmed/28160606?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10296 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/29968758?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9631 [http://www.ncbi.nlm.nih.gov/pubmed/29157600?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10294 (Partial agonist) [http://www.ncbi.nlm.nih.gov/pubmed/29157600?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9631 [http://www.ncbi.nlm.nih.gov/pubmed/28160606?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9630 [http://www.ncbi.nlm.nih.gov/pubmed/26386312?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9630 [http://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus]	



Comments
In humans, there is the possibility of two open‐reading frames (ORFs) for SUCNR1, one giving a protein of 330 amino acids (AA) and the other one 334‐AA. Wittenberger et al. [http://www.ncbi.nlm.nih.gov/pubmed/11273702?dopt=AbstractPlus] noted that the 330‐AA protein was more likely to be expressed given the Kozak sequence surrounding the second ATG. Some databases report SUCNR1 as being 334‐AA long.

Further reading on Succinate receptor
Ariza AC et al. (2012) The succinate receptor as a novel therapeutic target for oxidative and metabolic stress‐related conditions. Front Endocrinol (Lausanne)
3:22 [https://www.ncbi.nlm.nih.gov/pubmed/22649411?dopt=AbstractPlus]

de Castro Fonseca M et al. (2016) GPR91: expanding the frontiers of Krebs cycle intermediates. Cell Commun. Signal
14:3[https://www.ncbi.nlm.nih.gov/pubmed/26759054?dopt=AbstractPlus]

Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacol. Ther.
159: 56‐65[https://www.ncbi.nlm.nih.gov/pubmed/26808164?dopt=AbstractPlus]

Grimolizzi F et al. (2018) Multiple faces of succinate beyond metabolism in blood. Haematologica
103: 1586‐1592[https://www.ncbi.nlm.nih.gov/pubmed/29954939?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=62

Overview
Tachykinin receptors (provisional nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11517, http://www.uniprot.org/uniprot/P20366) (SP), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089) (NKA; previously known as substance K, neurokinin α, neuromedin L), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11521, http://www.uniprot.org/uniprot/Q9UHF0) (NKB; previously known as neurokinin β, neuromedin K), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2091 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11517, http://www.uniprot.org/uniprot/P20366) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3667 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11517) (N‐terminally extended forms of neurokinin A). The neurokinins (A and B) are mammalian members of the tachykinin family, which includes peptides of mammalian and nonmammalian origin containing the consensus sequence: Phe‐x‐Gly‐LeuMet. Marked species differences in in vitro pharmacology exist for all three receptors, in the context of nonpeptide ligands. Antagonists such as http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3490 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7623 were approved by FDA and EMA, in combination with other antiemetic agents, for the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=361
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=362
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11526, http://www.uniprot.org/uniprot/P25103
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11527, http://www.uniprot.org/uniprot/P21452
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11528, http://www.uniprot.org/uniprot/P29371
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11517, http://www.uniprot.org/uniprot/P20366) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11521, http://www.uniprot.org/uniprot/Q9UHF0)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11517, http://www.uniprot.org/uniprot/P20366) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11521, http://www.uniprot.org/uniprot/Q9UHF0) http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2090 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11521, http://www.uniprot.org/uniprot/Q9UHF0) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2089 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11517, http://www.uniprot.org/uniprot/P20366) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098)	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2101 [http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus]	–	–	
Selective agonists	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3850 [http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2095 [http://www.ncbi.nlm.nih.gov/pubmed/11786503?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8985159?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3849 [http://www.ncbi.nlm.nih.gov/pubmed/9243521?dopt=AbstractPlus] – Rat	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3843) [http://www.ncbi.nlm.nih.gov/pubmed/9718274?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3881 [http://www.ncbi.nlm.nih.gov/pubmed/1331460?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2112) [http://www.ncbi.nlm.nih.gov/pubmed/7682062?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2113 [http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2127, http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10349 (pIC50 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/11708932?dopt=AbstractPlus]	–	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3490 (pK
i 10.1) [http://www.ncbi.nlm.nih.gov/pubmed/10737756?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9804700?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2102 (pKi 9.3–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3522 (pIC50 7.7) [http://www.ncbi.nlm.nih.gov/pubmed/1281470?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3882 (pK
i 9.8) [http://www.ncbi.nlm.nih.gov/pubmed/8027981?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2111 (pK
i 9.4–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7682062?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2115 (pK
d 7.8–9.5) [http://www.ncbi.nlm.nih.gov/pubmed/7713168?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7562907?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3901 (pK
i 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/11063600?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2123 (pKi 8.5–8.7) [http://www.ncbi.nlm.nih.gov/pubmed/9484857?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16979621?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2110 (pK
i 8.4–9.7) [http://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9042606?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7476898?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7830490?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11757797?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7616392?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2132 (pK
i 7.4–9) [http://www.ncbi.nlm.nih.gov/pubmed/15265501?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8691422?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2125 (pIC50 7.8–7.9) [http://www.ncbi.nlm.nih.gov/pubmed/8648606?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3471 (Antagonist) (pK
d 9.5) [http://www.ncbi.nlm.nih.gov/pubmed/8287060?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3769 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1705465?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3835) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/2410593?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3805) (Agonist), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3473 (Antagonist) [367]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3481 (Antagonist) (pK
d 9.7) [http://www.ncbi.nlm.nih.gov/pubmed/7719707?dopt=AbstractPlus] – Rat, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3795) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10455255?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3822 (Antagonist) (pK
d 9.2) [http://www.ncbi.nlm.nih.gov/pubmed/8210508?dopt=AbstractPlus]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3480 (Antagonist) (pK
d 9.9), [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3834 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/1694464?dopt=AbstractPlus] – Guinea pig, [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3763 (Agonist)	



Comments
The NK1 receptor has also been described to couple to G proteins other than Gq/11 [http://www.ncbi.nlm.nih.gov/pubmed/9654151?dopt=AbstractPlus]. The crystal structure of the human NK1 receptor in complex with antagonists has been determined [http://www.ncbi.nlm.nih.gov/pubmed/30604743?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/30538204?dopt=AbstractPlus]. The hexapeptide agonist septide appears to bind to an overlapping but non‐identical site to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2098 (https://www.genenames.org/data/gene‐symbol‐report/%23!/hgnc_id/HGNC:11517, http://www.uniprot.org/uniprot/P20366) on the NK1 receptor. There are additional subtypes of tachykinin receptor;an orphan receptor (Swis‐sProt http://www.ncbi.nlm.nih.gov/protein/266702/) with structural similarities to the NK3 receptor was found to respond to NKB when expressed in Xenopus oocytes or Chinese hamster ovary cells [http://www.ncbi.nlm.nih.gov/pubmed/8947459?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8990205?dopt=AbstractPlus].

Further reading on Tachykinin receptors
Douglas SD et al. (2011) Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann. N. Y. Acad. Sci.
1217: 83‐95[https://www.ncbi.nlm.nih.gov/pubmed/21091716?dopt=AbstractPlus]

Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288[https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Jones S et al. (2008) The neurokinin 1 receptor: a potential new target for anti‐platelet therapy? Curr Opin Pharmacol
8: 114‐9[https://www.ncbi.nlm.nih.gov/pubmed/18296119?dopt=AbstractPlus]

Steinhoff MS et al. (2014) Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev.
94: 265‐301[https://www.ncbi.nlm.nih.gov/pubmed/24382888?dopt=AbstractPlus]

Yin J et al. (2018) Crystal structure of the human NK_1 tachykinin receptor. Proc. Natl. Acad. Sci. U.S.A.
115: 13264‐13269[https://www.ncbi.nlm.nih.gov/pubmed/30538204?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=63

Overview
Thyrotropin‐releasing hormone (TRH) receptors (provisional nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous tripeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2139 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12298, http://www.uniprot.org/uniprot/P20396) (pGlu‐His‐ProNH2). http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2139 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12298, http://www.uniprot.org/uniprot/P20396) and TRH analogues fail to distinguish TRH1 and TRH2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/12683933?dopt=AbstractPlus]. [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3836) is able to label both TRH1 and TRH2 receptors with Kd values of 13 and 9 nM respectively. Synthesis and biology of ring‐modified L‐Histidine containing TRH analogues has been reported [http://www.ncbi.nlm.nih.gov/pubmed/26854379?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=363
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=754
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12299, http://www.uniprot.org/uniprot/P34981
	–	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364 (pK
i 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus] – Rat	–	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3342 (pK
i 5.5) [http://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3370 (pK
i 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3370 (pK
i 4.7) [http://www.ncbi.nlm.nih.gov/pubmed/2175902?dopt=AbstractPlus] – Mouse	–	
Comments	–	A class A G protein‐coupled receptor: not present in man	



Further reading on Thyrotropin‐releasing hormone receptors
Bílek R etal. (2011) TRH‐like peptides. Physiol Res
60: 207‐15[https://www.ncbi.nlm.nih.gov/pubmed/21114375?dopt=AbstractPlus]

Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288[https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Nillni EA. (2010) Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol
31: 134‐56[https://www.ncbi.nlm.nih.gov/pubmed/20074584?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=64

Overview
Trace amine‐associated receptors were discovered from a search for novel 5‐HT receptors [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus], where 15 mammalian orthologues were identified and divided into two families. The TA1 receptor (nomenclature as agreed by the
NC‐IUPHAR Subcommittee for the Trace amine receptor [http://www.ncbi.nlm.nih.gov/pubmed/19325074?dopt=AbstractPlus]) has affinity for the endogenous trace amines http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144 and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2149 in addition to the classical amine http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus]. Emerging evidence suggests that TA1 is a modulator of monoaminergic activity in the brain [http://www.ncbi.nlm.nih.gov/pubmed/19482011?dopt=AbstractPlus] with TA1 and dopamine D2 receptors shown to form constitutive heterodimers when co‐expressed [http://www.ncbi.nlm.nih.gov/pubmed/21670104?dopt=AbstractPlus]. In addition to trace amines, receptors can be activated by amphetamine‐like psychostimulants, and endogenous thyronamines.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=364
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17734, http://www.uniprot.org/uniprot/Q96RJ0
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2149 = http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940 [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus]	
Agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5862 [http://www.ncbi.nlm.nih.gov/pubmed/21525407?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5457 (Inverse agonist) (pIC50 5.1) [http://www.ncbi.nlm.nih.gov/pubmed/19892733?dopt=AbstractPlus]	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2148 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus]	



Comments
In addition to TA1, in man there are up to 5 functional TAAR genes (TAAR2,5,6,8,9). See [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus] for detailed discussion. The product of the gene TAAR2 (also known as GPR58) appears to respond to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2144 > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150 and to couple through Gs [http://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_168, in some individuals, and http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_169 are pseudogenes in man, although functional in rodents. The signalling characteristics and pharmacology of http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_170 (PNR, Putative Neurotransmitter Receptor: https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30236, http://www.uniprot.org/uniprot/O14804), http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_171
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_171 (Trace amine receptor 4, TaR‐4: https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20978, http://www.uniprot.org/uniprot/96RI8), http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_172 (Trace amine receptor 5, GPR102: https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14964, http://www.uniprot.org/uniprot/Q969N4) and http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_173
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=115#show_object_173 (trace amine associated receptor 9: https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20977, http://www.uniprot.org/uniprot/96RI9) are lacking. The thyronamines, endogenous derivatives of thyroid hormone, have affinity for rodent cloned trace amine receptors, including TA1 [http://www.ncbi.nlm.nih.gov/pubmed/15146179?dopt=AbstractPlus]. An antagonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5457 has recently been described with a pKi of 9.1 at the mouse TA1 but >5.3 for human TA1 [http://www.ncbi.nlm.nih.gov/pubmed/21237643?dopt=AbstractPlus].

Further reading on Trace amine receptor
Maguire JJ et al. (2009) International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol. Rev.
61: 1‐8 [https://www.ncbi.nlm.nih.gov/pubmed/19325074?dopt=AbstractPlus]

Pei Y et al. (2016) Trace Amines and the Trace Amine‐Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications. Front Neurosci
10: 148 [https://www.ncbi.nlm.nih.gov/pubmed/27092049?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=65

Overview
The urotensin‐II (U‐II) receptor (UT, nomenclature as agreed by the NC‐IUPHAR Subcommittee on the Urotensin receptor [516, http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/25535277?dopt=AbstractPlus]) is activated by the endogenous dodecapeptide http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12636, http://www.uniprot.org/uniprot/O95399), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory system of teleost fish [http://www.ncbi.nlm.nih.gov/pubmed/2864726?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/20633133?dopt=AbstractPlus]. Several structural forms of U‐II exist in fish and amphibians. The goby orthologue was used to identify U‐II as the cognate ligand for the predicted receptor encoded by the rat gene gpr14 [http://www.ncbi.nlm.nih.gov/pubmed/9861051?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10581185?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10548501?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10559967?dopt=AbstractPlus]. Human http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153), an 11‐amino‐acid peptide [http://www.ncbi.nlm.nih.gov/pubmed/9861051?dopt=AbstractPlus], retains the cyclohexapeptide sequence of goby U‐II that is thought to beimportant in ligand binding [http://www.ncbi.nlm.nih.gov/pubmed/12807997?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12203418?dopt=AbstractPlus]. This sequence is also conserved in the deduced amino‐acid sequence of rat http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2155 {Rat} (14 amino‐acids) and mouse http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2154 {Mouse} (14 amino‐acids), although the N‐terminal is more divergent from the human sequence [http://www.ncbi.nlm.nih.gov/pubmed/10486557?dopt=AbstractPlus]. A second endogenous ligand for the UT has been discovered in rat [http://www.ncbi.nlm.nih.gov/pubmed/17628210?dopt=AbstractPlus]. This is the http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2156 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30894, http://www.uniprot.org/uniprot/Q765I0), an octapeptide that is derived from a different gene, but shares the C‐terminal sequence (CFWKYCV) common to U‐II from other species. Identical sequences to rat http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2156) are predicted for the mature mouse and human peptides [http://www.ncbi.nlm.nih.gov/pubmed/18710417?dopt=AbstractPlus]. UT exhibits relatively high sequence identity with somatostatin, opioid and galanin receptors [http://www.ncbi.nlm.nih.gov/pubmed/25535277?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=365
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4468, http://www.uniprot.org/uniprot/Q9UKP6
	
Endogenous agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2156 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30894, http://www.uniprot.org/uniprot/Q765I0) [http://www.ncbi.nlm.nih.gov/pubmed/18710417?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12636, http://www.uniprot.org/uniprot/O95399) [http://www.ncbi.nlm.nih.gov/pubmed/15852036?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11976263?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12238917?dopt=AbstractPlus]	
Selective agonists	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2160) [http://www.ncbi.nlm.nih.gov/pubmed/12238917?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2152], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9436) [http://www.ncbi.nlm.nih.gov/pubmed/12943190?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9441 [http://www.ncbi.nlm.nih.gov/pubmed/27791374?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3501 [http://www.ncbi.nlm.nih.gov/pubmed/19481466?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17112638?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2151 [http://www.ncbi.nlm.nih.gov/pubmed/12408704?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15781415?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2167 (pK
i 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/14645137?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9438 (pK
i 7.2) [http://www.ncbi.nlm.nih.gov/pubmed/18082287?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3516 (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/15146030?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3531 (pK
i 6.6) [http://www.ncbi.nlm.nih.gov/pubmed/16171813?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9439) (pK
i 6.4) [http://www.ncbi.nlm.nih.gov/pubmed/17125276?dopt=AbstractPlus] – Rat	
Labelled ligands	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2158) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10499587?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/1546952?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17125276?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9440) [http://www.ncbi.nlm.nih.gov/pubmed/22044114?dopt=AbstractPlus]	



Comments
In the human vasculature, human http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2153 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12636, http://www.uniprot.org/uniprot/O95399) elicits both vasoconstrictor (pD
2 9.3‐10.1, [http://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus]) and vasodilator (pIC50 10.3‐10.4, [http://www.ncbi.nlm.nih.gov/pubmed/11158995?dopt=AbstractPlus]) responses.

Further reading on Urotensin receptor
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein‐coupled receptor list. Pharmacol Rev
57: 279‐288[https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]

Hunt BD et al. (2010) A rat brain atlas of urotensin‐II receptor expression and a review of central urotensin‐II effects. Naunyn Schmiedebergs Arch. Pharmacol.
382:1‐31[https://www.ncbi.nlm.nih.gov/pubmed/20422157?dopt=AbstractPlus]

Maryanoff BE et al. (2010) Urotensin‐II receptor modulators as potential drugs. J. Med. Chem.
53: 2695‐708[https://www.ncbi.nlm.nih.gov/pubmed/20043680?dopt=AbstractPlus]

Ross B et al. (2010) Role of urotensin II in health and disease. Am.J.Physiol.Regul.Integr.Comp. Physiol.
298: R1156‐72[https://www.ncbi.nlm.nih.gov/pubmed/20421634?dopt=AbstractPlus]

Vaudry H et al. (2015) International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II‐related peptide, and their receptor: from structure to function. Pharmacol. Rev.
67: 214‐58[https://www.ncbi.nlm.nih.gov/pubmed/25535277?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=66

Overview
Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC‐IUPHAR [http://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus]) are activated by the endogenous cyclic nonapeptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:894, http://www.uniprot.org/uniprot/P01185) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8528, http://www.uniprot.org/uniprot/P01178). These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin). Vasopressin and oxytocin differ at only 2 amino acids (positions 3 and 8). There are metabolites of these neuropeptides that may be biologically active [http://www.ncbi.nlm.nih.gov/pubmed/8258377?dopt=AbstractPlus].
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=366
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=367
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:895, http://www.uniprot.org/uniprot/P37288
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:896, http://www.uniprot.org/uniprot/P47901
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:894, http://www.uniprot.org/uniprot/P01185) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8528, http://www.uniprot.org/uniprot/P01178) [http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:894, http://www.uniprot.org/uniprot/P01185) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8528, http://www.uniprot.org/uniprot/P01178) [http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2171 [http://www.ncbi.nlm.nih.gov/pubmed/11934825?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2191 [http://www.ncbi.nlm.nih.gov/pubmed/17300166?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2187 [http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus]	
Antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2203 (pK
i 8.2–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2202 (pK
i 8.4–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11861823?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2200 (pK
i 8.1–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3867 (pK
i 9)	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2207 (Antagonist) (pK
d 10.3–10.4) [http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2175) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11337500?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3813 (Antagonist) (pK
d 9)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2175) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus]	

Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:897, http://www.uniprot.org/uniprot/P30518
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8529, http://www.uniprot.org/uniprot/P30559
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:894, http://www.uniprot.org/uniprot/P01185) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8528, http://www.uniprot.org/uniprot/P01178) [http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17300166?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2174 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8528, http://www.uniprot.org/uniprot/P01178) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2168 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:894, http://www.uniprot.org/uniprot/P01185) [http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8955347?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/12660315?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7921228?dopt=AbstractPlus]	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3537 [http://www.ncbi.nlm.nih.gov/pubmed/16297621?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2173 [http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3869
	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2179 [http://www.ncbi.nlm.nih.gov/pubmed/8955347?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/2827511?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus]	
Antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2252 (pK
i 8.8) [http://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus]	
Selective antagonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2203 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/20471258?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2226 (pK
i 9.4) [http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2199 (pK
i 8.4–9.3) [http://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/8981918?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2238 (Inverse agonist) (pK
i 8.9–9.2) [http://www.ncbi.nlm.nih.gov/pubmed/9651149?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2236 (pK
i 6.9–8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2197 (Inverse agonist) (pK
i 7.4–8.1) [http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2201 (pK
i 8.8–9.1) [http://www.ncbi.nlm.nih.gov/pubmed/14722330?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3870 (pK
i 8.5), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2253 (pK
i 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/9622556?dopt=AbstractPlus]	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2175) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2228 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/2964362?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3817 (pK
d 8.6)	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3778 (Antagonist) (pK
d 10), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2176) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/6278592?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/7921228?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3756 (pK
d 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/12942128?dopt=AbstractPlus]	



Comments
Vasopressin and oxytocin receptors have a characteristic and sometimes overlapping distribution in a number of tissues including brain. There are phylogenetic, ontogenetic and sex‐specific differences in the levels and distribution of these receptors, particularly in the brain. The V2 receptor exhibits marked species differences, such that many ligands (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2236 and [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3817) exhibit low affinity at human V2 receptors [http://www.ncbi.nlm.nih.gov/pubmed/9773787?dopt=AbstractPlus]. Similarly, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2170 is more V2 selective in the rat than in the human [http://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus]. The gene encoding the V2 receptor is polymorphic in man, underlying nephrogenic diabetes insipidus [http://www.ncbi.nlm.nih.gov/pubmed/9756088?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2187 is selective only for the human and bovine V1B receptors [http://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus], while http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2191 has high affinity for the rat V1B receptor [http://www.ncbi.nlm.nih.gov/pubmed/17300166?dopt=AbstractPlus]. Knockouts of vasopressin and oxytocin receptors have systemspecific defects (e.g., impaired ability toconcentrate urine in V2 receptor knockouts) which include behavioural deficits (principally in V1A, V
1B and OT receptor knockouts).

Further reading on Vasopressin and oxytocin receptors
Knepper MA. (2012) Systems biology in physiology: the vasopressin signaling network in kidney. Am. J. Physiol., Cell Physiol.
303: C1115‐24[https://www.ncbi.nlm.nih.gov/pubmed/22932685?dopt=AbstractPlus]

Koshimizu TA et al. (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol. Rev.
92: 1813‐64[https://www.ncbi.nlm.nih.gov/pubmed/23073632?dopt=AbstractPlus]

Manning M et al. (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J. Neuroendocrinol.
24: 609‐28[https://www.ncbi.nlm.nih.gov/pubmed/22375852?dopt=AbstractPlus]

Meyer‐Lindenberg A et al. (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci.
12: 524‐38[https://www.ncbi.nlm.nih.gov/pubmed/21852800?dopt=AbstractPlus]

Neumann ID et al. (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci.
35: 649‐59[https://www.ncbi.nlm.nih.gov/pubmed/22974560?dopt=AbstractPlus]


http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=67

Overview
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase‐activating peptide (PACAP) receptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Vasoactive Intestinal Peptide Receptors [http://www.ncbi.nlm.nih.gov/pubmed/9647867?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/22289055?dopt=AbstractPlus]) are activated by the endogenous peptides http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12693, http://www.uniprot.org/uniprot/P01282), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257), peptide histidine isoleucineamide (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4397 {Mouse, Rat}), peptide histidine methionineamide (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2274)) and peptide histidine valine (http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3706)). VPAC1 and VPAC2 receptors display comparable affinity for the PACAP peptides, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258), and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12693, http://www.uniprot.org/uniprot/P01282), whereas http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258) are >100 fold more potent than http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152) as agonists of most isoforms of the PAC1 receptor. However, one splice variant of the human PAC1 receptor has been reported to respond to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152) with comparable affinity [http://www.ncbi.nlm.nih.gov/pubmed/10583729?dopt=AbstractPlus]. http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2272 [http://www.ncbi.nlm.nih.gov/pubmed/11068102?dopt=AbstractPlus] has been used as a selective VPAC2 receptor antagonist in a number of physiological studies, but has been reported to have significant activity at VPAC1 and PAC1 receptors [http://www.ncbi.nlm.nih.gov/pubmed/16930633?dopt=AbstractPlus]. The selective PAC1 receptor agonist http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264, was extracted from the salivary glands of sand flies (Lutzomyia longipalpis) and has no sequence homology to http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152) or the PACAP peptides [http://www.ncbi.nlm.nih.gov/pubmed/8995389?dopt=AbstractPlus]. Two deletion variants of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3305 [http://www.ncbi.nlm.nih.gov/pubmed/9928019?dopt=AbstractPlus] and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2265 [http://www.ncbi.nlm.nih.gov/pubmed/10438479?dopt=AbstractPlus] have been reported to be PAC1 receptor antagonists, but these peptides have not been extensively characterised.
Nomenclature	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=370
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=371
	
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=372
	
HGNC, UniProt	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:242, http://www.uniprot.org/uniprot/P41586
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12694, http://www.uniprot.org/uniprot/P32241
	
https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12695, http://www.uniprot.org/uniprot/P41587
	
Potency order of endogenous ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258) http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12693, http://www.uniprot.org/uniprot/P01282)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12693, http://www.uniprot.org/uniprot/P01282), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258) http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4265, http://www.uniprot.org/uniprot/P01286), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2273 {Pig}, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10607, http://www.uniprot.org/uniprot/P09683)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1152 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12693, http://www.uniprot.org/uniprot/P01282), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509) > http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2273 {Pig} ≫ http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2270 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4265, http://www.uniprot.org/uniprot/P01286), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3643 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10607, http://www.uniprot.org/uniprot/P09683)	
Selective agonists	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264 [http://www.ncbi.nlm.nih.gov/pubmed/16930633?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2264]	[http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3842 [http://www.ncbi.nlm.nih.gov/pubmed/11931347?dopt=AbstractPlus], [http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2278 [http://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2259 [http://www.ncbi.nlm.nih.gov/pubmed/9145428?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10570056?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/11931347?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2276 [http://www.ncbi.nlm.nih.gov/pubmed/9152366?dopt=AbstractPlus]	
Selective antagonists	–	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2268 (pIC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/9437716?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10570056?dopt=AbstractPlus]	–	
Labelled ligands	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2261 (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/11193823?dopt=AbstractPlus]	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2277) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2261 (Agonist)	
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2277) (Agonist) [http://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2261 (Agonist)	



Comments
Subtypes of PAC1 receptors have been proposed based on tissue differences in the potencies of http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2257 (https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:241, http://www.uniprot.org/uniprot/P18509) and http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2258); these might result from differences in G protein coupling and second messenger mechanisms [http://www.ncbi.nlm.nih.gov/pubmed/8967982?dopt=AbstractPlus], or from alternative splicing of PAC1 receptor mRNA [http://www.ncbi.nlm.nih.gov/pubmed/8396727?dopt=AbstractPlus].

Further reading on VIP and PACAP receptors
Harmar AJ et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide. Pharmacol Rev
50: 265‐270[https://www.ncbi.nlm.nih.gov/pubmed/9647867?dopt=AbstractPlus]

Harmar AJ et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR review 1. Br. J. Pharmacol.
166: 4‐17[https://www.ncbi.nlm.nih.gov/pubmed/22289055?dopt=AbstractPlus]

Reglodi D et al. (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides
46: 61‐70[https://www.ncbi.nlm.nih.gov/pubmed/21621841?dopt=AbstractPlus]

Smith CB et al. (2012) Is PACAP the major neurotransmitter for stress transduction at the adrenomedullary synapse? J. Mol. Neurosci.
48: 403‐12[https://www.ncbi.nlm.nih.gov/pubmed/22610912?dopt=AbstractPlus]
==== Refs
References
1 

Abbracchio 
MP 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12559763?dopt=AbstractPlus

2 

Abbracchio 
MP 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16968944?dopt=AbstractPlus

3 

AbdAlla 
S 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10993080?dopt=AbstractPlus

4 

Abdul-Ridha 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25326383?dopt=AbstractPlus

5 

Abdul-Ridha 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24443568?dopt=AbstractPlus

6 

Abo-Salem 
OM 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14563788?dopt=AbstractPlus

7 

Abramovitz 
M 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10634944?dopt=AbstractPlus

8 

Abramovitz 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8300593?dopt=AbstractPlus

9 

Adams 
CL 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17894647?dopt=AbstractPlus

10 

Adams 
JW 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18539757?dopt=AbstractPlus

11 

Adapa 
ID 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9413015?dopt=AbstractPlus

12 

Adham 
N 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9225282?dopt=AbstractPlus

13 

Adham 
N 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8380639?dopt=AbstractPlus

14 

af Forselles 
KJ 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21595651?dopt=AbstractPlus

15 

Afargan 
M 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11145612?dopt=AbstractPlus

16 

Agelis 
G 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22889560?dopt=AbstractPlus

17 

Ahmed 
K 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19561068?dopt=AbstractPlus

18 

Ahmed 
K 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20374963?dopt=AbstractPlus

19 

Ahn 
HS 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9203642?dopt=AbstractPlus

20 

Ahuja 
SK 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8702798?dopt=AbstractPlus

21 

Ahumada 
A 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12471263?dopt=AbstractPlus

22 

Ai 
LS 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12081481?dopt=AbstractPlus

23 

Aiyar 
N 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11693189?dopt=AbstractPlus

24 

Aiyar 
N 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8463997?dopt=AbstractPlus

25 

Akbulut 
H 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10323493?dopt=AbstractPlus

26 

Akerlund 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10519430?dopt=AbstractPlus

27 

Akgün 
E 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19271701?dopt=AbstractPlus

28 

Akiyama 
K 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/2986120?dopt=AbstractPlus

29 

Akunne 
HC 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7674830?dopt=AbstractPlus

30 

Al-Ani 
B 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10411588?dopt=AbstractPlus

31 

Ala 
Y 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9773787?dopt=AbstractPlus

32 

Albert 
DH 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9151941?dopt=AbstractPlus

33 

Albert 
R 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16078855?dopt=AbstractPlus

34 

Albert-Gasco 
H 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30368554?dopt=AbstractPlus

35 

Albrandt 
K 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7588285?dopt=AbstractPlus

36 

Albright 
JD 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9651149?dopt=AbstractPlus

37 

Alexander 
SP 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8937736?dopt=AbstractPlus

38 

Alexander 
SP 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus

39 

Alexander 
SP 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11164377?dopt=AbstractPlus

40 

Alikhani 
V 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15324892?dopt=AbstractPlus

41 

Alim 
K 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30358997?dopt=AbstractPlus

42 

Amano 
H 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12538661?dopt=AbstractPlus

43 

Amblard 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10514288?dopt=AbstractPlus

44 

Ames 
RS 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11342658?dopt=AbstractPlus

45 

Ames 
RS 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8898085?dopt=AbstractPlus

46 

Ames 
RS 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10499587?dopt=AbstractPlus

47 

Amisten 
S 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18213371?dopt=AbstractPlus

48 

Amlaiky 
N 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1328180?dopt=AbstractPlus

49 

Ancellin 
N 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10383399?dopt=AbstractPlus

50 

Andersen 
PH 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/1973652?dopt=AbstractPlus

51 

Anderson 
JJ 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12438526?dopt=AbstractPlus

52 

Andrade-Gordon 
P 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10535908?dopt=AbstractPlus

53 

Andres 
M 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11934825?dopt=AbstractPlus

54 

Ang 
SY 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29535183?dopt=AbstractPlus

55 

Ang 
SY 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/27243554?dopt=AbstractPlus

56 

Ann 
DK 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1313812?dopt=AbstractPlus

57 

Anthes 
JC 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12206858?dopt=AbstractPlus

58 

Antoniu 
SA 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21154168?dopt=AbstractPlus

59 

Antony 
J 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/18842964?dopt=AbstractPlus

60 

Araç 
D 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22333914?dopt=AbstractPlus

61 

Arbore 
G 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27313051?dopt=AbstractPlus

62 

Arcos-Burgos 
M 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20157310?dopt=AbstractPlus

63 

Arcuri 
L 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29232769?dopt=AbstractPlus

64 

Ariel 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12794159?dopt=AbstractPlus

65 

Aristotelous 
T 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24454993?dopt=AbstractPlus

66 

Arita 
M 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15753205?dopt=AbstractPlus

67 

Arita 
M 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17339491?dopt=AbstractPlus

68 

Armour 
SL 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/11033437?dopt=AbstractPlus

69 

Armstrong 
RA 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8242228?dopt=AbstractPlus

70 

Arnt 
J 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9430133?dopt=AbstractPlus

71 

Aronica 
SM 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8078914?dopt=AbstractPlus

72 

Arthofer 
E 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27458145?dopt=AbstractPlus

73 

Asahi 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12467628?dopt=AbstractPlus

74 

Asin 
KE 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1636779?dopt=AbstractPlus

75 

Attali 
P 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27673668?dopt=AbstractPlus

76 

Auchampach 
JA 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19141710?dopt=AbstractPlus

77 

Audinot 
V 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11375253?dopt=AbstractPlus

78 

Audinot 
V 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12764576?dopt=AbstractPlus

79 

Auerbach 
SS 

et al. National Toxicology Program: Dept of Health and Human Services.
80 

Austin 
CE 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9111052?dopt=AbstractPlus

81 

Austin 
KM 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23086754?dopt=AbstractPlus

82 

Avlani 
VA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20413650?dopt=AbstractPlus

83 

Ayme-Dietrich 
E 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28806488?dopt=AbstractPlus

84 

Ayoub 
MA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15266022?dopt=AbstractPlus

85 

Azran 
S 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23751098?dopt=AbstractPlus

86 

Baba 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9169459?dopt=AbstractPlus

87 

Baba 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10318947?dopt=AbstractPlus

88 

Bach 
P 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24215345?dopt=AbstractPlus

89 

Bach 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11218067?dopt=AbstractPlus

90 

Bachelerie 
F 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24218476?dopt=AbstractPlus

91 

Bachelerie 
F 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25958743?dopt=AbstractPlus

92 

Bae 
YS 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15210823?dopt=AbstractPlus

93 

Bahouth 
SW 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/2410593?dopt=AbstractPlus

94 

Baker 
JG 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20590599?dopt=AbstractPlus

95 

Baker 
JG 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21152092?dopt=AbstractPlus

96 

Baker 
JG 
. (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15655528?dopt=AbstractPlus

97 

Baker 
JG 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12770928?dopt=AbstractPlus

98 

Baker 
JG 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14645666?dopt=AbstractPlus

99 

Baker 
JG 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12920204?dopt=AbstractPlus

100 

Bakker 
RA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16415177?dopt=AbstractPlus

101 

Balan 
G 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19442519?dopt=AbstractPlus

102 

Balogh 
J 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15893764?dopt=AbstractPlus

103 

Bamberg 
CE 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20044484?dopt=AbstractPlus

104 

Bandholtz 
S 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27791374?dopt=AbstractPlus

105 

Bang-Andersen 
B 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21486038?dopt=AbstractPlus

106 

Bard 
JA 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7592911?dopt=AbstractPlus

107 

Bard 
JA 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8226867?dopt=AbstractPlus

108 

Barda 
DA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15149652?dopt=AbstractPlus

109 

Barnea 
G 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18165312?dopt=AbstractPlus

110 

Barrett 
MO 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23592514?dopt=AbstractPlus

111 

Barroso 
R 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22913878?dopt=AbstractPlus

112 

Barry 
GD 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20873792?dopt=AbstractPlus

113 

Barshop 
K 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25341626?dopt=AbstractPlus

114 

Bartfai 
T 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1720557?dopt=AbstractPlus

115 

Bartfai 
T 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7504301?dopt=AbstractPlus

116 

Bartoi 
T 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20406808?dopt=AbstractPlus

117 

Bassi 
MT 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7647783?dopt=AbstractPlus

118 

Bastian 
S 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9313952?dopt=AbstractPlus

119 

Bastien 
L 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8163486?dopt=AbstractPlus

120 

Bathgate 
RA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16507880?dopt=AbstractPlus

121 

Bayewitch 
M 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8626625?dopt=AbstractPlus

122 

Bayin 
NS 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27775701?dopt=AbstractPlus

123 

Beattie 
D 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22932315?dopt=AbstractPlus

124 

Beattie 
DT 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15466450?dopt=AbstractPlus

125 

Beaujouan 
JC 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9042606?dopt=AbstractPlus

126 

Bechtold 
DA 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22197240?dopt=AbstractPlus

127 

Beckers 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11726197?dopt=AbstractPlus

128 

Beckers 
T 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7649152?dopt=AbstractPlus

129 

Beckers 
T 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9300077?dopt=AbstractPlus

130 

Bedendi 
I 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12969753?dopt=AbstractPlus

131 

Bednarek 
MA 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11087562?dopt=AbstractPlus

132 

Bednarek 
MA 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11606131?dopt=AbstractPlus

133 

Behrens 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15178431?dopt=AbstractPlus

134 

Bekker 
P 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27768695?dopt=AbstractPlus

135 

Belgi 
A 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21866895?dopt=AbstractPlus

136 

Bell 
IM 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9622556?dopt=AbstractPlus

137 

Belley 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10658574?dopt=AbstractPlus

138 

Bellier 
B 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14698161?dopt=AbstractPlus

139 

Bellucci 
F 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11786503?dopt=AbstractPlus

140 

Ben-Baruch 
A 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7545673?dopt=AbstractPlus

141 

Bender 
E 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10646498?dopt=AbstractPlus

142 

Bennacef 
I 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15265501?dopt=AbstractPlus

143 

Benned-Jensen 
T 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20148890?dopt=AbstractPlus

144 

Benya 
RV 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7838118?dopt=AbstractPlus

145 

Benyahia 
C 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23850788?dopt=AbstractPlus

146 

Beresford 
IJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9618428?dopt=AbstractPlus

147 

Beresford 
IJ 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7713168?dopt=AbstractPlus

148 

Bergman 
JM 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18207395?dopt=AbstractPlus

149 

Berizzi 
AE 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27461343?dopt=AbstractPlus

150 

Bern 
HA 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/2864726?dopt=AbstractPlus

151 

Bernotas 
RC 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19523834?dopt=AbstractPlus

152 

Berque-Bestel 
I 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12801225?dopt=AbstractPlus

153 

Berrie 
CP 

et al (1984 ) https://www.ncbi.nlm.nih.gov/pubmed/6478115?dopt=AbstractPlus

154 

Berry 
CB 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25221667?dopt=AbstractPlus

155 

Bersani 
M 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1710578?dopt=AbstractPlus

156 

Bersani 
M 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1718731?dopt=AbstractPlus

157 

Bertini 
R 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15282370?dopt=AbstractPlus

158 

Besada 
P 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16942026?dopt=AbstractPlus

159 

Bettler 
B 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15269338?dopt=AbstractPlus

160 

Beukers 
MW 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11093773?dopt=AbstractPlus

161 

Beukers 
MW 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9384502?dopt=AbstractPlus

162 

Beukers 
MW 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12672250?dopt=AbstractPlus

163 

Bi 
Y 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25754495?dopt=AbstractPlus

164 

Bichet 
DG 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9756088?dopt=AbstractPlus

165 

Bigoni 
R 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12070757?dopt=AbstractPlus

166 

Binet 
V 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15126507?dopt=AbstractPlus

167 

Birdsall 
NJ 

et al (1979 ) https://www.ncbi.nlm.nih.gov/pubmed/497538?dopt=AbstractPlus

168 

Birke 
FW 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11259574?dopt=AbstractPlus

169 

Birrell 
MA 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/22747912?dopt=AbstractPlus

170 

Bjursell 
M 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16887097?dopt=AbstractPlus

171 

Blackhart 
BD 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8663335?dopt=AbstractPlus

172 

Blaho 
VA 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30343728?dopt=AbstractPlus

173 

Blaho 
VA 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26053123?dopt=AbstractPlus

174 

Blair 
JB 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11101361?dopt=AbstractPlus

175 

Blanpain 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10477718?dopt=AbstractPlus

176 

Bley 
KR 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16331286?dopt=AbstractPlus

177 

Blin 
N 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7903415?dopt=AbstractPlus

178 

Blondel 
O 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9603189?dopt=AbstractPlus

179 

Blue 
DR 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14678390?dopt=AbstractPlus

180 

Boatman 
PD 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22435740?dopt=AbstractPlus

181 

Bockaert 
J 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16896947?dopt=AbstractPlus

182 

Boden 
P 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8648606?dopt=AbstractPlus

183 

Boess 
FG 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9284367?dopt=AbstractPlus

184 

Boess 
FG 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9730917?dopt=AbstractPlus

185 

Bogdanov 
YD 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9647463?dopt=AbstractPlus

186 

Bohnekamp 
J 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/22025619?dopt=AbstractPlus

187 

Boie 
Y 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7512962?dopt=AbstractPlus

188 

Boie 
Y 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7642548?dopt=AbstractPlus

189 

Boie 
Y 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10513580?dopt=AbstractPlus

190 

Bolden 
C 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1346637?dopt=AbstractPlus

191 

Bolli 
MH 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20446681?dopt=AbstractPlus

192 

Bolli 
MH 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22862294?dopt=AbstractPlus

193 

Bolli 
MH 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15139756?dopt=AbstractPlus

194 

Bolliger 
MF 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21262840?dopt=AbstractPlus

195 

Bologa 
CG 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16520733?dopt=AbstractPlus

196 

Bolognini 
D 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27385588?dopt=AbstractPlus

197 

Bonaventure 
P 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22570363?dopt=AbstractPlus

198 

Bonaventure 
P 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14617685?dopt=AbstractPlus

199 

Bonhaus 
DW 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9225293?dopt=AbstractPlus

200 

Bonhaus 
DW 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10455251?dopt=AbstractPlus

201 

Bonhaus 
DW 

et al (1977 ) https://www.ncbi.nlm.nih.gov/pubmed/9225287?dopt=AbstractPlus

202 

Bonnefous 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15686941?dopt=AbstractPlus

203 

Bonnefous 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16046122?dopt=AbstractPlus

204 

Booth 
RG 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12065734?dopt=AbstractPlus

205 

Borowsky 
B 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11459929?dopt=AbstractPlus

206 

Borowsky 
B 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12118247?dopt=AbstractPlus

207 

Borowsky 
B 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9880084?dopt=AbstractPlus

208 

Borrmann 
T 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19569717?dopt=AbstractPlus

209 

Bosch 
MP 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15267242?dopt=AbstractPlus

210 

Bosnyak 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21542804?dopt=AbstractPlus

211 

Botto 
JM 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9001400?dopt=AbstractPlus

212 

Boulanger 
L 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11814616?dopt=AbstractPlus

213 

Boulenguez 
P 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1738002?dopt=AbstractPlus

214 

Bourguignon-Bellefroid 
C 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1546952?dopt=AbstractPlus

215 

Bowery 
NG 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12037141?dopt=AbstractPlus

216 

Bowery 
NG 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10604925?dopt=AbstractPlus

217 

Bowles 
NP 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25535367?dopt=AbstractPlus

218 

Boyce 
M 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22607579?dopt=AbstractPlus

219 

Boyden 
SE 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26841242?dopt=AbstractPlus

220 

Boyer 
JL 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8913364?dopt=AbstractPlus

221 

Brabet 
I 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8532171?dopt=AbstractPlus

222 

Bradaia 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19892733?dopt=AbstractPlus

223 

Bradshaw 
CG 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8027981?dopt=AbstractPlus

224 

Brady 
AE 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18772318?dopt=AbstractPlus

225 

Brambilla 
R 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10731034?dopt=AbstractPlus

226 

Brame 
AL 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25712721?dopt=AbstractPlus

227 

Branchek 
T 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2233697?dopt=AbstractPlus

228 

Breivogel 
CS 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9316881?dopt=AbstractPlus

229 

Brenchat 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19118950?dopt=AbstractPlus

230 

Brennan 

et al (2007 ) Patent number: US2007/0074299.
231 

Breton 
C 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11337500?dopt=AbstractPlus

232 

Breu 
V 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8612786?dopt=AbstractPlus

233 

Brezillon 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12401809?dopt=AbstractPlus

234 

Briddon 
SJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15070776?dopt=AbstractPlus

235 

Brighton 
PJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15331768?dopt=AbstractPlus

236 

Brink 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15001665?dopt=AbstractPlus

237 

Brinkmann 
V 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11967257?dopt=AbstractPlus

238 

Briscoe 
CP 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16702987?dopt=AbstractPlus

239 

Briscoe 
CP 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12496284?dopt=AbstractPlus

240 

Brkovic 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12807997?dopt=AbstractPlus

241 

Broad 
J 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23190027?dopt=AbstractPlus

242 

Broad 
LM 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30276808?dopt=AbstractPlus

243 

Broadhead 
GK 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21187282?dopt=AbstractPlus

244 

Brodbeck 
RM 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18753409?dopt=AbstractPlus

245 

Brodfuehrer 
J 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24190631?dopt=AbstractPlus

246 

Brodkin 
J 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12473093?dopt=AbstractPlus

247 

Bromidge 
SM 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9925723?dopt=AbstractPlus

248 

Bromidge 
SM 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11140733?dopt=AbstractPlus

249 

Brown 
AJ 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12496283?dopt=AbstractPlus

250 

Brown 
AM 

et al (1998 ) Br J Pharmacol 
123 : 233 

251 

Brown 
AM 

et al (1993 ) Br J Pharmacol 
110 : 10 

252 

Brown 
EM 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8255296?dopt=AbstractPlus

253 

Brown 
K 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28570277?dopt=AbstractPlus

254 

Browning 
C 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10696085?dopt=AbstractPlus

255 

Bruchas 
MR 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17702750?dopt=AbstractPlus

256 

Bruinvels 
AT 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8361548?dopt=AbstractPlus

257 

Bruns 
C 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8769372?dopt=AbstractPlus

258 

Bruns 
RF 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2174510?dopt=AbstractPlus

259 

Brunschweiger 
A 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16475938?dopt=AbstractPlus

260 

Bruzzone 
F 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17534937?dopt=AbstractPlus

261 

Bryant 
HU 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8845011?dopt=AbstractPlus

262 

Bryja 
V 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17426148?dopt=AbstractPlus

263 

Bryja 
V 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18953287?dopt=AbstractPlus

264 

Bräuner-Osborne 
H 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8759641?dopt=AbstractPlus

265 

Buckley 
NJ 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2704370?dopt=AbstractPlus

266 

Bunzow 
JR 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2974511?dopt=AbstractPlus

267 

Burford 
NT 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23754417?dopt=AbstractPlus

268 

Burford 
NT 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25901762?dopt=AbstractPlus

269 

Burgaud 
JL 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9434758?dopt=AbstractPlus

270 

Burmakina 
S 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24778228?dopt=AbstractPlus

271 

Burnstock 
G 

et al (2012 ) Purinergic signalling and the nervous system. Springer: 1 -715 

272 

Burris 
KD 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7576010?dopt=AbstractPlus

273 

Burstein 
ES 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16135699?dopt=AbstractPlus

274 

Buvinic 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12110609?dopt=AbstractPlus

275 

Buzard 
DJ 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25516790?dopt=AbstractPlus

276 

Bylund 
DB 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1353247?dopt=AbstractPlus

277 

Bylund 
DB 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7938162?dopt=AbstractPlus

278 

Byrne 
EFX 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27437577?dopt=AbstractPlus

279 

Bäck 
M 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21771892?dopt=AbstractPlus

280 

Bäck 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24588652?dopt=AbstractPlus

281 

Béguin 
C 
. (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15869877?dopt=AbstractPlus

282 

Bélanger 
S 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19111586?dopt=AbstractPlus

283 

Béraud-Dufour 
S 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19891061?dopt=AbstractPlus

284 

Búzás 
B 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1313131?dopt=AbstractPlus

285 

Büllesbach 
EE 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15708846?dopt=AbstractPlus

286 

Büscher 
R 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16495779?dopt=AbstractPlus

287 

Cabrele 
C 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12069595?dopt=AbstractPlus

288 

Cahalan 
SM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21445057?dopt=AbstractPlus

289 

Cai 
R 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24373935?dopt=AbstractPlus

290 

Cai 
TQ 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18952058?dopt=AbstractPlus

291 

Cain 
SA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11773063?dopt=AbstractPlus

292 

Calderon 
SN 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8035418?dopt=AbstractPlus

293 

Callander 
GE 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24376396?dopt=AbstractPlus

294 

Calo 
G 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12010780?dopt=AbstractPlus

295 

Campion 
KL 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25556167?dopt=AbstractPlus

296 

Canals 
M 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22086918?dopt=AbstractPlus

297 

Candelore 
MR 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10411574?dopt=AbstractPlus

298 

Capodanno 
D 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23809135?dopt=AbstractPlus

299 

Cappelli 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23466604?dopt=AbstractPlus

300 

Cappelli 
A 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15115399?dopt=AbstractPlus

301 

Capra 
V 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9504401?dopt=AbstractPlus

302 

Capra 
V 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25839425?dopt=AbstractPlus

303 

Capra 
V 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9547367?dopt=AbstractPlus

304 

Carmeci 
C 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9367686?dopt=AbstractPlus

305 

Carmon 
KS 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21693646?dopt=AbstractPlus

306 

Carnini 
C 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21753081?dopt=AbstractPlus

307 

Carpenter 
B 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27462812?dopt=AbstractPlus

308 

Carr 
JC 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/23158174?dopt=AbstractPlus

309 

Carroll 
FY 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11306677?dopt=AbstractPlus

310 

Carroll 
WA 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11354357?dopt=AbstractPlus

311 

Carter 
RL 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19759354?dopt=AbstractPlus

312 

Cascieri 
MA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10085108?dopt=AbstractPlus

313 

Castro 
SW 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8646408?dopt=AbstractPlus

314 

Catalioto 
RM 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9484857?dopt=AbstractPlus

315 

Catalán 
V 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17371481?dopt=AbstractPlus

316 

Cattaneo 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15476670?dopt=AbstractPlus

317 

Cattaneo 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12578987?dopt=AbstractPlus

318 

Caulfield 
MP 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9647869?dopt=AbstractPlus

319 

Caunt 
CJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15059960?dopt=AbstractPlus

320 

Caunt 
CJ 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22808094?dopt=AbstractPlus

321 

Cavallari 
U 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17803810?dopt=AbstractPlus

322 

Cavanaugh 
DJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19451647?dopt=AbstractPlus

323 

Cayabyab 
M 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11090199?dopt=AbstractPlus

324 

Cembala 
TM 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9846649?dopt=AbstractPlus

325 

Cencetti 
F 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23913862?dopt=AbstractPlus

326 

Cescato 
R 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18543899?dopt=AbstractPlus

327 

Chackalamannil 
S 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18447380?dopt=AbstractPlus

328 

Chagnon 
YC 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9392003?dopt=AbstractPlus

329 

Chaki 
S 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15677346?dopt=AbstractPlus

330 

Chaki 
S 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10357258?dopt=AbstractPlus

331 

Chambers 
JK 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10753868?dopt=AbstractPlus

332 

Chan 
SD 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1334084?dopt=AbstractPlus

333 

Chan 
WY 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18678919?dopt=AbstractPlus

334 

Chandrashekar 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10761935?dopt=AbstractPlus

335 

Chang 
DJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9490024?dopt=AbstractPlus

336 

Chang 
KJ 

et al (1983 ) https://www.ncbi.nlm.nih.gov/pubmed/6313901?dopt=AbstractPlus

337 

Chang 
RS 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2314387?dopt=AbstractPlus

338 

Chang 
RS 

et al (1986 ) https://www.ncbi.nlm.nih.gov/pubmed/3018478?dopt=AbstractPlus

339 

Chang 
W 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18765830?dopt=AbstractPlus

340 

Chang 
W 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17591780?dopt=AbstractPlus

341 

Chansel 
D 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8282008?dopt=AbstractPlus

342 

Chao 
TH 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10092660?dopt=AbstractPlus

343 

Chartrel 
N 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14657341?dopt=AbstractPlus

344 

Chatenet 
D 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17125276?dopt=AbstractPlus

345 

Chavkin 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14718611?dopt=AbstractPlus

346 

Chen 
C 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8893829?dopt=AbstractPlus

347 

Chen 
H 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15163697?dopt=AbstractPlus

348 

Chen 
J 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15772293?dopt=AbstractPlus

349 

Chen 
J 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12706455?dopt=AbstractPlus

350 

Chen 
JK 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12391318?dopt=AbstractPlus

351 

Chen 
LH 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25050158?dopt=AbstractPlus

352 

Chen 
Q 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22697179?dopt=AbstractPlus

353 

Chen 
R 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7692441?dopt=AbstractPlus

354 

Chen 
W 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12958365?dopt=AbstractPlus

355 

Chen 
YL 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18288792?dopt=AbstractPlus

356 

Chen 
Z 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15454210?dopt=AbstractPlus

357 

Cheng 
CK 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15561800?dopt=AbstractPlus

358 

Cheng 
K 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12235229?dopt=AbstractPlus

359 

Cheng 
LL 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15084136?dopt=AbstractPlus

360 

Cheng 
RKY 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28445455?dopt=AbstractPlus

361 

Cheng 
RKY 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28712806?dopt=AbstractPlus

362 

Cheng 
Z 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17615148?dopt=AbstractPlus

363 

Cherezov 
V 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17962520?dopt=AbstractPlus

364 

Chhatriwala 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15345752?dopt=AbstractPlus

365 

Chiang 
N 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10748237?dopt=AbstractPlus

366 

Chiang 
N 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22538616?dopt=AbstractPlus

367 

Chin 
FT 

et al (2006 ) J Label Comp Radiopharm 
17 -31 

368 

Chini 
B 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12942128?dopt=AbstractPlus

369 

Chini 
B 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7774575?dopt=AbstractPlus

370 

Chini 
B 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8955347?dopt=AbstractPlus

371 

Chiu 
AT 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2590220?dopt=AbstractPlus

372 

Chng 
SC 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24316148?dopt=AbstractPlus

373 

Chobanian 
HR 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/24900461?dopt=AbstractPlus

374 

Chopra 
M 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19389924?dopt=AbstractPlus

375 

Chou 
CC 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12381680?dopt=AbstractPlus

376 

Chow 
BK 
. (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7612008?dopt=AbstractPlus

377 

Chow 
BS 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24429402?dopt=AbstractPlus

378 

Chrencik 
JE 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26091040?dopt=AbstractPlus

379 

Christiansen 
E 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22724451?dopt=AbstractPlus

380 

Christiansen 
E 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23687558?dopt=AbstractPlus

381 

Christiansen 
E 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27074625?dopt=AbstractPlus

382 

Christiansen 
E 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25916176?dopt=AbstractPlus

383 

Christopher 
JA 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/29455526?dopt=AbstractPlus

384 

Christopoulos 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12446722?dopt=AbstractPlus

385 

Christopoulos 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9614217?dopt=AbstractPlus

386 

Christopoulos 
A 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9890565?dopt=AbstractPlus

387 

Christopoulos 
A 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11578621?dopt=AbstractPlus

388 

Christopoulos 
G 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10385705?dopt=AbstractPlus

389 

Chu 
ZL 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19901198?dopt=AbstractPlus

390 

Chun 
J 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30625282?dopt=AbstractPlus

391 

Chung 
AW 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11877318?dopt=AbstractPlus

392 

Chung 
DS 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9353394?dopt=AbstractPlus

393 

Chung 
FZ 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7476898?dopt=AbstractPlus

394 

Cialdai 
C 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16979621?dopt=AbstractPlus

395 

Ciana 
P 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16990797?dopt=AbstractPlus

396 

Cirillo 
R 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12660315?dopt=AbstractPlus

397 

Cirillo 
R 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17618756?dopt=AbstractPlus

398 

Claeysen 
S 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9351641?dopt=AbstractPlus

399 

Clark 
AL 

et al (1976 ) https://www.ncbi.nlm.nih.gov/pubmed/990587?dopt=AbstractPlus

400 

Clark 
BP 

et al (1997 ) Bioorg Med Chem Lett 
7 : 2777 -2780 

401 

Clish 
CB 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10393980?dopt=AbstractPlus

402 

Clozel 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15146030?dopt=AbstractPlus

403 

Clozel 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8035319?dopt=AbstractPlus

404 

Cogé 
F 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11284713?dopt=AbstractPlus

405 

Cohen 
JA 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21520239?dopt=AbstractPlus

406 

Combadiere 
C 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8530354?dopt=AbstractPlus

407 

Commery 
TA 
. (2010 ) Alzheimer's & Dementia 
6 : S548 -S549 

408 

Communi 
D 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10578132?dopt=AbstractPlus

409 

Comps-Agrar 
L 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21552208?dopt=AbstractPlus

410 

Congreve 
M 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22220592?dopt=AbstractPlus

411 

Conigrave 
AD 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10781086?dopt=AbstractPlus

412 

Conn 
PM 

et al (1982 ) https://www.ncbi.nlm.nih.gov/pubmed/6282571?dopt=AbstractPlus

413 

Conroy 
JL 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25660762?dopt=AbstractPlus

414 

Cook 
AE 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25220431?dopt=AbstractPlus

415 

Cooray 
SN 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24108355?dopt=AbstractPlus

416 

Corbett 
DF 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16002289?dopt=AbstractPlus

417 

Costantino 
G 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11249114?dopt=AbstractPlus

418 

Costes 
N 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16330560?dopt=AbstractPlus

419 

Cotte 
N 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10866830?dopt=AbstractPlus

420 

Cotte 
N 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9792651?dopt=AbstractPlus

421 

Cottingham 
C 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21859713?dopt=AbstractPlus

422 

Coulie 
B 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11461914?dopt=AbstractPlus

423 

Coulin 
F 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9346309?dopt=AbstractPlus

424 

Coulouarn 
Y 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10486557?dopt=AbstractPlus

425 

Coulouarn 
Y 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9861051?dopt=AbstractPlus

426 

Coulthard 
LG 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30449309?dopt=AbstractPlus

427 

Covic 
L 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12357249?dopt=AbstractPlus

428 

Cox 
BM 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/24528283?dopt=AbstractPlus

429 

Cox 
CD 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20565075?dopt=AbstractPlus

430 

Cox 
HM 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8590988?dopt=AbstractPlus

431 

Coy 
DH 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8993400?dopt=AbstractPlus

432 

Criscione 
L 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8242249?dopt=AbstractPlus

433 

Croker 
DE 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24060963?dopt=AbstractPlus

434 

Croker 
DE 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27108698?dopt=AbstractPlus

435 

Crombie 
AL 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20471258?dopt=AbstractPlus

436 

Croston 
GE 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12408704?dopt=AbstractPlus

437 

Croy 
CH 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24807965?dopt=AbstractPlus

438 

Cunha 
RA 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8692280?dopt=AbstractPlus

439 

Curtis 
AE 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19934405?dopt=AbstractPlus

440 

D’Amato 
M 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17854592?dopt=AbstractPlus

441 

Dairaghi 
DJ 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10419462?dopt=AbstractPlus

442 

Dalpiaz 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9827575?dopt=AbstractPlus

443 

Daniels 
DV 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10334511?dopt=AbstractPlus

444 

Dardonville 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15224384?dopt=AbstractPlus

445 

Darker 
JG 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11266181?dopt=AbstractPlus

446 

Das 
A 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19902968?dopt=AbstractPlus

447 

Das 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21245295?dopt=AbstractPlus

448 

Dass 
NB 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14504130?dopt=AbstractPlus

449 

Daugherty 
BL 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8642344?dopt=AbstractPlus

450 

Dautzenberg 
FM 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9326293?dopt=AbstractPlus

451 

Dautzenberg 
FM 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15450949?dopt=AbstractPlus

452 

Dautzenberg 
FM 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10583729?dopt=AbstractPlus

453 

Dautzenberg 
FM 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11123370?dopt=AbstractPlus

454 

Davenport 
AP 
. (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12037137?dopt=AbstractPlus

455 

Davenport 
AP 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23686350?dopt=AbstractPlus

456 

Davenport 
AP 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16382107?dopt=AbstractPlus

457 

Davenport 
AP 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9489609?dopt=AbstractPlus

458 

Davenport 
AP 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8012722?dopt=AbstractPlus

459 

Davey 
AE 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22210744?dopt=AbstractPlus

460 

Davis 
MD 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15590668?dopt=AbstractPlus

461 

Davis 
TL 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10952683?dopt=AbstractPlus

462 

Davoren 
JE 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27275946?dopt=AbstractPlus

463 

Dawson 
LA 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19499624?dopt=AbstractPlus

464 

De Backer 
MD 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9794809?dopt=AbstractPlus

465 

de Gasparo 
M 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10977869?dopt=AbstractPlus

466 

de Gasparo 
M 

et al (1994 ) In Medicinal Chemistry of the Renin-Angiotensin System . Edited by Timmermanns PBMWM  , Wexler RR  : Elsevier : 269 -294  [ISBN: 0444820531]
467 

de Lau 
W 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21727895?dopt=AbstractPlus

468 

De Lecea 
L 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8622767?dopt=AbstractPlus

469 

de Ligt 
RA 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15740718?dopt=AbstractPlus

470 

de Paulis 
T 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16722652?dopt=AbstractPlus

471 

De Ponti 
F 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8730727?dopt=AbstractPlus

472 

De Toni 
L 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30625346?dopt=AbstractPlus

473 

De Vry 
J 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9495870?dopt=AbstractPlus

474 

de Wied 
D 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8258377?dopt=AbstractPlus

475 

de Ávila 
C 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/28864207?dopt=AbstractPlus

476 

Deal 
MJ 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1331460?dopt=AbstractPlus

477 

DeAlmeida 
VI 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17545618?dopt=AbstractPlus

478 

Dearry 
A 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2144334?dopt=AbstractPlus

479 

Del Borgo 
MP 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16547350?dopt=AbstractPlus

480 

Delahaye 
R 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9484907?dopt=AbstractPlus

481 

Demberg 
LM 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26188515?dopt=AbstractPlus

482 

Demberg 
LM 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28154189?dopt=AbstractPlus

483 

Deng 
C 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25995451?dopt=AbstractPlus

484 

Dennis 
MK 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19430488?dopt=AbstractPlus

485 

Dennis 
MK 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21782022?dopt=AbstractPlus

486 

Derick 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12446593?dopt=AbstractPlus

487 

Devedjian 
JC 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7908642?dopt=AbstractPlus

488 

Dhawan 
BN 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8981566?dopt=AbstractPlus

489 

Di Marzo 
V 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11181068?dopt=AbstractPlus

490 

Di Pardo 
A 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29688337?dopt=AbstractPlus

491 

Di Salvo 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11104827?dopt=AbstractPlus

492 

Diallo 
M 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18082287?dopt=AbstractPlus

493 

Dickson 
L 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16930633?dopt=AbstractPlus

494 

Dietis 
N 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22194444?dopt=AbstractPlus

495 

Dietis 
N 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29524334?dopt=AbstractPlus

496 

Dijksterhuis 
JP 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24032637?dopt=AbstractPlus

497 

Dijkstra 
D 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12086487?dopt=AbstractPlus

498 

Dillon 
JS 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8404634?dopt=AbstractPlus

499 

Dinter 
J 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25706283?dopt=AbstractPlus

500 

Dionisotti 
S 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9179373?dopt=AbstractPlus

501 

Disse 
B 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8441333?dopt=AbstractPlus

502 

Divorty 
N 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25805994?dopt=AbstractPlus

503 

Doan 
ND 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22044114?dopt=AbstractPlus

504 

Dodé 
C 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23596439?dopt=AbstractPlus

505 

Dolan 
JA 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7912272?dopt=AbstractPlus

506 

Domenech 
T 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9303569?dopt=AbstractPlus

507 

Domschke 
K 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/20603625?dopt=AbstractPlus

508 

Donaldson 
CJ 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8612563?dopt=AbstractPlus

509 

Donaldson 
LF 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8947459?dopt=AbstractPlus

510 

Donner 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20705147?dopt=AbstractPlus

511 

Doods 
H 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10611450?dopt=AbstractPlus

512 

Doods 
H 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10711339?dopt=AbstractPlus

513 

Doods 
HN 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7562541?dopt=AbstractPlus

514 

Dooley 
CT 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9353393?dopt=AbstractPlus

515 

Doré 
AS 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25042998?dopt=AbstractPlus

516 

Douglas 
SA 


Ohlstein 
EH 
. (2000 ) Urotensinreceptors
In The IUPHAR Receptor Compendium of Receptor Characterization and Classification . Edited by Girdlestone D  : IUPHAR Media Ltd : 365 -372 

517 

Douglas 
SA 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15852036?dopt=AbstractPlus

518 

Doumazane 
E 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/20826542?dopt=AbstractPlus

519 

Dowling 
MR 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16847442?dopt=AbstractPlus

520 

Drake 
MT 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18086673?dopt=AbstractPlus

521 

Draper-Joyce 
CJ 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29925945?dopt=AbstractPlus

522 

Drummond 
AH 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2566295?dopt=AbstractPlus

523 

Dubessy 
C 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18710417?dopt=AbstractPlus

524 

Dubocovich 
ML 
. (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/2991499?dopt=AbstractPlus

525 

Dubocovich 
ML 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20605968?dopt=AbstractPlus

526 

Dubocovich 
ML 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9089668?dopt=AbstractPlus

527 

Dubocovich 
ML 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9737724?dopt=AbstractPlus

528 

Dudley 
DT 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2402226?dopt=AbstractPlus

529 

Dudley 
DT 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8469774?dopt=AbstractPlus

530 

Dufourny 
L 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18400093?dopt=AbstractPlus

531 

Duggal 
P 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12761559?dopt=AbstractPlus

532 

Dumont 
Y 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15337369?dopt=AbstractPlus

533 

Dunlop 
J 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15705738?dopt=AbstractPlus

534 

Dupuis 
DS 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16966477?dopt=AbstractPlus

535 

Dwyer 
MP 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17181143?dopt=AbstractPlus

536 

Díaz-González 
F 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17170051?dopt=AbstractPlus

537 

Dörje 
F 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1994002?dopt=AbstractPlus

538 

Eason 
MG 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7559592?dopt=AbstractPlus

539 

Eckle 
T 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17353435?dopt=AbstractPlus

540 

Edgar 
AJ 
. (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17454009?dopt=AbstractPlus

541 

Edinger 
AL 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9405683?dopt=AbstractPlus

542 

Edson 
MA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19887567?dopt=AbstractPlus

543 

Edwards 
RM 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1309870?dopt=AbstractPlus

544 

Egan 
C 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10611640?dopt=AbstractPlus

545 

Eggerickx 
D 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7639700?dopt=AbstractPlus

546 

Eison 
AS 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8246675?dopt=AbstractPlus

547 

El Messari 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15341513?dopt=AbstractPlus

548 

El-Tayeb 
A 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16213725?dopt=AbstractPlus

549 

El-Tayeb 
A 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17125260?dopt=AbstractPlus

550 

El-Tayeb 
A 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21417463?dopt=AbstractPlus

551 

Elands 
J 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2827511?dopt=AbstractPlus

552 

Ellacott 
KL 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15752583?dopt=AbstractPlus

553 

Elliott 
JD 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8201588?dopt=AbstractPlus

554 

Elshourbagy 
NA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11976263?dopt=AbstractPlus

555 

Emonds-Alt 
X 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7830490?dopt=AbstractPlus

556 

Emonds-Alt 
X 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7682062?dopt=AbstractPlus

557 

Emson 
PC 
. (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17499108?dopt=AbstractPlus

558 

Engel 
KM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/22216272?dopt=AbstractPlus

559 

Engers 
DW 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19469556?dopt=AbstractPlus

560 

Engers 
JL 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26335039?dopt=AbstractPlus

561 

Engstrom 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12606605?dopt=AbstractPlus

562 

Engstrom 
M 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15333679?dopt=AbstractPlus

563 

Enna 
SJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15451397?dopt=AbstractPlus

564 

Ennis 
MD 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9632349?dopt=AbstractPlus

565 

Erchegyi 
J 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15658864?dopt=AbstractPlus

566 

Eriksson 
H 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9802391?dopt=AbstractPlus

567 

Erlinge 
D 
. (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21586366?dopt=AbstractPlus

568 

Erspamer 
V 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2544892?dopt=AbstractPlus

569 

Esbenshade 
TA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15294456?dopt=AbstractPlus

570 

Esbenshade 
TA 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12606603?dopt=AbstractPlus

571 

Escribano 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9871538?dopt=AbstractPlus

572 

Espinoza 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21670104?dopt=AbstractPlus

573 

Eubelen 
M 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30026314?dopt=AbstractPlus

574 

Evangelou 
E 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21068099?dopt=AbstractPlus

575 

Evans 
BA 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/20978120?dopt=AbstractPlus

576 

Evans 
BA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10455305?dopt=AbstractPlus

577 

Evans 
BA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20132209?dopt=AbstractPlus

578 

Evans 
BN 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10903324?dopt=AbstractPlus

579 

Evans 
HF 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1714839?dopt=AbstractPlus

580 

Eveleigh 
P 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2704371?dopt=AbstractPlus

581 

Faedo 
S 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22796453?dopt=AbstractPlus

582 

Failli 
AA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16297621?dopt=AbstractPlus

583 

Fan 
H 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25176008?dopt=AbstractPlus

584 

Fan 
X 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12939143?dopt=AbstractPlus

585 

Farb 
TB 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28938487?dopt=AbstractPlus

586 

Farooqi 
IS 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18779842?dopt=AbstractPlus

587 

Faust 
R 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10737738?dopt=AbstractPlus

588 

Feighner 
SD 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10381885?dopt=AbstractPlus

589 

Felder 
CC 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9435190?dopt=AbstractPlus

590 

Felder 
CC 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7565624?dopt=AbstractPlus

591 

Feng 
YH 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7759541?dopt=AbstractPlus

592 

Feoktistov 
I 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11705449?dopt=AbstractPlus

593 

Fernández 
J 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15771415?dopt=AbstractPlus

594 

Fierens 
F 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10079018?dopt=AbstractPlus

595 

Filardo 
EJ 
. (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/28595943?dopt=AbstractPlus

596 

Filardo 
EJ 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11043579?dopt=AbstractPlus

597 

Finch 
AR 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20009083?dopt=AbstractPlus

598 

Finch 
AR 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19888967?dopt=AbstractPlus

599 

Finnerup 
NB 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24507378?dopt=AbstractPlus

600 

Fiore 
S 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8006586?dopt=AbstractPlus

601 

Fiore 
S 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1322894?dopt=AbstractPlus

602 

Fiore 
S 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8527441?dopt=AbstractPlus

603 

Fiorino 
F 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28943244?dopt=AbstractPlus

604 

Fischer 
DJ 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11562440?dopt=AbstractPlus

605 

Fischetti 
C 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19445927?dopt=AbstractPlus

606 

Fister 
S 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19638591?dopt=AbstractPlus

607 

Fitzgerald 
LW 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10217294?dopt=AbstractPlus

608 

Fitzgerald 
LW 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9808667?dopt=AbstractPlus

609 

Flacco 
N 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23373597?dopt=AbstractPlus

610 

Fong 
TM 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1281470?dopt=AbstractPlus

611 

Foord 
APDW 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8632751?dopt=AbstractPlus

612 

Foord 
SM 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15914470?dopt=AbstractPlus

613 

Forbes 
IT 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12392747?dopt=AbstractPlus

614 

Ford 
APDW 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9249248?dopt=AbstractPlus

615 

Forrest 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14747617?dopt=AbstractPlus

616 

Foss 
FW 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17113298?dopt=AbstractPlus

617 

Foudi 
N 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21323896?dopt=AbstractPlus

618 

Foudi 
N 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18516068?dopt=AbstractPlus

619 

Fox 
JC 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25497737?dopt=AbstractPlus

620 

Franchetti 
P 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19317449?dopt=AbstractPlus

621 

Francis 
BE 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8287060?dopt=AbstractPlus

622 

Fraser 
GL 
. (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18719021?dopt=AbstractPlus

623 

Fraser 
NJ 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10347248?dopt=AbstractPlus

624 

Fredholm 
BB 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11734617?dopt=AbstractPlus

625 

Fredman 
G 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20702811?dopt=AbstractPlus

626 

Fredriksson 
R 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12761335?dopt=AbstractPlus

627 

Free 
RB 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24755247?dopt=AbstractPlus

628 

Freedman 
SB 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8301582?dopt=AbstractPlus

629 

Freer 
RJ 

et al (1982 ) https://www.ncbi.nlm.nih.gov/pubmed/6280748?dopt=AbstractPlus

630 

Freer 
RJ 

et al (1980 ) https://www.ncbi.nlm.nih.gov/pubmed/7387981?dopt=AbstractPlus

631 

Fricker 
AC 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19285517?dopt=AbstractPlus

632 

Fricks 
IP 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18252808?dopt=AbstractPlus

633 

Frielle 
T 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2849109?dopt=AbstractPlus

634 

Froestl 
W 
. (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21428811?dopt=AbstractPlus

635 

Froestl 
W 

et al (1997 ) In The GABA Receptors  Edited by Enna SJ  , Bowery NG  : Humana Press : 271 -296  [ISBN: 0896034585]
636 

Fruchart-Gaillard 
C 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16439611?dopt=AbstractPlus

637 

Fuchs 
AR 

et al (1982 ) https://www.ncbi.nlm.nih.gov/pubmed/6278592?dopt=AbstractPlus

638 

Fujii 
R 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12118011?dopt=AbstractPlus

639 

Fukukawa 
C 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18271942?dopt=AbstractPlus

640 

Fukunaga 
K 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11560941?dopt=AbstractPlus

641 

Fukusumi 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12960173?dopt=AbstractPlus

642 

Furman 
CA 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25583363?dopt=AbstractPlus

643 

Gado 
F 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/29990428?dopt=AbstractPlus

644 

Galandrin 
S 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16901982?dopt=AbstractPlus

645 

Galandrin 
S 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18403719?dopt=AbstractPlus

646 

Galemmo 
RA 
Jr

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2170649?dopt=AbstractPlus

647 

Gallo-Rodriguez 
C 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8126704?dopt=AbstractPlus

648 

Gallwitz 
B 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8795084?dopt=AbstractPlus

649 

Galvani 
S 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26268607?dopt=AbstractPlus

650 

Galvez 
T 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10692480?dopt=AbstractPlus

651 

Gama 
L 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11489900?dopt=AbstractPlus

652 

Ganella 
DE 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23135160?dopt=AbstractPlus

653 

Ganella 
DE 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22854307?dopt=AbstractPlus

654 

Ganesh 
T 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23914286?dopt=AbstractPlus

655 

Gao 
H 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15784721?dopt=AbstractPlus

656 

Gao 
ZG 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10927024?dopt=AbstractPlus

657 

Gao 
ZG 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15193995?dopt=AbstractPlus

658 

Gao 
ZG 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15476669?dopt=AbstractPlus

659 

Gardell 
LR 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17519387?dopt=AbstractPlus

660 

Gardella 
TJ 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8702701?dopt=AbstractPlus

661 

Gardella 
TJ 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7896796?dopt=AbstractPlus

662 

Gardella 
TJ 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25713287?dopt=AbstractPlus

663 

Gareau 
Y 

et al (1996 ) Bioorg Med Chem Lett 
6 : 189 -194 

664 

Garin 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14607932?dopt=AbstractPlus

665 

Gasparini 
F 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11814808?dopt=AbstractPlus

666 

Gasparini 
F 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10336568?dopt=AbstractPlus

667 

Gasparini 
F 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10530811?dopt=AbstractPlus

668 

Gasser 
A 
. (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25831128?dopt=AbstractPlus

669 

Gassmann 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15240800?dopt=AbstractPlus

670 

Gaster 
LM 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9548813?dopt=AbstractPlus

671 

Gates 
E 
. (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9735753?dopt=AbstractPlus

672 

Gault 
VA 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12627321?dopt=AbstractPlus

673 

Gavrilyuk 
V 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15715664?dopt=AbstractPlus

674 

Gbahou 
F 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16432504?dopt=AbstractPlus

675 

Ge 
X 

et al (2018 ) Cell Metabolism 
https://www.ncbi.nlm.nih.gov/pubmed/29233536?dopt=AbstractPlus

676 

Gee 
CE 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24596089?dopt=AbstractPlus

677 

Gehlert 
DR 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8632753?dopt=AbstractPlus

678 

Gembardt 
F 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18636314?dopt=AbstractPlus

679 

Generoso 
SF 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25751279?dopt=AbstractPlus

680 

Genet 
C 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19911773?dopt=AbstractPlus

681 

Geng 
Y 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24305054?dopt=AbstractPlus

682 

Geng 
Y 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27434672?dopt=AbstractPlus

683 

Geng 
Y 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22660477?dopt=AbstractPlus

684 

Gentry 
PR 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24692176?dopt=AbstractPlus

685 

Gentry 
PR 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24164599?dopt=AbstractPlus

686 

Gentry 
PR 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25147929?dopt=AbstractPlus

687 

Georgsson 
J 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24937104?dopt=AbstractPlus

688 

Georgsson 
J 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25875054?dopt=AbstractPlus

689 

Gera 
L 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16368899?dopt=AbstractPlus

690 

Gerald 
C 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7796807?dopt=AbstractPlus

691 

Gerald 
C 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8700207?dopt=AbstractPlus

692 

Gerald 
C 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7592910?dopt=AbstractPlus

693 

Gerbino 
A 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16247029?dopt=AbstractPlus

694 

Gergely 
P 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22646698?dopt=AbstractPlus

695 

Gershon 
MD 
. (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10429737?dopt=AbstractPlus

696 

Geubelle 
P 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28160606?dopt=AbstractPlus

697 

Ghoneim 
OM 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16782354?dopt=AbstractPlus

698 

Giagulli 
C 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22262769?dopt=AbstractPlus

699 

Giannotti 
D 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11063600?dopt=AbstractPlus

700 

Giardina 
GA 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8691422?dopt=AbstractPlus

701 

Giles 
H 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2924081?dopt=AbstractPlus

702 

Gilet 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25316608?dopt=AbstractPlus

703 

Gilissen 
J 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26386312?dopt=AbstractPlus

704 

Gillberg 
PG 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9671109?dopt=AbstractPlus

705 

Gingell 
JJ 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24169554?dopt=AbstractPlus

706 

Ginsburg-Shmuel 
T 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22901672?dopt=AbstractPlus

707 

Gironacci 
MM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21670420?dopt=AbstractPlus

708 

Gladue 
RP 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12909630?dopt=AbstractPlus

709 

Glaenzel 
U 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29735753?dopt=AbstractPlus

710 

Glennon 
RA 
. (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12825922?dopt=AbstractPlus

711 

Glennon 
RA 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10715164?dopt=AbstractPlus

712 

Glukhova 
A 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28235198?dopt=AbstractPlus

713 

Gobeil 
F 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8901831?dopt=AbstractPlus

714 

Gobeil 
F 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8735629?dopt=AbstractPlus

715 

Gobeil 
Jr
F 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24361511?dopt=AbstractPlus

716 

Goldring 
WP 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15922596?dopt=AbstractPlus

717 

Goldstein 
A 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2549383?dopt=AbstractPlus

718 

Gomes 
I 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24043826?dopt=AbstractPlus

719 

Gomes 
I 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27117253?dopt=AbstractPlus

720 

Gong 
X 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9115216?dopt=AbstractPlus

721 

Gonzalez-Cabrera 
PJ 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18708635?dopt=AbstractPlus

722 

González 
N 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19463875?dopt=AbstractPlus

723 

González 
N 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26066663?dopt=AbstractPlus

724 

Goodfellow 
NM 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22539842?dopt=AbstractPlus

725 

Goold 
CP 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11602681?dopt=AbstractPlus

726 

Gorojankina 
T 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23448715?dopt=AbstractPlus

727 

Gottlieb 
DJ 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17903308?dopt=AbstractPlus

728 

Gouardères 
C 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17011599?dopt=AbstractPlus

729 

Gouardères 
C 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12421602?dopt=AbstractPlus

730 

Gouardères 
C 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17337079?dopt=AbstractPlus

731 

Goudet 
C 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22223752?dopt=AbstractPlus

732 

Gougat 
J 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14747609?dopt=AbstractPlus

733 

Gouldson 
P 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10988332?dopt=AbstractPlus

734 

Gourlet 
P 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9437716?dopt=AbstractPlus

735 

Gourlet 
P 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9145428?dopt=AbstractPlus

736 

Graaf 
Cd 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27630114?dopt=AbstractPlus

737 

Grailhe 
R 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11343685?dopt=AbstractPlus

738 

Granas 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10513577?dopt=AbstractPlus

739 

Grant 
GE 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19450703?dopt=AbstractPlus

740 

Grant 
MK 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16002459?dopt=AbstractPlus

741 

Gravel 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20956518?dopt=AbstractPlus

742 

Greaves 
DR 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9294138?dopt=AbstractPlus

743 

Gregor 
P 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8641440?dopt=AbstractPlus

744 

Gregori-Puigjané 
E 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22711801?dopt=AbstractPlus

745 

Grieco 
P 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11150170?dopt=AbstractPlus

746 

Grieco 
P 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17482720?dopt=AbstractPlus

747 

Grieco 
P 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12238917?dopt=AbstractPlus

748 

Griffante 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16158071?dopt=AbstractPlus

749 

Grisshammer 
R 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7719707?dopt=AbstractPlus

750 

Gronert 
K 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11141472?dopt=AbstractPlus

751 

Grosse 
J 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25028498?dopt=AbstractPlus

752 

Grosse 
R 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10734055?dopt=AbstractPlus

753 

Groves 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23518370?dopt=AbstractPlus

754 

Groves 
A 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30255127?dopt=AbstractPlus

755 

Grundt 
P 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17095222?dopt=AbstractPlus

756 

Grundt 
P 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17672446?dopt=AbstractPlus

757 

Gründker 
C 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12237622?dopt=AbstractPlus

758 

Gu 
ZF 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7529309?dopt=AbstractPlus

759 

Guan 
XM 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20096642?dopt=AbstractPlus

760 

Guard 
S 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/1694464?dopt=AbstractPlus

761 

Guerrero 
M 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21570287?dopt=AbstractPlus

762 

Guerrero 
M 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/23762933?dopt=AbstractPlus

763 

Guerrero 
M 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/22834040?dopt=AbstractPlus

764 

Guerrini 
R 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9191955?dopt=AbstractPlus

765 

Guilford 
WJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15056011?dopt=AbstractPlus

766 

Gully 
D 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11907190?dopt=AbstractPlus

767 

Gully 
D 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9023294?dopt=AbstractPlus

768 

Guo 
D 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22324512?dopt=AbstractPlus

769 

Guo 
Y 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21712392?dopt=AbstractPlus

770 

Gupte 
J 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22575658?dopt=AbstractPlus

771 

Gurney 
A 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22753465?dopt=AbstractPlus

772 

Göblyös 
A 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16722654?dopt=AbstractPlus

773 

Günther 
T 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30232095?dopt=AbstractPlus

774 

Haas 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24970757?dopt=AbstractPlus

775 

Habasque 
C 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11994538?dopt=AbstractPlus

776 

Haffar 
BM 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1702423?dopt=AbstractPlus

777 

Haga 
K 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22278061?dopt=AbstractPlus

778 

Hagan 
RM 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8210508?dopt=AbstractPlus

779 

Hague 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14718583?dopt=AbstractPlus

780 

Haidar 
M 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28100033?dopt=AbstractPlus

781 

Hale 
JJ 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10737756?dopt=AbstractPlus

782 

Hale 
JJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9804700?dopt=AbstractPlus

783 

Hall 
DA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10188995?dopt=AbstractPlus

784 

Hall 
H 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11044889?dopt=AbstractPlus

785 

Halls 
ML 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25761609?dopt=AbstractPlus

786 

Halls 
ML 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15649866?dopt=AbstractPlus

787 

Halls 
ML 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17293890?dopt=AbstractPlus

788 

Hamann 
J 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25713288?dopt=AbstractPlus

789 

Hamann 
J 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/9064337?dopt=AbstractPlus

790 

Hamblin 
MW 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1652050?dopt=AbstractPlus

791 

Hameg 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12527336?dopt=AbstractPlus

792 

Han 
G 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10187777?dopt=AbstractPlus

793 

Han 
S 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26048791?dopt=AbstractPlus

794 

Hancock 
AA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15033391?dopt=AbstractPlus

795 

Hancock 
AA 

et al (1998 ) Drug Dev Res 
44 : 140 -162 

796 

Handa 
BK 

et al (1981 ) https://www.ncbi.nlm.nih.gov/pubmed/6263640?dopt=AbstractPlus

797 

Hanessian 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12502358?dopt=AbstractPlus

798 

Hannan 
FM 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27647839?dopt=AbstractPlus

799 

Hannedouche 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21796212?dopt=AbstractPlus

800 

Hannon 
J 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18571247?dopt=AbstractPlus

801 

Hansen 
AH 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30247908?dopt=AbstractPlus

802 

Hansen 
C 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19651774?dopt=AbstractPlus

803 

Hansen 
W 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20200545?dopt=AbstractPlus

804 

Hanson 
J 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23643932?dopt=AbstractPlus

805 

Hanson 
MA 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22344443?dopt=AbstractPlus

806 

Hanus 
L 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10588688?dopt=AbstractPlus

807 

Harada 
K 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17074317?dopt=AbstractPlus

808 

Haramura 
M 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11806718?dopt=AbstractPlus

809 

Harford-Wright 
E 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/29053791?dopt=AbstractPlus

810 

Harland 
SP 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8587429?dopt=AbstractPlus

811 

Harmar 
AJ 
. (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11790261?dopt=AbstractPlus

812 

Harmar 
AJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9647867?dopt=AbstractPlus

813 

Harmar 
AJ 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22289055?dopt=AbstractPlus

814 

Harrison 
GS 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15613448?dopt=AbstractPlus

815 

Harrison 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11708932?dopt=AbstractPlus

816 

Hartig 
PR 
. (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8936345?dopt=AbstractPlus

817 

Hase 
M 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18347022?dopt=AbstractPlus

818 

Hasegawa 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12554733?dopt=AbstractPlus

819 

Haskell 
CA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16221874?dopt=AbstractPlus

820 

Hastrup 
H 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8985159?dopt=AbstractPlus

821 

Hata 
AN 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12721327?dopt=AbstractPlus

822 

Hatae 
N 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17312275?dopt=AbstractPlus

823 

Haugaard-Kedström 
LM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21384867?dopt=AbstractPlus

824 

Hauger 
RL 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12615952?dopt=AbstractPlus

825 

Hawkins 
KN 

et al (1987 ) https://www.ncbi.nlm.nih.gov/pubmed/3030778?dopt=AbstractPlus

826 

Hay 
DL 
. (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29797087?dopt=AbstractPlus

827 

Hay 
DL 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15692146?dopt=AbstractPlus

828 

Hay 
DL 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16959943?dopt=AbstractPlus

829 

Hay 
DL 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12970090?dopt=AbstractPlus

830 

Hay 
DL 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18552275?dopt=AbstractPlus

831 

Hay 
DL 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21051558?dopt=AbstractPlus

832 

Hayallah 
AM 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11906291?dopt=AbstractPlus

833 

He 
HQ 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23160941?dopt=AbstractPlus

834 

He 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19696113?dopt=AbstractPlus

835 

He 
L 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10669572?dopt=AbstractPlus

836 

He 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20167483?dopt=AbstractPlus

837 

He 
S 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/24900499?dopt=AbstractPlus

838 

He 
W 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15141213?dopt=AbstractPlus

839 

Heasley 
BH 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15125924?dopt=AbstractPlus

840 

Hecht 
JH 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8922387?dopt=AbstractPlus

841 

Hegde 
SS 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9113359?dopt=AbstractPlus

842 

Hegde 
SS 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8903510?dopt=AbstractPlus

843 

Heier 
RF 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9057850?dopt=AbstractPlus

844 

Heise 
CE 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10851239?dopt=AbstractPlus

845 

Heise 
CE 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15761110?dopt=AbstractPlus

846 

Heise 
CE 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11723223?dopt=AbstractPlus

847 

Heitman 
LH 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19161279?dopt=AbstractPlus

848 

Heitman 
LH 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16444290?dopt=AbstractPlus

849 

Hellyer 
SD 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29514854?dopt=AbstractPlus

850 

Hemstapat 
K 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17416742?dopt=AbstractPlus

851 

Henke 
BR 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9276016?dopt=AbstractPlus

852 

Henstridge 
CM 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20136841?dopt=AbstractPlus

853 

Herbert 
JM 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8395255?dopt=AbstractPlus

854 

Herbert 
JM 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/15199474?dopt=AbstractPlus

855 

Hermans 
E 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9283723?dopt=AbstractPlus

856 

Hern 
JA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20133736?dopt=AbstractPlus

857 

Herr 
KJ 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21878565?dopt=AbstractPlus

858 

Herrick-Davis 
K 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10991983?dopt=AbstractPlus

859 

Herron 
DK 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1316967?dopt=AbstractPlus

860 

Hertzog 
DL 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16870432?dopt=AbstractPlus

861 

Hesselgesser 
J 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9551924?dopt=AbstractPlus

862 

Hesselgesser 
J 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9624164?dopt=AbstractPlus

863 

Hetherington 
SL 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15514209?dopt=AbstractPlus

864 

Heusler 
P 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20799027?dopt=AbstractPlus

865 

Heynen-Genel 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/22091481?dopt=AbstractPlus

866 

Hidaka 
K 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7777184?dopt=AbstractPlus

867 

Hieble 
JP 
. (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10812954?dopt=AbstractPlus

868 

Hieble 
JP 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7658428?dopt=AbstractPlus

869 

Hieble 
JP 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7568329?dopt=AbstractPlus

870 

Hilditch 
A 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7853190?dopt=AbstractPlus

871 

Hill 
SJ 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9311023?dopt=AbstractPlus

872 

Hillard 
CJ 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10336536?dopt=AbstractPlus

873 

Hillmann 
P 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19419204?dopt=AbstractPlus

874 

Hilton 
JM 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10856900?dopt=AbstractPlus

875 

Hinuma 
S 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11025660?dopt=AbstractPlus

876 

Hirasawa 
A 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15619630?dopt=AbstractPlus

877 

Hirata 
T 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21819041?dopt=AbstractPlus

878 

Hirose 
H 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11303071?dopt=AbstractPlus

879 

Hirose 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14643355?dopt=AbstractPlus

880 

Hirst 
RA 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8981483?dopt=AbstractPlus

881 

Hirst 
WD 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12663046?dopt=AbstractPlus

882 

Hirst 
WD 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17069795?dopt=AbstractPlus

883 

Hisatsune 
C 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17925404?dopt=AbstractPlus

884 

Hla 
T 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2160972?dopt=AbstractPlus

885 

Ho 
C 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7493018?dopt=AbstractPlus

886 

Hoare 
BL 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30594862?dopt=AbstractPlus

887 

Hoare 
SR 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10854439?dopt=AbstractPlus

888 

Hoare 
SR 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10882389?dopt=AbstractPlus

889 

Hobson 
AD 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26509640?dopt=AbstractPlus

890 

Hoch 
L 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25636740?dopt=AbstractPlus

891 

Hoffmann 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14730417?dopt=AbstractPlus

892 

Hoffmann 
SH 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10894158?dopt=AbstractPlus

893 

Holenz 
J 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15771424?dopt=AbstractPlus

894 

Hollenberg 
MD 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12037136?dopt=AbstractPlus

895 

Hollenberg 
MD 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18477767?dopt=AbstractPlus

896 

Holloway 
AC 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11901215?dopt=AbstractPlus

897 

Holst 
B 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12907757?dopt=AbstractPlus

898 

Holst 
B 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/16959833?dopt=AbstractPlus

899 

Holst 
B 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/18923064?dopt=AbstractPlus

900 

Holst 
B 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15383539?dopt=AbstractPlus

901 

Homey 
B 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10725697?dopt=AbstractPlus

902 

Honczarenko 
M 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15990859?dopt=AbstractPlus

903 

Hong 
Y 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21658025?dopt=AbstractPlus

904 

Horie 
K 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8564227?dopt=AbstractPlus

905 

Horwell 
DC 

et al (1995 ) Bioorg Med Chem Lett 
5 : 2501 -2506 

906 

Hosken 
IT 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25257104?dopt=AbstractPlus

907 

Hosoda 
H 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10801861?dopt=AbstractPlus

908 

Hosoi 
T 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12065583?dopt=AbstractPlus

909 

Hosoya 
M 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10777510?dopt=AbstractPlus

910 

Hosoya 
M 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10887190?dopt=AbstractPlus

911 

Hossain 
MA 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/30155023?dopt=AbstractPlus

912 

Hossain 
MA 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18434306?dopt=AbstractPlus

913 

Hossain 
MA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20043231?dopt=AbstractPlus

914 

Hoyer 
D 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7938165?dopt=AbstractPlus

915 

Hoyer 
D 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11888546?dopt=AbstractPlus

916 

Hoyer 
D 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15135911?dopt=AbstractPlus

917 

Hoyer 
D 

et al (2004 ) 
Soc Neuroscience Abs
  -
918 

Hsu 
SH 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17652154?dopt=AbstractPlus

919 

Hsu 
SY 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10935549?dopt=AbstractPlus

920 

Hsu 
SY 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11809971?dopt=AbstractPlus

921 

Hu 
MJ 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28274616?dopt=AbstractPlus

922 

Huang 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/12954603?dopt=AbstractPlus

923 

Huang 
F 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/12049493?dopt=AbstractPlus

924 

Huang 
P 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29804838?dopt=AbstractPlus

925 

Huang 
XP 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26550826?dopt=AbstractPlus

926 

Hudson 
BD 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24870406?dopt=AbstractPlus

927 

Hudson 
BD 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/23066016?dopt=AbstractPlus

928 

Huete-Toral 
F 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25344385?dopt=AbstractPlus

929 

Huey 
R 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/4020139?dopt=AbstractPlus

930 

Huffman 
JW 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10658595?dopt=AbstractPlus

931 

Hughes 
J 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/1975695?dopt=AbstractPlus

932 

Humphries 
RG 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7582510?dopt=AbstractPlus

933 

Humphries 
RG 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7858849?dopt=AbstractPlus

934 

Hunter 
JC 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2178014?dopt=AbstractPlus

935 

Hunter 
JC 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8474432?dopt=AbstractPlus

936 

Hutchinson 
DS 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11959793?dopt=AbstractPlus

937 

Hwang 
SB 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2841449?dopt=AbstractPlus

938 

Ichimura 
A 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22343897?dopt=AbstractPlus

939 

Ignatov 
A 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15111018?dopt=AbstractPlus

940 

Ignatov 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12574419?dopt=AbstractPlus

941 

Ignatov 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14592418?dopt=AbstractPlus

942 

Ignatov 
A 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17001303?dopt=AbstractPlus

943 

Ignatowska-Jankowska 
BM 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26052038?dopt=AbstractPlus

944 

Ihara 
M 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7768260?dopt=AbstractPlus

945 

Ikubo 
M 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25970039?dopt=AbstractPlus

946 

Im 
DS 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10799507?dopt=AbstractPlus

947 

Imai 
T 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9430724?dopt=AbstractPlus

948 

Inngjerdingen 
M 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11154210?dopt=AbstractPlus

949 

Inoue 
A 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22983457?dopt=AbstractPlus

950 

Iredale 
PA 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8032613?dopt=AbstractPlus

951 

Irukayama-Tomobe 
Y 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28507129?dopt=AbstractPlus

952 

Irwin 
DM 
. (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11179772?dopt=AbstractPlus

953 

Isberg 
V 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24826842?dopt=AbstractPlus

954 

Ishibashi 
T 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20404009?dopt=AbstractPlus

955 

Ishiwata 
K 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15093820?dopt=AbstractPlus

956 

Isogaya 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10531390?dopt=AbstractPlus

957 

Ito 
M 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8349705?dopt=AbstractPlus

958 

Itoh 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12629551?dopt=AbstractPlus

959 

Ivanov 
AA 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17088057?dopt=AbstractPlus

960 

Ivanov 
AA 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17302398?dopt=AbstractPlus

961 

Ivell 
R 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30204868?dopt=AbstractPlus

962 

Ivell 
R 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/20952422?dopt=AbstractPlus

963 

Iwamoto 
Y 

et al (1987 ) https://www.ncbi.nlm.nih.gov/pubmed/2437574?dopt=AbstractPlus

964 

Jaakola 
VP 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18832607?dopt=AbstractPlus

965 

Jackson 
RH 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1320692?dopt=AbstractPlus

966 

Jacobson 
KA 
. (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23597047?dopt=AbstractPlus

967 

Jacobson 
KA 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21484092?dopt=AbstractPlus

968 

Jacobson 
KA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16518376?dopt=AbstractPlus

969 

Jacobson 
KA 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/18600475?dopt=AbstractPlus

970 

Jacobson 
KA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12213051?dopt=AbstractPlus

971 

Jacobson 
KA 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9364471?dopt=AbstractPlus

972 

Jacobson 
MA 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7558011?dopt=AbstractPlus

973 

Jacobson 
SG 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18463160?dopt=AbstractPlus

974 

Jagerschmidt 
A 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8720482?dopt=AbstractPlus

975 

Jagoda 
EM 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12668051?dopt=AbstractPlus

976 

Jakubik 
J 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9224827?dopt=AbstractPlus

977 

Jakubik 
J 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16675658?dopt=AbstractPlus

978 

Jalan-Sakrikar 
N 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25225882?dopt=AbstractPlus

979 

Jane 
DE 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/9121605?dopt=AbstractPlus

980 

Jansen 
FP 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7834183?dopt=AbstractPlus

981 

Janssens 
R 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10401562?dopt=AbstractPlus

982 

January 
B 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9295336?dopt=AbstractPlus

983 

Jarvis 
MF 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2600819?dopt=AbstractPlus

984 

Jasper 
JR 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7475979?dopt=AbstractPlus

985 

Jasper 
JR 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9605427?dopt=AbstractPlus

986 

Jayasekara 
PS 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24712832?dopt=AbstractPlus

987 

Jenck 
F 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10758169?dopt=AbstractPlus

988 

Jenei 
V 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19901340?dopt=AbstractPlus

989 

Jenh 
CH 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10201891?dopt=AbstractPlus

990 

Jensen 
RT 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18055507?dopt=AbstractPlus

991 

Jensen 
RT 

et al (2013 ) In Handbook of Biologically Active Peptides . 2nd Revised edition  Edited by Kastin AJ  : Elsevier : 1188 -1196  [ISBN: 9780123850959]
992 

Jensen 
RT 

et al (2013 ) In Handbook of Biologically Active Peptides . 2nd Revised edition  Edited by Kastin AJ  : Elsevier : 506 -511  [ISBN: 9780123850959]
993 

Jensen 
T 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25442311?dopt=AbstractPlus

994 

Jerning 
E 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9851589?dopt=AbstractPlus

995 

Ji 
X 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11266650?dopt=AbstractPlus

996 

Ji 
XD 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10624567?dopt=AbstractPlus

997 

Jia 
XC 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1922095?dopt=AbstractPlus

998 

Jiang 
JL 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8917655?dopt=AbstractPlus

999 

Jiang 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12714592?dopt=AbstractPlus

1000 

Jiang 
Y 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29263243?dopt=AbstractPlus

1001 

Jimenez-Vargas 
NN 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30012612?dopt=AbstractPlus

1002 

Jin 
C 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18487371?dopt=AbstractPlus

1003 

Jinsmaa 
Y 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11179594?dopt=AbstractPlus

1004 

Jo 
E 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22971058?dopt=AbstractPlus

1005 

Jockers 
R 
. (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7798201?dopt=AbstractPlus

1006 

Johansson 
B 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7566470?dopt=AbstractPlus

1007 

Johansson 
L 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9336327?dopt=AbstractPlus

1008 

Johnson 
BG 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10530814?dopt=AbstractPlus

1009 

Johnson 
MP 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12852748?dopt=AbstractPlus

1010 

Johnson 
MP 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15717213?dopt=AbstractPlus

1011 

Jolkkonen 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7925952?dopt=AbstractPlus

1012 

Jones 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10422787?dopt=AbstractPlus

1013 

Jones 
CE 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus

1014 

Jones 
CK 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18842902?dopt=AbstractPlus

1015 

Jones 
KA 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9872315?dopt=AbstractPlus

1016 

Jones 
PG 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17363172?dopt=AbstractPlus

1017 

Jones 
RM 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10822054?dopt=AbstractPlus

1018 

Jonsson 
KB 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11159842?dopt=AbstractPlus

1019 

Jordan 
BA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10385123?dopt=AbstractPlus

1020 

Jorgensen 
R 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15528268?dopt=AbstractPlus

1021 

Joseph 
SS 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15060759?dopt=AbstractPlus

1022 

Joshi 
P 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24405707?dopt=AbstractPlus

1023 

Juarranz 
MG 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10570056?dopt=AbstractPlus

1024 

Jugus 
MJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19486006?dopt=AbstractPlus

1025 

Jung 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/8978752?dopt=AbstractPlus

1026 

Juteau 
H 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11504634?dopt=AbstractPlus

1027 

Kabarowski 
JH 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11474113?dopt=AbstractPlus

1028 

Kaku 
K 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25787200?dopt=AbstractPlus

1029 

Kalant 
D 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12540846?dopt=AbstractPlus

1030 

Kalant 
D 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15833747?dopt=AbstractPlus

1031 

Kalinichev 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23257312?dopt=AbstractPlus

1032 

Kalipatnapu 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15628665?dopt=AbstractPlus

1033 

Kalk 
P 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17558436?dopt=AbstractPlus

1034 

Kamali 
F 
. (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11757797?dopt=AbstractPlus

1035 

Kamohara 
M 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15823563?dopt=AbstractPlus

1036 

Kanaoka 
Y 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23504326?dopt=AbstractPlus

1037 

Kanatani 
A 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10872822?dopt=AbstractPlus

1038 

Kanesaka 
M 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17486669?dopt=AbstractPlus

1039 

Kania 
A 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28098344?dopt=AbstractPlus

1040 

Kanke 
T 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15765104?dopt=AbstractPlus

1041 

Kapas 
S 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7592696?dopt=AbstractPlus

1042 

Kapur 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19723626?dopt=AbstractPlus

1043 

Karamitri 
A 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30531911?dopt=AbstractPlus

1044 

Kargl 
J 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23639801?dopt=AbstractPlus

1045 

Karnik 
SS 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26315714?dopt=AbstractPlus

1046 

Karteris 
E 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15687100?dopt=AbstractPlus

1047 

Katafuchi 
T 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12556539?dopt=AbstractPlus

1048 

Kathmann 
M 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16489449?dopt=AbstractPlus

1049 

Kato 
K 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15695169?dopt=AbstractPlus

1050 

Katugampola 
SD 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11250876?dopt=AbstractPlus

1051 

Katugampola 
SD 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11522606?dopt=AbstractPlus

1052 

Kaupmann 
K 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9069281?dopt=AbstractPlus

1053 

Kawabata 
A 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9862790?dopt=AbstractPlus

1054 

Kawai 
M 
. (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1732540?dopt=AbstractPlus

1055 

Kawamata 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12524422?dopt=AbstractPlus

1056 

Kawamata 
Y 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11336787?dopt=AbstractPlus

1057 

Kawamoto 
H 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10602690?dopt=AbstractPlus

1058 

Kawamoto 
Y 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29208511?dopt=AbstractPlus

1059 

Kazda 
CM 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26681715?dopt=AbstractPlus

1060 

Keir 
MJ 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10521582?dopt=AbstractPlus

1061 

Kelly 
E 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/24973897?dopt=AbstractPlus

1062 

Kelly 
LM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21844396?dopt=AbstractPlus

1063 

Kelly 
RP 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25656305?dopt=AbstractPlus

1064 

Kemp 
PA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15231488?dopt=AbstractPlus

1065 

Kennedy 
AJ 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29279348?dopt=AbstractPlus

1066 

Kennedy 
AJ 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27742615?dopt=AbstractPlus

1067 

Kennedy 
C 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10779375?dopt=AbstractPlus

1068 

Kennedy 
K 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7654246?dopt=AbstractPlus

1069 

Kennedy 
PC 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21632869?dopt=AbstractPlus

1070 

Kennedy 
SP 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9535752?dopt=AbstractPlus

1071 

Kennett 
GA 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9225286?dopt=AbstractPlus

1072 

Kerkhof 
HJ 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20112360?dopt=AbstractPlus

1073 

Khanolkar 
AD 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8893848?dopt=AbstractPlus

1074 

Khattar 
SK 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16369696?dopt=AbstractPlus

1075 

Khawaja 
X 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9048968?dopt=AbstractPlus

1076 

Khroyan 
TV 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21177476?dopt=AbstractPlus

1077 

Khusal 
KG 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25324134?dopt=AbstractPlus

1078 

Kiefer 
L 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21406038?dopt=AbstractPlus

1079 

Kiesel 
LA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12072036?dopt=AbstractPlus

1080 

Kihara 
Y 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24602016?dopt=AbstractPlus

1081 

Kikuchi 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19208479?dopt=AbstractPlus

1082 

Kikuchi 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10052959?dopt=AbstractPlus

1083 

Kilander 
MB 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24873871?dopt=AbstractPlus

1084 

Kim 
GH 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17476309?dopt=AbstractPlus

1085 

Kim 
HO 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7932588?dopt=AbstractPlus

1086 

Kim 
HS 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14584948?dopt=AbstractPlus

1087 

Kim 
HS 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11754592?dopt=AbstractPlus

1088 

Kim 
J 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7775460?dopt=AbstractPlus

1089 

Kim 
SV 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23661644?dopt=AbstractPlus

1090 

Kim 
TH 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23721409?dopt=AbstractPlus

1091 

Kim 
Y 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23541835?dopt=AbstractPlus

1092 

Kim 
YC 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10737749?dopt=AbstractPlus

1093 

Kim 
YC 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8863790?dopt=AbstractPlus

1094 

Kim 
YC 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15913566?dopt=AbstractPlus

1095 

Kimura 
I 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21518883?dopt=AbstractPlus

1096 

Kimura 
T 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7921228?dopt=AbstractPlus

1097 

Kimura 
Y 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14709324?dopt=AbstractPlus

1098 

Kinghorn 
AD 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21650152?dopt=AbstractPlus

1099 

Kingston 
AE 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9680254?dopt=AbstractPlus

1100 

Kinney 
GG 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15608073?dopt=AbstractPlus

1101 

Kinney 
WA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12203418?dopt=AbstractPlus

1102 

Kirby 
HR 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21079036?dopt=AbstractPlus

1103 

Kirihara 
T 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29332128?dopt=AbstractPlus

1104 

Kiselev 
E 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26303895?dopt=AbstractPlus

1105 

Kiselev 
E 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25299434?dopt=AbstractPlus

1106 

Kiss 
GN 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22968304?dopt=AbstractPlus

1107 

Kitamura 
H 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22343749?dopt=AbstractPlus

1108 

Kitaura 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10488147?dopt=AbstractPlus

1109 

Kitbunnadaj 
R 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15771452?dopt=AbstractPlus

1110 

Kitbunnadaj 
R 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15115383?dopt=AbstractPlus

1111 

Kittaka 
H 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28176353?dopt=AbstractPlus

1112 

Klein 
J 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9175608?dopt=AbstractPlus

1113 

Klein 
MT 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21422162?dopt=AbstractPlus

1114 

Klos 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23383423?dopt=AbstractPlus

1115 

Klotz 
K‐N 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9459566?dopt=AbstractPlus

1116 

Knepper 
SM 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7616455?dopt=AbstractPlus

1117 

Knight 
AR 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15322733?dopt=AbstractPlus

1118 

Knoflach 
F 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11606768?dopt=AbstractPlus

1119 

Knudsen 
LB 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10794683?dopt=AbstractPlus

1120 

Kobayashi 
T 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20580563?dopt=AbstractPlus

1121 

Kobilka 
B 
. (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23650120?dopt=AbstractPlus

1122 

Koe 
BK 

et al (1992 ) Drug Dev Res 
26 : 241250 

1123 

Koga 
H 

et al (1994 ) Bioorg Med Chem Lett 
4 : 1347 -1352 

1124 

Kogushi 
M 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21300059?dopt=AbstractPlus

1125 

Kohara 
A 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15976016?dopt=AbstractPlus

1126 

Kohno 
M 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16844083?dopt=AbstractPlus

1127 

Koike 
H 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11451212?dopt=AbstractPlus

1128 

Kojima 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10604470?dopt=AbstractPlus

1129 

Kolakowski 
Jr
LF 
. (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8081729?dopt=AbstractPlus

1130 

Kolczewski 
S 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10465539?dopt=AbstractPlus

1131 

Kongsamut 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12176106?dopt=AbstractPlus

1132 

Konkel 
MJ 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16789730?dopt=AbstractPlus

1133 

Konkel 
MJ 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16730981?dopt=AbstractPlus

1134 

Kono 
M 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/29079828?dopt=AbstractPlus

1135 

Kono 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24667638?dopt=AbstractPlus

1136 

Konteatis 
ZD 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7930622?dopt=AbstractPlus

1137 

Koo 
C 

et al (1982 ) https://www.ncbi.nlm.nih.gov/pubmed/6285921?dopt=AbstractPlus

1138 

Kopanchuk 
S 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15840392?dopt=AbstractPlus

1139 

Kopin 
AS 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1373504?dopt=AbstractPlus

1140 

Korstanje 
R 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18796533?dopt=AbstractPlus

1141 

Kortagere 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15448188?dopt=AbstractPlus

1142 

Kotani 
M 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11457843?dopt=AbstractPlus

1143 

Kotani 
M 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7476918?dopt=AbstractPlus

1144 

Kotarsky 
K 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12565875?dopt=AbstractPlus

1145 

Kottyan 
LC 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19641187?dopt=AbstractPlus

1146 

Kovacs 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/15107597?dopt=AbstractPlus

1147 

Kovacs 
I 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9454790?dopt=AbstractPlus

1148 

Kozian 
DH 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22801643?dopt=AbstractPlus

1149 

Kraus 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19072936?dopt=AbstractPlus

1150 

Krause 
JE 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/8990205?dopt=AbstractPlus

1151 

Krauss 
AH 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8882612?dopt=AbstractPlus

1152 

Krishnamoorthy 
S 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22449948?dopt=AbstractPlus

1153 

Krishnamoorthy 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20080636?dopt=AbstractPlus

1154 

Kritikou 
E 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27883026?dopt=AbstractPlus

1155 

Kroeger 
KM 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11278883?dopt=AbstractPlus

1156 

Kroeze 
WK 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12629531?dopt=AbstractPlus

1157 

Krsmanovic 
LZ 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12591945?dopt=AbstractPlus

1158 

Kruse 
AC 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24256733?dopt=AbstractPlus

1159 

Krushinski 
Jr
JH 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17804228?dopt=AbstractPlus

1160 

Ku 
GM 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22253604?dopt=AbstractPlus

1161 

Kubo 
Y 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15922585?dopt=AbstractPlus

1162 

Kuc 
D 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18235993?dopt=AbstractPlus

1163 

Kuc 
RE 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8587419?dopt=AbstractPlus

1164 

Kuc 
RE 

et al (2006 ) Proceedings ofthe British Pharmacological Society 
4 : abst186 

1165 

Kuei 
C 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17606621?dopt=AbstractPlus

1166 

Kukkonen 
JP 
. (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23034387?dopt=AbstractPlus

1167 

Kukkonen 
JP 
. (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27237973?dopt=AbstractPlus

1168 

Kukkonen 
JP 
. (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26582739?dopt=AbstractPlus

1169 

Kukkonen 
JP 
. (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/27909990?dopt=AbstractPlus

1170 

Kukkonen 
JP 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/23902572?dopt=AbstractPlus

1171 

Kulagowski 
JJ 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8642550?dopt=AbstractPlus

1172 

Kulkarni 
PM 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26529344?dopt=AbstractPlus

1173 

Kull 
B 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9920286?dopt=AbstractPlus

1174 

Kumagai 
J 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12114498?dopt=AbstractPlus

1175 

Kumar 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12604693?dopt=AbstractPlus

1176 

Kumar 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19786130?dopt=AbstractPlus

1177 

Kunishima 
N 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11069170?dopt=AbstractPlus

1178 

Kuphal 
D 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8013367?dopt=AbstractPlus

1179 

Kursar 
JD 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8078486?dopt=AbstractPlus

1180 

Kuszak 
AJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19542234?dopt=AbstractPlus

1181 

Kuwano 
K 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17545310?dopt=AbstractPlus

1182 

Kuwasako 
K 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14722252?dopt=AbstractPlus

1183 

Kuwasako 
K 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12565884?dopt=AbstractPlus

1184 

Köhler 
C 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/4015674?dopt=AbstractPlus

1185 

Kühn 
B 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8961278?dopt=AbstractPlus

1186 

Laas 
K 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/23325374?dopt=AbstractPlus

1187 

Labarrere 
P 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12943190?dopt=AbstractPlus

1188 

Labbé-Jullié 
C 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7746272?dopt=AbstractPlus

1189 

Laeremans 
H 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21931076?dopt=AbstractPlus

1190 

Lagerström 
MC 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15885496?dopt=AbstractPlus

1191 

Lahti 
RA 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8102973?dopt=AbstractPlus

1192 

Lahti 
RA 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/2986999?dopt=AbstractPlus

1193 

Laitinen 
T 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15073379?dopt=AbstractPlus

1194 

Lameh 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20354177?dopt=AbstractPlus

1195 

Lan 
R 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/11741201?dopt=AbstractPlus

1196 

Lan 
R 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10052983?dopt=AbstractPlus

1197 

Lang 
R 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15944009?dopt=AbstractPlus

1198 

Langmead 
CJ 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18454168?dopt=AbstractPlus

1199 

Langmead 
CJ 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16207821?dopt=AbstractPlus

1200 

Langmead 
CJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14691055?dopt=AbstractPlus

1201 

Langmead 
CJ 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11030716?dopt=AbstractPlus

1202 

Lansu 
K 
. (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28288109?dopt=AbstractPlus

1203 

Lappano 
R 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/28249728?dopt=AbstractPlus

1204 

Laprairie 
RB 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26218440?dopt=AbstractPlus

1205 

Laprairie 
RB 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28103441?dopt=AbstractPlus

1206 

Lau 
J 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26308095?dopt=AbstractPlus

1207 

Lau 
OC 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24511227?dopt=AbstractPlus

1208 

Lautner 
RQ 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23446738?dopt=AbstractPlus

1209 

Lavreysen 
H 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12695537?dopt=AbstractPlus

1210 

Lavreysen 
H 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15555631?dopt=AbstractPlus

1211 

Lawrence 
AJ 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12110614?dopt=AbstractPlus

1212 

Lazareno 
S 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7651370?dopt=AbstractPlus

1213 

Lazareno 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14722259?dopt=AbstractPlus

1214 

Lazareno 
S 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9495826?dopt=AbstractPlus

1215 

Lazareno 
S 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10860942?dopt=AbstractPlus

1216 

Lazareno 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12435818?dopt=AbstractPlus

1217 

Lazarowski 
ER 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8564228?dopt=AbstractPlus

1218 

Lazarowski 
ER 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8825364?dopt=AbstractPlus

1219 

Le Bourdonnec 
B 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18313920?dopt=AbstractPlus

1220 

Le Bourdonnec 
B 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18788723?dopt=AbstractPlus

1221 

Le Bourdonnec 
B 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19694468?dopt=AbstractPlus

1222 

Le 
MT 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12006574?dopt=AbstractPlus

1223 

Le Poul 
E 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12711604?dopt=AbstractPlus

1224 

Le 
Y 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12401407?dopt=AbstractPlus

1225 

Leach 
K 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21300722?dopt=AbstractPlus

1226 

Leach 
K 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27002221?dopt=AbstractPlus

1227 

Leach 
K 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19940843?dopt=AbstractPlus

1228 

Leach 
K 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24111791?dopt=AbstractPlus

1229 

Leach 
K 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23372019?dopt=AbstractPlus

1230 

Leaños-Miranda 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12843188?dopt=AbstractPlus

1231 

Leban 
JJ 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8446610?dopt=AbstractPlus

1232 

Lebon 
G 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25762024?dopt=AbstractPlus

1233 

Lebon 
G 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21593763?dopt=AbstractPlus

1234 

Ledent 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15956199?dopt=AbstractPlus

1235 

Leduc 
M 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19584306?dopt=AbstractPlus

1236 

Lee 
C 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21124972?dopt=AbstractPlus

1237 

Lee 
DK 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11574155?dopt=AbstractPlus

1238 

Lee 
DK 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15486224?dopt=AbstractPlus

1239 

Lee 
J 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1379593?dopt=AbstractPlus

1240 

Lee 
JW 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27759003?dopt=AbstractPlus

1241 

Lee 
MC 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18179608?dopt=AbstractPlus

1242 

Lee 
YM 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7681836?dopt=AbstractPlus

1243 

Leeb-Lundberg 
LM 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15734727?dopt=AbstractPlus

1244 

Lefkowitz 
RJ 
. (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23650015?dopt=AbstractPlus

1245 

Legros 
C 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23698757?dopt=AbstractPlus

1246 

Lehmann 
F 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19481466?dopt=AbstractPlus

1247 

Lehmann 
F 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15781415?dopt=AbstractPlus

1248 

Lehmann 
F 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17112638?dopt=AbstractPlus

1249 

Leibowitz 
SF 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1283559?dopt=AbstractPlus

1250 

Leja 
J 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/18953328?dopt=AbstractPlus

1251 

Lejeune 
F 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9067310?dopt=AbstractPlus

1252 

Lelianova 
VG 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9261169?dopt=AbstractPlus

1253 

Lembo 
PM 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11850634?dopt=AbstractPlus

1254 

Lennertz 
L 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22078257?dopt=AbstractPlus

1255 

Leonard 
CS 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/23848055?dopt=AbstractPlus

1256 

Leonardi 
A 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9190863?dopt=AbstractPlus

1257 

Leopoldo 
M 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17649988?dopt=AbstractPlus

1258 

Leopoldo 
M 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18800769?dopt=AbstractPlus

1259 

Leprince 
J 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28613414?dopt=AbstractPlus

1260 

Lesage 
AS 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9605573?dopt=AbstractPlus

1261 

Leung 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18755178?dopt=AbstractPlus

1262 

Leurs 
R 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7921611?dopt=AbstractPlus

1263 

Leuthauser 
K 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11023820?dopt=AbstractPlus

1264 

Lever 
JR 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9696425?dopt=AbstractPlus

1265 

Levoye 
A 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16778767?dopt=AbstractPlus

1266 

Lewis 
TA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15482930?dopt=AbstractPlus

1267 

Leysen 
JE 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8967979?dopt=AbstractPlus

1268 

Li 
AH 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9703464?dopt=AbstractPlus

1269 

Li 
JJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15027861?dopt=AbstractPlus

1270 

Li 
L 

et al (2002 ) Neuropharmacology 
43 : 295 

1271 

Li 
R 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23239822?dopt=AbstractPlus

1272 

Li 
X 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12013525?dopt=AbstractPlus

1273 

Liang 
BT 


Urso 
R 


Sambraski 
E 

et al (2010 ) In Adenosine Receptors from Cell Biology to Pharmacology  Edited by Borea P  : Springer : 257 -280  [ISBN: 9789048131440]
1274 

Liang 
M 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10748002?dopt=AbstractPlus

1275 

Liang 
TS 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11714831?dopt=AbstractPlus

1276 

Liaw 
CW 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19630535?dopt=AbstractPlus

1277 

Liebscher 
I 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21097509?dopt=AbstractPlus

1278 

Liebscher 
I 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25533341?dopt=AbstractPlus

1279 

Liggett 
SB 
. (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/15090197?dopt=AbstractPlus

1280 

Ligneau 
X 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11090094?dopt=AbstractPlus

1281 

Liljebris 
C 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7830272?dopt=AbstractPlus

1282 

Lim 
HD 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17154494?dopt=AbstractPlus

1283 

Lim 
HD 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15947036?dopt=AbstractPlus

1284 

Limonta 
P 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14726258?dopt=AbstractPlus

1285 

Lin 
DC 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11886876?dopt=AbstractPlus

1286 

Lin 
DC 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22859723?dopt=AbstractPlus

1287 

Lin 
L 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10458611?dopt=AbstractPlus

1288 

Lin 
Q 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9890897?dopt=AbstractPlus

1289 

Linden 
J 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10496952?dopt=AbstractPlus

1290 

Lindsley 
CW 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15537338?dopt=AbstractPlus

1291 

Lindström 
E 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10385255?dopt=AbstractPlus

1292 

Linz 
K 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24713140?dopt=AbstractPlus

1293 

Litschig 
S 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10051528?dopt=AbstractPlus

1294 

Liu 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15465925?dopt=AbstractPlus

1295 

Liu 
C 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14522967?dopt=AbstractPlus

1296 

Liu 
C 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14522968?dopt=AbstractPlus

1297 

Liu 
C 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22434674?dopt=AbstractPlus

1298 

Liu 
C 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11179434?dopt=AbstractPlus

1299 

Liu 
C 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11561071?dopt=AbstractPlus

1300 

Liu 
C 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19047060?dopt=AbstractPlus

1301 

Liu 
C 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21796211?dopt=AbstractPlus

1302 

Liu 
JJ 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22267580?dopt=AbstractPlus

1303 

Liu 
JJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19369576?dopt=AbstractPlus

1304 

Liu 
Q 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10581185?dopt=AbstractPlus

1305 

Liu 
Q 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/20004959?dopt=AbstractPlus

1306 

Liu 
S 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9822540?dopt=AbstractPlus

1307 

Liu 
W 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22798613?dopt=AbstractPlus

1308 

Llinares 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10231715?dopt=AbstractPlus

1309 

Lobo 
MK 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17934457?dopt=AbstractPlus

1310 

Loetscher 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8276799?dopt=AbstractPlus

1311 

Loetscher 
P 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9712844?dopt=AbstractPlus

1312 

Logue 
SF 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19796684?dopt=AbstractPlus

1313 

Londregan 
AT 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23337601?dopt=AbstractPlus

1314 

Long 
DD 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22959244?dopt=AbstractPlus

1315 

Longrois 
D 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22342278?dopt=AbstractPlus

1316 

Lopez 
VM 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18828673?dopt=AbstractPlus

1317 

Lopez-Gimenez 
JF 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11562430?dopt=AbstractPlus

1318 

Lorenzen 
A 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8937447?dopt=AbstractPlus

1319 

Louis 
SN 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10079020?dopt=AbstractPlus

1320 

Lovenberg 
TW 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10869375?dopt=AbstractPlus

1321 

Lu 
X 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15944007?dopt=AbstractPlus

1322 

Lu 
X 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20660766?dopt=AbstractPlus

1323 

Lu 
ZL 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17452338?dopt=AbstractPlus

1324 

Lucchelli 
A 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9283717?dopt=AbstractPlus

1325 

Luchetti 
G 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27705744?dopt=AbstractPlus

1326 

Lumley 
P 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2527074?dopt=AbstractPlus

1327 

Lundell 
I 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7493937?dopt=AbstractPlus

1328 

Lundkvist 
J 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8874139?dopt=AbstractPlus

1329 

Luo 
J 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19605502?dopt=AbstractPlus

1330 

Luo 
R 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21768377?dopt=AbstractPlus

1331 

Luo 
X 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25514935?dopt=AbstractPlus

1332 

Luttrell 
LM 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20427692?dopt=AbstractPlus

1333 

Lynch 
KR 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10391245?dopt=AbstractPlus

1334 

Lüttichau 
HR 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20044480?dopt=AbstractPlus

1335 

Lüttichau 
HR 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12554737?dopt=AbstractPlus

1336 

Ma 
L 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19717450?dopt=AbstractPlus

1337 

Ma 
L 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26808470?dopt=AbstractPlus

1338 

Macaluso 
NJ 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21560248?dopt=AbstractPlus

1339 

MacDonald 
E 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9227000?dopt=AbstractPlus

1340 

Machwate 
M 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11408598?dopt=AbstractPlus

1341 

MacKenzie 
RG 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7907989?dopt=AbstractPlus

1342 

MacLennan 
SJ 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9283709?dopt=AbstractPlus

1343 

Maddox 
JF 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8551217?dopt=AbstractPlus

1344 

Madsen 
K 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21831646?dopt=AbstractPlus

1345 

Madsen 
P 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9857085?dopt=AbstractPlus

1346 

Madsen 
U 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15996690?dopt=AbstractPlus

1347 

Maeda 
DY 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25254640?dopt=AbstractPlus

1348 

Maeda 
K 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16476734?dopt=AbstractPlus

1349 

Maeda 
K 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11454872?dopt=AbstractPlus

1350 

Maekawa 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19561298?dopt=AbstractPlus

1351 

Maggio 
R 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7805774?dopt=AbstractPlus

1352 

Maggiolini 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15090535?dopt=AbstractPlus

1353 

Maguire 
JJ 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7647976?dopt=AbstractPlus

1354 

Maguire 
JJ 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11015293?dopt=AbstractPlus

1355 

Maguire 
JJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19325074?dopt=AbstractPlus

1356 

Maier 
DL 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19401496?dopt=AbstractPlus

1357 

Maiti 
K 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14651258?dopt=AbstractPlus

1358 

Maj 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14573382?dopt=AbstractPlus

1359 

Majumdar 
ID 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21042212?dopt=AbstractPlus

1360 

Majumdar 
ID 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22157398?dopt=AbstractPlus

1361 

Majumdar 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21621410?dopt=AbstractPlus

1362 

Malgouris 
C 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8472747?dopt=AbstractPlus

1363 

Malherbe 
P 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19751316?dopt=AbstractPlus

1364 

Malherbe 
P 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19542319?dopt=AbstractPlus

1365 

Malherbe 
P 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10216218?dopt=AbstractPlus

1366 

Malherbe 
P 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18536733?dopt=AbstractPlus

1367 

Malherbe 
P 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20404073?dopt=AbstractPlus

1368 

Mallee 
JJ 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11847213?dopt=AbstractPlus

1369 

Mamedova 
LK 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15081875?dopt=AbstractPlus

1370 

Mamillapalli 
R 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20032198?dopt=AbstractPlus

1371 

Mandala 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11923495?dopt=AbstractPlus

1372 

Manglik 
A 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25981665?dopt=AbstractPlus

1373 

Mannaioni 
G 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10428410?dopt=AbstractPlus

1374 

Manning 
DR 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26179037?dopt=AbstractPlus

1375 

Mantey 
S 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7684815?dopt=AbstractPlus

1376 

Mantey 
SA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15102928?dopt=AbstractPlus

1377 

Mantey 
SA 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9325344?dopt=AbstractPlus

1378 

Marathe 
GK 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10497200?dopt=AbstractPlus

1379 

Maravillas-Montero 
JL 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25411203?dopt=AbstractPlus

1380 

Marazziti 
D 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19398891?dopt=AbstractPlus

1381 

Marazziti 
D 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21372109?dopt=AbstractPlus

1382 

Marazziti 
D 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17519329?dopt=AbstractPlus

1383 

Marchingo 
AJ 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2964362?dopt=AbstractPlus

1384 

Marin 
P 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21777185?dopt=AbstractPlus

1385 

Marlo 
JE 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19047481?dopt=AbstractPlus

1386 

Marteau 
F 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12815166?dopt=AbstractPlus

1387 

Martin 
PL 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8632314?dopt=AbstractPlus

1388 

Martin 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12360476?dopt=AbstractPlus

1389 

Maruoka 
H 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20446735?dopt=AbstractPlus

1390 

Maruoka 
H 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21528910?dopt=AbstractPlus

1391 

Maruyama 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11454473?dopt=AbstractPlus

1392 

Maruyama 
T 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12419312?dopt=AbstractPlus

1393 

Masuda 
Y 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12054613?dopt=AbstractPlus

1394 

Mathiesen 
JM 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16418339?dopt=AbstractPlus

1395 

Mathiesen 
JM 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12684257?dopt=AbstractPlus

1396 

Mathieu 
MC 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16154494?dopt=AbstractPlus

1397 

Matsufuji 
T 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25497965?dopt=AbstractPlus

1398 

Matsufuji 
T 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24412111?dopt=AbstractPlus

1399 

Matsumoto 
M 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11549267?dopt=AbstractPlus

1400 

Matsuura 
B 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15677347?dopt=AbstractPlus

1401 

Matsuura 
B 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11781320?dopt=AbstractPlus

1402 

Matsuura 
B 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16531413?dopt=AbstractPlus

1403 

Matteson 
PG 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18250320?dopt=AbstractPlus

1404 

Matthes 
H 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8450829?dopt=AbstractPlus

1405 

Mattsson 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16055331?dopt=AbstractPlus

1406 

Matuszek 
MA 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9718274?dopt=AbstractPlus

1407 

Maudsley 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15492280?dopt=AbstractPlus

1408 

May 
LT 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17525129?dopt=AbstractPlus

1409 

Mayeux 
PR 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1830308?dopt=AbstractPlus

1410 

Mayo 
KE 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12615957?dopt=AbstractPlus

1411 

Mazella 
J 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8795617?dopt=AbstractPlus

1412 

Maïga 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23935897?dopt=AbstractPlus

1413 

McAllister 
G 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1608964?dopt=AbstractPlus

1414 

McAtee 
LC 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15261275?dopt=AbstractPlus

1415 

McCall 
RB 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15980060?dopt=AbstractPlus

1416 

McCall 
RB 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7965808?dopt=AbstractPlus

1417 

McClellan 
KJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9878991?dopt=AbstractPlus

1418 

McDonald 
J 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12967935?dopt=AbstractPlus

1419 

McGuire 
JJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14976230?dopt=AbstractPlus

1420 

McHugh 
D 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20346144?dopt=AbstractPlus

1421 

McHugh 
D 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16207832?dopt=AbstractPlus

1422 

McHugh 
D 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21595653?dopt=AbstractPlus

1423 

McKeage 
K 
. (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25859983?dopt=AbstractPlus

1424 

McKee 
KK 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9441746?dopt=AbstractPlus

1425 

McKinnell 
RM 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23756062?dopt=AbstractPlus

1426 

McLatchie 
LM 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9620797?dopt=AbstractPlus

1427 

Mead 
EJ 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17023533?dopt=AbstractPlus

1428 

Medhurst 
AD 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12603839?dopt=AbstractPlus

1429 

Meena 
CL 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26854379?dopt=AbstractPlus

1430 

Meis 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19815812?dopt=AbstractPlus

1431 

Mejean 
A 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8719421?dopt=AbstractPlus

1432 

Meng 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18358099?dopt=AbstractPlus

1433 

Methven 
L 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19572943?dopt=AbstractPlus

1434 

Methven 
L 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19888965?dopt=AbstractPlus

1435 

Metra 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23273292?dopt=AbstractPlus

1436 

Meyer 
MD 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9379432?dopt=AbstractPlus

1437 

Meyer 
MR 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/28343901?dopt=AbstractPlus

1438 

Meyer 
RC 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23690594?dopt=AbstractPlus

1439 

Meyerhof 
W 
. (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9600011?dopt=AbstractPlus

1440 

Mialet 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10683202?dopt=AbstractPlus

1441 

Mialet 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11030734?dopt=AbstractPlus

1442 

Mialet 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10821780?dopt=AbstractPlus

1443 

Michel 
AD 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/1970500?dopt=AbstractPlus

1444 

Michel 
MC 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9549761?dopt=AbstractPlus

1445 

Middlemiss 
DN 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10443589?dopt=AbstractPlus

1446 

Mierau 
J 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7664822?dopt=AbstractPlus

1447 

Migeotte 
I 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15623572?dopt=AbstractPlus

1448 

Millan 
MJ 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7988633?dopt=AbstractPlus

1449 

Millan 
MJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9732398?dopt=AbstractPlus

1450 

Millan 
MJ 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10869410?dopt=AbstractPlus

1451 

Millan 
MJ 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12388666?dopt=AbstractPlus

1452 

Millan 
MJ 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10611634?dopt=AbstractPlus

1453 

Millan 
MJ 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7473180?dopt=AbstractPlus

1454 

Millar 
R 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11493674?dopt=AbstractPlus

1455 

Millar 
RP 
. (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16140177?dopt=AbstractPlus

1456 

Millar 
RP 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15082521?dopt=AbstractPlus

1457 

Miller 
BE 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26092545?dopt=AbstractPlus

1458 

Minamino 
N 

et al (1985 ) https://www.ncbi.nlm.nih.gov/pubmed/3839674?dopt=AbstractPlus

1459 

Minneman 
KP 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7969082?dopt=AbstractPlus

1460 

Miranda 
LP 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18412318?dopt=AbstractPlus

1461 

Mirzadegan 
T 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10770925?dopt=AbstractPlus

1462 

Mitselos 
A 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17074305?dopt=AbstractPlus

1463 

Mitsukawa 
K 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16339898?dopt=AbstractPlus

1464 

Miura 
S 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10066768?dopt=AbstractPlus

1465 

Mizuguchi 
T 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9113361?dopt=AbstractPlus

1466 

Mizuno 
H 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30463988?dopt=AbstractPlus

1467 

Moeller 
I 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9166749?dopt=AbstractPlus

1468 

Mogha 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24227709?dopt=AbstractPlus

1469 

Moguilevsky 
N 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7925364?dopt=AbstractPlus

1470 

Mohr 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15163212?dopt=AbstractPlus

1471 

Molenaar 
P 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1472961?dopt=AbstractPlus

1472 

Molenaar 
P 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9117106?dopt=AbstractPlus

1473 

Molinari 
EJ 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8773460?dopt=AbstractPlus

1474 

Mollay 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10422759?dopt=AbstractPlus

1475 

Mollereau 
C 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11325787?dopt=AbstractPlus

1476 

Mollereau 
C 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12242085?dopt=AbstractPlus

1477 

Mollereau 
C 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8849681?dopt=AbstractPlus

1478 

Mollereau 
C 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8137918?dopt=AbstractPlus

1479 

Mombaerts 
P 
. (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15034552?dopt=AbstractPlus

1480 

Monczor 
F 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12869657?dopt=AbstractPlus

1481 

Monk 
KR 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19745155?dopt=AbstractPlus

1482 

Monn 
JA 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25602126?dopt=AbstractPlus

1483 

Monn 
JA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10090786?dopt=AbstractPlus

1484 

Monneret 
G 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12490611?dopt=AbstractPlus

1485 

Monnier 
C 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21063387?dopt=AbstractPlus

1486 

Montrose-Rafizadeh 
C 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9261127?dopt=AbstractPlus

1487 

Moody 
TW 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11931347?dopt=AbstractPlus

1488 

Moody 
TW 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25554218?dopt=AbstractPlus

1489 

Moody 
TW 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15134870?dopt=AbstractPlus

1490 

Moore 
K 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19723586?dopt=AbstractPlus

1491 

Moreland 
RB 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16153699?dopt=AbstractPlus

1492 

Moreno 
D 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11068102?dopt=AbstractPlus

1493 

Moreno Delgado 
D 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28661401?dopt=AbstractPlus

1494 

Moreno 
P 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23892571?dopt=AbstractPlus

1495 

Morfis 
M 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18599553?dopt=AbstractPlus

1496 

Morgan 
K 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12538601?dopt=AbstractPlus

1497 

Mori 
K 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15635449?dopt=AbstractPlus

1498 

Mori 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10548501?dopt=AbstractPlus

1499 

Moriconi 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25385614?dopt=AbstractPlus

1500 

Morinelli 
TA 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2530338?dopt=AbstractPlus

1501 

Morishima 
S 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17162094?dopt=AbstractPlus

1502 

Moriya 
Y 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30044673?dopt=AbstractPlus

1503 

Moro 
O 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/8995389?dopt=AbstractPlus

1504 

Moro 
O 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10438479?dopt=AbstractPlus

1505 

Morokata 
T 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16339911?dopt=AbstractPlus

1506 

Moroni 
F 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12015200?dopt=AbstractPlus

1507 

Moroni 
F 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9152378?dopt=AbstractPlus

1508 

Morrow 
GB 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25015314?dopt=AbstractPlus

1509 

Morse 
KL 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11181941?dopt=AbstractPlus

1510 

Morton 
MF 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21493750?dopt=AbstractPlus

1511 

Mosberg 
HI 

et al (1983 ) https://www.ncbi.nlm.nih.gov/pubmed/6310598?dopt=AbstractPlus

1512 

Motoike 
T 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27140610?dopt=AbstractPlus

1513 

Mould 
R 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/23692283?dopt=AbstractPlus

1514 

Moulin 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/22798076?dopt=AbstractPlus

1515 

Muccioli 
G 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11314756?dopt=AbstractPlus

1516 

Muda 
M 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16051677?dopt=AbstractPlus

1517 

Muff 
R 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10342886?dopt=AbstractPlus

1518 

Muley 
MM 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26140667?dopt=AbstractPlus

1519 

Munk 
SA 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8784451?dopt=AbstractPlus

1520 

Munro 
TA 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23976952?dopt=AbstractPlus

1521 

Murai 
N 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28859883?dopt=AbstractPlus

1522 

Murakami 
A 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20097776?dopt=AbstractPlus

1523 

Murakami 
M 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18466763?dopt=AbstractPlus

1524 

Murphy 
PM 
. (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12037138?dopt=AbstractPlus

1525 

Murphy 
PM 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10699158?dopt=AbstractPlus

1526 

Murphy 
PM 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1373134?dopt=AbstractPlus

1527 

Murugesan 
N 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12502366?dopt=AbstractPlus

1528 

Murza 
A 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26986036?dopt=AbstractPlus

1529 

Mutel 
V 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11080213?dopt=AbstractPlus

1530 

Muto 
T 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17360426?dopt=AbstractPlus

1531 

Müller 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23335960?dopt=AbstractPlus

1532 

Müller 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25516095?dopt=AbstractPlus

1533 

Müller 
A 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26505631?dopt=AbstractPlus

1534 

Müller 
T 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12727981?dopt=AbstractPlus

1535 

Nagahara 
T 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26267383?dopt=AbstractPlus

1536 

Nagase 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18598020?dopt=AbstractPlus

1537 

Nagata-Kuroiwa 
R 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21390312?dopt=AbstractPlus

1538 

Naka 
M 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1386885?dopt=AbstractPlus

1539 

Nakamura 
M 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1657923?dopt=AbstractPlus

1540 

Nakamura 
M 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1333988?dopt=AbstractPlus

1541 

Nakamura 
S 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10780976?dopt=AbstractPlus

1542 

Nakamura 
T 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11118334?dopt=AbstractPlus

1543 

Nakane 
M 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15992586?dopt=AbstractPlus

1544 

Nambi 
P 
. (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8301559?dopt=AbstractPlus

1545 

Nambu 
H 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21971119?dopt=AbstractPlus

1546 

Namour 
F 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26852904?dopt=AbstractPlus

1547 

Napier 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16298345?dopt=AbstractPlus

1548 

Napier 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10193663?dopt=AbstractPlus

1549 

Navarro 
G 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25926444?dopt=AbstractPlus

1550 

Nawaratne 
V 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20406819?dopt=AbstractPlus

1551 

Nawaratne 
V 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18628403?dopt=AbstractPlus

1552 

Naya 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12614873?dopt=AbstractPlus

1553 

Neale 
JH 
. (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21740441?dopt=AbstractPlus

1554 

Nederpelt 
I 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26398856?dopt=AbstractPlus

1555 

Nederpelt 
I 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26774084?dopt=AbstractPlus

1556 

Nef 
S 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10391220?dopt=AbstractPlus

1557 

Negishi 
M 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7608175?dopt=AbstractPlus

1558 

Negoro 
N 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/24900210?dopt=AbstractPlus

1559 

Negri 
L 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16113687?dopt=AbstractPlus

1560 

Neill 
JD 
. (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11861490?dopt=AbstractPlus

1561 

Nelson 
CP 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16188951?dopt=AbstractPlus

1562 

Nelson 
DL 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9933142?dopt=AbstractPlus

1563 

Nelson 
DL 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20855361?dopt=AbstractPlus

1564 

Nelson 
G 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11509186?dopt=AbstractPlus

1565 

Nemeth 
EF 
. (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24050279?dopt=AbstractPlus

1566 

Nemeth 
EF 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11561095?dopt=AbstractPlus

1567 

Nemeth 
EF 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9520489?dopt=AbstractPlus

1568 

Nenasheva 
TA 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23357106?dopt=AbstractPlus

1569 

Nergårdh 
R 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16318870?dopt=AbstractPlus

1570 

Neschadim 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24812057?dopt=AbstractPlus

1571 

Neumeyer 
JL 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14613319?dopt=AbstractPlus

1572 

Neveu 
C 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22800498?dopt=AbstractPlus

1573 

Newman-Tancredi 
A 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11040052?dopt=AbstractPlus

1574 

Newman-Tancredi 
A 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10431754?dopt=AbstractPlus

1575 

Newman-Tancredi 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9760039?dopt=AbstractPlus

1576 

Newman-Tancredi 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19154445?dopt=AbstractPlus

1577 

Newman-Tancredi 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9550290?dopt=AbstractPlus

1578 

Newman-Tancredi 
A 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1386736?dopt=AbstractPlus

1579 

Nguyen 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11179435?dopt=AbstractPlus

1580 

Ni 
YY 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24574718?dopt=AbstractPlus

1581 

Nickolls 
SA 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12604699?dopt=AbstractPlus

1582 

Nicole 
P 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10801840?dopt=AbstractPlus

1583 

Nie 
YY 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22410249?dopt=AbstractPlus

1584 

Niedernberg 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12618218?dopt=AbstractPlus

1585 

Nielsen 
MS 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10085125?dopt=AbstractPlus

1586 

Nieto-Posadas 
A 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22101604?dopt=AbstractPlus

1587 

Nieuwenhuijs 
VB 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10092986?dopt=AbstractPlus

1588 

Nikaido 
Y 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25425658?dopt=AbstractPlus

1589 

Nile 
AH 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29632413?dopt=AbstractPlus

1590 

Nilsson 
I 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11738246?dopt=AbstractPlus

1591 

Nilsson 
NE 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12684041?dopt=AbstractPlus

1592 

Ning 
Y 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18724386?dopt=AbstractPlus

1593 

Nishizawa 
N 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27589480?dopt=AbstractPlus

1594 

Niswender 
CM 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20026717?dopt=AbstractPlus

1595 

Niswender 
CM 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18664603?dopt=AbstractPlus

1596 No authors listed. (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/3071214?dopt=AbstractPlus

1597 No authors listed. (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16498716?dopt=AbstractPlus

1598 

Noble 
F 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10581329?dopt=AbstractPlus

1599 

Noda 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12558985?dopt=AbstractPlus

1600 

Nonaka 
Y 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16185654?dopt=AbstractPlus

1601 

Nosjean 
O 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10913150?dopt=AbstractPlus

1602 

Nosjean 
O 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11331072?dopt=AbstractPlus

1603 

Nothacker 
H‐P 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10559967?dopt=AbstractPlus

1604 

Nothacker 
HP 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11093801?dopt=AbstractPlus

1605 

Nygaard 
R 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23374348?dopt=AbstractPlus

1606 

Näsman 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10799315?dopt=AbstractPlus

1607 

O’Flaherty 
JT 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9829988?dopt=AbstractPlus

1608 

O’Sullivan 
SE 
. (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17704824?dopt=AbstractPlus

1609 

Obiefuna 
PC 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16020631?dopt=AbstractPlus

1610 

Obika 
K 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8719417?dopt=AbstractPlus

1611 

Ochi 
T 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15686911?dopt=AbstractPlus

1612 

Oda 
T 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10973974?dopt=AbstractPlus

1613 

Oertel 
BG 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19116204?dopt=AbstractPlus

1614 

Offermanns 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21454438?dopt=AbstractPlus

1615 

Ogita 
T 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9038918?dopt=AbstractPlus

1616 

Oh da 
Y 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24997608?dopt=AbstractPlus

1617 

Oh 
DY 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20813258?dopt=AbstractPlus

1618 

Ohashi 
T 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25959255?dopt=AbstractPlus

1619 

Ohki-Hamazaki 
H 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9367152?dopt=AbstractPlus

1620 

Ohlmann 
P 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/22892887?dopt=AbstractPlus

1621 

Ohsu 
T 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19892707?dopt=AbstractPlus

1622 

Ohta 
H 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14500756?dopt=AbstractPlus

1623 

Ohtaki 
T 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10601261?dopt=AbstractPlus

1624 

Ohtaki 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11385580?dopt=AbstractPlus

1625 

Oka 
S 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17765871?dopt=AbstractPlus

1626 

Oka 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20361937?dopt=AbstractPlus

1627 

Oka 
S 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/18845565?dopt=AbstractPlus

1628 

Okamoto 
H 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9765227?dopt=AbstractPlus

1629 

Okamura 
N 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17669576?dopt=AbstractPlus

1630 

Okawa 
H 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10369464?dopt=AbstractPlus

1631 

Okinaga 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12899627?dopt=AbstractPlus

1632 

Okuda-Ashitaka 
E 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8940129?dopt=AbstractPlus

1633 

Okuno 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18378794?dopt=AbstractPlus

1634 

Olender 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/19129093?dopt=AbstractPlus

1635 

Olianas 
MC 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9862767?dopt=AbstractPlus

1636 

Ongini 
E 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9933143?dopt=AbstractPlus

1637 

Oo 
ML 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17237497?dopt=AbstractPlus

1638 

Osada 
M 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12445827?dopt=AbstractPlus

1639 

Osborn 
O 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22653059?dopt=AbstractPlus

1640 

Ott 
TR 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16904643?dopt=AbstractPlus

1641 

Oury-Donat 
F 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7616392?dopt=AbstractPlus

1642 

Overington 
JP 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus

1643 

Overton 
HA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16517404?dopt=AbstractPlus

1644 

Padmanabhan 
S 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19059244?dopt=AbstractPlus

1645 

Palacios 
JM 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28265714?dopt=AbstractPlus

1646 

Palani 
A 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/24900372?dopt=AbstractPlus

1647 

Palani 
A 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11585437?dopt=AbstractPlus

1648 

Palchaudhuri 
MR 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9851694?dopt=AbstractPlus

1649 

Pan 
S 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24900670?dopt=AbstractPlus

1650 

Pan 
S 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17114004?dopt=AbstractPlus

1651 

Pang 
L 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9832122?dopt=AbstractPlus

1652 

Pantel 
J 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16511605?dopt=AbstractPlus

1653 

Panula 
P 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26084539?dopt=AbstractPlus

1654 

Parent 
JL 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8798529?dopt=AbstractPlus

1655 

Park 
D 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17960134?dopt=AbstractPlus

1656 

Parker 
CA 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22223878?dopt=AbstractPlus

1657 

Parker 
EM 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8863519?dopt=AbstractPlus

1658 

Parody 
TR 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15207250?dopt=AbstractPlus

1659 

Paruchuri 
S 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19822647?dopt=AbstractPlus

1660 

Pasternak 
GW 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24076545?dopt=AbstractPlus

1661 

Patacchini 
R 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14645137?dopt=AbstractPlus

1662 

Patane 
MA 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9548811?dopt=AbstractPlus

1663 

Patat 
O 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27476656?dopt=AbstractPlus

1664 

Patel 
P 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18292294?dopt=AbstractPlus

1665 

Patel 
S 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8967990?dopt=AbstractPlus

1666 

Patel 
YC 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7988476?dopt=AbstractPlus

1667 

Patra 
MC 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24938207?dopt=AbstractPlus

1668 

Pauli 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24407481?dopt=AbstractPlus

1669 

Pauwels 
PJ 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2462161?dopt=AbstractPlus

1670 

Pauwels 
PJ 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12649300?dopt=AbstractPlus

1671 

Payza 
K 
. (2003 ) In The Delta Receptor  Edited by Chang KJ  : CRC Press : 261 -275  [ISBN: 0824740319]
1672 

Pazos 
A 

et al (1984 ) https://www.ncbi.nlm.nih.gov/pubmed/6519175?dopt=AbstractPlus

1673 

Pearlstein 
R 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12747773?dopt=AbstractPlus

1674 

Peirce 
SM 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11406470?dopt=AbstractPlus

1675 

Pellegrini-Giampietro 
DE 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8799579?dopt=AbstractPlus

1676 

Pellicciari 
R 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/20014870?dopt=AbstractPlus

1677 

Pellicciari 
R 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8667369?dopt=AbstractPlus

1678 

Peltonen 
JM 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9760042?dopt=AbstractPlus

1679 

Pena 
A 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17300166?dopt=AbstractPlus

1680 

Pendergast 
W 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11206448?dopt=AbstractPlus

1681 

Peng 
Y 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29398112?dopt=AbstractPlus

1682 

Peng 
YM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21724806?dopt=AbstractPlus

1683 

Peralta 
EG 

et al (1987 ) https://www.ncbi.nlm.nih.gov/pubmed/3443095?dopt=AbstractPlus

1684 

Perdonà 
E 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21034740?dopt=AbstractPlus

1685 

Pereira 
JP 
. (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19597478?dopt=AbstractPlus

1686 

Perkins 
AV 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7595134?dopt=AbstractPlus

1687 

Perlman 
S 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7829475?dopt=AbstractPlus

1688 

Perretti 
M 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12368905?dopt=AbstractPlus

1689 

Perron 
A 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15637074?dopt=AbstractPlus

1690 

Pertwee 
RG 
. (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/23108552?dopt=AbstractPlus

1691 

Pertwee 
RG 
. (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11060760?dopt=AbstractPlus

1692 

Pertwee 
RG 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21079038?dopt=AbstractPlus

1693 

Peter 
MG 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/7881728?dopt=AbstractPlus

1694 

Petersen 
J 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28790300?dopt=AbstractPlus

1695 

Petersen 
KF 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11719833?dopt=AbstractPlus

1696 

Petersen 
PS 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21784784?dopt=AbstractPlus

1697 

Petersen 
SC 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25695270?dopt=AbstractPlus

1698 

Petitet 
F 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8733746?dopt=AbstractPlus

1699 

Petrel 
C 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14506236?dopt=AbstractPlus

1700 

Petrie 
WK 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24379833?dopt=AbstractPlus

1701 

Petrucci 
V 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28842619?dopt=AbstractPlus

1702 

Phebus 
LA 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9395253?dopt=AbstractPlus

1703 

Piali 
L 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/29226621?dopt=AbstractPlus

1704 

Pihlavisto 
M 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9824686?dopt=AbstractPlus

1705 

Pin 
J‐P 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10443583?dopt=AbstractPlus

1706 

Pin 
JP 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12769621?dopt=AbstractPlus

1707 

Pin 
JP 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27905440?dopt=AbstractPlus

1708 

Pin 
JP 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19723778?dopt=AbstractPlus

1709 

Pin 
JP 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15451400?dopt=AbstractPlus

1710 

Pin 
JP 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17329545?dopt=AbstractPlus

1711 

Pinard 
A 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20655485?dopt=AbstractPlus

1712 

Pisegna 
JR 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11193823?dopt=AbstractPlus

1713 

Pitkin 
SL 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20605969?dopt=AbstractPlus

1714 

Pittolo 
S 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25173999?dopt=AbstractPlus

1715 

Pizzonero 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25380412?dopt=AbstractPlus

1716 

Planagumà 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23607720?dopt=AbstractPlus

1717 

Plöckinger 
U 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22065857?dopt=AbstractPlus

1718 

Pohl 
SL 

et al (1969 ) https://www.ncbi.nlm.nih.gov/pubmed/4305077?dopt=AbstractPlus

1719 

Popova 
JS 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7798906?dopt=AbstractPlus

1720 

Popp 
BD 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14744619?dopt=AbstractPlus

1721 

Porcher 
C 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15726424?dopt=AbstractPlus

1722 

Porter 
RA 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11459658?dopt=AbstractPlus

1723 

Porter 
RH 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16040814?dopt=AbstractPlus

1724 

Portoghese 
PS 

et al (1987 ) https://www.ncbi.nlm.nih.gov/pubmed/2444704?dopt=AbstractPlus

1725 

Portoghese 
PS 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2832195?dopt=AbstractPlus

1726 

Posokhova 
E 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25558062?dopt=AbstractPlus

1727 

Poulain 
R 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11585443?dopt=AbstractPlus

1728 

Powell 
WS 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9920859?dopt=AbstractPlus

1729 

Powell 
WS 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1326548?dopt=AbstractPlus

1730 

Power 
CA 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9294137?dopt=AbstractPlus

1731 

Powers 
SP 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/3410633?dopt=AbstractPlus

1732 

Poyner 
DR 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12037140?dopt=AbstractPlus

1733 

Prat 
M 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19653626?dopt=AbstractPlus

1734 

Price 
MJ 
. (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/27886821?dopt=AbstractPlus

1735 

Price 
MR 
. (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16113085?dopt=AbstractPlus

1736 

Primus 
RJ 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9262371?dopt=AbstractPlus

1737 

Procopiou 
PA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20462258?dopt=AbstractPlus

1738 

Procopiou 
PA 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21381763?dopt=AbstractPlus

1739 

Proia 
RL 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25831442?dopt=AbstractPlus

1740 

Prossnitz 
ER 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26023144?dopt=AbstractPlus

1741 

Prossnitz 
ER 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26189910?dopt=AbstractPlus

1742 

Pruneau 
D 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10596852?dopt=AbstractPlus

1743 

Prömel 
S 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23850273?dopt=AbstractPlus

1744 

Prömel 
S 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22837050?dopt=AbstractPlus

1745 

Pugsley 
TA 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8531103?dopt=AbstractPlus

1746 

Putula 
J 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22079339?dopt=AbstractPlus

1747 

Putula 
J 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25132134?dopt=AbstractPlus

1748 

Putula 
J 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21362456?dopt=AbstractPlus

1749 

Pérez-Garci 
E 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16701210?dopt=AbstractPlus

1750 

Qi 
T 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/22946511?dopt=AbstractPlus

1751 

Quancard 
J 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22999882?dopt=AbstractPlus

1752 

Quinn 
SJ 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15201280?dopt=AbstractPlus

1753 

Quinn 
SJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9677383?dopt=AbstractPlus

1754 

Quinn 
SJ 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9357776?dopt=AbstractPlus

1755 

Quinton 
L 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20015090?dopt=AbstractPlus

1756 

Quitterer 
U 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30503206?dopt=AbstractPlus

1757 

Quock 
RM 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9178661?dopt=AbstractPlus

1758 

Raczka 
KA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20628342?dopt=AbstractPlus

1759 

Rajaratnam 
SM 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19054552?dopt=AbstractPlus

1760 

Rakowski 
E 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16171813?dopt=AbstractPlus

1761 

Raleigh 
DR 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30340023?dopt=AbstractPlus

1762 

Ramachandran 
R 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21576245?dopt=AbstractPlus

1763 

Ramachandran 
R 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28126849?dopt=AbstractPlus

1764 

Ramachandran 
R 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22212680?dopt=AbstractPlus

1765 

Ramage 
AG 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/19086344?dopt=AbstractPlus

1766 

Ramos-Álvarez 
I 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25976083?dopt=AbstractPlus

1767 

Ramos-Álvarez 
I 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26524625?dopt=AbstractPlus

1768 

Ramsay 
D 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15266013?dopt=AbstractPlus

1769 

Randeva 
HS 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11600545?dopt=AbstractPlus

1770 

Rao 
A 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28476646?dopt=AbstractPlus

1771 

Rashid 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12738034?dopt=AbstractPlus

1772 

Rask-Andersen 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus

1773 

Rasmussen 
SG 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21228869?dopt=AbstractPlus

1774 

Rasmussen 
SG 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21772288?dopt=AbstractPlus

1775 

Ratnala 
VR 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15206929?dopt=AbstractPlus

1776 

Raufman 
JP 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1704369?dopt=AbstractPlus

1777 

Ravasi 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11996896?dopt=AbstractPlus

1778 

Rawashdeh 
O 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21182402?dopt=AbstractPlus

1779 

Raychowdhury 
MK 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8034687?dopt=AbstractPlus

1780 

Raynor 
K 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8114680?dopt=AbstractPlus

1781 

Read 
C 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27475715?dopt=AbstractPlus

1782 

Reavill 
C 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10188965?dopt=AbstractPlus

1783 

Reavill 
C 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10945872?dopt=AbstractPlus

1784 

Regoli 
D 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9650825?dopt=AbstractPlus

1785 

Reid 
RC 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25259874?dopt=AbstractPlus

1786 

Reid 
RC 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24257095?dopt=AbstractPlus

1787 

Reinscheid 
RK 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16144971?dopt=AbstractPlus

1788 

Resnati 
M 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11818541?dopt=AbstractPlus

1789 

Revankar 
CM 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15705806?dopt=AbstractPlus

1790 

Revel 
FG 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21525407?dopt=AbstractPlus

1791 

Rexen Ulven 
E 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29968758?dopt=AbstractPlus

1792 

Reynaud 
R 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22466334?dopt=AbstractPlus

1793 

Reynolds 
EE 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7733918?dopt=AbstractPlus

1794 

Reynolds 
GP 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7780656?dopt=AbstractPlus

1795 

Rezgaoui 
M 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16443751?dopt=AbstractPlus

1796 

Rhee 
MH 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9379442?dopt=AbstractPlus

1797 

Ricci 
A 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8051291?dopt=AbstractPlus

1798 

Ricci 
A 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7759603?dopt=AbstractPlus

1799 

Riccio 
G 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29293331?dopt=AbstractPlus

1800 

Rice 
AS 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24507377?dopt=AbstractPlus

1801 

Richard 
F 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11723247?dopt=AbstractPlus

1802 

Richardson 
RM 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12626541?dopt=AbstractPlus

1803 

Riddy 
DM 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/27864425?dopt=AbstractPlus

1804 

Rinaldi-Carmona 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8070571?dopt=AbstractPlus

1805 

Rinaldi-Carmona 
M 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9454810?dopt=AbstractPlus

1806 

Rinaldi-Carmona 
M 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8614277?dopt=AbstractPlus

1807 

Rinne 
MK 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30194937?dopt=AbstractPlus

1808 

Riobo 
NA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16885213?dopt=AbstractPlus

1809 

Rivail 
L 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15351779?dopt=AbstractPlus

1810 

Rivier 
J 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12361401?dopt=AbstractPlus

1811 

Rivier 
J 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1850267?dopt=AbstractPlus

1812 

Rivier 
JE 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24269930?dopt=AbstractPlus

1813 

Rivkees 
SA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9920910?dopt=AbstractPlus

1814 

Rizzi 
A 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9095082?dopt=AbstractPlus

1815 

Robas 
N 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12915402?dopt=AbstractPlus

1816 

Roecker 
AJ 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26317591?dopt=AbstractPlus

1817 

Rohrer 
SP 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9784130?dopt=AbstractPlus

1818 

Romano 
M 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8757340?dopt=AbstractPlus

1819 

Roos 
RS 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9211859?dopt=AbstractPlus

1820 

Rosenbaum 
DM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21228876?dopt=AbstractPlus

1821 

Rosengren 
AH 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/19965390?dopt=AbstractPlus

1822 

Roseweir 
AK 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19321788?dopt=AbstractPlus

1823 

Rosier 
A 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/9027929?dopt=AbstractPlus

1824 

Ross 
RA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10188977?dopt=AbstractPlus

1825 

Roth 
BL 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12192085?dopt=AbstractPlus

1826 

Roth 
BL 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7908055?dopt=AbstractPlus

1827 

Rothman 
RB 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11104741?dopt=AbstractPlus

1828 

Roush 
ED 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9654151?dopt=AbstractPlus

1829 

Roussin 
A 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16129413?dopt=AbstractPlus

1830 

Rovati 
GE 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1329767?dopt=AbstractPlus

1831 

Rowley 
M 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8642551?dopt=AbstractPlus

1832 

Royer 
JF 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17714552?dopt=AbstractPlus

1833 

Ruffing 
N 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9790730?dopt=AbstractPlus

1834 

Ruffner 
H 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22815884?dopt=AbstractPlus

1835 

Ruiu 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12663689?dopt=AbstractPlus

1836 

Ruiz-Ferrer 
M 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21858136?dopt=AbstractPlus

1837 

Ruiz-Medina 
J 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21352831?dopt=AbstractPlus

1838 

Russell 
FD 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8904635?dopt=AbstractPlus

1839 

Russell 
JL 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22462679?dopt=AbstractPlus

1840 

Ruzza 
C 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25692025?dopt=AbstractPlus

1841 

Ruzza 
C 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20172007?dopt=AbstractPlus

1842 

Ryan 
PJ 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24297931?dopt=AbstractPlus

1843 

Ryberg 
E 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17876302?dopt=AbstractPlus

1844 

Ryman-Rasmussen 
JP 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17067639?dopt=AbstractPlus

1845 

Römpler 
H 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15987686?dopt=AbstractPlus

1846 

Rühmann 
A 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11835994?dopt=AbstractPlus

1847 

Saar 
I 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23600864?dopt=AbstractPlus

1848 

Sabbatini 
FM 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20593439?dopt=AbstractPlus

1849 

Sabroe 
I 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10854442?dopt=AbstractPlus

1850 

Sairam 
MR 
. (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2542111?dopt=AbstractPlus

1851 

Saito 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9264324?dopt=AbstractPlus

1852 

Sakurai 
T 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9491897?dopt=AbstractPlus

1853 

Sakurai 
T 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24486398?dopt=AbstractPlus

1854 

Sakurai 
T 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2175397?dopt=AbstractPlus

1855 

Sallinen 
J 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17220913?dopt=AbstractPlus

1856 

Salmon 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23435542?dopt=AbstractPlus

1857 

Salvatore 
CA 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18039958?dopt=AbstractPlus

1858 

Salvatore 
CA 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8234299?dopt=AbstractPlus

1859 

Sams 
AG 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20684563?dopt=AbstractPlus

1860 

Sanger 
GJ 
. (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24438586?dopt=AbstractPlus

1861 

Sanger 
GJ 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21531468?dopt=AbstractPlus

1862 

Sanger 
GJ 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23189978?dopt=AbstractPlus

1863 

Sanger 
GJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19374732?dopt=AbstractPlus

1864 

Sanna 
MG 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14732717?dopt=AbstractPlus

1865 

Sanna 
MG 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16829954?dopt=AbstractPlus

1866 

Sano 
H 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15203211?dopt=AbstractPlus

1867 

Sarau 
HM 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10462554?dopt=AbstractPlus

1868 

Sarau 
HM 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11226387?dopt=AbstractPlus

1869 

Sarau 
HM 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9190866?dopt=AbstractPlus

1870 

Sarau 
HM 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9336350?dopt=AbstractPlus

1871 

Sato 
H 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17825251?dopt=AbstractPlus

1872 

Sato 
M 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17717109?dopt=AbstractPlus

1873 

Sato 
M 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18684840?dopt=AbstractPlus

1874 

Sato 
Y 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8982677?dopt=AbstractPlus

1875 

Saussy 
DL 
Jr

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8764344?dopt=AbstractPlus

1876 

Sautel 
F 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7756621?dopt=AbstractPlus

1877 

Sautel 
F 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8531087?dopt=AbstractPlus

1878 

Savall 
BM 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24495018?dopt=AbstractPlus

1879 

Savard 
M 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26565554?dopt=AbstractPlus

1880 

Savard 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23362191?dopt=AbstractPlus

1881 

Scanlan 
TS 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15146179?dopt=AbstractPlus

1882 

Schachter 
JB 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9154346?dopt=AbstractPlus

1883 

Schaerlinger 
B 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12970106?dopt=AbstractPlus

1884 

Schaffhauser 
H 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14500736?dopt=AbstractPlus

1885 

Schally 
AV 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15350601?dopt=AbstractPlus

1886 

Schally 
AV 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10542394?dopt=AbstractPlus

1887 

Schechter 
LE 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/17625499?dopt=AbstractPlus

1888 

Schiller 
PW 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8230106?dopt=AbstractPlus

1889 

Schioth 
HB 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7774675?dopt=AbstractPlus

1890 

Schiöth 
HB 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15862553?dopt=AbstractPlus

1891 

Schiöth 
HB 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9630346?dopt=AbstractPlus

1892 

Schlachter 
SK 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9098699?dopt=AbstractPlus

1893 

Schmid 
HA 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15477717?dopt=AbstractPlus

1894 

Schmidt 
J 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21220428?dopt=AbstractPlus

1895 

Schmitz 
B 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25666387?dopt=AbstractPlus

1896 

Schmitz 
K 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28578681?dopt=AbstractPlus

1897 

Schoepp 
DD 

et al (2000 ) In IUPHAR Compendium of Receptor Characterization and Classification  Edited by Watson SP  , Girdlestone D  : IUPHAR Press : 195 -208 

1898 

Schoepp 
DD 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9144636?dopt=AbstractPlus

1899 

Schoepp 
DD 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/9076745?dopt=AbstractPlus

1900 

Scholz 
N 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25937282?dopt=AbstractPlus

1901 

Schotte 
A 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8935801?dopt=AbstractPlus

1902 

Schulte 
G 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21079039?dopt=AbstractPlus

1903 

Schulte 
G 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30049420?dopt=AbstractPlus

1904 

Schwartz 
JC 

et al (1998 ) In The IUPHAR Compendium of Receptor Characterization and Classification  Edited by Girdlestone D  : IUPHAR media : 141 -151 

1905 

Schweitz 
H 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10567694?dopt=AbstractPlus

1906 

Schweitzer 
C 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10884552?dopt=AbstractPlus

1907 

Schwenk 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20400944?dopt=AbstractPlus

1908 

Schwenk 
U 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7797484?dopt=AbstractPlus

1909 

Schöppe 
J 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30604743?dopt=AbstractPlus

1910 

Scola 
AM 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19100624?dopt=AbstractPlus

1911 

Scott 
DJ 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15956681?dopt=AbstractPlus

1912 

Scott 
DJ 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15956680?dopt=AbstractPlus

1913 

Scott 
DJ 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16963451?dopt=AbstractPlus

1914 

Scott 
MK 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10896115?dopt=AbstractPlus

1915 

Sebhat 
IK 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/24900253?dopt=AbstractPlus

1916 

Sebhat 
IK 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12361385?dopt=AbstractPlus

1917 

Sedaghat 
K 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18706979?dopt=AbstractPlus

1918 

Seeman 
P 
. (2001 ) Clin Neurosci Res 
1 : 53 -60 

1919 

Seeman 
P 

et al (1975 ) https://www.ncbi.nlm.nih.gov/pubmed/1060115?dopt=AbstractPlus

1920 

Seeman 
P 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9015795?dopt=AbstractPlus

1921 

Seeman 
P 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9577836?dopt=AbstractPlus

1922 

Segala 
E 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27312113?dopt=AbstractPlus

1923 

Seifert 
R 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12626648?dopt=AbstractPlus

1924 

Selkirk 
JV 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9776361?dopt=AbstractPlus

1925 

Semple 
G 
. (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16480258?dopt=AbstractPlus

1926 

Serradeil-Le Gal 
C 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8981918?dopt=AbstractPlus

1927 

Serradeil-Le Gal 
C 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11012895?dopt=AbstractPlus

1928 

Serradeil-Le Gal 
C 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14722330?dopt=AbstractPlus

1929 

Serradeil-Le Gal 
C 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11861823?dopt=AbstractPlus

1930 

Sethi 
A 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27088579?dopt=AbstractPlus

1931 

Setoh 
M 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24884590?dopt=AbstractPlus

1932 

Seuwen 
K 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17118800?dopt=AbstractPlus

1933 

Sevigny 
LM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21536878?dopt=AbstractPlus

1934 

Shabanpoor 
F 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22257012?dopt=AbstractPlus

1935 

Shabanpoor 
F 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22425984?dopt=AbstractPlus

1936 

Shabanpoor 
F 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17120268?dopt=AbstractPlus

1937 

Shabanpoor 
F 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18529069?dopt=AbstractPlus

1938 

Shabanpoor 
F 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/20560146?dopt=AbstractPlus

1939 

Shahid 
M 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/18308814?dopt=AbstractPlus

1940 

Sharif 
NA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11999132?dopt=AbstractPlus

1941 

Sharif 
NA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17076623?dopt=AbstractPlus

1942 

Sharif 
NA 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11572462?dopt=AbstractPlus

1943 

Sheffler 
DJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19407080?dopt=AbstractPlus

1944 

Shemesh 
R 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18854305?dopt=AbstractPlus

1945 

Shen 
F 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23292797?dopt=AbstractPlus

1946 

Shen 
HC 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20184326?dopt=AbstractPlus

1947 

Shi 
J 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27089991?dopt=AbstractPlus

1948 

Shibata 
K 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7651358?dopt=AbstractPlus

1949 

Shichijo 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12975488?dopt=AbstractPlus

1950 

Shihoya 
W 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30413709?dopt=AbstractPlus

1951 

Shihoya 
W 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28805809?dopt=AbstractPlus

1952 

Shimizu 
N 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10233994?dopt=AbstractPlus

1953 

Shimomura 
Y 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12130646?dopt=AbstractPlus

1954 

Shimon 
I 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15636423?dopt=AbstractPlus

1955 

Shimpukade 
B 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22519963?dopt=AbstractPlus

1956 

Shinagawa 
Y 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/24900301?dopt=AbstractPlus

1957 

Shinkre 
BA 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20801028?dopt=AbstractPlus

1958 

Shinohara 
T 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15037633?dopt=AbstractPlus

1959 

Shire 
D 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8679694?dopt=AbstractPlus

1960 

Shitara 
K 

et al (2009 ) Patent number: US7504104.
1961 

Shore 
DM 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25926795?dopt=AbstractPlus

1962 

Showalter 
VM 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8819477?dopt=AbstractPlus

1963 

Showell 
HJ 

et al (1976 ) https://www.ncbi.nlm.nih.gov/pubmed/1262785?dopt=AbstractPlus

1964 

Showell 
HJ 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7714764?dopt=AbstractPlus

1965 

Siegl 
AM 

et al (1979 ) https://www.ncbi.nlm.nih.gov/pubmed/372237?dopt=AbstractPlus

1966 

Siehler 
S 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9652348?dopt=AbstractPlus

1967 

Siehler 
S 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10598788?dopt=AbstractPlus

1968 

Siehler 
S 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9650799?dopt=AbstractPlus

1969 

Sikand 
P 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21593341?dopt=AbstractPlus

1970 

Sillard 
R 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1283627?dopt=AbstractPlus

1971 

Silver 
MR 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15878963?dopt=AbstractPlus

1972 

Sim 
LJ 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8987831?dopt=AbstractPlus

1973 

Simonin 
F 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7624359?dopt=AbstractPlus

1974 

Simonin 
F 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16407169?dopt=AbstractPlus

1975 

Simonin 
F 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11239918?dopt=AbstractPlus

1976 

Singh 
G 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15261118?dopt=AbstractPlus

1977 

Singh 
L 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/8605955?dopt=AbstractPlus

1978 

Sinha 
S 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16408088?dopt=AbstractPlus

1979 

Sinha 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20590605?dopt=AbstractPlus

1980 

Skerlj 
RT 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20297846?dopt=AbstractPlus

1981 

Skinner 
PJ 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19524438?dopt=AbstractPlus

1982 

Skofitsch 
G 

et al (1986 ) https://www.ncbi.nlm.nih.gov/pubmed/2436195?dopt=AbstractPlus

1983 

Skrzydelski 
D 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12869647?dopt=AbstractPlus

1984 

Slack 
JP 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20537538?dopt=AbstractPlus

1985 

Sleight 
AJ 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9647481?dopt=AbstractPlus

1986 

Sleight 
AJ 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8534270?dopt=AbstractPlus

1987 

Slipetz 
DM 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7651369?dopt=AbstractPlus

1988 

Sliwoski 
G 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27294784?dopt=AbstractPlus

1989 

Slusarski 
DC 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9389482?dopt=AbstractPlus

1990 

Small 
KM 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16605244?dopt=AbstractPlus

1991 

Smart 
D 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11250867?dopt=AbstractPlus

1992 

Smith 
CM 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21899720?dopt=AbstractPlus

1993 

Smith 
CM 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9029489?dopt=AbstractPlus

1994 

Smith 
JA 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18415081?dopt=AbstractPlus

1995 

Smith 
JP 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12429993?dopt=AbstractPlus

1996 

Smith 
KE 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9305929?dopt=AbstractPlus

1997 

Smith 
KE 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9722565?dopt=AbstractPlus

1998 

Smith 
MT 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23489258?dopt=AbstractPlus

1999 

Smith 
PW 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7562907?dopt=AbstractPlus

2000 

Smith 
RD 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7850406?dopt=AbstractPlus

2001 

Smits 
RA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16854056?dopt=AbstractPlus

2002 

Sodin-Semrl 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15171815?dopt=AbstractPlus

2003 

Sofuoglu 
M 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1851833?dopt=AbstractPlus

2004 

Soga 
T 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=AbstractPlus

2005 

Soga 
T 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12427552?dopt=AbstractPlus

2006 

Sokoloff 
P 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1354163?dopt=AbstractPlus

2007 

Sokoloff 
P 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1586393?dopt=AbstractPlus

2008 

Sokoloff 
P 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/1975644?dopt=AbstractPlus

2009 

Solinski 
HJ 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24867890?dopt=AbstractPlus

2010 

Sollenberg 
UE 

et al (2006 ) Int J Pept Res Ther 
12 : 115 -119 

2011 

Song 
H 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18955481?dopt=AbstractPlus

2012 

Song 
I 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8415658?dopt=AbstractPlus

2013 

Song 
ZH 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8622639?dopt=AbstractPlus

2014 

Soriano-Ursúa 
MA 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19168263?dopt=AbstractPlus

2015 

Southern 
C 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23396314?dopt=AbstractPlus

2016 

Spadoni 
G 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26334942?dopt=AbstractPlus

2017 

Spagnolo 
B 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17329552?dopt=AbstractPlus

2018 

Spalding 
TA 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16959945?dopt=AbstractPlus

2019 

Spalding 
TA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12021390?dopt=AbstractPlus

2020 

Spengler 
D 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8396727?dopt=AbstractPlus

2021 

Speth 
RC 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2194459?dopt=AbstractPlus

2022 

Sprecher 
D 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25773497?dopt=AbstractPlus

2023 

Srivastava 
A 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25043059?dopt=AbstractPlus

2024 

Stacey 
M 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12829604?dopt=AbstractPlus

2025 

Stalder 
H 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21237643?dopt=AbstractPlus

2026 

Stam 
NJ 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9303561?dopt=AbstractPlus

2027 

Stefano 
GB 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1329092?dopt=AbstractPlus

2028 

Steinfeld 
T 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17478612?dopt=AbstractPlus

2029 

Steinhart 
Z 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/27869803?dopt=AbstractPlus

2030 

Stenfeldt 
AL 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17687636?dopt=AbstractPlus

2031 

Stevens 
WC 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10893314?dopt=AbstractPlus

2032 

Stewart 
AJ 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/17942747?dopt=AbstractPlus

2033 

Stewart 
M 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15194002?dopt=AbstractPlus

2034 

Stillman 
BA 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10462542?dopt=AbstractPlus

2035 

Stirrat 
A 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11158995?dopt=AbstractPlus

2036 

Stitham 
J 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17704830?dopt=AbstractPlus

2037 

Stocks 
MJ 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21036043?dopt=AbstractPlus

2038 

Stoddart 
LA 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17200419?dopt=AbstractPlus

2039 

Stoddart 
LA 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/19047536?dopt=AbstractPlus

2040 

Storka 
A 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/19021699?dopt=AbstractPlus

2041 

Stoveken 
HM 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25918380?dopt=AbstractPlus

2042 

Straub 
RE 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2175902?dopt=AbstractPlus

2043 

Strizki 
JM 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16304152?dopt=AbstractPlus

2044 

Strosberg 
AD 
. (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9131260?dopt=AbstractPlus

2045 

Struthers 
RS 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17095587?dopt=AbstractPlus

2046 

Sturino 
CF 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17300164?dopt=AbstractPlus

2047 

Su 
SB 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9892621?dopt=AbstractPlus

2048 

Sudo 
H 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18164286?dopt=AbstractPlus

2049 

Sudo 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12506116?dopt=AbstractPlus

2050 

Suen 
JY 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21806599?dopt=AbstractPlus

2051 

Sugden 
D 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10420436?dopt=AbstractPlus

2052 

Sugimoto 
H 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16256979?dopt=AbstractPlus

2053 

Sugo 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/17628210?dopt=AbstractPlus

2054 

Sugo 
T 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16460680?dopt=AbstractPlus

2055 

Sullivan 
GW 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11226132?dopt=AbstractPlus

2056 

Sumichika 
H 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12384495?dopt=AbstractPlus

2057 

Sun 
Q 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20685848?dopt=AbstractPlus

2058 

Sun 
R 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15210802?dopt=AbstractPlus

2059 

Sun 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12683933?dopt=AbstractPlus

2060 

Sunahara 
RK 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1826762?dopt=AbstractPlus

2061 

Sur 
C 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14595031?dopt=AbstractPlus

2062 

Suzawa 
T 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10746663?dopt=AbstractPlus

2063 

Suzuki 
G 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17609420?dopt=AbstractPlus

2064 

Suzuki 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23449982?dopt=AbstractPlus

2065 

Suzuki 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/19007110?dopt=AbstractPlus

2066 

Suzuki 
T 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7902433?dopt=AbstractPlus

2067 

Svetlov 
S 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8380690?dopt=AbstractPlus

2068 

Swaney 
JS 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21159750?dopt=AbstractPlus

2069 

Swanson 
CJ 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16287967?dopt=AbstractPlus

2070 

Swayne 
GT 

et al (1988 ) https://www.ncbi.nlm.nih.gov/pubmed/2975605?dopt=AbstractPlus

2071 

Syed 
NI 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25542069?dopt=AbstractPlus

2072 

Sykes 
D 

et al (2014 ) Eur Respir J 
44 : 4074 

2073 

Sykes 
DA 
. (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26916831?dopt=AbstractPlus

2074 

Szpakowska 
M 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29530506?dopt=AbstractPlus

2075 

Säfholm 
A 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18927296?dopt=AbstractPlus

2076 

Tabata 
K 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17905198?dopt=AbstractPlus

2077 

Taggart 
AK 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15929991?dopt=AbstractPlus

2078 

Tahara 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9884074?dopt=AbstractPlus

2079 

Tahara 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9459574?dopt=AbstractPlus

2080 

Taipale 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10984056?dopt=AbstractPlus

2081 

Takada 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12960358?dopt=AbstractPlus

2082 

Takahashi 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9145417?dopt=AbstractPlus

2083 

Takahashi 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7804141?dopt=AbstractPlus

2084 

Takahashi 
M 

et al (1998 ) Pept Sci 
4 : 1.7 

2085 

Takanashi 
H 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17183187?dopt=AbstractPlus

2086 

Takano 
T 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9151906?dopt=AbstractPlus

2087 

Takasaki 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10913337?dopt=AbstractPlus

2088 

Takasaki 
J 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11502873?dopt=AbstractPlus

2089 

Takasu 
T 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17293563?dopt=AbstractPlus

2090 

Takayasu 
S 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16648250?dopt=AbstractPlus

2091 

Takechi 
H 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8621463?dopt=AbstractPlus

2092 

Takeda 
S 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15173198?dopt=AbstractPlus

2093 

Takekawa 
S 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11909603?dopt=AbstractPlus

2094 

Takinami 
Y 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9042983?dopt=AbstractPlus

2095 

Talmont 
F 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19682524?dopt=AbstractPlus

2096 

Tamamura 
H 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9918823?dopt=AbstractPlus

2097 

Tamura 
M 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10024318?dopt=AbstractPlus

2098 

Tan 
CP 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12036292?dopt=AbstractPlus

2099 

Tan 
M 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19126537?dopt=AbstractPlus

2100 

Tanaka 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18320172?dopt=AbstractPlus

2101 

Tang 
H 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18722346?dopt=AbstractPlus

2102 

Tang 
L 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8301592?dopt=AbstractPlus

2103 

Taniguchi 
H 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8813597?dopt=AbstractPlus

2104 

Taniguchi 
T 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10433504?dopt=AbstractPlus

2105 

Taniguchi 
Y 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16934253?dopt=AbstractPlus

2106 

Tatemoto 
K 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9792798?dopt=AbstractPlus

2107 

Teh 
MT 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9840420?dopt=AbstractPlus

2108 

Terakado 
M 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27774128?dopt=AbstractPlus

2109 

Terakita 
A 
. (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15774036?dopt=AbstractPlus

2110 

Testa 
R 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9190864?dopt=AbstractPlus

2111 

Thal 
DM 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26958838?dopt=AbstractPlus

2112 

Thathiah 
A 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19213921?dopt=AbstractPlus

2113 

Theiler 
A 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27664754?dopt=AbstractPlus

2114 

Theis 
JG 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1387312?dopt=AbstractPlus

2115 

Thibonnier 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8106369?dopt=AbstractPlus

2116 

Thibonnier 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9322919?dopt=AbstractPlus

2117 

Thielemans 
L 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15764739?dopt=AbstractPlus

2118 

Thomas 
BF 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9536023?dopt=AbstractPlus

2119 

Thomas 
DR 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10807680?dopt=AbstractPlus

2120 

Thomas 
DR 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9720804?dopt=AbstractPlus

2121 

Thomas 
JB 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11495579?dopt=AbstractPlus

2122 

Thomas 
NK 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11166323?dopt=AbstractPlus

2123 

Thomas 
P 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15539556?dopt=AbstractPlus

2124 

Thomsen 
AR 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22192592?dopt=AbstractPlus

2125 

Thomsen 
WJ 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18252809?dopt=AbstractPlus

2126 

Thoreson 
WB 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9144637?dopt=AbstractPlus

2127 

Thorsell 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23761908?dopt=AbstractPlus

2128 

Thulesen 
J 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11738243?dopt=AbstractPlus

2129 

Thurmond 
RL 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14722321?dopt=AbstractPlus

2130 

Tian 
Y 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8702757?dopt=AbstractPlus

2131 

Tibaduiza 
EC 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11498540?dopt=AbstractPlus

2132 

Tiberi 
M 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7525564?dopt=AbstractPlus

2133 

Tice 
MA 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7862709?dopt=AbstractPlus

2134 

Tilakaratne 
N 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10871296?dopt=AbstractPlus

2135 

Timmermans 
PBMWM 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8372104?dopt=AbstractPlus

2136 

Ting 
KN 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10433507?dopt=AbstractPlus

2137 

Tobo 
A 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26070068?dopt=AbstractPlus

2138 

Toda 
N 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24900747?dopt=AbstractPlus

2139 

Todde 
S 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11087559?dopt=AbstractPlus

2140 

Tokita 
K 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11463790?dopt=AbstractPlus

2141 

Toledo 
MA 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24678969?dopt=AbstractPlus

2142 

Toll 
L 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9686407?dopt=AbstractPlus

2143 

Tomita 
K 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18302161?dopt=AbstractPlus

2144 

Torisu 
K 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15388164?dopt=AbstractPlus

2145 

Torrens 
Y 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9243521?dopt=AbstractPlus

2146 

Torres 
D 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18178816?dopt=AbstractPlus

2147 

Tosh 
DK 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22559880?dopt=AbstractPlus

2148 

Tosh 
DK 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30605331?dopt=AbstractPlus

2149 

Tough 
IR 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16807358?dopt=AbstractPlus

2150 

Tousignant 
C 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/1705465?dopt=AbstractPlus

2151 

Townsend-Nicholson 
A 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/8300561?dopt=AbstractPlus

2152 

Tran 
DT 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21679703?dopt=AbstractPlus

2153 

Trauelsen 
M 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/29157600?dopt=AbstractPlus

2154 

Trivellin 
G 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25470569?dopt=AbstractPlus

2155 

Tränkle 
C 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12815174?dopt=AbstractPlus

2156 

Tsuchiya 
D 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11867751?dopt=AbstractPlus

2157 

Tsujihata 
Y 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21752941?dopt=AbstractPlus

2158 

Tuckmantel 
W 

et al (1997 ) Bioorg Med Chem Lett . 7 : 601 -606 

2159 

Tunaru 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12563315?dopt=AbstractPlus

2160 

Turecek 
R 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24836506?dopt=AbstractPlus

2161 

Turner 
MR 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15689356?dopt=AbstractPlus

2162 

Turner 
MW 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27338657?dopt=AbstractPlus

2163 

Tzschentke 
TM 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17656655?dopt=AbstractPlus

2164 

Uberti 
MA 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15615865?dopt=AbstractPlus

2165 

Uchida 
D 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9928019?dopt=AbstractPlus

2166 

Uehara 
H 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21729729?dopt=AbstractPlus

2167 

Uguccioni 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9276730?dopt=AbstractPlus

2168 

Uhlenbrock 
K 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12220620?dopt=AbstractPlus

2169 

Uhlén 
S 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/7996470?dopt=AbstractPlus

2170 

Ullmann 
H 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16250663?dopt=AbstractPlus

2171 

Ulman 
LG 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7693918?dopt=AbstractPlus

2172 

Ulrich 
2nd
CD 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9843782?dopt=AbstractPlus

2173 

Ulrich 
D 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17433877?dopt=AbstractPlus

2174 

Ulven 
T 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15715457?dopt=AbstractPlus

2175 

Underwood 
DJ 

et al (1994 ) https://www.ncbi.nlm.nih.gov/pubmed/9383393?dopt=AbstractPlus

2176 

Unson 
C 

et al (1987 ) https://www.ncbi.nlm.nih.gov/pubmed/3035568?dopt=AbstractPlus

2177 

Unson 
CG 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2560175?dopt=AbstractPlus

2178 

Urbano 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24125884?dopt=AbstractPlus

2179 

Urbano 
M 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21982495?dopt=AbstractPlus

2180 

Ursini 
A 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11020274?dopt=AbstractPlus

2181 

Urwyler 
S 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11641424?dopt=AbstractPlus

2182 

Urwyler 
S 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12954816?dopt=AbstractPlus

2183 

Uyama 
Y 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9106476?dopt=AbstractPlus

2184 

Vacher 
CM 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16606363?dopt=AbstractPlus

2185 

Valant 
C 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21989256?dopt=AbstractPlus

2186 

Valant 
C 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18723515?dopt=AbstractPlus

2187 

Valdes 
AM 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20090528?dopt=AbstractPlus

2188 

Vallon 
M 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30304675?dopt=AbstractPlus

2189 

Van Brocklyn 
JR 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10753843?dopt=AbstractPlus

2190 

Van den Wyngaert 
I 

et al (1997 )https://www.ncbi.nlm.nih.gov/pubmed/9349523?dopt=AbstractPlus

2191 

van der Westhuizen 
ET 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20159943?dopt=AbstractPlus

2192 

Van Lith 
LH 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19641221?dopt=AbstractPlus

2193 

van Muijlwijk-Koezen 
JE 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10841801?dopt=AbstractPlus

2194 

Van Poppel 
H 
. (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/21188095?dopt=AbstractPlus

2195 

Van Rampelbergh 
J 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8967982?dopt=AbstractPlus

2196 

Van Tol 
HHM 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1840645?dopt=AbstractPlus

2197 

van Wieringen 
JP 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24183974?dopt=AbstractPlus

2198 

Vanderheyden 
PM 

et al (2000 )https://www.ncbi.nlm.nih.gov/pubmed/11303957?dopt=AbstractPlus

2199 

Vanderheyden 
PML 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10193788?dopt=AbstractPlus

2200 

Vanhollebeke 
B 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26051822?dopt=AbstractPlus

2201 

Vanover 
KE 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15102927?dopt=AbstractPlus

2202 

Vanti 
WB 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14559210?dopt=AbstractPlus

2203 

Varani 
K 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/16219300?dopt=AbstractPlus

2204 

Varani 
K 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10779381?dopt=AbstractPlus

2205 

Varga 
JL 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9892695?dopt=AbstractPlus

2206 

Varga 
JL 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14755056?dopt=AbstractPlus

2207 

Varnäs 
K 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/20424633?dopt=AbstractPlus

2208 

Varty 
GB 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18492950?dopt=AbstractPlus

2209 

Vassileva 
G 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16724960?dopt=AbstractPlus

2210 

Vaudry 
H 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20633133?dopt=AbstractPlus

2211 

Vaudry 
H 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25535277?dopt=AbstractPlus

2212 

Vaughan 
J 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7477349?dopt=AbstractPlus

2213 

Venail 
F 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30152527?dopt=AbstractPlus

2214 

Verdonk 
K 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22802221?dopt=AbstractPlus

2215 

Vergura 
R 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18069089?dopt=AbstractPlus

2216 

Vigot 
R 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16701209?dopt=AbstractPlus

2217 

Vilardaga 
JP 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18193048?dopt=AbstractPlus

2218 

Vilboux 
T 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28052552?dopt=AbstractPlus

2219 

Villalón 
CM 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17703282?dopt=AbstractPlus

2220 

Violin 
JD 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20801892?dopt=AbstractPlus

2221 

Virag 
T 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12695531?dopt=AbstractPlus

2222 

Vita 
N 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9851594?dopt=AbstractPlus

2223 

Vlachou 
S 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21181127?dopt=AbstractPlus

2224 

Volpe 
DA 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21215785?dopt=AbstractPlus

2225 

Volz 
A 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7589426?dopt=AbstractPlus

2226 

von Geldern 
TW 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10479298?dopt=AbstractPlus

2227 

von Kügelgen 
I 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21586365?dopt=AbstractPlus

2228 

von Kügelgen 
I 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26519900?dopt=AbstractPlus

2229 

von Maltzahn 
J 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22179044?dopt=AbstractPlus

2230 

Vonvoigtlander 
PF 

et al (1983 ) https://www.ncbi.nlm.nih.gov/pubmed/6129321?dopt=AbstractPlus

2231 

Wacker 
D 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23519215?dopt=AbstractPlus

2232 

Wacker 
DA 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12067561?dopt=AbstractPlus

2233 

Waeber 
C 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9928243?dopt=AbstractPlus

2234 

Waelbroeck 
M 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8813552?dopt=AbstractPlus

2235 

Wainscott 
DB 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8450835?dopt=AbstractPlus

2236 

Wainscott 
DB 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15900510?dopt=AbstractPlus

2237 

Wainscott 
DB 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9459568?dopt=AbstractPlus

2238 

Waldo 
GL 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12391289?dopt=AbstractPlus

2239 

Walker 
AW 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25849482?dopt=AbstractPlus

2240 

Walker 
CS 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20633935?dopt=AbstractPlus

2241 

Walker 
CS 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26125036?dopt=AbstractPlus

2242 

Wallrabenstein 
I 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23393561?dopt=AbstractPlus

2243 

Walter 
S 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23674604?dopt=AbstractPlus

2244 

Walters 
MJ 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20660125?dopt=AbstractPlus

2245 

Walther 
A 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10882119?dopt=AbstractPlus

2246 

Wan 
W 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2213023?dopt=AbstractPlus

2247 

Wan 
Y 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12450563?dopt=AbstractPlus

2248 

Wandel 
E 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22210915?dopt=AbstractPlus

2249 

Wang 
C 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23519210?dopt=AbstractPlus

2250 

Wang 
C 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25008467?dopt=AbstractPlus

2251 

Wang 
C 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23636324?dopt=AbstractPlus

2252 

Wang 
J 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/23063522?dopt=AbstractPlus

2253 

Wang 
J 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16754668?dopt=AbstractPlus

2254 

Wang 
J 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16966319?dopt=AbstractPlus

2255 

Wang 
JJ 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24113187?dopt=AbstractPlus

2256 

Wang 
M 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16455645?dopt=AbstractPlus

2257 

Wang 
S 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9742938?dopt=AbstractPlus

2258 

Wang 
S 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9281594?dopt=AbstractPlus

2259 

Wang 
S 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9405385?dopt=AbstractPlus

2260 

Wang 
S 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30257206?dopt=AbstractPlus

2261 

Wang 
SZ 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7687290?dopt=AbstractPlus

2262 

Wang 
T 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15576472?dopt=AbstractPlus

2263 

Wank 
SA 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1313582?dopt=AbstractPlus

2264 

Ward 
SE 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15887956?dopt=AbstractPlus

2265 

Warne 
T 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21228877?dopt=AbstractPlus

2266 

Warne 
T 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18594507?dopt=AbstractPlus

2267 

Warner 
FJ 
. (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10455255?dopt=AbstractPlus

2268 

Watakabe 
T 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1320877?dopt=AbstractPlus

2269 

Watanabe 
K 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10537280?dopt=AbstractPlus

2270 

Watanabe 
N 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26136644?dopt=AbstractPlus

2271 

Watanabe 
T 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7780649?dopt=AbstractPlus

2272 

Watanabe 
Y 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10349870?dopt=AbstractPlus

2273 

Watson 
M 

et al (1984 ) https://www.ncbi.nlm.nih.gov/pubmed/6546354?dopt=AbstractPlus

2274 

Watson 
RR 

et al (2017 ) In Nutrients in Dairy and Their Implications for Health and Disease 
Academic Press : 490  [ISBN: 9780128097632]
2275 

Watson 
SJ 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22282525?dopt=AbstractPlus

2276 

Watts 
AO 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23341447?dopt=AbstractPlus

2277 

Weber 
AE 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9873496?dopt=AbstractPlus

2278 

Webster 
EL 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8940412?dopt=AbstractPlus

2279 

Weierstall 
U 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24525480?dopt=AbstractPlus

2280 

Weinshank 
RL 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1834671?dopt=AbstractPlus

2281 

Weisman 
GA 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22963441?dopt=AbstractPlus

2282 

Wellendorph 
P 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15576628?dopt=AbstractPlus

2283 

Wen 
W 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25176330?dopt=AbstractPlus

2284 

Weng 
J 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18424556?dopt=AbstractPlus

2285 

Weng 
Y 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9660793?dopt=AbstractPlus

2286 

Wenthur 
CJ 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23718281?dopt=AbstractPlus

2287 

Wentland 
MP 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19282177?dopt=AbstractPlus

2288 

Wenzel-Seifert 
K 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/8387097?dopt=AbstractPlus

2289 

Wermuth 
CG 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8632404?dopt=AbstractPlus

2290 

Werner 
U 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20570597?dopt=AbstractPlus

2291 

Werry 
TD 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18554725?dopt=AbstractPlus

2292 

Wess 
J 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/2043926?dopt=AbstractPlus

2293 

Westaway 
SM 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/21544957?dopt=AbstractPlus

2294 

Wetzel 
JM 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7752182?dopt=AbstractPlus

2295 

Weyler 
S 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16902942?dopt=AbstractPlus

2296 

White 
JR 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9553055?dopt=AbstractPlus

2297 

White 
PJ 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12761346?dopt=AbstractPlus

2298 

Whitebread 
S 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2775266?dopt=AbstractPlus

2299 

Whitebread 
SE 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1764088?dopt=AbstractPlus

2300 

Whittle 
BJ 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22480736?dopt=AbstractPlus

2301 

Wichmann 
J 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11006485?dopt=AbstractPlus

2302 

Widler 
L 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20158186?dopt=AbstractPlus

2303 

Wieland 
HA 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9806339?dopt=AbstractPlus

2304 

Wieland 
HA 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7562543?dopt=AbstractPlus

2305 

Wieland 
K 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11714875?dopt=AbstractPlus

2306 

Wiener 
A 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/21940398?dopt=AbstractPlus

2307 

Wiesenfeld-Hallin 
Z 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1373497?dopt=AbstractPlus

2308 

Wiest 
SA 

et al (1991 ) https://www.ncbi.nlm.nih.gov/pubmed/1709220?dopt=AbstractPlus

2309 

Wilbanks 
A 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11290797?dopt=AbstractPlus

2310 

Wilde 
C 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26499266?dopt=AbstractPlus

2311 

Williams 
BL 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25344287?dopt=AbstractPlus

2312 

Williams 
TJ 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10369480?dopt=AbstractPlus

2313 

Willsey 
AJ 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28472652?dopt=AbstractPlus

2314 

Wilson 
RJ 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16604093?dopt=AbstractPlus

2315 

Wilson 
RJ 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15655509?dopt=AbstractPlus

2316 

Wilson 
S 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15946947?dopt=AbstractPlus

2317 

Wilson 
SM 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21173040?dopt=AbstractPlus

2318 

Windischhofer 
W 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9333122?dopt=AbstractPlus

2319 

Winrow 
CJ 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22019562?dopt=AbstractPlus

2320 

Wise 
A 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=AbstractPlus

2321 

Witte 
ON 

et al (2005 ) https://www.ncbi.nlm.nih.gov/pubmed/15653487?dopt=AbstractPlus

2322 

Wittenberger 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11273702?dopt=AbstractPlus

2323 

Wong 
AK 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9719594?dopt=AbstractPlus

2324 

Wong 
LLL 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30131340?dopt=AbstractPlus

2325 

Wong 
PC 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28053157?dopt=AbstractPlus

2326 

Wood 
MD 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10323594?dopt=AbstractPlus

2327 

Wood 
MD 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11082110?dopt=AbstractPlus

2328 

Woodward 
DF 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18700152?dopt=AbstractPlus

2329 

Woodward 
DF 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21752876?dopt=AbstractPlus

2330 

Wright 
DH 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9579725?dopt=AbstractPlus

2331 

Wright 
DH 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10448933?dopt=AbstractPlus

2332 

Wright 
SC 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30514810?dopt=AbstractPlus

2333 

Wright 
SC 

et al (2019 ) https://www.ncbi.nlm.nih.gov/pubmed/30737406?dopt=AbstractPlus

2334 

Wu 
C 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9171878?dopt=AbstractPlus

2335 

Wu 
H 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24603153?dopt=AbstractPlus

2336 

Wu 
L 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8940121?dopt=AbstractPlus

2337 

Wu 
S 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9473604?dopt=AbstractPlus

2338 

Wulff 
BS 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12393057?dopt=AbstractPlus

2339 

Wunder 
F 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20423349?dopt=AbstractPlus

2340 

Wurch 
T 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9855638?dopt=AbstractPlus

2341 

Wuyts 
A 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9692902?dopt=AbstractPlus

2342 

Wynick 
D 

et al (1993 ) https://www.ncbi.nlm.nih.gov/pubmed/7683428?dopt=AbstractPlus

2343 

Xi 
ZX 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17627675?dopt=AbstractPlus

2344 

Xia 
M 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9152366?dopt=AbstractPlus

2345 

Xiao 
C 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27055378?dopt=AbstractPlus

2346 

Xiao 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/23905199?dopt=AbstractPlus

2347 

Xiao 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/24260782?dopt=AbstractPlus

2348 

Xiao 
J 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24666157?dopt=AbstractPlus

2349 

Xiao 
J 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23764525?dopt=AbstractPlus

2350 

Xie 
Z 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10452531?dopt=AbstractPlus

2351 

Xie 
Z 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19482011?dopt=AbstractPlus

2352 

Xiong 
Y 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14722361?dopt=AbstractPlus

2353 

Xiong 
Y 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23403053?dopt=AbstractPlus

2354 

Xu 
F 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21393508?dopt=AbstractPlus

2355 

Xu 
L 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16757564?dopt=AbstractPlus

2356 

Xu 
X 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29615471?dopt=AbstractPlus

2357 

Xu 
Y 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16508674?dopt=AbstractPlus

2358 

Xu 
Y 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10806476?dopt=AbstractPlus

2359 

Xu 
YC 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/9986723?dopt=AbstractPlus

2360 

Xu 
YL 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/15312648?dopt=AbstractPlus

2361 

Yamada 
K 

et al (2019 ) ACS Med Chem Lett 

2362 

Yamamoto 
R 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25347187?dopt=AbstractPlus

2363 

Yamamoto 
T 
. (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11107061?dopt=AbstractPlus

2364 

Yamamura 
MS 

et al (1992 ) https://www.ncbi.nlm.nih.gov/pubmed/1313133?dopt=AbstractPlus

2365 

Yamamura 
Y 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9864265?dopt=AbstractPlus

2366 

Yamane 
S 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25788650?dopt=AbstractPlus

2367 

Yamashita 
A 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23714700?dopt=AbstractPlus

2368 

Yan 
H 

et al (1996 ) https://www.ncbi.nlm.nih.gov/pubmed/8643460?dopt=AbstractPlus

2369 

Yan 
L 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/14662005?dopt=AbstractPlus

2370 

Yan 
P 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/17082621?dopt=AbstractPlus

2371 

Yanagida 
K 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19386608?dopt=AbstractPlus

2372 

Yanagisawa 
T 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/11249148?dopt=AbstractPlus

2373 

Yang 
D 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10521347?dopt=AbstractPlus

2374 

Yang 
J 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18267071?dopt=AbstractPlus

2375 

Yang 
J 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22645144?dopt=AbstractPlus

2376 

Yang 
L 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9724791?dopt=AbstractPlus

2377 

Yang 
LV 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17145776?dopt=AbstractPlus

2378 

Yang 
P 

et al. http://circ.aha journals.org/ content/130/Suppl_2/A15352.
2379 

Yang 
P 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28137936?dopt=AbstractPlus

2380 

Yang 
S 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30135577?dopt=AbstractPlus

2381 

Yao 
BB 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16894349?dopt=AbstractPlus

2382 

Yao 
XC 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22358838?dopt=AbstractPlus

2383 

Yasuda 
H 

et al (2007 ) https://www.ncbi.nlm.nih.gov/pubmed/17214962?dopt=AbstractPlus

2384 

Yates 
L 

et al (2006 ) https://www.ncbi.nlm.nih.gov/pubmed/16553647?dopt=AbstractPlus

2385 

Yau 
MK 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26819675?dopt=AbstractPlus

2386 

Ye 
C 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24633425?dopt=AbstractPlus

2387 

Ye 
RD 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19498085?dopt=AbstractPlus

2388 

Yerxa 
BR 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/12183642?dopt=AbstractPlus

2389 

Yin 
H 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19286662?dopt=AbstractPlus

2390 

Yin 
J 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/26950369?dopt=AbstractPlus

2391 

Yin 
J 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/30538204?dopt=AbstractPlus

2392 

Yin 
J 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25533960?dopt=AbstractPlus

2393 

Yin 
S 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24381270?dopt=AbstractPlus

2394 

Yokomizo 
T 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9177352?dopt=AbstractPlus

2395 

Yokomizo 
T 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11278893?dopt=AbstractPlus

2396 

Yokoyama 
K 

et al (2009 ) https://www.ncbi.nlm.nih.gov/pubmed/19081254?dopt=AbstractPlus

2397 

Yona 
S 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18789697?dopt=AbstractPlus

2398 

Yoshida 
R 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9153236?dopt=AbstractPlus

2399 

Yoshida 
R 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9507024?dopt=AbstractPlus

2400 

Yoshida 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20804735?dopt=AbstractPlus

2401 

Yoshie 
O 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10714678?dopt=AbstractPlus

2402 

Yoshikawa 
M 
. (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26297549?dopt=AbstractPlus

2403 

Yoshio 
R 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11459121?dopt=AbstractPlus

2404 

Yosten 
GL 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23759446?dopt=AbstractPlus

2405 

Young 
P 

et al (1989 ) https://www.ncbi.nlm.nih.gov/pubmed/2573535?dopt=AbstractPlus

2406 

Young 
RN 

et al (2004 ) Heterocycles 
64 : 437 -446 

2407 

Yu 
M 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/24900757?dopt=AbstractPlus

2408 

Yung 
YC 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21900594?dopt=AbstractPlus

2409 

Zagon 
IS 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11890982?dopt=AbstractPlus

2410 

Zajdel 
P 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23279866?dopt=AbstractPlus

2411 

Zaratin 
PF 

et al (2004 ) https://www.ncbi.nlm.nih.gov/pubmed/14593080?dopt=AbstractPlus

2412 

Zaveri 
N 
. (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12801588?dopt=AbstractPlus

2413 

Zaveri 
NT 
. (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25635572?dopt=AbstractPlus

2414 

Zech 
G 

et al (2012 ) https://www.ncbi.nlm.nih.gov/pubmed/22984835?dopt=AbstractPlus

2415 

Zhang 
C 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/26057358?dopt=AbstractPlus

2416 

Zhang 
C 

et al (2016 ) https://www.ncbi.nlm.nih.gov/pubmed/27746744?dopt=AbstractPlus

2417 

Zhang 
D 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25822790?dopt=AbstractPlus

2418 

Zhang 
H 

et al (2018 ) https://www.ncbi.nlm.nih.gov/pubmed/29300013?dopt=AbstractPlus

2419 

Zhang 
K 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/24670650?dopt=AbstractPlus

2420 

Zhang 
L 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/22911445?dopt=AbstractPlus

2421 

Zhang 
LL 

et al (2011 ) https://www.ncbi.nlm.nih.gov/pubmed/21924326?dopt=AbstractPlus

2422 

Zhang 
S 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20570702?dopt=AbstractPlus

2423 

Zhang 
SP 

et al (1998 ) https://www.ncbi.nlm.nih.gov/pubmed/9651119?dopt=AbstractPlus

2424 

Zhang 
SP 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11379050?dopt=AbstractPlus

2425 

Zhang 
W 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/29207657?dopt=AbstractPlus

2426 

Zhang 
WB 

et al (2002 ) https://www.ncbi.nlm.nih.gov/pubmed/11923301?dopt=AbstractPlus

2427 

Zhang 
X 

et al (2017 ) https://www.ncbi.nlm.nih.gov/pubmed/28513578?dopt=AbstractPlus

2428 

Zhang 
Y 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18555684?dopt=AbstractPlus

2429 

Zhang 
Y 

et al (2003 ) https://www.ncbi.nlm.nih.gov/pubmed/12581520?dopt=AbstractPlus

2430 

Zhao 
DM 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10749750?dopt=AbstractPlus

2431 

Zhao 
P 

et al (2015 ) https://www.ncbi.nlm.nih.gov/pubmed/25878251?dopt=AbstractPlus

2432 

Zhao 
P 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20826425?dopt=AbstractPlus

2433 

Zhen 
J 

et al (2010 ) https://www.ncbi.nlm.nih.gov/pubmed/20122961?dopt=AbstractPlus

2434 

Zhou 
J 

et al (2013 ) https://www.ncbi.nlm.nih.gov/pubmed/23392769?dopt=AbstractPlus

2435 

Zhou 
QZ 

et al (1990 ) https://www.ncbi.nlm.nih.gov/pubmed/2168520?dopt=AbstractPlus

2436 

Zhou 
Y 

et al (2014 ) https://www.ncbi.nlm.nih.gov/pubmed/25373781?dopt=AbstractPlus

2437 

Zhu 
J 

et al (1995 ) https://www.ncbi.nlm.nih.gov/pubmed/7869844?dopt=AbstractPlus

2438 

Zhu 
J 

et al (2008 ) https://www.ncbi.nlm.nih.gov/pubmed/18582868?dopt=AbstractPlus

2439 

Zhu 
J 

et al (1997 ) https://www.ncbi.nlm.nih.gov/pubmed/9262330?dopt=AbstractPlus

2440 

Zhu 
K 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11535583?dopt=AbstractPlus

2441 

Zhu 
Y 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11179436?dopt=AbstractPlus

2442 

Zobel 
AW 

et al (2000 ) https://www.ncbi.nlm.nih.gov/pubmed/10867111?dopt=AbstractPlus

2443 

Zoffmann 
S 

et al (2001 ) https://www.ncbi.nlm.nih.gov/pubmed/11170631?dopt=AbstractPlus

2444 

Zygmunt 
PM 

et al (1999 ) https://www.ncbi.nlm.nih.gov/pubmed/10440374?dopt=AbstractPlus

